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Abstract 
 
Human immunodeficiency virus type 1 (HIV-1) entry into cells is mediated by 
the functional envelope spike, which consists of trimers of gp120 bound to gp41. 
Most variants of HIV-1 enter cells through attachment of the envelope spike to 
the main cellular receptor CD4, allowing interaction with a co-receptor and 
eventually fusion of viral and cellular membranes. Neutralising antibodies inhibit 
HIV-1 entry by targeting epitopes on the functional spike. HIV-1 has, however, 
evolved several ways to evade recognition by antibodies, including variable 
regions, carbohydrates, and conformational masking. As a result, the neutralising 
antibody response in HIV-1 infection and post-immunisation is generally narrow, 
and only a handful of broadly neutralising monoclonal antibodies have been 
reported. In this thesis, the isolation and characterisation of novel, broadly 
neutralising antibody fragments derived from llamas is described. Llamas 
produce antibodies devoid of light chains, which have their antigen-binding 
properties confined to a single fragment, the VHH, and a preference for cleft-
recognition. VHH were isolated from llamas immunised with recombinant gp120 
using phage display-based methods. In order increase the chances of isolating 
neutralising VHH, a functional selection strategy was employed, involving a 
competitive elution with soluble CD4. Three VHH able to neutralise HIV-1 
primary isolates of subtype B and C were characterised. These VHH bound to 
gp120 with high affinities and competed with soluble CD4 and antibodies to the 
CD4-binding site for this binding, indicating that their mechanism of 
neutralisation involves interacting with the functional envelope spike prior to 
binding to CD4. These results indicate that llama VHH can be potent HIV-1 
entry inhibitors. Since VHH are stable and can be produced at a relatively low 
cost, they may be considered for HIV-1 microbicide development. Anti-gp120 
VHH might also prove useful in defining neutralising and non-neutralising 
epitopes on HIV-1 envelope proteins, with implications for HIV-1 vaccine 
design. 
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Chapter 1 
Introduction 
 
In this thesis, the isolation and characterisation of llama antibody fragments able 
to inhibit human immunodeficiency virus type 1 (HIV-1) infection will be 
described. This chapter will provide a scientific background to the data 
presented. The first part of the chapter will focus on the research fields of HIV-1 
and acquired immunodeficiency syndrome (AIDS) and the second part on the 
humoral immune system of camelids. 
 
1.1 HIV-1 and AIDS 
In the first part of this chapter, an introduction to the research fields of HIV-1 
and AIDS will be given, with a particular focus on HIV-1 envelope proteins, 
neutralising antibodies to HIV-1 envelope, and HIV-1 vaccine and microbicide 
development. 
 
1.1.1 A historical introduction to HIV-1 and AIDS 
In June 1981, the Centres for Disease Control and Prevention (CDC) in the USA 
published a report in the Morbidity and Mortality Weekly Report of 
Pneumocystis carinii pneumonia, a disease usually only seen in 
immunosuppressed individuals, in five previously healthy, young, homosexual 
men in Los Angeles (1). This report would later be referred to as the beginning of 
AIDS. The CDC report was followed by two publications in the New England 
Journal of Medicine a few months later, where the Pneumocystis carinii 
pneumonia was recognised as being associated with a depletion of T helper cells 
(2, 3). The same year, there were reports of an aggressive form of the usually 
relatively benign cancer Kaposi’s sarcoma in young homosexual men in New 
York (4, 5). These cases were also associated with a loss of T helper cells (6). A 
number of reports on the newly described immune deficiency were to follow, 
including reports of cases outside of the USA (7-9). At the end of 1982, the 
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condition was officially named acquired immunodeficiency syndrome, or AIDS 
(10). Although it was initially associated with the homosexual community, it was 
soon detected in intravenous drug users, individuals from Haiti that had recently 
entered the USA, and individuals who had received blood transfusions (3, 11, 
12). These observations, together with the observation of a possible mother-to-
child transmission, and disease among a group of homosexual men in California, 
led to the proposal that the immunodeficiency syndrome was caused by an 
infectious agent (13-16). 
 
In 1980, Poiesz et al. (17), in the group of Robert Gallo, had isolated the first 
infectious human retrovirus, human leukaemia virus type 1 (HTLV-1). HTLV-1 
had been shown to have a tropism for T cells and was assumed to be transmitted 
along the same routes as what had been suggested for the AIDS agent. In 
addition, retroviruses, for example the feline leukaemia virus (FeLV), had 
previously been associated with immune deficiencies (18, 19). Because of these 
notions, and since AIDS had been associated with a loss of T helper cells, it was 
suggested that AIDS might be caused by a retrovirus and more specifically by a 
member of the HTLV family (20). In 1983, HTLV-1 was also reported to be 
present in some individuals with AIDS and suggested as a possible aetiological 
agent of AIDS (21-23). However, the frequency by which HTLV-1 was detected 
in patients with AIDS was low. In addition, antibodies to HTLV were not often 
detected in individuals with AIDS symptoms (24, 25). In conclusion, no evidence 
for an aetiological role was presented, and it would later become apparent that 
the reported cases were merely co-infections. 
 
Meanwhile, at the end of 1982, the group of Luc Montagnier at the Pasteur 
Institute in France had set out to discover whether a retrovirus might be the cause 
of AIDS (26). Their results were published in May 1983, when Barré-Sinoussi et 
al. (27) described the isolation of a novel retrovirus from a lymph node of a 
patient with AIDS-like illness. Reverse transcriptase activity was detected in the 
culture supernatant after 15 days of culturing the lymph node lymphocytes, 
indicating the presence of a retrovirus. Electron microscopy as well as sucrose 
gradient experiments further supported this notion. The virus could be 
transmitted to lymphocytes from healthy adult donors as well as to lymphocytes 
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from umbilical cord blood in two subsequent propagation steps. Antisera to 
HTLV-1 did not react with cells infected with the novel virus, indicating that the 
new virus was distinct from HTLV. Serum from the patient did, however, show 
reactivity with HTLV-1-infected cells. A protein of similar size to the p24 core 
protein of HTLV-1 was found, but was not recognised by antibodies to the 
HTLV-1 p24 protein. Based on these observations, Barré-Sinoussi et al. 
concluded that the novel virus belonged to a general family of T lymphotropic 
retroviruses, that is was related to but distinct from HTLV, and finally that its 
role in the aetiology of AIDS remained unclear. The virus was subsequently 
called lymphadenopathy virus, or LAV. 
 
In September 1983, at the Cold Spring Harbor Meeting in New York, a few 
months after the first publication on LAV, Luc Montagnier presented data on 
further LAV-like isolates from other individuals with AIDS, including additional 
electron microscopy data on the virus morphology. These data were later 
published, along with data on a selective tropism for T helper cells and further 
evidence for an aetiological role in AIDS (28-30, reviewed in 31). 
 
One year after Barré-Sinoussi and colleagues published their first set of data on 
LAV (27), the group of Robert Gallo, in May 1984, published four reports 
describing the isolation of a novel retrovirus from individuals with AIDS, the 
establishment of a cell line continuously producing the virus, and extensive 
evidence for a role in the aetiology of AIDS (32-35). The virus was called human 
T lymphotropic virus type 3, or HTLV-3. In August 1984, Jay Levy et al. (36) 
reported an additional isolation of retroviruses from patients with AIDS. This 
virus was called AIDS-associated retrovirus, or ARV. Molecular cloning (37-39) 
and sequencing (40-43) of the LAV, HTLV-3 and ARV genomes soon made it 
clear that these viruses belonged to the same species (44, 45). Moreover, the 
reported nucleotide sequences along with additional genetic and morphological 
studies (45-48), suggested the AIDS virus to be more related to the Lentivirus 
genus of the Retroviridae family than to the Deltavirus genus to which HTLV 
belongs. In 1986, the virus was named human immunodeficiency virus, HIV 
(49). A series of important findings were to follow. Antibody and antigen tests 
had already been made available (50, 51), the main cellular receptor was 
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discovered (52, 53) and the first anti-HIV drug was developed and proven 
efficient in clinical trials (54). Moreover, by the mid-1980s the severity of the 
epidemic had started to show, as it had become apparent that HIV and AIDS 
were widespread in several regions of Africa, including Zambia, Zaire, Uganda 
and Rwanda (55-61). Evidence of seropositivity in individuals in central Africa 
was even found from as far back as 1959 (62). In the south-western parts of 
Uganda, a disease referred to as slim disease, which would later be identified as 
AIDS, had been observed with increasing frequency since 1982 (61). 
 
Another novel lentivirus, related to but distinct from the HIV strains already 
described, was isolated from individuals with AIDS in 1986 by Clavel et al. (63). 
Serological evidence for a novel lentivirus distinct from previous HIV isolates 
had, however, already been presented the year before by Barin et al. (64). This 
virus was eventually termed HIV-2, while the HIV isolated by Barré-Sinoussi 
and colleagues was called HIV-1. HIV-2 would later turn out to cause a more 
confined epidemic in the western parts of Africa, whereas HIV-1 is the cause of 
the worldwide AIDS pandemic (65, 66). 
 
Now, almost exactly 25 years after the identification of HIV as the cause of 
AIDS, there are estimated to be 33.2 million people infected worldwide (65). 
Despite the acquisition of a vast amount of knowledge of the biology of HIV, 
and considerable advances in addressing the pandemic, there is still no cure or 
vaccine and the pandemic continues to have a devastating impact on society. 
Even though antiretroviral therapy has proven effective in slowing disease 
progression, these drugs are expensive and not readily available to the majority 
of HIV infected individuals. Hence, there is a need for effective preventive 
methods to control the HIV pandemic, such as an HIV vaccine or alternative 
preventive strategies such as a topically applied HIV microbicide. All attempts to 
design a vaccine have, however, so far failed. The latest major drawback came at 
the end of 2007, when the second vaccine candidate to be tested in efficacy 
studies failed to slow down or protect against infection (67). 
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1.1.2 Epidemiology of HIV-1  
The total number of people living with HIV continues to increase. Among the 
estimated 33.2 million people living with HIV worldwide, 2.1 million are 
children under 15 years (65). During 2007, there was an estimated 2.1 million 
deaths due to AIDS, and an estimated 2.5 million new HIV infections, the 
majority of these acquired through heterosexual transmission (65). The global 
HIV incidence is, however, estimated to be on the decline, having peaked at the 
end of the 1990s. According to the Joint United Nations Programme on 
HIV/AIDS (UNAIDS) 2007 AIDS epidemic update (65), there are currently two 
main trends in pandemic, that of a widespread epidemic in the general population 
in regions of sub-Saharan Africa, as well as the epidemics in the rest of the 
world, which are concentrated to high-risk populations, such as sex workers, men 
who have sex with men, and intravenous drug users and their partners. The AIDS 
pandemic is caused by HIV-1, whereas HIV-2 is the cause of a small epidemic 
limited to relatively few countries in western Africa, with some presence in 
Portugal and also in India (65, 66, 68). 
 
Sub-Saharan Africa continues to be the worst affected region (Fig. 1.1.2.1), with 
an estimated 68% of the total number of infections and almost 90% of the 
infected children. In contrast to in the rest of the world, the majority (61%) of the 
infected people are women. In this region, AIDS remains the major cause of 
death, with 76% of the global annual AIDS deaths (65). The estimated number of 
annual new infections has, however, decreased between 2001 and 2007. In the 
western, central and eastern parts of sub-Saharan Africa, the adult HIV 
prevalence seems to have stabilised or declined. In most countries in southern 
Africa, however, the adult prevalence has just reached, or is still approaching, a 
plateau (65). In Mozambique, the prevalence is even increasing. In eight sub-
Saharan countries (Botswana, Lesotho, Mozambique, Namibia, South Africa, 
Swaziland, Zambia and Zimbabwe) the adult prevalence is more than 15%. Adult 
prevalence is highest in Botswana, Lesotho and Swaziland, where recent 
estimates suggest that around one in four people is infected (65). South Africa 
remains the country with the largest number of HIV infections in the world. 
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In Southeast Asia, the HIV prevalence in Vietnam and Indonesia continues to 
increase, while it is on the decline in Thailand, Burma and Cambodia. In China, 
the epidemic is continuing to grow, with slightly less than half of all new 
infections thought to be acquired during intravenous drug use. In India, the 
country with the second largest number of HIV infections, an extended HIV 
surveillance system has estimated the proportion of people living with HIV to be 
lower than what was previously thought. In Eastern Europe and Central Asia, the 
epidemics continue to grow, with a 150% increase in the total number of infected 
people between 2001 and 2007. More than 90% of the new infections in this 
region occurred in Russia and Ukraine (65). Almost two thirds of the estimated 
new infections in 2006 were thought to be acquired during intravenous drug use. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1.2.1. Number of people estimated to be living with HIV in 2007. Figure obtained 
from the ‘2007 AIDS epidemic update’, Joint United Nations Programme on HIV/AIDS 
(UNAIDS) and World Health Organisation (WHO), http://www.unaids.org/. 
 
In Latin America, the HIV epidemic remains stable, with the majority of new 
infections occurring in high-risk populations, including sex workers and their 
partners, injecting drug users and men who have sex with men (65). In the 
Caribbean, the adult prevalence is around 1%, with Haiti and the Dominican 
Republic being the worst affected (65). Transmission occurs primarily through 
the heterosexual route. The annual incidence has stabilised but HIV remains one 
of the leading causes of death among people aged 25-44. In North America, 
Western & 
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[1.4 – 1.9 million]
East Asia
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Total: 33.2 (30.6 – 36.1) million
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Western and Central Europe, the total number of people infected with HIV 
continues to increase. In North America, around half of all new infections are 
estimated to occur among men who have sex with men, whereas in Western 
Europe, the majority of new infections are thought to be acquired through 
heterosexual transmission (65). 
 
1.1.3 Biology of HIV-1 
The virus that Barré-Sinoussi et al. (27) isolated from an individual with AIDS 
symptoms, and which was subsequently named HIV-1, belongs to the Lentivirus 
genus of the Retroviridae family. In this section, a general introduction to 
retroviruses will be given, as well as an overview of the origin and virology of 
HIV-1. 
  
1.1.3.1 Retroviruses 
The Retroviridae is a large and diverse family of viruses able to infect a wide 
range of species. It has been associated with a number of diseases such as 
cancers and immunological disorders. Its members are enveloped viruses with 
diploid, linear, single-stranded RNA genomes of positive polarity, which use a 
virus-encoded reverse transcriptase to convert their genomic RNA into DNA. 
The DNA is subsequently incorporated into the host genomic DNA where it 
resides as a provirus. A typical retroviral provirus is 6-11 kb and contains three 
main open reading frames, the gag (group-specific antigen), pol (polymerase) 
and env (envelope) genes (69). Retroviruses containing these three genes only are 
referred to as simple retroviruses, whereas retroviruses with several additional, 
accessory or regulatory genes are referred to as complex. 
 
The first retroviruses to be described were the avian leukosis virus (ALV) and 
the Rous sarcoma virus (RSV), which were isolated when Ellermann and Bang, 
in 1908, and Rous, in 1911, showed that neoplastic diseases in chicken could be 
transmitted experimentally by cell-free filtrates (70). The transmission of a 
disease caused by a retrovirus had, however, already been observed a few years 
earlier, in 1904, when Vallée and Carré showed that equine anaemia was 
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experimentally transmissible by a filtrate (70). These discoveries were followed 
by the isolation of other viruses causing tumours in additional hosts such as mice 
(71-73). The particles of these tumour-causing viruses were eventually shown to 
contain RNA and the viruses were subsequently called RNA tumour viruses (69, 
74). After the formulation of the DNA provirus hypothesis by Temin in 1964 
(75, 76), the Nobel prize-awarded discovery of the reverse transcriptase by 
Baltimore (77) and Temin and Mizutani (78) in 1970, and the transfection of an 
infectious DNA provirus from RSV-infected cells by Hill and Hillova in 1972 
(79), more became known about the biology of these RNA tumour viruses and 
they were eventually named retroviruses in 1974 (80). Retroviruses have since 
been detected in a variety of species, including mammals, reptiles and fish (69). 
The first human-to-human transmissible retrovirus to be described was HTLV-1, 
which was detected and isolated from a patient with cutaneous T cell lymphoma 
in 1980 by Poiesz et al. (17). The same virus was independently detected in 
Japan in 1981, using serology and electron microscopy (81, 82) and subsequently 
molecular approaches (83), and reported as adult T cell leukaemia virus (ATLV). 
 
Historically, retroviruses have been divided into three subfamilies, the onco-, 
lenti- and spumaviruses, according to their biological properties and the type of 
disease they caused, and further classified into genera according to the 
morphology of the mature virion, as observed by electron microscopy. Present-
day classification is, however, based mainly on the sequence of the pol gene. 
According to current taxonomy, the Retroviridae family can be divided into two 
subfamilies, the Orthoretrovirinae and the Spumaretrovirinae (84). The 
Orthoretrovirinae is divided into six genera, the Alpha-, Beta-, Gamma-, Delta- 
and Epsilonretrovirus genera as well as the Lentivirus genus, whereas the 
Spumaretrovirinae consists of the Spumavirus genus only (84). 
 
Viruses belonging to the Alpharetrovirus genus have simple genomes and have 
so far only been isolated in birds. ALV is the type species. Viruses belonging to 
the Betaretrovirus genus, on the other hand, have been detected mainly in 
mammals. They include the jaagsiekte sheep retrovirus (JSRV), which causes 
ovine pulmonary adenocarcinoma in sheep (85), the mouse mammary tumour 
virus (MMTV), which causes mammary carcinoma in mice (72) and the Mason-
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Pfizer monkey virus (MPMV), which was the first retrovirus to be isolated from 
primates (86, 87). Viruses of the Gammaretrovirus genus have been detected in a 
variety of vertebrate species and includes the gibbon ape leukaemia virus 
(GALV) and the type species murine leukaemia virus (MLV), which cause 
leukaemia in their respective hosts (73, 88). All retroviruses in this genus have 
simple genomes. Unlike the gammaretroviruses, viruses in the Deltaretrovirus 
genus have complex genomes (69). The type species is the bovine leukaemia 
virus (BLV). The genus also includes the first transmissible retroviruses to be 
detected in humans, HTLV-1 and -2 (17, 89). The Epsilonretrovirus genus 
consists of viruses with complex genomes that are primarily found in fish. The 
type species is the walleye dermal sarcoma virus (WDSV), which was first 
described in the 1960s (90, 91). The Lentivirus genus, to which HIV belongs, 
consists of retroviruses with complex genomes. They have so far only been 
isolated from mammals, are known to cause slow disease syndromes, and can 
induce immunodeficiency in their hosts (69, 92). The term lentivirus was coined 
by Björn Sigurdsson in Iceland in the mid-1950s from the Latin word lentus, 
meaning slow, after his description of the visna and maedi diseases in sheep and 
the isolation of the virus that causes them, the visna/maedi lentivirus (93, 94). 
The visna/maedi virus causes paralysis (visna) or pneumonia (maedi) in sheep 
and goats and gave rise to epidemics in sheep in Iceland between 1930 and 1950. 
Its genome was first sequenced in 1985, around the same time as the HIV 
genome, helping to classify HIV to the Lentivirus genus (48). Like the 
lentiviruses, the spumaviruses have complex genomes. The type species of the 
Spumavirus genus is the simian foamy virus (84). Spumavirus infections are 
widespread among mammals but have still not been observed to cause disease, 
despite having cytopathic effects in vitro (95). 
 
Retroviruses have been linked to a range of diseases, such as cancers and 
immunodeficiencies, but have also been associated with persistent infections 
without any apparent pathogenic effects. Retroviruses that have integrated into 
the germ-line of their hosts, and which replicate in a Mendelian fashion, were 
first discovered in the late 1960s (96-101). Such so-called endogenous 
retroviruses have since been detected in all vertebrate species in which they have 
been searched for, and endogenous counterparts have been found for all genera 
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of the Retroviridae, with the exception of the Deltavirus genus. Endogenous 
lentiviral sequences were only recently described, in one species of rabbit (102). 
These lentiviral sequences were determined to be more than seven million years 
old, providing evidence for an ancient origin of the Lentivirus genus. The first 
human endogenous retrovirus was detected in 1981 (103). Whether expression of 
endogenous retroviruses have any pathogenic effect in humans remains disputed, 
although association with autoimmune disease, endometriosis and some cancers 
have been suggested (104). There are, however, some examples where retroviral 
genes have become important for physiological processes in their hosts. The 
envelope protein of a human endogenous retrovirus has, for example, been 
shown to be essential in the human placental morphogenesis (105). In addition, a 
murine protein of retroviral origin, Friend virus susceptibility factor 1 (Fv1), has 
been shown to confer resistance to exogenous retroviruses in mice as well as in 
other mammals (106, 107). Since the complete sequence of the human genome 
was made available at the beginning of this century, it has been estimated that 
endogenous retroviral sequences make up approximately 8% of the human 
genome (108-113). In light of these notions, it is apparent that retroviruses have 
played a significant role in the biological history of several species, not only as 
disease-causing agents and as the cause of global burdens such as the HIV 
pandemic, but also as contributors to, for example, the plasticity of vertebrate 
genomes and thus to the overall evolution of the vertebrate species (108, 110, 
114-116). 
 
1.1.3.2 Origin and diversity of HIV 
Lentiviruses have been detected in more than 30 non-human primate species in 
sub-Saharan Africa (117, 118). These simian immunodeficiency viruses (SIVs) 
form host-specific clades and appear to be non-pathogenic in their hosts. HIV is 
thought to have been brought into the human population by several cross-species 
transmissions of SIVs. HIV-1 is most closely related to SIVcpz, which is present 
in the chimpanzee (Pan troglodytes) population. In 2006, Keele et al. (119) 
reported data confirming SIVcpz from the Pan t. troglodytes subspecies of 
chimpanzees (SIVcpzPtt) as the progenitor of HIV-1. They showed that HIV-1 of 
group M (major) and N (non-major, non-outlier) arose from two distinct SIVcpzPtt 
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strains, circulating in two geographically separated chimpanzee populations 
present in west central Africa. Other studies have indicated that SIVcpz itself is a 
result of a recombination event between SIVs from red capped mangabey and 
greater spot-nosed monkey (120). HIV-1 of group O (outlier), on the other hand, 
may have been brought into the human population as the result of a cross-species 
transmission of SIVgor in gorillas, as related SIVs have been found in both 
chimpanzees and gorillas (121). HIV-2 is thought to have its origin in SIVsm, 
which naturally infects sooty mangabeys (118). From here onwards, this thesis 
will focus on HIV-1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1.3.2.1. Global distribution of HIV-1 group M subtypes and CRFs. Data obtained 
from Taylor, B. S., M. E. Sobieszczyk, F. E. McCutchan, and S. M. Hammer, 2008, ‘The 
challenge of HIV-1 subtype diversity’, N Engl J Med 358:1590-602. 
 
Phylogenetically, HIV-1 can be classified into group M (major), N (non-major, 
non-outlier) and O (outlier). Group N infections have been detected in only a few 
individuals in Cameroon, whereas group O is present in Cameroon and a few 
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surrounding countries (122). Group M, on the other hand, accounts for over 99% 
of infections and is the most variable, with extraordinary diversity in the 
envelope sequence between isolates. Group M can be divided into subtypes A-D, 
F-H, J and K, plus a number of circulating recombinant forms (CRFs; defined as 
circulating when isolated from at least three individuals without epidemiologic 
linkage), with subtype C accounting for around 50% of infections worldwide and 
currently infecting more people than any other subtype (122-124). Genetic 
variation between subtypes is usually around 25-35% (123). The geographical 
distribution of HIV-1 group M genetic subtypes and CRFs is shown in Fig. 
1.1.3.2.1. 
 
1.1.3.3 The HIV-1 genome and gene products 
Like all retroviruses, HIV-1 has a diploid genome composed of two identical 
positive-sense RNA molecules of approximately 9 kb. The genome was first 
sequenced in 1985 (40-43) and found to resemble the genomes of other complex 
retroviruses (40). Like all retroviruses, it contains the gag, pol and env genes 
(125). The gag gene encodes a 55 kDa Gag precursor polyprotein (Pr55Gag), 
which is cleaved by the viral protease into the matrix (MA or p17), capsid (CA or 
p24), nucleocapsid (NC or p7) and p6 proteins, as well as the two smaller spacer 
peptides SP1 and SP2, located between CA and NC, and NC and p6 in Pr55Gag, 
respectively (126). The pol gene encodes the viral enzymes protease (PR or p15), 
reverse transcriptase (RT or p66 and p51) and integrase (IN or p31). These 
enzymes are initially synthesised as part of a Gag-Pol precursor polyprotein 
(Pr160Gag-Pol) but cleaved into individual enzymes by the viral protease (125, 
127, 128). The env gene encodes an Env precursor glycoprotein (gp160), which, 
like for all retroviruses, is cleaved and processed by cellular enzymes into a 
surface glycoprotein, SU or gp120, and a transmembrane glycoprotein, TM or 
gp41 (128-131). 
 
In addition to the gag, pol and env genes, the HIV-1 genome contains genes 
encoding regulatory and accessory proteins, located downstream of the pol gene 
(125, 127). The tat and rev genes contain two exons each and encode the gene 
regulatory proteins Tat (transactivator of transcription) and Rev (regulator of 
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virion), whereas the vif, vpr, vpu and nef genes encode the accessory proteins Vif 
(viral infectivity factor), Vpr (viral protein R), Vpu (viral protein U) and Nef 
(negative factor). The gag, vif and the second exon of tat are in the first reading 
frame, whereas the first exon of tat, vpu and the second exon of rev are in the 
second reading frame, and pol, vpr and the first exon of rev in the third reading 
frame (125). A schematic representation of the HIV-1 proviral genome is shown 
in Fig. 1.1.3.3.1. 
 
     
      
  
 
 
 
Figure 1.1.3.3.1. Schematic representation of the HIV-1 proviral genome. Open reading 
frames are represented as rectangles. The gag, pol and env open reading frames encode structural 
proteins and enzymes, whereas rev and tat encode gene regulatory proteins and vif, vpr, vpu and 
nef encode accessory proteins. The HIV-1 genome is flanked by two long terminals repeats 
(LTRs). Details are given in the text. The vertical position of each box in the diagram represents 
the reading frame of the gene. 
 
The HIV-1 RNA genome is flanked by two untranslated repeat regions (R). 
Internal of the repeat regions are a unique 5´ (U5) region at the 5′ end and a 
unique 3´ (U3) region at the 3′ end. During reverse transcription of the RNA 
genome into double-stranded DNA, longer repeat regions are generated. Thus, 
the proviral DNA genome is flanked by two identical long terminals repeats 
(LTRs) containing the U3, R and U5 regions. The HIV-1 LTRs were first 
analysed in 1985 and found to be 630-640 bp long (40, 132). The U3 region 
contains the viral promoter and enhancer sequences, whereas the R region 
contains the polyadenylation signal and the transactivation response element 
(TAR) that serves as the binding site for the viral Tat protein (133, 134). 
Differences in the LTR sequence and in the enhancer/promoter configuration 
have been observed for different HIV-1 subtypes and have been linked to in vitro 
replication rate (135, 136). 
3´LTR   vpu 
pol env  vpr 
gag vif tat nef 
5´LTR rev
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1.1.3.4 The mature HIV-1 virion 
The structure of HIV-1 virions has been extensively studied using electron 
microscopy and cryo-electron microscopy techniques. The diameter of mature 
HIV-1 virions vary but is on average around 145 nm (137). A schematic 
representation and a cryo-electron micrograph of a mature HIV-1 particle are 
shown in Fig. 1.1.3.4.1. 
 
A.                       B. 
                      
 
Figure 1.1.3.4.1. Structure of the mature HIV-1 virion. A. Schematic representation of a 
mature HIV-1 particle. The diploid viral RNA genome is associated with the nucleocapsid 
protein (NC) and surrounded by a conical core made up of the capsid protein (CA). Within the 
core are several viral proteins such as the reverse transcriptase (RT), integrase (IN), protease 
(PR), viral protein R (Vpr) and p6. Surrounding the conical core is a lipid bilayer, which is 
derived from the cellular plasma membrane. The viral matrix protein (MA) forms a layer beneath 
the membrane. The lipid bilayer membrane contains viral envelope spikes made up of the surface 
glycoprotein gp120 non-covalently bound to the transmembrane glycoprotein gp41. B. Cryo-
electron micrograph of a mature HIV-1 particle obtained from infected T cells. The cryo-electron 
micrograph is obtained from Briggs, J. A., T. Wilk, R. Welker, H. G. Kräusslich, and S. D. 
Fuller, 2003, ‘Structural organization of authentic, mature HIV-1 virions and cores’, Embo J 
22:1707-15. Reprinted by permission from Macmillan Publishers Ltd. 
 
The exterior of an HIV-1 particle is made up of an outer, host cell-derived lipid 
bilayer, the envelope. Embedded in the envelope bilayer are virus-encoded 
envelope spikes, made up of the surface glycoprotein gp120 non-covalently 
linked to the transmembrane glycoprotein gp41, as well as host-cell specific 
proteins. The functional viral envelope spike exists as a trimer of gp120/gp41 on 
Envelope spike 
MA
CA
NC
RT 
IN 
PR 
Vpr 
p6 
RNA 
Lipid bilayer 
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the virus surface (138-140), although there is evidence for the presence of non-
functional envelope spikes such as gp41 stumps and gp120/gp41 monomers 
(141, 142). Viral envelope spikes will be further discussed in section 1.1.6.  
 
Beneath and associated with the envelope bilayer is a layer of trimeric MA 
proteins, which interact with the lipid bilayer via amino (N)-terminal myristoyl 
groups (143). The MA shell surrounds the characteristic cone-shaped core, 
consisting of hexameric CA proteins forming a hexagonal lattice (137, 144, 145). 
The conical core, in turn, surrounds the viral nucleocapsid, or ribonucleoprotein 
complex, which is made up of the viral genomic RNA closely associated with the 
NC protein. The NC protein is a small, 55 amino acid residue-protein, which 
contains zinc-finger motifs common to many proteins that bind nucleic acids 
(127). The RNA genome is diploid and the two molecules are associated at the 5′ 
end. Dimerisation is mediated by so-called kissing-loop interactions between 
hairpin structures in the dimer initiation site located downstream of the U5 region 
(146-149). Also contained in the viral core are PR, RT and IN, as well as Vpr. 
 
1.1.3.5  The HIV-1 life-cycle 
The HIV-1 life-cycle is initiated by interaction of the viral envelope spike with 
the main cellular receptor, the cluster of differentiation 4 (CD4) antigen, as well 
as a co-receptor, typically the CC-chemokine receptor 5 (CCR5) or the CXC-
chemokine receptor 4 (CXCR4). Interaction with the receptors eventually leads 
to the fusion of the viral and cellular membranes, allowing for entry of the 
conical viral core. HIV-1 entry into host cells will be further discussed in section 
1.1.6. A schematic overview of the HIV-1 life-cycle is shown in Fig. 1.1.3.5.1 
and described below. 
 
Entry into the cytoplasm is followed by reverse transcription of the viral genomic 
RNA into DNA, as well as partial disassembly and rearrangement of the viral 
core in a process called uncoating, leading to the formation of a reverse 
transcription complex, RTC (150). The viral uncoating process, the co-ordination 
and initiation of the reverse transcription, and the mechanisms behind RTC 
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formation and are not well understood and little is known about the viral and 
cellular factors involved (150, 151). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1.3.5.1. Schematic representation of the HIV-1 life-cycle. The HIV-1 life-cycle is 
similar to that of other retroviruses and consists, in brief, of virus entry, uncoating, reverse 
transcription of the viral RNA into DNA, nuclear import of a pre-integration complex, integration 
of viral DNA into the cellular genomic DNA, transcription and splicing of RNA transcripts, 
nuclear export of mRNAs, translation, multimerisation and assembly of Gag and Gag-Pol 
precursors at the cellular plasma membrane, encapsidation of viral RNA, synthesis, 
glycosylation, folding, oligomerisation and cleavage of the gp160 precursor in the ER and Golgi, 
incorporation of viral envelope glycoproteins into virions, budding and release of immature 
virions followed by maturation into infectious mature HIV-1 particles. Each step is described in 
more detail in the text. 
 
Uncoating involves the disassembly of CA and release of the viral 
ribonucleoprotein complex. This process remains to be elucidated but has been 
suggested to involve both viral and cellular factors (151). Studies using CA 
mutants have indicated that the amount of CA in the viral core is important for 
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core stability and proper uncoating in host cells. A deviation in the amount of CA 
led to changes in core stability and in impaired HIV-1 infectivity (151). In 
addition to CA, MA and NC may also affect uncoating (151). Alongside viral 
factors, cellular factors may also be required. One study has suggested the 
involvement of cell cycle-dependent host factors in the uncoating process (152). 
Cellular proteins, such as cyclophilin A, which binds to CA and is incorporated 
into virions (153-155), may also affect uncoating (151). In addition, the cellular 
tripartite motif protein TRIM5α restricts retroviral infection in a species-specific 
manner by blocking an early, post-entry event in the retroviral replication (156). 
This block to infection is mediated by TRIM5α associating with CA and 
promoting its degradation, leading to accelerated core disassembly and uncoating 
(157). 
 
The uncoating process leads to the formation of an RTC. Sedimentation velocity 
and electron and confocal microscopy studies have indicated that the RTCs are 
large nucleoprotein structures consisting of packed filaments containing IN and 
Vpr, where the viral genome is covered with proteins that are not NC (158, 159). 
CA has, however, been shown to be absent from functional RTCs, although trace 
amounts have also been detected, indicating that most of the CA proteins 
disassociate soon after entry of the viral core (158, 160). The extent to which 
cellular factors are part of or important for the formation of RTCs remains 
unclear, but studies have shown that RTCs interact with the cytoskeleton (160, 
161). This interaction has been suggested to occur via association of MA with 
actin (161). In addition, NC has been shown to interact with actin (162, 163), as 
has the p66 subunit of RT (164). Other viral proteins such as IN, Rev, Vpr and 
Vif have also been suggested to have an effect on the cytoskeleton, although the 
role of these effects and interactions in the viral replication remain unresolved 
(150). 
 
Reverse transcription of the viral genomic RNA into DNA is thought to take 
place essentially within the RTC. The active form of the viral RT is a 
heterodimer consisting of the p66 and p51 subunits. The p51 subunit contains the 
domain responsible for the DNA polymerase activity, whereas the p66 subunit 
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contains a domain with RNase H activity in addition to the DNA polymerase 
domain (165). Reverse transcription is initiated using a cellular tRNALys-3, which 
is packaged into virions and which anneals to the primer binding site (PBS) 
located downstream of the U5 region at the 5´-end of the viral RNA genome 
(166). DNA is synthesised from the 3´-end of the tRNALys-3 towards the 5´-end 
of the RNA genome. The 5´-end of the viral genome, the R and U5 regions, are 
then removed by the RNase H domain of RT. The newly synthesised DNA 
segment does then transfer and anneal to the R region at the 3’-end of the RNA 
genome, by means of sequence homology, in a process called first strand 
transfer. This DNA segment is then extended and most of the genomic RNA 
strand is degraded by the RNase H domain of RT. A second strand of DNA is 
subsequently synthesised using the remaining parts of the genomic RNA as 
primers. After removal of the tRNALys-3 and the remaining genomic RNA by the 
RNase H domain, a second strand transfer occurs, when the PBS region of the 
second strand hybridises with the PBS region of the first strand. Both DNA 
strands are then extended, forming a double-stranded DNA genome flanked by 
two identical LTRs. 
 
The RT polymerase lacks the proof-reading ability seen in cellular DNA 
polymerases. Because of this characteristic, the RT is highly error-prone, making 
approximately 3.4 × 10-5 errors per base pair per cycle (167). This error rate 
contributes to the extreme sequence variation observed among HIV-1 isolates. In 
addition, RT binds with low affinity to its template and can hence make frequent 
jumps between the two RNA genomic molecules. If the two genomic RNA 
molecules are different, this ability results in the generation of genetically 
recombinant DNA genomes, thus contributing to genetic variability (168). Vpr 
has been suggested to have an effect on the accuracy of the reverse transcription, 
thus modulating the in vivo mutation rate of HIV-1 (169). 
 
While the biochemical basis for reverse transcription is well described, the 
mechanism that triggers it is poorly understood. Again, little is known about the 
importance of cellular factors for the formation of the reverse transcriptase 
complex and the reverse transcription process. Recent studies have indicated that 
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cellular factors may be important for efficient reverse transcription (170, 171). 
Importantly, cellular factors can modulate reverse transcription in a way that 
inhibits viral replication. In 2002, Sheehy et al. (172) identified a novel 
mechanism by which a member of the apolipoprotein B mRNA-editing enzyme 
catalytic polypeptide-like (APOBEC) protein family of cellular cytidine 
deaminases, APOBEC3G, interferes with HIV-1 reverse transcription, hence 
restricting viral replication. APOBEC3G restricts retroviral replication by 
deaminating cytosine residues in the first retroviral DNA strand that is 
synthesised during reverse transcription. Deamination of cytosine leads to the 
formation of uracil, resulting in guanine-to-adenine hypermutation of the viral 
DNA and impaired viral replication. APOBEC proteins are present throughout 
the vertebrate lineage, highlighting the conservation of this innate restriction 
mechanism (173). In HIV-1, this restriction mechanism is overcome by the viral 
Vif protein. Vif mediates polyubiquitylation and proteasomal degradation of 
APOBEC3G, thus preventing APOBEC3G incorporation into virions and its 
modulation of the reverse transcription process (174-176). 
 
Once the reverse transcription is complete, the RTCs are gradually transformed 
into integration-competent pre-integration complexes (PICs). The mechanism 
behind this transformation is unknown. As for RTCs, the definite composition of 
PICs remains to be determined, but includes the viral genomic DNA and IN 
(177, 178). PR, RT and Vpr are also thought to be included, whereas the 
presence of CA, MA and NC has been debated (150). 
 
HIV-1 replication requires that the virus enters the nucleus. The viral genome, 
both in the context of the RTC and the PIC, is thought to continuously migrate 
towards the nucleus, utilising the cytoskeleton. Once at the nuclear membrane, 
the integration-competent PIC has to be imported into the nucleus. Most 
retroviruses, such as the gammaretrovirus MLV, rely on cell proliferation for 
their replication, as they are thought to require the partial breakdown of the 
nuclear membrane that occurs during mitosis for their genomes to enter into the 
nucleus (179). Unlike these retroviruses, HIV-1 and other members of the 
Lentivirus genus can infect terminally differentiated, non-dividing cells, such as 
macrophages (180), or cells arrested in the G1 or G2 phase of the cell cycle 
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through treatment with DNA synthesis inhibitors or irradiation (181, 182), 
indicating that their genomes are actively imported into the nucleus. The precise 
mechanism behind this nuclear import is unknown. It is thought to be mediated 
by engagement of the viral PIC with the cellular nuclear import machinery, 
although the precise cellular and viral elements that participate in this process 
remain to be identified (183). It is, however, thought that viral Vpr enhances 
nuclear import of the PIC (169, 184). Vpr contains nuclear localisation signals 
and has been shown to localise to the nucleus both in infected cells and when 
expressed in cells on its own (185). In addition to Vpr, it has been suggested that 
MA contains nuclear localisation signals, although this notion remains debated 
(183). Viral IN and Rev as well as the central polypurine tract (cPPT) present in 
the pol gene have also been proposed to take part in the nuclear localisation 
process, along with cellular factors such as importins (nuclear import receptors) 
and tRNAs (183, 186). 
 
In addition to promoting nuclear import, Vpr has been shown to cause G2 cell 
cycle arrest in infected cells (169). The relevance of this function is not known, 
but it is thought that the HIV-1 LTRs are more active in the G2 phase. This arrest 
does not require de novo synthesis of Vpr but only Vpr from the infecting virus 
particles, suggesting that the arrest occurs prior to integration. 
 
Once the pre-integration complex has been imported into the nucleus, the viral 
DNA is integrated into the cellular genomic DNA and resides as a provirus in the 
host genome (187). Integration is mediated by the viral IN, which has three 
distinct enzymatic functions (188). In the initial phase of the integration process, 
an exonuclease activity of IN hydrolyses a dinucleotide from the 3´-end of both 
strands of the viral DNA (189). This reaction is known as 3´-end processing and 
takes place in the cytoplasm. Following the 3´-end processing and nuclear import 
of the PIC, a double-stranded endonuclease activity of IN cuts the cellular DNA 
in a staggered fashion and a ligase activity connects the generated 5´-overhangs 
to the recessed 3´-ends of the viral DNA in a reaction known as strand transfer 
(190). Cellular repair enzymes then fill in any gaps between viral and cellular 
DNA. 
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HIV-1 has been shown to specifically integrate into transcriptionally active 
regions of the host genome (191). Recent three-dimensional confocal microscopy 
studies has shown that HIV-1 PICs preferentially target regions of lightly packed 
euchromatin in the nuclear periphery as opposed to the dense heterochromatin 
(192). Even though the integration process has been extensively studied in vitro 
using recombinant IN, the in vivo process, including PIC and IN targeting to 
chromatin, is not fully understood, nor is the extent to which cellular components 
and viral factors other than IN play a role. In addition to viral IN, Gag proteins 
have been shown to play a role in the selection of target sites (193). 
 
Cherepanov et al. (194) have shown that IN isolated from the nucleus of IN-
expressing 293T cells exists as homotetramers associated with the cellular lens 
epithelium-derived growth factor (LEDGF/p75), a transcriptional co-activator 
and a ubiquitous nuclear protein that is tightly associated with chromatin 
throughout the cell-cycle. In the same study, the catalytic activity of IN was 
shown to be enhanced by LEDGF/p75. Subsequent studies have found 
LEDGF/p75 to be important for the targeting of IN to chromatin and for 
directing viral integration into transcription units, suggesting that chromatin-
associated LEDGF/p75 may function as a receptor for HIV-1 PICs (195-198). 
However, while LEDGF/p75 is required for efficient viral integration and 
replication, it is not essential, as some level of integration takes place in cells 
where LEDGF/p75 expression has been knocked out or silenced (199, 200). The 
frequency and distribution of integration was, however, significantly altered 
(201). 
 
Once integrated into the host genome, the provirus can stay latent or be 
transcribed by the cellular machinery. The HIV-1 promoter is located in the 
5´LTR and contains a number of regulatory elements essential for transcription 
(202). Proviral transcription is initiated from the U3/R junction and mediated by 
the cellular RNA polymerase II. Upstream of the transcription start site is a 
TATA box to which the cellular transcription factor IID binds. In addition to the 
TATA box, the U3 region also contains three binding sites for transcription 
factor Sp1 and two binding sites for transcription factor nuclear factor κB 
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(NFκB). Upstream of these sites are binding sites for additional cellular 
transcription factors (202). 
 
Initially, the early viral transcripts, encoding for Tat, Rev and Nef, are produced. 
Prior to the production of the viral transactivator Tat, the LTR is activated by 
cellular transcription factors alone, resulting in low transcriptional levels and 
short transcripts. Once Tat is present, it strongly enhances transcriptional 
activation and elongation in a positive feedback loop (203). Tat binds to an RNA 
stem-loop structure in the nascent viral RNA, the transactivation response region, 
TAR (133, 134). This interaction leads to the subsequent recruitment of the 
cellular co-factor positive transcription elongation factor b (P-TEFb) complex to 
the HIV-1 promoter. The P-TEFb complex phosphorylates the carboxy (C)-
terminal domain of RNA polymerase II, leading to increased polymerase 
processivity and enhanced elongation. Tat recruits the P-TEFb complex to the 
viral promoter by interacting with the cellular protein cyclin T1, which forms a 
heterodimer with the cyclin-dependent kinase CDK9 and makes up part of the P-
TEFb complex (204). 
 
In addition to TAR-dependent transcriptional activation, Tat has been shown to 
activate transcription in a TAR-independent manner (205). A direct interaction 
between Tat and the NFκB enhancer sequence could explain the TAR-
independent transactivation (206). Tat is also thought to recruit cellular 
acetylating enzymes able to acetylate histones, such as the histone 
acetyltransferase cyclic adenosine monophosphate (cAMP) response element 
binding (CREB)-binding protein p300/CBP, the p300/CBP-associating factor 
P/CAF, and the histone acetyltransferase human general control of amino acid 
synthesis protein 5 (hGCN5), leading to modification of the chromatin structure 
and improved access for polymerases (207-210). Moreover, cycles of acetylation 
and deacetylation of Tat itself by acetylating and deacetylating cellular enzymes, 
like p300/CBP and the class III histone deacetylase SIRT 1 (silent mating type 
information regulation 2 homologue 1), have been shown to regulate the 
disassociation and association of Tat from the TAR element, thus having an 
important role in regulating HIV-1 transcription (211, 212). In addition to 
recruiting acetylating enzymes to modify chromatin structure and improve 
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polymerase access to proviral DNA, a recent report from Vardabasso et al. (213) 
has suggested that Tat interacts with the human nucleosome assembly protein 1 
(hNAP-1), a histone chaperone that promotes chromatin fluidity and thus gene 
transcription. 
 
In addition to regulating transcription, Tat is thought to have additional effects, 
which may influence HIV-1 pathogenesis (214). Extracellular Tat secreted from 
HIV-1-infected cells is believed to affect uninfected bystander cells in various 
ways, such as being able to induce apoptosis or to have immunomodulatory 
abilities, including being able to up- or down-regulate the expression of 
immunoregulatory cytokines and activate uninfected T cells in an antigen-
independent way (214). Because of its immunomodulatory properties, Tat has 
been suggested to contribute to T cell hyperactivation, a mechanism thought to 
be important in HIV-1 pathogenesis. Kwon et al. (215) have proposed a model 
where Tat contributes to T cell hyperactivation by inhibiting the normal function 
of the SIRT1 deacetylase as a negative regulator of T cell activation. On a final 
note regarding Tat, it should be remembered that, as with HIV-1 research in 
general, most Tat-related research is carried out using HIV-1 of subtype B and 
that differences in Tat in vitro properties have been observed between different 
HIV-1 subtypes (216, 217). 
 
After transcription, the viral RNAs are polyadenylated, spliced and exported 
from the nucleus. The primary HIV-1 RNA transcript is 9 kb and contains at 
least four splice donors and eight splice acceptors, enabling alternative splicing 
and generation of more than 40 different viral mRNAs (218-220). The obtained 
transcripts are either unspliced (9 kb), incompletely spliced (around 4 kb), or 
fully spliced RNAs (around 2 kb). Unspliced RNAs are used for expression of 
Gag and Gag-Pol precursors or packaged into virions as genomic RNA. 
Incompletely spliced mRNAs, on the other hand, have had the gag-pol region 
spliced out and can be used for expression of Env, Vif, Vpr and Vpu, whereas 
fully spliced mRNAs have had the gag, pol and most of env removed, contain no 
intron sequences, and are used to express Tat, Rev and Nef (218, 220). 
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Typically, mRNAs containing introns are retained in the nucleus and not 
exported into the cytoplasm for translation, meaning that only the fully spliced 
viral mRNAs encoding for Tat, Rev and Nef can be exported from the nucleus by 
means of the cellular RNA export machinery. These proteins are referred to as 
the early HIV-1 proteins, whereas Gag, Pol, Env, Vif, Vpr and Vpu are referred 
to as the late HIV-1 proteins. To facilitate nuclear export of the intron-containing 
mRNAs encoding the late proteins, HIV-1 produces the Rev protein (221). When 
Rev accumulates in the nucleus, it promotes nuclear export of unspliced and 
incompletely spliced viral RNAs, thus inducing and regulating the transition 
from early to late HIV-1 gene expression in a negative feedback loop (222, 223). 
Rev binds to a cis-acting, highly structured RNA region called the Rev 
responsive element (RRE) (222, 224). The RRE, which is around 250 bp and 
consists of a series of stem-loop structures, is present in the env region in all 
unspliced or incompletely spliced viral RNAs. Rev is a 19-kDa phosphoprotein 
containing at least two functional domains as well as sequences responsible for 
multimerisation. The N-terminal domain is rich in arginine and responsible for 
nuclear localisation and interaction with the RRE (225), while the leucine-rich C-
terminal domain contains a nuclear export signal, thus mediating nuclear export 
(226, 227). Rev has been shown to bind to one of the stem-loops of the RRE and 
to multimerise with other Rev molecules until around eight Rev molecules bind 
to the RRE. Once associated with the RRE, Rev recruits the cellular 
chromosomal region maintenance 1 (CRM1) protein, which is an export receptor 
for leucine-rich nuclear export signals (228-230). Interaction of the Rev-mRNA 
complex with CRM1 leads to nuclear export by means of the cellular nuclear 
export machinery via a pathway that is typically used for small nuclear and 
ribosomal RNAs rather than cellular mRNAs (221). Additional cellular proteins, 
such as the human Rev-interacting protein (hRIP) or Sam68, are important for 
Rev function and viral replication (231, 232). 
 
The Gag (Pr55Gag) and Gag-Pol (Pr160Gag-Pol) polyproteins are synthesised on 
polyribosomes in the cytoplasm. These two polyproteins are produced at an 
estimated 20:1 ratio as a result of a ribosomal frameshift event mediated by a cis-
acting RNA motif (166). The Gag polyprotein contains most of the viral 
determinants required for viral assembly, since the expression of the Gag 
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polyprotein alone leads to the generation and release of virus-like particles (233). 
Still, the precise mechanism behind Gag assembly into virus particles, in 
particular the involvement of cellular factors, is poorly understood. By and large, 
HIV-1 assembly involves the targeting of Gag and Gag-Pol polyproteins to the 
cellular plasma membrane, association of Gag to the membrane, multimerisation 
of Gag, encapsidation of viral genomic RNA and association with viral envelope 
glycoproteins anchored to the plasma membrane (128, 234). Interestingly, the 
function of each of the four main structural domains of the Gag polyprotein (MA, 
CA, NC and p6) in virus assembly, as part of the polyprotein, differs to the roles 
they have as individual proteins after virus maturation. The Gag polyprotein 
contains at least three functional elements shown to be important for assembly 
and budding. The M domain in MA is largely responsible for membrane 
targeting and binding, the I domain in NC mediates Gag-Gag interactions, and L 
domains in p6 are important for particle budding and release (128, 234). 
 
The M domain is localised in the N-terminus of MA, and includes a cluster of 
basic residues and a myristoyl group on the first glycine residue. Mutations and 
deletions within this region abolish membrane binding and virus budding and 
release (235). Myristoylation occurs during translation and is required for virus 
replication (236). The myristoyl group is thought to insert into the lipid bilayer, 
thus anchoring MA to plasma membrane (143). It has been suggested that a 
‘myristoyl switch’ is responsible for targeting of Gag to the membrane, where 
the myristoyl group is thought to be largely concealed in the context of 
monomeric Gag but that multimerisation of Gag leads to exposure of the 
myristoyl, resulting in membrane binding (237, 238). In addition, recent studies 
carried out by Ono et al. (239) have indicated that Gag localisation and assembly 
is regulated by the cellular factor phosphatidylinositol 4,5-bisphosphate, 
PI(4,5)P2, as altering the levels and localisation of PI(4,5)P2 could redirect 
localisation of Gag. Saad et al. (240) subsequently used NMR techniques to 
show that MA interacts directly with PI(4,5)P2 and that this interaction exposes 
the myristoyl group of MA, hence enhancing membrane binding. As PI(4,5)P2 is 
present in lipid raft-like structures in the plasma membrane, interaction of MA 
with PI(4,5)P2 would thereby target Gag to lipid raft-like microdomains. 
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Gag multimerisation is mediated by the I domain, which is localised in the NC. 
Several regions in Gag are, however, important for mediating Gag-Gag 
interactions, including the C-terminal region of CA (241). Cellular proteins such 
the ATP-binding cassette, sub-family E, member 1 (ABCE1 or HP68), have been 
shown to be required for Gag assembly (242), possibly through interacting with 
NC and promoting multimerisation of Gag (243). Some multimerisation is 
thought to take place soon after Gag synthesis, during trafficking of Gag to the 
plasma membrane. At the plasma membrane, high-order multimerisation occurs 
and a layer of Gag-particles associated with the inner layer of the plasma 
membrane will eventually form a spherical immature virus particle (128, 234, 
241). 
 
In addition to mediating Gag-Gag interactions, NC is thought to be responsible 
for encapsidation of viral genomic RNA by interacting with the packaging signal 
in the RNA dimer (128, 234, 241). The HIV-1 genome packaging signal, or the 
Ψ-site, is composed of four stem loop structures (SL1-SL4) present in the 5´-
region of the genome. SL3 seems to be the major signal. 
 
The HIV-1 envelope glycoprotein is synthesised as a precursor polyprotein 
designated gp160, based on its molecular mass (128-131). Unlike the Gag and 
Gag-Pol polyproteins, gp160 is synthesised and post-translationally processed on 
the rough endoplasmatic reticulum (ER) and in the Golgi, following the same 
route as other glycoproteins destined for the plasma membrane and cellular 
proteins directed into the secretory pathway (139, 244, 245). It is initially 
synthesised as a 90-kDa polypeptide that is co-translationally translocated into 
the lumen of the ER where it undergoes glycosylation, folding and 
oligomerisation. The ER is specialised for protein glycosylation and folding, 
containing a range of cellular folding factors such as folding enzymes and 
molecular chaperones, needed to prevent aggregation of newly synthesised 
proteins in the protein-rich milieu of the ER. 
 
Translocation into the ER is initiated when the N-terminal signal peptide of the 
nascent gp160 polypeptide chain, as soon as it emerges from the ribosome, 
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interacts with the signal recognition particle (SRP). The SRP-nascent peptide 
chain-ribosome complex then associates with the SRP receptor, targeting the 
complex to the ER, where the nascent peptide is transferred into the lumen of the 
ER through the Sec61 translocation channel (244). In addition to the Sec61 
complex, a range of cellular factors including the molecular chaperone 78-kDa 
glucose-regulated protein/immunoglobulin binding protein (GRP78/BiP) are 
thought to take part in the translocation process (244). 
 
Once in the lumen of the ER, the gp160 polypeptide is co-translationally 
glycosylated (128). The gp160 contains around 30 potential N-linked 
glycosylation sites (40-43), which are made up of asparagine-X-serine/threonine 
motifs where X is any amino acid except proline. Initially, N-linked glycan 
precursors (glucose3-mannose9-N-acetylglucosamine2) are added to the amide 
groups of the asparagine residue (128). The first two glucoses are then removed 
by ER glucosidases. At this stage, bearing N-linked glycan precursors with only 
one glucose residue, the gp160 precursor is a substrate for the molecular 
chaperones calnexin and calreticulin. These chaperones are found throughout the 
eukaryotic kingdom and bind different but overlapping sets of glycoproteins 
carrying N-linked glycans with only one glucose residue. Newly synthesised 
HIV-1 gp160 has been shown to interact with both calnexin and calreticulin 
(246, 247). Calnexin and calreticulin bind and release glycoproteins in cycles, 
thereby prolonging localisation in the ER and allowing for correct folding (244). 
The final glucose residue of the N-linked glycan precursor is removed by an ER 
glucosidase, releasing the glycoprotein from calnexin/calreticulin and allowing it 
to exit the ER. Glycoproteins, which have had the final glucose removed, are 
checked for correct folding in a process involving an ER glycosyltransferase. If 
the glycoprotein is not correctly folded, the glycosyltransferase adds a new 
glucose to the N-linked glycan precursors of the glycoprotein, again making it a 
substrate for calnexin and calreticulin, thus prolonging ER localisation. 
Glycoproteins which are correctly folded, hence not recognised by the 
glycosyltransferase, are allowed to exit the ER and proceed to the Golgi. Whilst 
bound to calnexin and calreticulin, the gp160 precursor interacts with other ER 
molecular chaperones such as the GRP78/BiP (244, 248). 
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Folding of HIV-1 gp160, and retroviral glycoproteins in general, has been shown 
to be a slow process compared to the folding of many other glycoproteins, and 
depends not only on amino acid sequence and glycosylation but also on the 
formation and isomerisation of disulphide bonds (128, 244, 246, 248-253). 
Disulphide bond formation is catalysed by protein thiol-disulphide 
oxidoreductases, such as ER protein 57 (ERp57) and protein disulphide 
isomerise (PDI), and favoured by the oxidising milieu that the ER constitutes 
(244). For HIV-1 gp160, disulphide bonds start forming during translation but 
undergo extensive isomerisation during the folding process until correct folding 
is obtained. Land et al. (252) have suggested that there is a relationship between 
disulphide bond isomerisation and cleavage of the HIV-1 signal peptide, which 
may be responsible for the slow maturation kinetics of HIV-1 gp160, whilst at 
the same time ensuring a highly productive folding process where little gp160 is 
subject to degradation. Unlike the signal peptides of many other proteins 
produced in the ER, the gp160 signal peptide is not cleaved off until protein 
synthesis has been completed (244, 249, 252, 254). Replacement of the gp160 
signal peptide with other signal peptides has led to increased secretion of gp120, 
indicating that release from ER is linked to the rate of signal peptide removal 
(249). 
 
In addition to being subjected to modifications such as attachment of glycans and 
formation of disulphide bonds, gp160 undergoes oligomerisation in the ER (128, 
255-258). This step is thought to be required for exit from the ER and entry into 
the Golgi. Although dimers and tetramers have been observed, the functional 
spike exists as a trimer (138-140, 259-261). 
 
In the ER, the HIV-1 glycoprotein precursor may interact prematurely with the 
main cellular receptor utilised by HIV-1, CD4 (128). This premature interaction 
may inhibit transport of HIV-1 envelope glycoproteins to the cell surface, but is 
prevented by the viral protein Vpu, which has been shown to mediate CD4 
degradation through ubiquitin-mediated proteolysis (262). CD4 cell-surface 
expression is also down-regulated by the viral protein Nef. Nef interacts with the 
CD4 cytoplasmic tail and recruits the clathrin adaptor protein 2 (AP-2) complex, 
which mediates internalisation and eventually degradation of CD4 via clathrin-
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coated pits and lysosomes (263). Nef is also responsible for down-regulating 
cell-surface expression of major histocompatibility complex (MHC) class I 
molecules on infected cells, limiting recognition of infected cells by cytotoxic T 
cells (264). Moreover, the observation that deletions in the nef gene of HIV-1 or 
SIV have an effect on virus replication and viral load in humans and macaques, 
leading to delayed onset of disease and long-term survival (265, 266), has led to 
the conclusion that Nef is important for viral pathogenicity. 
 
After synthesis, folding and glycosylation in the ER, the oligomeric gp160 is 
transferred from the ER to the Golgi, where the newly added N-linked high-
mannose glycans are modified by mannosidase enzymes, initiating the formation 
of complex carbohydrate glycans and eventually leaving only three mannose 
residues (128, 267, 268). This allows for the addition of a variety of different 
monosaccharides including fucose, galactose, sialic acid, N-acetylglucosamine 
and N-acetylgalactosamine, resulting in the formation of complex N-linked 
glycans (128, 267, 268). However, only the high-mannose glycans that are 
accessible to the cellular modification enzymes will be processed in the Golgi. 
For HIV-1 envelope glycoproteins, around half of all the N-linked glycans are 
inaccessible and will remain in the high-mannose form (269, 270). The 
variability in glycosylation and processing of glycans contributes to the 
heterogeneity of the HIV-1 envelope. 
 
In the Golgi, the trimeric gp160 is proteolytically cleaved into the surface 
glycoprotein gp120 and the transmembrane glycoprotein gp41 by cellular 
subtilisin-like serine proteinases also known as protein convertases, like furin or 
other furin-like enzymes (268, 271-273). Cleavage occurs at a highly conserved 
lysine/arginine-X-lysine/arginine-arginine motif (where X is any amino acid) and 
is essential for the fusogenic ability of the viral envelope spike. After cleavage, 
gp120 and gp41 associate non-covalently with each other. 
 
Following modification of glycans and proteolytic cleavage in the Golgi, the 
envelope glycoprotein complex traffics to the plasma membrane (128). This 
process is not fully understood (274). For example, it is not known whether the 
HIV-1 glycoproteins traffic to the cell surface via the constitutive or regulated 
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secretory pathway. While it has been proposed that around 5-15% of envelope 
glycoproteins traffic directly from the Golgi to the plasma membrane (271), 
studies in T cells have suggested that a proportion transit to intracellular granules 
containing the cytotoxic T lymphocyte antigen 4, CTLA-4 (275). CTLA-4 is a T 
cell regulatory protein whose cell surface expression is controlled through the 
regulated secretory pathway. It has been shown to traffic to the cell surface 
where it is rapidly internalised by endocytosis and delivered to intracellular 
regulated secretory granules. The co-localisation of HIV-1 envelope 
glycoproteins with CTLA-4 may indicate that HIV-1 envelope glycoproteins 
traffic to the plasma membrane via the regulated secretory pathway, rather than 
being constitutively delivered to the cell surface. Regulated delivery of envelope 
glycoproteins to the cell surface may offer advantages for the virus, such as 
limited or delayed exposure of envelope spike to the immune system, and has 
implications for the timing and co-ordination of virus assembly (275). 
 
At the plasma membrane, viral envelope spikes are incorporated into virions. 
Again, the molecular mechanism behind this process remains largely unknown 
(274). The envelope spikes are anchored to the plasma membrane by gp41. 
Several studies have indicated that an interaction between the cytoplasmic tail of 
gp41 and the MA domain of Gag is responsible for the recruitment of envelope 
glycoproteins to Gag (235, 274, 276-282). For example, mutations in either MA 
and the cytoplasmic tail of gp41 have been shown to abolish incorporation of the 
envelope glycoproteins into virions, without having an effect on virus particle 
release (235, 274, 276-282). In addition, gp41 and MA have been shown to 
interact in vitro (283). However, envelope spikes lacking the gp41 cytoplasmic 
tail can still be incorporated into virions (276-278) and it is widely known that 
HIV-1 can be pseudotyped with heterologous envelope proteins (284), as used 
for lentiviral vectors (285, 286). Incorporation of envelope spikes containing full-
length gp41 has also been shown to be cell-type dependent, indicating that 
cellular factors influence this process (287). This notion was verified by the 
identification of the cellular factor TIP47 (tail-interacting protein of 47 kDa) as 
required for HIV-1 envelope glycoprotein incorporation into virions (288, 289). 
TIP47, which has previously been shown to be required for intracellular transport 
of cellular proteins such as the mannose 6-phosphate receptor, was shown to 
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serve as a bridge between MA and the gp41 cytoplasmic tail (289). In addition, it 
was shown to influence trafficking by re-cycling cell surface expressed HIV-1 
envelope glycoproteins to the Golgi network (288). 
 
In addition to TIP47, other cellular factors are thought to affect trafficking of 
HIV-1 glycoproteins. For example, several studies have shown that HIV-1 
envelope spikes undergo clathrin-mediated endocytosis after reaching the cell 
surface (274, 290, 291). So-called endocytosis motifs in the cytoplasmic tail of 
gp41 are believed to initiate endocytosis by interacting with clathrin-associated 
adaptor protein complexes AP-1 or AP-2 as a first step in the formation of 
clathrin-coated vesicles (274, 290, 291). Endocytosis of envelope glycoproteins 
has been suggested to be important for immune evasion. Indeed, immunisation of 
mice with a DNA vaccine encoding an HIV-1 envelope glycoprotein with 
mutations in a highly-conserved tyrosine-based gp41 endocytosis motif resulted 
in enhanced antibody responses (292). The same tyrosine-based endocytosis 
motif has also been shown to be important for basolateral targeting of virions 
during budding from polarised cells (293). Furthermore, SIVmac239 carrying 
mutations in the same motif displayed reduced in vivo pathogenicity in macaques 
despite ongoing viral replication, suggesting that this motif is important not only 
for endocytosis of envelope glycoproteins but also for viral pathogenesis (294). 
 
Additional understanding of the mechanism behind envelope glycoprotein 
incorporation into virions was obtained in a recent study by Leung et al. (295), 
who showed that co-expression of the HIV-1 and Ebola envelope glycoproteins 
with HIV-1 Gag in cells gave rise to two distinct populations of pseudotyped 
viruses, bearing one, but not both, of the two glycoproteins. In addition, confocal 
microscopy experiments showed that the HIV-1 and Ebola glycoproteins 
segregated to separate lipid raft-like microdomains in the plasma membrane, 
despite being expressed from the same vector, indicating that each virus particle 
is formed from a single lipid raft domain. 
 
It has been generally believed that HIV-1, like all lentiviruses, assembles at and 
buds from the plasma membrane of infected cells (128, 234). Since the discovery 
of HIV-1, this notion has been supported by a vast number of studies (128, 234). 
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However, in the last decade the location of HIV-1 assembly and budding has 
been subject to debate and suggested to be cell-type dependent (296-310). In T 
cells, it has been largely established that HIV-1 assembles at the plasma 
membrane. This assembly has been suggested to take place at glycolipid-
enriched membrane domains or lipid rafts (306, 311, 312). In contrast, several 
studies have shown that in macrophages, HIV-1 assembly and budding take place 
in intracellular compartments thought to be late endosomes or intracellular 
multivesicular bodies because of the presence of the tetraspanin and late 
endosomal marker CD63 (296-298, 313, 314). In fact, cytoplasmic assembly of 
HIV-1 in monocytes and macrophages was reported already in the late 1980s 
(313, 314). In addition to intracellular assembly in macrophages, several studies 
have reported HIV-1 virions and Gag in intracellular compartments in epithelial-
derived cell lines and, controversial to what has been observed in previous 
studies, in T cells, suggesting HIV-1 assembly and budding on endosomal 
membranes also in these cell types (299-302). The observation that MA interacts 
with AP-3, an adaptor protein that normally functions in the sorting of proteins to 
late endosomes, was suggested to support the notion that trafficking of Gag to the 
late endosome is part of a productive virus pathway (315). 
 
These studies, along with the studies on HIV-1 assembly into late endosomes in 
macrophages, gave rise to the suggestion that, in most cells, Gag is initially 
targeted to late endosomal membranes, where it can either assemble and bud or 
assemble and traffic to the plasma membrane via vesicles. Alternatively, the Gag 
polyprotein could be targeted to late endosomal membranes and then traffic 
unassembled to the plasma membrane via vesicles. In addition to being 
controversial to early studies of HIV-1 assembly and budding, these suggestions 
have also been contradicted by several recent reports. For example, a study 
carried out by Deneka et al. (316) has shown that, in macrophages, HIV-1 
assembles and buds into intracellular compartments that are in fact not late 
endosomes but surface-connected, internally sequestered extensions of the 
plasma membrane. These compartments were found to contain markers not 
present in late endosomes, and to lack the late endosome marker CD63. CD63 
was, however, recruited to the compartment in HIV-1-infected cells post-
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infection, explaining previous reports and assumptions of HIV-1 assembly into 
endosomes. 
 
A study by Welsch et al. (305) has supported these findings, detecting HIV-1 
assembly at seemingly intracellular plasma membrane structures in macrophages 
but not at endosomal membranes. In addition, Jouvenet et al. (303) have shown 
that in macrophages and in a cell line of epithelial origin, HIV-1 does not 
assemble on endosomes. Instead, Gag is directly targeted to the plasma 
membrane. Moreover, a small proportion of Gag was internalised as a result of 
endocytosis or phagocytosis, suggesting that virus particles only reaches 
endosomes after endocytosis of virions formed at the plasma membrane. This 
notion has been supported by the observation that release of already assembled 
virions at the plasma membrane is inhibited by endocytosis in certain cells (304, 
308). 
 
In addition to the above models, some reports have indicated that the plasma 
membrane contains microdomains derived from late endosomes as a result of 
fusion of plasma and endosome membranes (307, 310). Furthermore, it has been 
shown that Gag co-localises with tetraspanins such as CD63 and CD81, both 
intracellularly and at the membrane of T cells, with the majority of viral proteins 
present on the plasma membrane, indicating that HIV-1 assembly and budding 
takes place in tetraspanin-enriched plasma membrane domains (317). The 
cytoskeleton has also been proposed to have a role in HIV-1 assembly and 
budding (318). Real-time imaging of Gag assembly has further supported the 
notion that HIV-1 assembles at the plasma membrane (319). 
 
After virus assembly, a series of partially unknown mechanisms leads to virus 
budding and release of immature virus particles. Since the beginning of the 
1990s, it has been clear that the viral protein p6 is crucial for the release of virus 
particles, as the deletion of p6 has been shown to cause accumulation of 
assembled virus particles tethered to the plasma membrane (320). The domains 
in p6 responsible for this function are referred to as the late (L) domains. There is 
now a growing body of evidence indicating that HIV-1 employs the cellular 
endosomal budding machinery, in particular the endosomal sorting complexes 
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required for transport (ESCRT) machinery, for virus release and budding, as the 
late domains of p6 have been shown to interact with the ESCRT factors Tsg101 
(tumour susceptibility gene 101) and Alix (apoptosis-linked gene 2 interacting 
protein X), interactions shown to be essential for virus release (321-324). In 
addition to the p6 protein, the Vpu protein is also important for virus release. It 
has long been known that Vpu enhances virus release and that budding from 
certain cell types requires Vpu (325). Early in 2008, it was reported that a human 
membrane protein with previously unknown function called CD317, and 
renamed tetherin, was responsible for tethering virus particles to the cell surface 
prior to endocytosis into tetherin-containing compartments (326). Tetherin was 
present only in cells requiring Vpu for virus release and depletion of tetherin 
abolished the need for Vpu, indicating that Vpu somehow inhibits tetherin-
mediated retention of virus on the cell surface. 
 
HIV-1 buds from the membrane of infected cells in an immature, non-infectious 
form (128). In an immature virus particle, the Gag precursor polyprotein Pr55Gag 
(MA-CA-SP1-NC-SP2-p6) is arranged radially, with the MA anchored to the 
lipid bilayer, and p6 in the centre. Vpr is incorporated into the virus particle via 
its association with p6 (327). Upon budding, the viral PR is activated and cleaves 
the Gag precursor Pr55Gag in a stepwise fashion into the MA, CA, NC and p6 
proteins. PR also cleaves the Gag-Pol polyprotein Pr160Gag-Pol, generating PR, 
RT and IN from the Pol part. The viral PR is an aspartyl protease that functions 
as a homodimer with the active site located in a cleft formed in between the two 
monomers (328). 
 
Cleavage of the Gag and Gag-Pol polyproteins leads to structural rearrangement 
of the individual Gag proteins and the formation of a mature, infectious HIV-1 
virion containing the characteristic conical core. The spacer peptide SP1 has been 
suggested to have a role in the maturation process, as Gag constructs have been 
shown to assemble into immature cores if SP1 is present and mature cores if SP1 
is absent (329, 330). In addition, recent electron cryotomography studies of 
immature virions have indicated that the spacer peptide SP1 stabilises the CA 
hexamers in an immature lattice formation, whereas cleavage and separation of 
the CA and SP1 units destabilises the CA hexamers and allow them to rearrange 
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and form the mature hexagonal lattice (331). One mature core has been estimated 
to be made up by 1000-1500 CA molecules (137, 145). In contrast, an immature 
virus particle has been estimated to contain around 5000 copies of Gag, meaning 
that less than half of the CA proteins present in the immature virion forms the 
mature core (332). Furthermore, a third of viral particles produced in vitro by T 
cells have been observed to contain two cores (137). 
 
Overall, despite encoding for only 15 proteins, the HIV-1 replication cycle is 
extraordinary complex. Several aspects of the HIV-1 life-cycle remain poorly 
understood, especially the way the virus exploits cellular processes (333). A 
recent study (334) has shed further light on this matter. Brass et al. (334) used a 
genome-wide siRNA screening experiment, targeting over 21000 genes, to 
identify more than 250 host factors required for HIV-1 replication, the majority 
of which had not previously been associated with HIV-1. These findings are 
likely to be important for furthering the understanding of the HIV-1 life-cycle. 
 
1.1.4 Immunopathology of HIV-1 
HIV-1 infection is characterised by a progressive loss of CD4+ T cells. Host 
immune responses generally fail to control infection, and the decline in 
circulating CD4+ T cells eventually culminates in the development of AIDS. 
However, the reason why HIV-1 infection is pathogenic remains unclear. In this 
section, a brief overview of the cellular tropism, pathogenesis and natural course 
of HIV-1 infection will be given, as well as an introduction to the host immune 
responses. 
 
1.1.4.1 HIV-1 cellular receptors and tropism 
In 1984, HIV-1 was shown to have a selective tropism for CD4+ T cells (30). 
This finding was soon followed by the identification of CD4 as a cellular 
receptor for HIV-1 by Klatzmann et al. (52) and Dalgleish et al. (53), making 
CD4 the first receptor to be discovered for any human or animal retrovirus. 
Klatzmann et al. (52) reported of the inhibition of HIV-1 infection by three 
mAbs to CD4, but not by antibodies to four other lymphocyte markers. Dalgleish 
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et al. (53) showed that only cells expressing CD4 were sensitive to syncytium-
induction when mixed with an HIV-1-producing T cell line. In addition, only 
CD4+ cells were susceptible to infection by vesicular stomatitis virus (VSV) 
particles pseudotyped with the HIV-1 envelope (53). Dalgleish and colleagues 
furthermore showed that this syncytium-induction and pseudotype infection was 
blocked by antibodies to CD4. To come to this conclusion, they screened 155 
different monoclonal antibodies (mAbs) to T cell surface antigens, showing that 
14 out of 14 antibodies to CD4 could inhibit infection, whereas the majority of 
the remaining 141 antibodies could not (53). Two years later, Maddon et al. 
(335) further confirmed the role of CD4 as a receptor for HIV-1 by showing that 
engineering human cell lines to express CD4 rendered them susceptible to HIV-1 
infection. In conclusion, the reports by Klatzmann et al. (30, 52), Dalgleish et al. 
(53) and Maddon et al. (335), together with the early recognition of the 
association of AIDS with a selective depletion of CD4+ T cells (2, 3, 6), 
suggested CD4 to be an essential part of the HIV-1 receptor and the CD4+ subset 
of T cells to be a major target for HIV-1 infection.  
 
The CD4+ T helper cell and CD8+ cytotoxic T cell subsets were first 
discriminated in 1979 by Reinherz et al. (336), using mAbs to what would later 
be known as the CD4 and CD8 antigens. Biochemical analysis of the CD4 
protein (337) and the subsequent cloning and sequencing of a CD4-encoding 
cDNA (338) later revealed that CD4 is a transmembrane glycoprotein belonging 
to the immunoglobulin superfamily of receptors. It is expressed predominantly 
on T helper cells as well as on most thymocytes but also, to lower levels, on 
several other cell types including monocytes, macrophages, dendritic cells, 
eosinophils and mast cells (339-344). CD4 on T helper cells binds to MHC class 
II molecules on antigen-presenting cells. While the T cell antigen receptor binds 
to the polymorphic region of the MHC class II, CD4 acts as a co-receptor, 
binding to the non-polymorphic regions (345). Its binding restricts the T helper 
cell to recognising peptides presented on MHC class II only and enhances the 
interaction between the T helper cell and the antigen-presenting cell. In addition, 
the CD4-MHC class II interaction mediates intracellular T helper cell signalling 
through the tyrosine protein kinase p56LCK, which is associated with the CD4 
cytoplasmic domain, leading to activation of the T helper cell and enhancement 
 58
of antigen-driven T cell responses (339, 343). CD4 is also thought to play a role 
in T cell maturation (346). It has a molecular mass of 55 kDa and consists of an 
extracellular part, a transmembrane domain and an intracellular domain. The 
extracellular portion consists of four immunoglobulin-like domains, D1-D4. 
Domains D1 and D3 are antibody variable domain-like, whereas D2 and D4 are 
antibody constant domain-like (338, 347). Binding to the MHC class II molecule 
extends over the D1 and D2 domains (345). HIV-1 gp120, however, binds to the 
D1 domain only, in its initiation of the HIV-1 entry process (348). HIV-1 entry 
into cells will be further discussed in section 1.1.6. 
 
Soon after the identification of CD4 as a receptor for HIV-1, it became apparent 
that CD4 alone was not sufficient for virus entry into cells. While Maddon et al. 
(335) had showed that human cell lines engineered to express CD4 were 
susceptible to HIV-1 infection, a range of mouse cell lines made to express CD4 
were not. Efficient binding of HIV-1 to the CD4+ mouse cells was, however, 
demonstrated, as was production of infectious virus following transfection of the 
cells with HIV-1 DNA, indicating that the block to infection resided in the viral 
entry step but after the initial binding event. Susceptibility of human cell lines 
engineered to express CD4, but not of a range of non-human cell lines, was later 
also reported in other studies (349-351). Cell hybrid experiments subsequently 
revealed that the absence of a human factor in the non-human cell lines, rather 
than the presence of an inhibitory factor, was responsible for the block to 
infection (352-354). 
 
Around the same time, it became evident that two distinct HIV-1 phenotypes 
could be recognised, with different tropism for CD4+ cells. Åsjö et al. (355) 
propagated viruses from 31 HIV-1 seropositive individuals in peripheral blood 
mononuclear cells (PBMC) from healthy donors whilst assaying RT activity, 
observing two patterns of virus production, rapid/high or slow/low. They further 
found that viruses with the rapid/high phenotype in PBMC could replicate 
continuously and induce syncytia in immortalised CD4+ T cell lines, whereas 
isolates with the slow/low phenotype were less likely to. In addition, they 
observed that the viruses with the rapid/high phenotype were all isolated from 
individuals with low CD4+ cell counts and AIDS symptoms. In contrast, the 
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majority of individuals with no or mild symptoms and normal CD4+ cell counts 
had viruses with the slow/low phenotype, indicating a relation between the 
clinical severity of HIV-1 infection and the in vitro replication properties of the 
virus. Similar findings were made by other groups (356-358). Viruses with the 
rapid/high phenotype were later referred to as syncytium-inducing (SI), whereas 
viruses with the slow/low phenotype were referred to as non-syncytium-inducing 
(NSI), based on their ability to induce syncytia in immortalised T cell lines (357, 
359, 360). The SI isolates were also referred to as T cell line-tropic. The NSI 
isolates, on the other hand, whilst being able to replicate in CD4+ PBMC, were 
unable to replicate in T cell lines. Instead, their tropism extended to 
macrophages; hence they were referred to as macrophage-tropic (180, 361). 
Macrophage-tropic viruses could, however, be adapted to growth in immortalised 
T cell lines through extensive passaging (362). Cell hybrid experiments 
subsequently indicated this selective cellular tropism was due to the existence of 
cell type-specific fusion co-factors, rather than the presence of inhibitory factors 
(363). 
 
In 1996, ten years after it first became evident that presence of CD4 alone was 
not enough to support HIV-1 entry into cells, light was finally shed on the 
missing fusion co-factor, when Feng et al. (364) used a cDNA library approach 
to identify a member of the superfamily of seven-transmembrane chemokine 
receptors as a co-receptor for HIV-1. This receptor was named fusin or LESTR, 
but would later be called CXCR4 according to an agreed chemokine receptor 
classification. Feng et al. showed that co-expression of CD4 and CXCR4, but not 
CD4 alone, rendered previously non-permissive cells susceptible to infection. 
Co-expression of CXCR4 did, however, only support infection with so-called T 
cell line-tropic isolates and not with macrophage-tropic strains, indicating that 
yet another co-factor was responsible for mediating entry of the macrophage-
tropic isolates, offering an explanation into the different tropisms. Shortly after 
the identification of CXCR4 as a co-receptor for HIV-1, Bleul et al. (365) and 
Oberlin et al. (366) identified the stromal cell-derived factor 1 (SDF-1) as the 
natural ligand for CXCR4. In the same studies, SDF-1 was also shown to inhibit 
infection by T cell line-tropic but not macrophage-tropic HIV-1 isolates, further 
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confirming the role of CXCR4 as an essential co-receptor for the so-called T cell 
line-tropic viruses. 
 
Meanwhile, a report from Cocchi et al. (367) had shown that the chemokines 
RANTES (regulated upon activation, normal T cell expressed and secreted), 
MIP-1α and MIP-1β (macrophage inflammatory proteins) displayed HIV-
inhibitory properties. It was already known that CD8+ T cells secreted HIV-
suppressive factors. Cocchi et al. used fractionation and chromatography 
techniques to identify RANTES, MIP-1α and MIP-1β as the proteins responsible 
for the inhibition. The chemokines were able to inhibit infection by HIV-1 
macrophage-tropic isolates but not infection by T cell line-tropic HIV-1 isolates. 
 
Shortly after the identification of CXCR4 as an essential co-receptor for the so-
called T cell line-tropic isolates and the observation that RANTES, MIP-1α and 
MIP-1β could inhibit infection by macrophage-tropic viruses, several groups 
simultaneously identified CCR5, the receptor for RANTES, MIP-1α and MIP-
1β, as a co-receptor for macrophage-tropic HIV-1 (368-372). The reports from 
these groups showed that expression of CCR5 in previously non-permissive 
CD4+ cells rendered them selectively susceptible to infection by macrophage-
tropic viruses. 
 
CXCR4 and CCR5 are chemokine receptors. Chemokines are small cytokines 
primarily involved in the chemoattraction of lymphocytes, monocytes and 
neutrophils. They are secreted by a variety of cell types, including activated 
lymphocytes and monocytes/macrophages as well as endothelial cells, platelets, 
neutrophils and fibroblasts. Chemokines are grouped into four different classes, 
the CC, CXC, C and CX3C chemokines, based on the number and spacing of 
conserved cysteine residues in their amino acid sequence. Chemokine receptors, 
in turn, are classified according to the group of chemokines that they bind. 
Chemokine receptors belong to the superfamily of seven-transmembrane G-
protein-coupled receptors (GPCRs). They are integral membrane proteins that 
consist of an extracellular N-terminal domain followed by seven helical 
membrane-spanning regions connected by three intracellular and three 
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extracellular loops and a cytoplasmic tail. They are coupled to heterotrimeric G 
(guanine nucleotide-binding) proteins, which act as the signal moiety of the 
receptor, and are thought to form a rod spanning the membrane, with a central 
hole surrounded by the seven transmembrane domains. There is, however, little 
structural information available for chemokine receptors, as no structure has been 
resolved to date (373). Instead, structural models of CCR5 and CXCR4 have 
been based on the crystal structure of bovine rhodopsin. Rhodopsin, a seven-
transmembrane GPCR present in the retina, was until recently the only GPCR for 
which a high-resolution structure was available (374). However, the first 
structure of a human GPCR, the adrenergic receptor β2AR, which was solved at 
the end of 2007, might give further insight into the structures of CCR5 and 
CXCR4 (375). In the absence of three-dimensional structural data, the binding 
site for gp120 has been mapped to the N-terminus and the second extracellular 
loop of CCR5 or CXCR4 (376-378). This notion have been supported by recent 
nuclear magnetic resonance (NMR) data (379). 
 
The identification of CXCR4 and CCR5 as co-receptors for HIV-1 provided an 
explanation for the two distinct HIV-1 phenotypes that had been observed. In 
addition, it became clear that the old classification system and the assumed 
relationship between replication kinetics (rapid/high or slow/low), ability to 
induce syncytia (SI or NSI) and tropism (T cell line- or macrophage-tropic) was 
not completely clear-cut (380). The terms SI/NSI and T cell line-/macrophage-
tropic had been used interchangeably, despite not being synonymous (381). It is 
now recognised that while only the SI or T cell line-tropic viruses can replicate 
and induce syncytia in immortalised CD4+ T cell lines (which usually express 
CXCR4 but not CCR5), all primary viruses can replicate in primary CD4+ T 
cells and induce syncytia in cells expressing the right co-receptor. In addition, 
some CXCR4-using isolates have been found to infect macrophages (382-384). 
A new classification system based on co-receptor usage was therefore suggested 
to replace the old nomenclature (381). Virus isolates selectively able to use 
CCR5 or CXCR4 are now referred to as CCR5- or CXCR4-using, or R5 or X4 
viruses, respectively, whereas virus isolates able to use both receptors are 
referred to as R5X4- or dual-tropic. In addition to the nomenclature based on co-
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receptor usage, virus isolates are distinguished on the basis of how they have 
been propagated. Isolates that have been adapted for growth in T cell lines are 
referred to as T cell line-adapted (TCLA), whereas viruses only cultured in 
primary PBMC or macrophages are referred to as primary. 
 
All primary HIV-1 isolates use one or both of CCR5 and CXCR4 as co-receptor 
(385). In addition, some virus isolates have been shown to use alternative 
chemokine receptors in vitro. At least a dozen other seven-transmembrane 
GPCRs, such as CCR3, CCR2b, CCR8, Strl33 and D6, have been reported to 
function as co-receptors in vitro (386, 387). However, the in vivo relevance of 
these alternative receptors remains to be determined. The frequency by which 
viruses use receptors other than CXCR4 and CCR5 on primary target cells has 
been questioned, as infection is usually blocked by inhibitors to CXCR4 or 
CCR5 (388). 
 
While most HIV-1 strains depend on CD4 for initial attachment and entry into 
cells, some reports have shown that certain HIV-1 isolates can infect cells 
lacking CD4 in vitro (386). These strains are able to infect cells through direct 
contact with the co-receptor. However, it remains uncertain whether such CD4-
independent infection is of any relevance in vivo. 
 
In spite of the relative promiscuity of some HIV-1 isolates in vitro, 
epidemiological studies indicate that the number of co-receptors used in vivo is 
rather limited. The first evidence for the importance of CCR5 as a co-receptor in 
vivo came from genetic studies of HIV-1-exposed uninfected individuals. It was 
found that individuals homozygous for a defective CCR5 allele (CCR5-∆32) 
were strongly protected from HIV-1 infection (389-392). The CCR5-∆32 allele 
contains a 32-bp deletion in the CCR5 gene, which results in a truncated receptor 
that is retained and degraded in the endoplasmatic reticulum. While 
homozygousity for the CCR5-∆32 allele confers strong protection, 
heterozygousity is associated with a slower progression to AIDS (389, 390). The 
distribution of the CCR5-∆32 polymorphism is largely restricted to Northern 
Europe and populations of Northern European descent (393). Its prevalence 
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decreases in the southern and Mediterranean regions of Europe and almost 
disappears in Asia and Africa. It is estimated that around 1% and 20% of 
Caucasians are homozygous and heterozygous for the allele, respectively. 
 
In addition to the CCR5-∆32 allele, several other polymorphisms in the CCR5 
gene, or in the genes encoding its ligands, have been associated with 
susceptibility to HIV-1 infection or disease progression, further highlighting the 
importance of CCR5 as a co-receptor in vivo (394). For example, plasma levels 
of the CCR5 ligands MIP-1α, MIP-1β and RANTES have been shown to 
influence disease progression (395, 396). Moreover, a low copy number of the 
gene encoding MIP-1α has been associated with an increased susceptibility to 
HIV-1 infection and a more rapid progression to AIDS, especially in 
combination with other known disease-accelerating CCR5 genotypes (397). 
Polymorphisms in the gene encoding the CXCR4 ligand SDF-1 have also been 
suggested to influence HIV-1 resistance and disease progression (394). Further 
evidence for the importance CCR5 and CXCR4 as co-receptors in vivo has come 
from the antiviral effects observed in clinical trials of several CCR5-binding 
agents and one CXCR4 antagonist (398). 
 
The protective effects of these CCR5-related polymorphisms, especially the 
CCR5-∆32 allele, suggest a major role for CCR5 in HIV-1 transmission. Indeed, 
CCR5-using viruses have been suggested to be preferentially transmitted over 
CXCR4-using viruses (399). The reason behind the selective transmission is 
unclear, although several mechanisms that restrict transmission of CXCR4-using 
viruses have been suggested (400). In addition to being preferentially 
transmitted, early studies (some of which are mentioned above) have shown that 
CCR5-using viruses predominate during the acute and asymptotic phase of 
natural HIV-1 infection, whereas CXCR4-using viruses emerge at a later stage in 
around 50% of individuals infected with subtype B viruses (355, 401-405). The 
emergence of CXCR4-using viruses have been associated with lower CD4+ T 
cell counts and faster progression to AIDS (355, 401-405), although loss of 
CD4+ T cells and AIDS have also been reported in individuals harbouring 
CCR5-using viruses only (406, 407). 
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Most studies looking at co-receptor usage have, however, been carried out in 
relatively small cohorts, as methods for determining HIV-1 co-receptor use have 
typically been relatively low-throughput and cost-intensive. Recent technological 
advances have allowed for large-scale studies of the prevalence of co-receptor 
usage. These studies have confirmed the association of lower CD4+ T cell count 
with the appearance of CXCR4-using viruses but have detected CXCR4 usage in 
a lower percentage of individuals (408-412). For example, Moyle et al. (412) 
assessed co-receptor use in 563 treatment-naïve and treatment-experienced HIV-
1-infected individuals, with known viral load and CD4+ T cell counts, and found 
that approximately 80% of the individuals had viruses exclusively using CCR5. 
The remaining 20% had CXCR4-using, dual-tropic or mixed virus populations. 
However, only 0.7% of the samples showed exclusive CXCR4-usage. CCR5-
usage was significantly associated with a lower viral load and higher CD4+ T 
cell count and the presence of CXCR4-using, dual-tropic or mixed populations 
were more common at higher viral load and lower CD4+ cell count. No 
significant association was found between co-receptor use and exposure to 
antiretroviral therapy. Similarly, Brumme et al. (411) found CXCR4-using, dual-
tropic or mixed virus populations viruses in 18% of almost a thousand treatment-
naïve HIV-1-infected individuals. Viruses that exclusively used CXCR4 were, 
however, only detected in less than 1% of the individuals. Presence of CXCR4-
using virus was again associated with lower CD4+ T cell levels. Whether the 
appearance of CXCR4-using viruses is a cause or a consequence of disease 
progression remains to be determined. 
 
The viral determinants for co-receptor usage have, unsurprisingly, been mapped 
to the viral envelope proteins. HIV-1 cellular tropism and co-receptor usage was 
first shown to be determined by the envelope protein (413-416) and in particular 
by the V3 region of gp120 (417) in the early 1990s. Several studies have since 
shown that the V3 region is a major determinant of co-receptor tropism, but 
sequence changes in the V1, V2, C3 and C4 regions of gp120 and in gp41 have 
also been shown to modulate co-receptor use (418-422). 
 
As for most HIV-1 research, the majority of studies on HIV-1 co-receptor usage 
and tropism have been carried out using HIV-1 of subtype B. As subtype B 
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infections only account for around a tenth of infection worldwide (124), co-
receptor usage among non-subtype B viruses is of interest and has been 
addressed by some studies. Although some studies have found no significant 
difference in phenotype among different genetic subtypes (412, 423, 424), others 
have reported of subtype-specific differences. For example, CXCR4 usage has 
been less frequently observed among subtype C isolates, compared to among 
HIV-1 of subtype B, even in isolates from individuals with AIDS (407, 425-430). 
In addition, CXCR4 usage has been reported to be more prevalent among 
subtype D viruses compared to among subtype A viruses (431), which is 
consistent with other reports observing a more rapid progression to AIDS among 
individuals infected with subtype D isolates compared to individuals infected 
with subtype A isolates (432-434). Further large-scale studies are needed to 
assess co-receptor use in non-subtype B isolates, especially in light of the recent 
developments of CCR5 antagonists as antiretroviral drugs. 
 
So which cells are infected by HIV-1 in vivo? As HIV-1 tropism is largely 
determined by the distribution of the cellular receptors, HIV-1 should be able to 
infect all cells expressing CD4 and either of the identified co-receptors. CCR5 is 
expressed to high levels on activated memory CD4+ T cells (435, 436). These 
cells are the main target cells of HIV-1 infection in vivo  (437). Activated 
memory CD4+ T cells are especially abundant in the gut-associated lymphoid 
tissue (GALT), which has been shown to be a major site of HIV and SIV 
replication (438, 439). Compared to CCR5, CXCR4 is expressed on a wider 
range of CD4+ T cells, including antigen naïve T cells, providing CXCR4-using 
viruses with a wider tropism (435, 436). Consistent with this notion, an increased 
proportion of the viral load has been found in antigen naïve CD4+ T cells in 
individuals harbouring CXCR4-using viruses (440). 
 
However, CD4+ T cells are not the only target cells for HIV-1 in vivo. Like other 
members of the Lentivirus genus, HIV-1 is able to infect cells of the 
mononuclear phagocyte lineage. Macrophages express CD4, CCR5 and CXCR4 
and were first shown to be infected with HIV-1 in 1986 (180). Latent as well as 
productive infection of tissue macrophages, such as brain macrophages or 
microglia, has since been frequently observed in vivo. The viral dynamics of 
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HIV-1 infection of macrophages has been found to be different to that in CD4+ T 
cells. Compared to HIV-1-infected CD4+ T cells, the turnover of infected 
macrophages is rather slow (441). Instead, there seem to be an absence of 
cytopathic effects and production of virus over a prolonged period of time, for up 
to 60 days after infection in vitro (442). These notions, along with the tendency 
of viruses to accumulate in what was initially thought to be intracellular 
multivesicular bodies or late endosomes (297, 298) but subsequently shown to be 
internally sequestered, surface-connected extensions of the plasma membrane 
(305, 316), has led to the suggestion that cells of the mononuclear phagocyte 
lineage serve as reservoirs for HIV-1 (443). Importantly, perivascular 
macrophages are also the main target for HIV-1 infection in the central nervous 
system (CNS) and may have a role in the progressive encephalopathy often seen 
in AIDS patients (444, 445). 
 
In addition of CD4+ T cells and macrophages, the distribution of the HIV-1 
cellular receptors also allows for infection of dendritic cells (DCs). DCs are 
antigen-presenting cells of haematopoietic origin crucial to the activation of T 
cells and the initiation of primary immune responses (446). The DC population is 
highly heterogeneous and several DC subsets have been described, based on their 
lineage, anatomical localisation and cell surface expression markers (447). 
Anatomically, DCs can be divided into lymphoid-tissue resident DCs and 
migratory DCs (447, 448). The lymphoid-tissue resident DCs can be further 
divided into the conventional lymphoid-tissue resident DCs and the relatively 
recently described plasmacytoid DCs (447, 448). The conventional lymphoid-
tissue resident DCs have the typical dendritic form and capture and present 
antigens within the lymphoid organs, whereas the plasmacytoid DCs are round, 
non-dendritic and have been shown to produce interferon following viral 
infection (447, 448). The migratory DCs are conventional DCs that reside in an 
immature form in the peripheral tissues, such as the skin and mucosal tissues. 
Immature DCs in the periphery capture and process antigens, develop into 
mature DCs as a result of antigen deposition and inflammation, and migrate to 
lymph nodes where they stimulate T helper cells (446). DCs that reside in tissues 
include the Langerhans cells in the epidermis and mucosal epithelia, and the 
dermal and interstitial DCs in the dermis, submucosal epithelia and rectal 
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epithelia. Langerhans cells, characterised by the surface expression of the C-type 
lectin Langerin and containing the Langerhans cell-specific organelles Birbeck 
granules, were the first DCs to be described, by Langerhans in 1868. The next 
description of DCs did not come until a hundred years later, when Steinman and 
Cohn reported data on a novel cell type with dendritic morphology isolated from 
spleen (449). Initially, conventional DCs were thought to be of myeloid lineage. 
This notion was, however, contradicted by reports showing that fractions of both 
myeloid and lymphoid precursors can give rise to conventional DCs, in vitro and 
in vivo (450, 451). Even though the precise ontogeny and differentiation 
pathways of the various DC subsets remain unclear, two recent reports have 
identified a common progenitor that can give rise to both conventional and 
plasmacytoid DCs (452, 453). Many DC subsets express CD4, CCR5 and 
CXCR4, although the expression levels may differ between subsets and at 
different maturation stages. DC subset not expressing CD4 have also been 
observed (454). 
 
Because of their expression of the HIV-1 cellular receptors, their location in 
mucosal tissues and their antigen-presenting role, DCs have been suggested to be 
the first cells to encounter HIV-1 during mucosal transmission and to mediate 
spread to CD4+ T cells (455). In vitro infection of human peripheral blood 
dendritic cells was first demonstrated in the 1980s (456). Subsequent in vitro 
experiments as well as in vivo studies in SIV and rhesus macaque models have, 
however, shown that the frequency by which DCs are infected is low (457-460). 
One study showed that, on average, only a few percent of DCs isolated from 
healthy donors can be productively infected by HIV-1 (461). In addition, 
infection of DCs has been shown to be less productive than infection of CD4+ T 
cells (462). These notions have, in part, been explained by observations 
indicating that different DC subsets show different susceptibility to productive 
HIV-1 infection (461, 463). This differential susceptibility may be due to 
different expression levels of the HIV-1 cellular receptors but also to intracellular 
restriction factors such as APOBEC3G (464). In addition to depending on 
phenotype, the susceptibility of DCs to HIV-1 infection depends on the 
maturation stage (458, 465). Langerhans cells have been shown to be susceptible 
to productive HIV-1 infection (466, 467). 
 68
In addition to being able to support infection, thus aiding in transmitting 
infection to CD4+ T cells, DCs are thought to mediate HIV-1 infection of CD4+ 
T cells in trans, i.e. without becoming infected themselves. Transfer of HIV-1 
from DCs to CD4+ T cells was first reported in the early 1990s, when infection 
of CD4+ T cells was observed after co-culture with DCs that had been exposed 
to HIV-1 and washed (468, 469). Since then, several studies have shown that 
DCs can capture and keep virus in an infectious state even for several days 
before transfer to CD4+ T cells (462). Several mechanisms underlying this 
transfer have been proposed. DCs possess unique pathways which facilitate 
capture and internalisation of pathogens. In addition to CD4, DCs express other 
receptors that can capture HIV-1. For example, DCs have been shown to capture 
HIV-1 via C-type lectins, a family of cell surface receptors that recognise 
carbohydrate structures. Capture by C-type lectins leads to internalisation of 
HIV-1 into endosomes. Transfer to CD4+ T cells can then occur via an infectious 
synapse formed between DCs and CD4+ T cells (470, 471). In addition, to being 
transferred across an infectious synapse, HIV-1 captured by C-type lectins and 
internalised into endosomes has been shown to be targeted to multivesicular 
bodies and subsequently transferred to CD4+ T cells via exosomes (472). 
Alternatively, upon internalisation, HIV-1 can be targeted to proteasomes or 
lysosomes, leading to degradation and presentation on MHC class I or II. Capture 
by C-type lectins can also enhance infection of the DC in cis (473). 
 
The C-type lectin DC-specific intercellular adhesion molecule 3-grabbing non-
integrin (DC-SIGN), was identified in 2000 and shown to be able to capture 
HIV-1 and promote efficient infection of CD4+ T cells in trans (474, 475). DC-
SIGN binds to gp120. It is expressed on a subset of immature DCs, including 
DCs in the submucosal epithelia and the rectal epithelia. Other receptors present 
on DCs and able to capture HIV-1 include the mannose receptor and galactosyl 
ceramide (476, 477). In spite of the identification of DC-SIGN and other 
attachment receptors, the initial interactions between HIV-1 and DCs remain 
unclear and debated. Some studies have reported of DC-SIGN-independent 
transfer of HIV-1 infection from DCs to CD4+ T cells, indicating that additional, 
unknown receptors are involved (478, 479). A recent study has demonstrated the 
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DC-specific heparan sulphate proteoglycan syndecan-3 as a major HIV-1 
attachment factor on DCs (480). 
 
Unlike other DCs, Langerhans cells have been shown to bind HIV-1 via the C-
type lectin Langerin (481). It has previously been though that Langerin on 
Langerhans cells function in a manner similar to that of DC-SIGN (476). This 
notion has, however, been contradicted by a recent study carried out by de Witte 
et al. (481), showing that capture of HIV-1 particles by Langerin leads to 
internalisation of the virus and degradation in the Birbeck granules, thus 
preventing infection rather than mediating it to CD4+ T cells. Blocking Langerin 
with antibodies or saturating it with high concentrations of virus did, however, 
result in infection of the Langerhans cells and transfer of HIV-1 to CD4+ T cells. 
 
Due to the low abundance of DCs in vivo, many studies on HIV-1 infection of 
DCs are carried out using monocyte-derived DCs, which are cells with DC-like 
properties generated in vitro from human monocytes. While these cells provide a 
good model, they may not accurately represent DCs in vivo. For example, it has 
been shown that monocyte-derived DCs mainly interact with HIV-1 gp120 via 
C-type lectins, whereas primary DCs isolated from blood were found to bind 
gp120 mainly via CD4 (482). Studies on primary DCs isolated from blood have 
furthermore shown that DC ability to transfer infection to CD4+ T cells varies 
with DC subset and with maturation stage. While conventional DCs can 
efficiently mediate infection of CD4+ T cells, plasmacytoid DCs have been 
shown to inhibit HIV-1 replication in CD4+ T cells, probably because of their 
interferon (IFN)-α production (483). This notion has, however, been contradicted 
by another study reporting efficient transfer of HIV-1 to CD4+ T cells by 
plasmacytoid DCs (484). In light of these observations, it is clear that further 
studies using primary DCs are needed to elucidate the mechanisms by which 
DCs interact with HIV-1 in vivo. Increased understanding of how HIV-1 interacts 
with DCs would shed light on the events involved in sexual transmission of HIV-
1, with obvious implications for the development of strategies to prevent HIV-1 
transmission. Transmission of HIV-1 will be further discussed in the next section 
(section 1.1.4.2). 
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In conclusion, it is the distribution of the cellular receptors that is the main 
determinant for HIV-1 tropism. Even so, cellular tropism, in particular the 
species-specific aspect, is in part determined by cellular restriction factors that 
act post-entry (485). 
 
1.1.4.2 Transmission of HIV-1 
HIV-1 can be transmitted along three major routes, either through exposure to 
HIV-1 positive blood or blood products, via mother-to-child transmission, or 
through sexual contact. For all routes of transmission, the probability of 
transmission depends on a number of factors, including host susceptibility and 
infectiousness, viral properties and environmental factors (486). 
 
Transfusion of infected blood or blood products poses the greatest risk of 
infection based on a single exposure, as it leads to infection in more than 90% of 
cases (487). The risk of acquiring HIV-1 through the use of shared, contaminated 
needles is lower, as the probability of infection per injection with a contaminated 
syringe is less than 1%  (488, 489). Exposure to HIV-1 positive blood, blood 
products, and the use of contaminated needles accounts for around 5-10% of 
HIV-1 infections worldwide (490). The majority of these infections are, 
however, acquired through intravenous drug use, as routine screening of blood 
and blood-derived products has reduced the spread of HIV-1 via blood and blood 
product transfusions (65, 490, 491). 
 
Mother-to-child transmission of HIV-1 can occur in utero via the placenta, 
during delivery or via breastfeeding. While a few cases may be the result of true 
vertical transmission, the majority are believed to represent mucosal transmission 
due to exposure of the small intestine or the oral mucosa to maternal body fluids 
(492). This notion is, in part, supported by studies carried out in macaque 
models, which have indicated that neonates are more susceptible to oral 
transmission than adults (493, 494). In the absence of antiretroviral treatment, 
30-45% of infants born to HIV-1 positive mothers become infected (495). Risk 
of transmission can, however, be reduced to less than 10% with a short course of 
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antiretroviral therapy. Still, an estimated half a million infants acquire HIV-1 
annually through mother-to-child transmission (65, 495). 
 
Sexual transmission of HIV-1 accounts for the vast majority of HIV-1 infections 
worldwide and occurs primarily at the genital and rectal mucosa (65). The 
probability of sexual transmission varies with anatomical site. The risk of 
acquiring HIV-1 during oral sex appears to be almost negligible, whereas anal 
sex confers the highest risk, with an estimated transmission probability per coital 
act of around 0.001-0.01, and vaginal sex an intermediate risk with an estimated 
transmission probability of around 0.0001-0.001 (486, 496-500). Transmission 
can be facilitated by breaks in the epithelium but can also occur across intact 
mucosal surfaces (501, 502). Both cell-free and cell-associated virus can be 
mucosally transmitted, although cell-free virus seem to be more infectious in the 
macaque model (503, 504). Most HIV-1 infections worldwide result from genital 
exposure to semen of HIV-1-infected men (486). Semen can contain both cell-
free virus and infected cells (505, 506). Recently, Münch et al. (507) have 
reported that amyloid fibrils, composed of fragments of prostatic acidic 
phosphatase and naturally present in semen, strongly enhance HIV-1 infection of 
T cells, macrophages and human tonsillar explants. 
 
Transmission to women during vaginal intercourse can occur through the 
vaginal, ectocervical, or endocervical mucosa (490). The intact vaginal and 
ectocervical mucosa is made up of several layers of stratified squamous 
epithelium, whereas the endocervix is lined by a single-layer columnar 
epithelium. It is not known whether most women are infected via the vagina or 
via the cervix. However, studies of macaques, who lack the cervix after surgical 
removal of the uterus, have shown that the vaginal mucosa is sufficient for SIV 
transmission (508). In addition, treating macaques with progestins, which leads 
to thinning of the vaginal mucosa without having an effect on the cervix, 
increases the risk of SIV infection, suggesting the vaginal mucosa as the primary 
site of transmission (509). Moreover, the risk of acquiring HIV-1 infection has 
been suggested to be higher during pregnancy, when progesterone levels are 
higher (510).  In contrast, treating macaques with oestrogen thickens the vaginal 
mucosa and decreases the risk of HIV-1 transmission (511). Disruption of the 
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mucosal integrity as a result of physical abrasion induced by intercourse (512-
514), abnormalities in the vaginal flora caused by e.g. bacterial vaginosis (515, 
516), or inflammation or genital ulcers caused by sexually transmitted diseases or 
chemical agents such as a topical microbicide (517, 518), all lead to increased 
risk of HIV-1 transmission. The single-layer epithelium of the endocervix is 
believed to support viral transmission, but is protected by a mucus plug thought 
to acts as a barrier to infection (519). 
 
In men, HIV-1 transmission across the genital mucosa occurs most frequently 
through the inner foreskin and perhaps also through the penile urethra. An 
estimated 70-75% of all male infections are acquired through vaginal intercourse 
(490). The inner foreskin is lined by a multilayer stratified squamous epithelium, 
and has been shown to contain target cells for HIV-1 infection and to be 
susceptible to HIV-1 infection in an explant model (520-522). The urethra is 
lined by some layers of columnar epithelial cells. Circumcision confers a reduced 
risk of HIV-1 infection, highlighting the important role of the foreskin in HIV-1 
transmission (523-525).  
 
While much understanding has come from epidemiological studies, human 
explant studies, and in vivo studies of SIV- or SHIV-infected macaques (437, 
486, 490, 501, 502, 526, 527), the biology of mucosal transmission of HIV-1 is 
still poorly understood, and the events from when HIV-1 reaches the epithelium 
and until there is an established infection remain unclear. For example, it is not 
known which cells are initially infected, although potential target cells include 
Langerhans cells, subepithelial DCs, macrophages and CD4+ T cells (490, 501, 
528). According to current dogma and as discussed in section 1.1.4.1, HIV-1 is 
believed to hijack DCs to reach CD4+ T cells (462). However, the exact role of 
DCs in HIV-1 transmission remains obscure. DCs in the mucosal tissues include 
the subepithelial DC-SIGN+ DCs and Langerhans cells in the epithelia. 
Langerhans cells have long been thought to be an initial target for HIV-1 
infection because of their susceptibility to infection and the observation that 
Langerhans cells harbour virus after vaginal inoculation of macaques with SIV 
(466, 467, 501), as well as the location of Langerhans cells in the mucosal 
epithelium and the fact that they can reach into and sample antigen in the lumen 
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of for example the vagina (529, 530). Recent studies by de Witte et al. (481) 
have, however, indicated that Langerhans cells, instead of becoming infected or 
transferring infection to other target cells, trap and degrade incoming virus.  
 
CD4+ T cells have been found beneath the epithelia of the vagina and cervix, as 
well as dispersed within in the epithelia (531, 532). These CD4+ T cells are 
primarily memory T cells. Several studies carried out in female genital tissue 
explant models (533-535) have shown that HIV-1 productively infects CD4+ T 
cells in the genital mucosa (536-538). A study carried out in a vaginal explant 
model by Hladik et al. (536), showed that the initial infection of CD4+ T cells in 
the vaginal mucosa is likely to be independent of Langerhans cells. Instead, virus 
was found to be endocytosed by Langerhans cells, a notion which is in 
concordance with the observations made by de Witte et al. (481), discussed 
above. The important role of genital CD4+ T cells in SIV transmission has also 
been supported by data obtained in the macaque model (539, 540). 
 
In addition to CD4+ T cells, macrophages have been shown to be infected in 
human genital explant models (533, 534, 541). Infected macrophages could, 
however, not be detected, or were rarely detected, in genital compartments in 
macaques infected with SIV (459, 460, 540). The precise role of macrophages in 
HIV-1 transmission is therefore unclear. 
 
Little is also known about the nature of the virus that is transmitted (542). The 
characteristics of the transmitted virus and the early diversification of the virus 
population have been difficult to study, since there is a delay of at least a week 
before viral RNA can be isolated from blood of infected individuals. Several 
studies of newly transmitted viruses have, however, indicated that the virus 
passes through a genetic bottleneck during mucosal transmission, since viral 
diversity is limited in the early stages of infection compared to later on or in the 
donor (401, 542-548). In contrast to the above reports, several studies have 
reported heterogeneous virus populations soon in early infection and also that 
there are gender differences (549-551). In addition, it has been suggested that 
transmission of multiple virus variants occurs frequently but that the population 
is homogenised soon after transmission (552). Furthermore, it is not known 
 74
whether compartmentalisation of virus between the blood and genital 
compartments of the transmitting individual contributes to the reduced viral 
diversity frequently observed soon after transmission, or whether selection takes 
place primarily at the mucosal membrane of the receiver (542). Miller et al. 
(519) have shown that in macaques, the mucosal barrier greatly limits the initial 
infection of target cells present in the vaginal and cervical tissues, leading to a 
small founder population of viruses, suggesting that the mucosa is responsible for 
the initial, limited viral diversity. These observations has been further supported 
by Chomont et al. (548), who suggested that virus variants from the male donor 
are selected in the female mucosa during HIV-1 transmission, since HIV-1 gp120 
sequences from the vaginal and blood compartments were virtually identical 
soon after infection, but not in chronic disease. 
 
Salazar-Gonzalez et al. (553) have described an experimental strategy using 
single-genome amplification and sequencing of viral genes, which facilitates 
identification of the transmitted virus, or at least of early founder viruses that 
have initiated productive clinical infection, as well as analysis of early virus 
diversification. Using this approach and phylogenetic techniques, Salazar-
Gonzalez and colleagues found that out of twelve Zambian individuals infected 
with HIV-1, eight were originally infected with a single virus, or at least that a 
single founder virus that gave rise to the clinical infection, whereas the remaining 
four were originally infected with several viruses. This approach is likely to be 
useful in furthering the knowledge of the properties of the transmitted virus. 
 
Several studies have indicated that there may be differences in the biology of 
sexual transmission between HIV-1 subtypes. For example, for HIV-1 of subtype 
A and C, transmission of viruses bearing envelope glycoproteins with shorter and 
more compact variable loops seems to be favoured (547, 554), whereas among 
subtype B viruses, this observation has not been made (555, 556). 
 
Several factors contribute to the probability of transmission (486). Plasma viral 
load has, for example, been associated with sexual transmission of HIV-1 (557-
560). Higher plasma loads are found in the early stages of HIV-1 infection, and 
several phylogenetic studies have highlighted the importance of primary HIV-1 
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infection in onward transmission (505, 561-564). Wawer et al. (497) were first to 
present empirical data on the variation in HIV-1 transmission by stage of 
infection. Using data from studies of 235 HIV-1-discordant couples in the Rakai 
district of Uganda, Wawer and colleagues estimated that the probability of HIV-1 
transmission within the first 2.5 months after seroconversion of the infected 
partner (0.0082 per coital act) was almost twelve-fold higher than that observed 
during asymptomatic infection (0.0007 per coital act). During the last two years 
before death, the probability of transmission increased again to 0.0031 per coital 
act. Subsequent studies carried out in the Rakai district of Uganda have estimated 
primary and late-stage infection to be around 26 and 7 times more infectious than 
asymptomatic infection, respectively (565). Transmission does, however, occur 
throughout the course of HIV-1 infection. Fraser et al. (566) used 
epidemiological tools to quantify the transmission potential of HIV-1 as a 
function of the viral load set-point, and found that the most commonly observed 
viral load set-points resulted in nearly optimal transmissibility over the life-time 
of the infected host, which may indicate that HIV-1 has evolved to have a 
maximised transmission potential in humans. 
 
1.1.4.3 Natural course of HIV-1 infection 
Within the first hours and days after mucosal transmission of HIV-1, infection is 
established in target cells located in the lamina propria of the mucosal tissue. 
Infection then spreads to the draining lymph nodes and subsequently to other 
lymphoid tissues via the circulation (502). Miller et al. (519) have shown that a 
small founder population of infected cells is developed at the point of entry in 
macaques following intravaginal challenge with SIV, and that local proliferation 
and continued seeding of distal lymphoid tissues was needed to establish 
systemic infection. 
 
Once established, natural HIV-1 infection is characterised by three phases. The 
first phase is the primary or acute infection, which is associated with intense viral 
replication, a rapid increase in viral load and a decline in CD4+ T cells, 
especially the effector memory CD4+ T cells at mucosal sites. Over the 
following weeks, as antiviral immune responses are developed, the number of 
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circulating CD4+ T cells start to recover and plasma viral load decreases to a set-
point. This viral load set-point has been proposed to be a strong predictor of 
disease progression (567, 568). 
 
The second phase is the chronic, and in general clinically asymptomatic, 
infection, which is characterised by a gradual increase in plasma viral load and a 
progressive decrease in circulating CD4+ T cells. Despite the lack of clinical 
symptoms, persistent viral replication occurs throughout this phase (569, 570). 
The duration of the chronic phase varies and can last from a few to fifteen or 
more years. 
 
The third phase is characterised by the terminal failure of the immune system, 
symptomatic infection and onset of AIDS. AIDS is defined as the occurrence of 
any of more than twenty opportunistic infections or HIV-related cancers, as 
defined by the United States Centres for Disease Control and Prevention (CDC) 
and the European Centre for the Epidemiological Monitoring of AIDS 
(EuroHIV). The CDC also includes a circulating CD4+ T cell count below 200 
cells/µl of blood in the definition of AIDS (571). A schematic representation of 
the natural course of pathogenic HIV-1 infection is shown in Fig. 1.1.4.3.1. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1.4.3.1. Schematic representation of the natural course of HIV-1 infection. Figure 
obtained from Forsman, A. and Weiss, R. A., ‘Why is HIV a pathogen?’, Trends in microbiology, 
in press. 
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The course of HIV-1 infection and the rate of disease progression vary between 
individuals. A proportion of HIV-1-infected individuals do not seem to develop 
AIDS, but have low viral loads and stable circulating CD4+ T cell levels (572, 
573). These individuals are referred to as long-term non-progressors, or LTNP. 
Several host genetic factors such as the CCR5-∆32 allele and some human 
leukocyte antigen (HLA) genotypes have been associated with the rate of disease 
progression and the LTNP phenotype (574-577). In addition to host factors, viral 
elements have also been implied to have a role in the rate of disease progression 
in humans (578). Deletions in the viral nef gene have, for example, been 
associated with slower disease progression (265, 266). Differences have also 
been observed between different HIV-1 genetic subtypes (432-434). 
 
The major characteristic of AIDS is a selective depletion of CD4+ T cells 
followed by the onset of immune deficiency. Loss of CD4+ T cells is particularly 
striking in mucosal tissues, especially in the GALT of HIV-infected humans 
(439, 579, 580) and SIV-infected macaques (438, 581-585). Containing the 
majority of the T cells of the body, the GALT is a major site for HIV-1 
replication. In the GALT, most CD4+ T cells are depleted within the first few 
weeks of infection, resulting in potentially irreversible tissue damage, which is 
thought to determine further disease progression (586). The mechanism behind 
the rapid depletion of CD4+ T cells in the GALT remains obscure. A recent 
report by Arthos et al. (587) has, however, shown that HIV-1 gp120 can bind to 
the integrin α4β7, which is a receptor that mediates migration of peripheral CD4+ 
T cells to the GALT, possibly indicating that HIV-1 preferentially attaches to and 
infects cells in the GALT. 
 
Loss of CD4+ T cells can occur through direct infection of CD4+ T cells but also 
through indirect effects, such as immune activation, apoptosis and killing of 
bystander CD4+ T cells by CD8+ T cells (588). In addition, certain viral proteins 
can be toxic to CD4+ T cells and the virus has also been suggested to impair 
thymic regeneration of CD4+ T cells (588). Overall, the mechanisms behind 
CD4+ T cell depletion and development of AIDS remain poorly understood. 
Some understanding has, however, come from studies of SIV infection of non-
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human primates. Unlike in non-natural or recent hosts, such as macaques or 
humans, SIV does not cause immunodeficiency in its natural hosts. African 
monkey species that are naturally infected with SIVs, including chimpanzee, 
sooty mangabey and African green monkey, do not develop disease and 
generally retain normal levels of peripheral CD4+ T cells despite high levels of 
viral replication and high plasma viral loads (589). Depletion of mucosal CD4+ 
T cells does, however, occur in non-pathogenic SIV infection of sooty 
mangabeys, with a kinetics similar to that observed in pathogenic SIV infection 
of macaques, indicating that mucosal CD4+ T cell depletion is not sufficient for, 
or predictive of, disease progression (590, 591). 
 
Studies of SIV infection of natural and non-natural hosts have, instead, 
highlighted the importance of immune activation in pathogenic SIV/HIV 
infection. Several studies have shown that in their natural monkey hosts, SIV 
infections are not associated with elevated levels of immune inactivation, 
whereas elevated levels of immune activation is observed in non-natural hosts 
such as macaques (589, 592). Elevated levels of immune activation have also 
been associated with HIV-1 disease progression in humans, and markers of 
immune activation have been shown to have prognostic value (593-601). For 
example, cell-surface expression of CD38 on CD8+ T cells, a measurement of 
CD8+ T cell activation, strongly correlates with disease progression to AIDS and 
death in HIV-1-infected individuals, and appears to be a better predictor of 
disease progression than CD4+ cell count or viral load (595-597, 599). The 
importance of immune activation in HIV-1 and AIDS pathogenesis is further 
supported by the observations that in HIV-2 infected individuals, the majority of 
the non-progressors show limited levels of immune activation, whereas elevated 
levels are seen in individuals who progress to AIDS (602). 
 
Even though it is clear that systemic immune activation is a major characteristic 
of pathogenic HIV/SIV infection, the aetiology behind it and the mechanisms 
behind its association with disease progression remain unclear. It has, however, 
been suggested that bystander activation of T cells may play a role (603). 
Circulating microbial products such as lipopolysaccharide, thought to have 
translocated across a damaged gastrointestinal mucosa, have also been proposed 
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to contribute to systemic immune activation, as elevated levels have been 
observed in HIV-1-infected individuals and in SIV-infected macaques, but not in 
SIV-infected sooty mangabeys (604). 
 
The observation that natural hosts for SIV infection, such as chimpanzees and 
sooty mangabeys, but not non-natural and recent hosts, such as humans and 
macaques, express lower levels of CCR5 on their blood, lymph node and 
mucosal CD4+ T cells, may indicate that this receptor is important in pathogenic 
SIV and HIV infection and perhaps in immune activation (605). Differences in 
the ability of SIV, HIV-1 and HIV-2 Nef to suppress T cell activation have, 
furthermore, been suggested to have a role (606). Recently, it has been proposed 
that self-reactive CD8+ T cells, recognising caspase-generated protein fragments 
released by dying CD4+ T cells, may contribute to the systemic immune 
activation seen in chronic HIV-1 infection (607). 
 
1.1.4.4 Host immune responses to HIV-1 infection 
In the natural course of HIV-1 infection, the host immune responses fail to clear 
infection and to contain virus replication, allowing for persistent viraemia (608). 
While virus-specific CD8+ T cell responses are thought to suppress primary 
HIV-1 replication, the contribution of anti-HIV-1 antibodies in clearance of 
primary infection has been debated. Although the majority of research on host 
immune responses to HIV-1 infection has focused on the adaptive immune 
response, attention has also been given to the role of the innate immune response 
in HIV-1 pathogenesis (609, 610). In addition, there has been a growing interest 
in so-called ‘intrinsic immunity’ to retroviral infection, conferred by cellular 
factors such as TRIM5α, APOBEC3G and Fv1, which restrict retroviral 
replication in post-entry events (485). The discussion in this section, however, 
will focus on the adaptive host immune responses to HIV-1 infection, in 
particular the humoral responses. 
 
HIV-1-specific CD8+ T cells emerge within weeks of the initial infection, 
coinciding with the decline in viral load and restoration of circulating CD4+ T 
cells, suggesting that CD8+ T cell responses have a role in controlling viraemia 
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(611-613). CD8+ T cells have been shown to be important in the control of SIV 
infection of macaques, as a rapid increase and decrease in viral load was 
observed in macaques after the elimination and reappearance of CD8+ T cells 
during chronic SIV infection (614, 615). Further support for a role of the 
adaptive cellular immune response in the control of HIV-1 infection has come 
from studies demonstrating the selection of cytotoxic T Lymphocyte (CTL) 
epitope escape mutants of the virus in primary SIV infection of macaques (616) 
and in primary HIV-1 infection of humans (617, 618). 
 
The antibody response to HIV-1 infection is generally vigorous and primarily 
directed against the gp120, gp41, CA and MA viral proteins (608, 619). The 
neutralising antibody response, however, appears relatively poor. It varies widely 
in terms of kinetics, magnitude and neutralisation breadth between individuals, 
and is restricted to antibodies recognising gp120 and gp41 epitopes (139, 619-
622). Neutralising anti-envelope antibodies are thought to constitute only a 
fraction of the total antibody response, as the majority of anti-envelope 
antibodies are unable to bind functional envelope glycoprotein spikes on the 
virus surface (141, 142, 623-627). The presence of antibodies able to neutralise 
HIV-1 in vitro in sera from HIV-1-infected individuals was first demonstrated in 
1985 (628-630). 
 
While serum anti-envelope antibodies can be detected within in weeks of HIV-1 
infection, neutralising antibodies have been observed to appear at a later stage, 
typically around 3-12 months after acute infection, after the decline in primary 
infection viral load (631-643). Because of these observations, it has been 
assumed that neutralising antibodies do not contribute to the control of primary 
viraemia. A number of studies have, however, demonstrated the development of 
neutralising activity within weeks of infection in some study subjects (555, 631, 
641, 643-646), although this observation was sometimes found to depend on 
assay stringency (631). These reports indicate a possible role for neutralising 
antibodies in the control of primary viraemia. The initial neutralising antibody 
response is, in general, highly specific for the autologous early virus variants and 
show limited cross-neutralisation properties (631, 636, 638, 643, 645, 647). The 
specificities of anti-envelope antibodies in sera of HIV-1-infected individuals 
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and the antigenic properties of the envelope glycoproteins will be further 
discussed in section 1.1.6. 
 
Soon after the emergence of a neutralising antibody response, neutralisation 
escape mutants of the virus can be isolated, as shown in longitudinal studies of 
HIV-1 infection (622, 632, 643, 644). The appearance of neutralisation-resistant 
viruses prompts the generation of new antibodies able to neutralise the escape 
mutants, which in turn drives the evolution of new escape mutants, the mounting 
of new antibody responses, and so on (620, 622, 648). The average HIV-1 
generation time, i.e. the time from the release of a virus particle until it has 
infected a new target cell and caused the release of a new round of virus particles 
is as short as 2.6 days (441). This high replication rate, together with a mutation 
rate of 3.4 × 10-5 mutations per bp per cycle (167), contributes to the ability of 
HIV-1 to escape neutralising antibodies faster than new antibodies can be 
generated, contributing to the low titres of neutralising antibodies observed in 
sera from infected individuals. The observations that serum samples from late in 
infection can often neutralise early virus isolates (632, 638, 643, 645, 649-651), 
suggest that the neutralising antibody response may well be vigorous, although 
not able to keep up with virus evolution. 
 
The selective pressure of the neutralising antibody response thus drives virus 
evolution (648), contributing to the extreme genetic diversity observed in the env 
gene and the variation in neutralisation sensitivity observed among HIV-1 
variants, even within single plasma samples (652). Similarly, viral evolution and 
escape from autologous antibody responses is likely to drive the gradual 
broadening of serum neutralising activity and the slow increase in heterologous 
neutralising responses that have been observed throughout the course of HIV-1 
infection (555, 641, 643). Moderate titres of broadly neutralising antibodies can, 
however, only be detected in around a tenth of chronically infected individuals 
(641, 653, 654). In spite of the rapid rate of evolution, recent data suggest that 
there may be limits to the ability of HIV-1 to continuously evolve to escape 
neutralising antibody responses in chronic infection (655). In further support of 
this notion, studies of twins infected with the same HIV-1 isolate through needle-
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sharing have shown similar neutralising antibody responses and similar changes 
in the patterns of evolution in the env gene, suggesting that there are constraints 
on the mutational pathways HIV-1 can follow to evade antibody responses (656). 
 
The in vivo role of the neutralising antibody response remains unclear. The 
emergence of neutralisation escape mutants in HIV-1 infection, however, 
provides indirect evidence for in vivo activity of neutralising antibodies. Direct 
evidence has come from several passive immunisation studies in animal models 
and in humans. Systemic infusion of neutralising antibodies has protected 
macaques against systemic and mucosal SIV or SHIV challenge in several 
studies (657-665). However, the serum titres required to achieve protection are 
high. In one study, the serum titre (90% in vitro neutralisation) required for 
sterilising protection was estimated to be 1:400 (662), whereas another study 
estimated that a titre of 1:38 (100% in vitro neutralisation) in plasma would 
protect 99% of macaques (666). Passive immunisation with the broadly 
neutralising mAb b12 has also been shown to protect severe combined 
immunodeficient (SCID) mice populated with human PBMCs against HIV-1 
challenge (667). In addition, vaginal application of mAb b12 has been shown to 
protect macaques against mucosal challenge with SHIV (668). 
 
A role for neutralising antibodies in established infection has also come from 
studies in the macaque model. Haigwood et al. (669, 670) have in two 
subsequent reports demonstrated that passive immunisation of SIV-infected 
macaques, early in infection, led to reduced viraemia and delayed disease 
progression. In addition, in 2007 Yamamoto et al. (671) showed that passive 
immunisation of macaques with pooled neutralising sera from chronically 
infected animals, a week post-challenge with SIV, resulted in a significant 
reduction of set-point plasma viral loads and preservation of central memory 
CD4+ T cell levels. Additional support for a possible role of neutralising 
antibodies in partial control of viraemia in vivo has come from studies of acutely 
and chronically HIV-1-infected humans undergoing interruption of antiretroviral 
treatment. The study showed that acutely infected individuals who received a 
cocktail of three neutralising mAbs had a delay in viral rebound compared to 
study subjects not receiving the mAbs or chronically infected individuals (672). 
 83
In contrast, it has been shown that passive immunisation of HIV-1-infected SCID 
mice populated with human PBMC, with a cocktail of neutralising antibodies, 
has little effect on viral load and furthermore that virus escape occurs within a 
few days (673). The observation that less potent and cross-reactive antibody 
responses predisposes to HIV-1 superinfection further points to a protective role 
for neutralising antibodies against HIV-1 infection (674). 
 
The presence and role of mucosal IgA in HIV-1 infection has been debated 
(675). While low levels of HIV-1-specific IgA antibodies has been demonstrated 
in female and male genital tract secretions of HIV-1-infected patients, the 
frequency of detection and the levels were much lower than for HIV-1-specific 
IgG, indicating that unlike many other mucosally encountered microbes, HIV-1 
does not induce vigorous specific IgA responses (676). The presence of HIV-1-
specific IgA in mucosal secretions of HIV-1-exposed but seronegative 
individuals has been controversial (677, 678). 
 
In addition to being able to directly neutralise virus, anti-envelope antibodies can 
induce additional antiviral immune functions, mediated by interaction of the Fc 
portion of the antibody with Fc receptors (FcRs) or with complement (679). Such 
antiviral immune functions can be mediated by neutralising as well as non-
neutralising antibodies specific for the HIV-1 envelope glycoproteins (679). The 
so-called non-neutralising antibodies fail to recognise functional envelope spike 
but have the potential to bind to non-functional spikes present on the virus 
surface (142). The non-neutralising anti-envelope glycoprotein antibodies 
detected early in infection, prior to the appearance of neutralising antibodies, 
may induce such FcR- or complement-mediated immune effector functions, 
possibly contributing to the decline in plasma viral load seen at the interface of 
acute and chronic infection (680-682).  
 
FcR-mediated effector functions include antibody-dependent cellular toxicity, 
ADCC. In ADCC, FcRs expressed on effector cells such as natural killer cells, 
granulocytes, monocytes, macrophages and subsets of γδ T cells interact with the 
Fc portion of antibodies bound to infected cells, leading to the release of 
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granzymes and perforins and subsequent lysis of the infected cell. In HIV-1-
infected individuals, anti-envelope glycoprotein antibodies able to mediate 
ADCC have been demonstrated early in infection (681, 683-686). In addition to 
mediating lysis of HIV-1-infected cells, interaction of FcR-bearing effector cells 
with antibody-virus complexes can lead to the release of cytokines and 
chemokines that inhibit virus replication in a mechanism referred to as antibody-
dependent cell-mediated virus inactivation, or ADCVI (687). ADCVI activity 
has also been demonstrated in non-neutralising serum that prevents SIV infection 
of neonatal macaques after oral challenge, possibly suggesting that the 
mechanism has relevance in vivo (688). Serum with potent ADCVI activity has, 
however, failed to protect against SIV infection of macaques in other studies 
(689). 
 
Although ADCC and ADCVI have been suggested to influence disease 
progression in HIV-1-infected individuals, the importance of these mechanisms 
in vivo remain uncertain (679). Antibody-dependent FcR-mediated effector 
functions also include phagocytosis of antibody-coated viruses by phagocytic 
cells. Non-neutralising or poorly neutralising antibodies from HIV-1-infected 
individuals have been shown to inhibit HIV-1 infection of macrophages and 
immature dendritic cells in an FcR-dependent manner that did not require natural 
killer cells (690, 691). The relevance of FcR-mediated effector functions in vivo 
has been highlighted by the recent observation that the ability of the broadly 
neutralising mAb b12 to protect macaques against SHIV challenge was reduced 
if mutations that impair FcR binding were introduced into the Fc portion of b12 
(692). Further support for a possible role of FcR-mediated immune functions in 
HIV-1 pathogenesis has come from the observation that polymorphisms in 
certain FcR genes have been associated with progression of HIV-1 infection 
(693). 
 
Complement can be activated either by direct interaction with HIV-1 envelope 
glycoproteins on the virus surface or by interaction with antibody bound to virus 
particles. Activation of the complement system initiates a cascade of events 
leading to the formation of a membrane attack complex and lysis of the virus or 
of infected cells. Several studies have indicated that HIV-1 uses complement 
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regulatory proteins, present in its host cell-derived membrane, to resist 
complement-mediated lysis (679). In addition to mediating lysis, the complement 
system can induce opsonisation and phagocytosis through binding of 
complement-opsonised virus to complement receptors on phagocytic cells. Aasa-
Chapman et al. (682) have shown that non-neutralising anti-envelope antibodies 
detected during peak viral load in acute HIV-1 infection, before the appearance 
of neutralising antibodies, can induce complement-mediated inactivation of 
autologous and heterologous virus in vitro. Similarly, Huber et al. (680) showed 
that antibodies present in plasma of HIV-1-infected individuals induced 
complement-mediated inactivation of autologous virus in vitro, and that acute 
infection plasma virus load correlated inversely with complement lysis activity. 
The observations made in these two studies may indicate a possible role for 
complement-mediated viral inactivation in control of HIV-1 viraemia. 
 
In addition to mediating effector functions that cause viral inactivation, anti-
envelope antibodies have been shown to mediate enhancement of HIV-1 
infection in vitro (679, 694, 695). Antibody-dependent enhancement of HIV-1 
infection can be mediated by binding of antibody-virus complexes to FcRs or by 
binding of antibody and complement-opsonised virus to complement receptors 
present on target or bystander cells. Binding to target cells can enhance infection 
in cis, whereas binding to bystander cells can result in enhancement of infection 
in trans. Up to 300-fold complement-mediated antibody-dependent enhancement 
of infection of target cells bearing complement receptors has been observed 
using early primary HIV-1 isolates and autologous sera (695). The role of these 
antibody-mediated effector functions in HIV-1 pathogenesis remains unclear, but 
is of importance to HIV-1 vaccine design. 
 
As touched upon above, HIV-1, like many viruses, has evolved a number of 
ways to evade immune responses. For example, the integration of proviral DNA 
into the host cell genome provides a reservoir of latency since virus is only 
recognised by the immune system when it is actively replicating. In addition, 
HIV-1 is able to down-regulate cell surface expression of MHC class I 
molecules, making infected cells less recognisable by CTLs (263). The main 
reason for the immune evasive properties of HIV-1 might, however, be credited 
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to the extreme sequence heterogeneity and the characteristics of the HIV-1 
envelope glycoproteins. The immune evasive properties conferred by the HIV-1 
envelope glycoproteins will be briefly discussed in section 1.1.6. 
 
1.1.5 Treatment and preventive strategies 
In the absence of host immune control of HIV-1 infection, antiretroviral 
treatment has reduced HIV-1 mortality substantially. However, while current 
HIV-1 therapy can control viral load and prevent progression to AIDS, it is not 
available to the majority of the infected population, nor can it completely clear 
infection. Therefore, in order to control the HIV-1 pandemic, there is an urgent 
need for preventive measures, such as an effective HIV-1 vaccine or alternative 
preventive strategies such as HIV-1 microbicides. In this section, antiretroviral 
therapy, HIV-1 vaccine development, and HIV-1 microbicides will be briefly 
discussed. 
 
1.1.5.1 Antiretroviral therapy 
Available antiretroviral therapy targets several steps in the HIV-1 lifecycle. The 
first antiretroviral drug to be tested and proven efficient in clinical trials was 
azidothymidine, or AZT (54). AZT is a nucleoside analogue, which inhibits the 
viral reverse transcriptase process by terminating DNA chain elongation when 
incorporated into the nascent DNA chain. It was the most effective of about a 
hundred nucleoside analogues screened for antiretroviral activity at the 
Burroughs Wellcome laboratories (now GlaxoSmithKline) in the UK and the 
National Cancer Institute in the USA. AZT was approved and released into the 
market in 1987 as Zidovudine, as the first in a series of nucleoside or nucleotide 
analogue reverse transcriptase inhibitors (NRTIs). Despite the initial success, it 
soon became apparent that NRTI monotherapy led to the development of HIV-1 
resistance and would not have long-lasting efficacy (696). Combination therapy, 
using more than one NRTIs would, however, prove more efficient (697, 698). 
 
Within ten years after the introduction of NRTI therapy, additional drugs such as 
the non-nucleoside reverse transcriptase inhibitors (NNRTIs), specifically 
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targeting the HIV-1 reverse transcriptase, as well as protease inhibitors, binding 
to the HIV-1 protease hence inhibiting virion maturation, had been developed 
and approved (699). The introduction of highly active antiretroviral therapy 
(HAART) in 1996, using a combination of at least three antiretroviral 
compounds from at least two classes of antiretrovirals, resulted in a massive drop 
in the number of AIDS deaths in the industrialised part of the world (700-702). 
Today, there are a total of 24 approved antiretroviral drugs, including eight 
NRTIs, three NNRTIs, and ten protease inhibitors (699). In addition, there are 
two approved entry inhibitors, the fusion inhibitor Enfuvirtide, also known as T-
20, which targets gp41 (703), and the CCR5 antagonist Maraviroc (704). The 
latest antiretroviral drug to be approved, in 2007, was an integrase inhibitor 
(705). Additional antiretroviral drugs are in advanced clinical trials, including 
further integrase and reverse transcriptase inhibitors, as well as a range of entry 
inhibitors such as CCR5 and CXCR4 antagonists and compounds targeting CD4 
and the HIV-1 envelope glycoproteins (398, 706). Also in clinical trials is the 
first of the so-called maturation inhibitors, which bind to the Gag precursor 
polyprotein, thus inhibiting polyprotein cleavage, resulting in the release of 
defective virions (707). Strategies involving gene therapy are also being 
investigated (708), as are therapeutic vaccines. 
 
Despite the advances and successes in the development of antiretroviral drugs, 
the cost and toxicity of antiretroviral therapy remains substantial, as does the 
problem with drug resistance in circulating and transmitted viruses (709, 710). 
Moreover, antiretroviral therapy remains unavailable to the vast majority of 
infected people. To expand the access to antiretroviral therapy in low-income 
countries, the WHO/UNAIDS launched its ‘3 by 5’ initiative in 2003, aiming at 
having 3 million people in resource-poor settings on HAART by the end of 2005. 
While this target was not met in 2005, it is estimated that at the end of 2007 
around 3 million people in low- and middle-income countries were receiving 
antiretroviral therapy, nearly a million more than at the end of 2006 (711). In 
spite of the progress, the treatment coverage remains low, with less than a third 
of the people who would need it receiving therapy (711). 
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1.1.5.2 HIV-1 vaccine development 
The field of vaccinology is said to have started with the experiments carried out 
by Edward Jenner in 1796, showing that inoculation with cowpox virus could 
protect humans against smallpox infection (712). Since then, smallpox has been 
declared eradicated following a mass vaccination programme (713, 714), and 
vaccines have been effective in preventing human disease caused by a range of 
viruses, including influenza, rabies, hepatitis A and B, rubella, measles, mumps 
and poliovirus (712, 715). For these and most other successful vaccines, 
protection has typically been achieved by mimicking infection with the pathogen 
itself, using live attenuated or inactivated pathogen preparations or subunit 
vaccines (715). Although antibody titre appears to be the primary immune 
correlate of protection in most cases, the relative contributions of different 
antibody functions are unclear and the precise mechanisms by which vaccines 
prevent infection or disease remain undefined (716). For many pathogens, it is 
likely that both the humoral and the cellular arms of the immune system are 
important for long-lasting protection (716). 
 
Despite the overall success in developing vaccines against a range of other viral 
diseases, all attempts to develop a successful HIV-1 vaccine have so far failed 
(717). Several features of HIV-1 make it a challenging target for vaccine design, 
in particular its high mutation rate and remarkable genetic diversity, which by far 
exceeds that of other entire virus families. The immune evasive properties of the 
HIV-1 envelope glycoproteins (discussed in section 1.1.6) are other major 
obstacles in vaccine development, as is the ability of HIV-1 to remain latent in 
cells and to down-regulate cell surface expression of MHC. 
 
Moreover, the correlates of immune protection in HIV-1 infection remain 
undefined, further contributing to the difficulties in developing an HIV-1 vaccine 
(718-720). However, even though the role of antibodies in natural HIV-1 
infection is unclear, the observation that passively transferred neutralising 
antibodies can protect macaques against SHIV and SIV challenge (657-665) 
indicates that if elicited, antibodies could potentially prevent infection. Similarly, 
evidence for a role of T cells in the control of viraemia in HIV and SIV infection, 
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has provided a rationale for the development of vaccine aimed at inducing T cell 
responses (717, 721, 722). Overall, it is generally believed that a successful 
vaccine against HIV-1 will need to elicit both humoral and cellular immune 
responses in order to prevent infection, disease, or both (717, 723, 724). 
 
The lack of known correlates of immune protection makes it difficult to estimate 
the efficacy of vaccine candidates prior to testing in costly human trials (717, 
718, 725-727). Although the immune responses in vaccinees and infected 
individuals can be evaluated in in vitro assays, such as neutralisation and IFN-γ 
enzyme-linked immunosorbent spot (ELISPOT) assays, data obtained in vitro do 
not necessarily correspond to the in vivo situation in humans, nor do they 
necessarily correlate with results obtained in animal models (718, 727). In 
addition, data from animal models do not necessarily predict outcome in human 
trials (725). Virus transmission in the best available animal model, the SHIV/SIV 
macaque model, is likely to differ substantially from HIV-1 transmission in 
humans (725, 726). For example, the artificial virus preparations used in animal 
models may not be representative of the virus swarms involved in sexual 
transmission of HIV-1. Moreover, the limited number of SIV or SHIV isolates 
available may not accurately represent the vast majority of the circulating HIV-1 
strains. 
 
The vaccine candidates that has so far provided the best protection in the 
macaque model are live attenuated SIVs (726, 728, 729). A live attenuated viral 
vaccine contains live virus that have been attenuated, for example through 
extensive cell-culture passaging or direct genetic modification. This kind of 
vaccine typically elicits long-lasting humoral and cellular immune responses and 
has been highly successful when developing vaccines against measles, rubella, 
mumps, yellow fever and poliovirus (716). Immunising macaques with live 
attenuated SIV has been shown to provide protection against challenge with 
homologous pathogenic SIV for up to more than two years after immunisation 
(730-733). Interestingly, strong protection of macaques immunised with a live 
attenuated SIV have been observed even in the absence of high-titre anti-SIV 
antibodies and high-frequency anti-SIV cellular immune responses, as measured 
by neutralisation and IFN-γ ELISPOT assays, high-lighting the lack of 
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knowledge of what correlates with immune protection (734). Even though 
immunisation with live attenuated SIV provides protection against homologous 
challenge, protection against heterologous SIV isolates has been less effective 
(735-737). In addition, there are safety issues with this approach, as there is a 
possibility that the virus may revert back to a pathogenic form, or prove to be 
pathogenic after a prolonged period of time or in immunocompromised 
individuals. The in vivo repair of an attenuating deletion in the nef gene of a SIV 
molecular clone, associated with a reversion to virulence, has been reported in 
macaques (738). In another study, carried out by Baba et al. (739), macaques 
were infected with an SIV isolate with large deletions in the nef, vpr and negative 
regulatory element genes. Adult monkeys that were infected with this attenuated 
virus were protected from subsequent infection with pathogenic SIV but did 
develop disease with a delayed onset from the attenuated virus. Moreover, the 
attenuated virus caused disease soon after infection in newborn monkeys (739), 
albeit in some studies only after challenge with high viral doses (740). 
 
Immunising with inactivated or killed virus preparations may be safer, and have 
proven effective when developing vaccines against hepatitis A, rabies, influenza 
and poliovirus (715). However, even though inactivated SIV has conferred some 
short-lived protection in the macaque model, it has been mainly against identical 
virus (741). Virus-like particles (VLPs) are also being explored as vaccine 
candidates (742). 
 
Subunits vaccines can be purified from crude viral extractions, or made from 
recombinant proteins. Recombinant viral proteins are easily produced and 
generally thought to be safe to administer. This approach has been used to 
develop a vaccine against hepatitis B virus. The recombinant hepatitis B vaccine 
was licensed in 1986 and contains recombinant viral surface antigen expressed in 
yeast (743, 744). Two recombinant vaccines against certain strains of human 
papilloma virus (HPV-6, -11, -16 and -18 or HPV-16 and -18 only) have recently 
been approved (745-748). These vaccines are based on yeast- or baculovirus-
expressed recombinant HPV capsid protein L1, which self-assembles into virus-
like particles, VLPs (749). 
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The first HIV-1 vaccine candidates to enter clinical efficacy trials in humans 
were two vaccine candidates developed by VaxGen (San Francisco, USA), 
containing recombinant gp120 derived from HIV-1 of subtype B and A/E. The 
subtype B gp120 had previously been shown to protect chimpanzees against 
challenge with homologous virus (750). Both candidates were taken through 
clinical safety and efficacy trials in the USA and/or in Thailand, but did not 
prevent infection, had no effect on subsequent viral load, and did not elicit 
antibodies that could neutralise primary isolates of HIV-1 in vitro (751-753). 
 
Given what is now known about the immune evasive mechanisms of the HIV-1 
envelope glycoproteins and the extreme HIV-1 genetic diversity, the results of 
the VaxGen trials were perhaps not surprising (721). Great efforts are currently 
focused on designing immunogens that can elicit a broader and more potent 
neutralising antibody response (259, 754). This includes the generation of stable 
recombinant trimeric envelope proteins that mimic the functional HIV-1 
envelope spike, as well as peptide and protein constructs that better present 
conserved epitopes recognised by a handful of broadly neutralising antibodies to 
the HIV-1 envelope glycoproteins (section 1.1.6). However, so far, no 
immunogen have been developed that elicit a neutralising antibody response of 
the breadth and potency that will be required of a vaccine (717, 754). To solve 
the problem of how to elicit broadly neutralising antibodies, further knowledge 
about the antigenicity and immunogenicity of the HIV-1 envelope glycoproteins 
is needed. 
 
In light of the difficulties in eliciting a neutralising antibody response to HIV-1, 
along with the evidence for a role of T cells in the control of SIV and HIV-1 
infection, much focus has been on developing vaccines that elicit T cell 
responses, which even though they may not prevent infection may contain viral 
replication, leading to lower viral load set-points (Fig. 1.1.4.3.1) and delayed 
onset of disease (717, 721, 722). One of these strategies involves the evaluation 
of naked DNA encoding HIV-1 proteins. However, even though intramuscular 
administration of plasmid DNA encoding HIV-1 proteins can elicit cellular 
responses in mice, these DNA vaccines have been shown to be less immunogenic 
in non-human primates (722, 755) and even less immunogenic in humans (756). 
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Instead, the use of DNA vaccines as priming vaccines in various prime-boost 
strategies has been more successful, eliciting better responses than the boosting 
vaccine alone (757-762). Co-expression with cytokines may also increase 
immunogenicity (763). 
 
HIV-1 genes can also be incorporated into the genome of microorganisms that 
are not pathogenic in humans, which may be a way of mimicking the efficacy of 
live attenuated vaccines but without the safety concerns associated with live 
attenuated HIV-1 (755). For this purpose, the use of adenoviruses, adeno-
associated viruses and poxviruses, including modified vaccinia virus Ankara, 
canarypox and fowlpox virus, have been explored (755). These vectors have 
been engineered to express various HIV-1 antigens, such as Gag, Pol and the 
envelope glycoproteins. A vaccine candidate developed by Merck, based on a 
replication-defective adenovirus type 5 vector engineered to express HIV-1 Gag, 
Pol and Nef proteins, was taken forward to clinical efficacy testing in 2004 in the 
so-called STEP trial conducted by Merck and the HIV Vaccine Trials Network 
(764). This vaccine candidate had been shown to induce CD8+ T cell responses 
in clinical phase I and II trials of safety and immunogenicity in humans. 
Moreover, results obtained in the macaque model had indicated some level of 
protection, as immunisation with a replication-defective adenovirus type 5 vector 
expressing SIV proteins could partially protect against subsequent challenge with 
pathogenic SHIV89.6P (758). Whereas control animals showed rapid disease 
progression, the immunised animals were generally able to contain virus 
replication and rarely developed disease, showing a 1-3 log decrease in viral load 
(758). However, when tested in humans, the Merck vaccine candidate failed to 
prevent infection and did not reduce the viral load in subsequently infected 
individuals (67, 764). In addition, it may even have enhanced infection in 
vaccinated individuals with pre-existing immunity to adenovirus of serotype 5 
(765, 766). 
 
While results obtained in the SHIV89.6 macaque model did not predict the 
outcome of the STEP trial, the failure of the STEP trial has been mirrored by 
results observed in other macaque experiments (725, 767). Although the vaccine 
strategy used in the STEP trial, along with a number of other vector-based 
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vaccine candidates, has been able to partially protect macaques against 
pathogenic SHIV89.6 challenge (758, 759, 763, 768), vector-based vaccine 
regimens have rarely led to reduced levels of disease or viral load in macaques 
challenged with various SIV isolates, including SIVmac239 (767, 769-771). In 
addition, in some cases protection has only been observed in macaques carrying 
a specific HLA allele (767, 772). It has been argued that infection of macaques 
with CCR5-using SIV isolates represents a better model of HIV-1 infection in 
humans than infection of macaques with the CXCR4-using SHIV89.6 (773-776). 
 
In addition to the Merck vaccine candidate, one canarypox vector developed by 
Sanofi-Pasteur is currently in clinical efficacy trials in Thailand in around 16000 
volunteers, in a prime-boost regime together with the recombinant gp120 vaccine 
candidate developed by VaxGen (722). This vector expresses HIV-1 Gag, Pol 
and envelope glycoproteins. Unfortunately, the immunogenicity of this vaccine 
regimen has been shown to be fairly low in clinical phase I and II trials and 
preliminary data has suggested no effect on viral load in individuals who have 
become infected (777, 778). The results of the large-scale efficacy trial are 
expected in 2009. 
 
Since HIV-1 is predominantly spread across mucosal surfaces, efforts to develop 
mucosal vaccine candidates have also been made (779). It has been shown that 
mucosal administration of a vaccine often induces more potent mucosal immune 
responses than administration by injection (780, 781). Mucosal administration of 
several vaccine candidates have been shown to reduce viral loads in macaques 
after mucosal challenge with SHIV (782-786). 
 
Overall, a large number of HIV-1 vaccine candidates have been evaluated in 
phase I or II clinical safety and immunogenicity trials (717, 721, 724, 755). None 
of these vaccine strategies have, however, been able to protect macaques against 
SIV challenge (725, 726). The two candidates that have completed large-scale 
efficacy trials in humans have failed to prevent or control infection. Moreover, 
no vaccine candidate has been able to elicit neutralising antibodies, in any 
species, of the breath and potency likely required of a vaccine (717). In light of 
these notions, an HIV-1 vaccine remains elusive. It is clear that further 
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knowledge is needed about the correlates of immune protection in HIV-1 and 
SIV infection, and how to elicit such protective immune responses. 
 
1.1.5.3 Topical preventive strategies 
Without a promising HIV-1 vaccine candidate in sight, there is a need for 
alternative preventive strategies to stop the rapid spread of the HIV-1 pandemic. 
While the use of condoms can prevent transmission, it is largely male-controlled 
and may not be compatible with marriage, nor can it be combined with 
reproduction. Therefore, alternative prevention strategies are being explored, 
such as the development of topical microbicides aimed at inhibiting sexual 
transmission of HIV-1 (787-794). Microbicides are agents that can be applied 
topically in the vagina or rectum. As microbicides could be potentially 
inexpensive, readily available and socially acceptable, they could offer a 
promising preventive intervention for sexual transmission of HIV-1. 
 
A useful microbicide must fulfil several criteria (787-794). First, self-evidently, 
it must show good efficacy against relevant HIV-1 variants. The extraordinary 
genetic heterogeneity observed among HIV-1 isolates may hence be a problem 
(123). Evaluating efficacy prior to clinical efficacy testing in humans may also 
be problematic, as results obtained in in vitro experiments and animal models 
may not necessarily predict outcome in human trials (791, 794-797). Currently, 
in vitro cell culture systems, human explant models (533, 541), and animal 
models are being used, including humanised mice models (798, 799) and the 
SHIV (or SIV) macaque vaginal transmission model (509, 668, 800-804). While 
the macaque transmission model is the most relevant animal model available, it 
has drawbacks. For example, the limited number of SHIVs available may not be 
representative of the majority of the genetically diverse circulating HIV-1 strains. 
In addition, it is not clear which of the currently used protocols, involving low or 
high doses of challenge virus administered on single or multiple occasions, that 
better represents human HIV-1 transmission (509, 668, 800-812). Some (805) but 
not all (806, 811) microbicide candidates have failed to protect macaques against 
repeated vaginal virus challenges, despite being able to protect against a single 
challenge. 
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In addition to being efficacious, it must be ensured that microbicides do not 
reduce the natural defences against HIV-1 infection. A potential microbicide 
must not cause inflammation or have adverse effects on the resident microflora 
or the structural integrity of the mucosal epithelia, as this might increase the risk 
of transmission (788, 789, 793, 794, 796). Microbicide safety is initially assessed 
in in vitro systems as well as in animal models, and eventually in clinical safety 
trials in humans. Moreover, a useful microbicide should retain its potency in the 
presence of semen (813). It would also need to be stable at a range of 
temperatures, easy to use, inexpensive, readily accessible, compatible with 
condom use, and acceptable to users and sexual partners (787-794). 
 
A large number of compounds are currently being evaluated as microbicides 
(787, 788). Many of them aim at inactivating the incoming virus before it has the 
chance to infect (788). Compounds such as detergents or surfactants inactivate 
free virus by disrupting the viral envelope, and may also be active against other 
sexually transmitted pathogens, including enveloped viruses such as herpes 
simplex virus (788). However, many of these compounds show little selectivity, 
and could potentially be toxic for host cells and for resident microflora. As a 
result, rather than providing protection, such agents could actually increase the 
risk of HIV-1 transmission, as observed for nonoxynol-9, the first compound to 
be evaluated as an HIV-1 microbicide in clinical efficacy trials (Table 1.1.5.3.1). 
 
Nonoxynol-9 is a membrane-disruptive non-ionic surfactant originally developed 
in the 1960s as a spermicide used in lubricants and to coat condoms. Anti-HIV-1 
activity was first demonstrated in vitro in 1985 (814) and in vivo in animal 
models in 1992 (815). Safety studies conducted in women predicted low doses of 
nonoxynol-9 to be safe, although signs of inflammation were also reported (796, 
816, 817). Two large-scale clinical efficacy trials were carried out (Table 
1.1.5.3.1). In one of them, nonoxynol-9 was found to have no effect on HIV-1 
incidence (818), whereas in the other, it increased the risk of transmission when 
used more than three times a day (819). Studies carried out after the clinical 
efficacy trials indicated that nonoxynol-9 increased the risk of transmission by 
disrupting the membranes of the cells in the epithelial layer of the vagina and 
cervix, thereby damaging the protective barrier of the epithelium and causing 
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inflammation, leading to the recruitment of target cells to the mucosa (796, 820, 
821). A second surfactant, 31G or Savvy (Cellegy Pharmaceuticals, Huntingdon 
Valley, USA), was also entered into large-scale clinical efficacy trials (Table 
1.1.5.3.1). These trials were, however, prematurely discontinued, as the observed 
HIV-1 incidence at the trial sites were determined to be too low (822). In a total 
of 2153 women, 33 seroconversions were observed, 21 in the group receiving 
Savvy and 12 in the placebo group (822). 
 
So-called pH-modifying or buffering agents are also being evaluated as 
microbicides. These agents aim at inactivating virus particles by maintaining a 
low vaginal pH, in particular in presence of the alkaline semen. The low pH of 
the vagina, normally around 3.5-4.5, is part of the innate defence against 
microbial pathogens, and is predominantly due to lactic acid and H2O2 
production by vaginal lactobacilli (823). HIV-1 is typically inactivated at pH 
below 4.5. One buffering agent, the carbopol polymer Buffergel (ReProtect, 
Baltimore, USA), is currently being evaluated in clinical efficacy trials (Table 
1.1.5.3.1). In addition to inhibiting HIV-1 transmission, it has been shown to 
inhibit pregnancy, herpes simplex virus (HSV), HPV, and Chlamydia 
trachomatis infections in preclinical studies carried out in animal models, 
without damaging the resident microflora or the reproductive epithelium (824). 
Furthermore, data from clinical safety trials have indicated that it is well 
tolerated and safe to use in humans (825, 826), although some changes in the 
vaginal microflora have been observed (827). Lime juice has also been suggested 
as a candidate microbicide aimed at keeping the vaginal environment acidic. 
However, studies have indicated that the concentrations needed for effective 
HIV-1 prevention would potentially cause damage to the mucosa, increasing the 
risk of infection (828). 
 
Other microbicide candidates under development aim at blocking steps in the 
early stages of the HIV-1 life-cycle, such as virus entry into cells. Candidates 
aimed at non-specifically inhibiting HIV-1 entry include a variety of anionic 
polymers or polyanions, which are thought to bind to positively charged regions 
of gp120, such as the V3 region and the co-receptor binding site (829, 830). 
Polyanions are often more active against CXCR4-using viruses (830-834), as the 
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V3 regions of CXCR4-using viruses tend to have a higher net positive charge 
than those of CCR5-using viruses (421). Three polyanions have so far entered 
large-scale clinical efficacy trials, cellulose sulphate, Carraguard, and PRO 
2000/5 (Table 1.1.5.3.1). 
 
Cellulose sulphate, also known as Ushercell (Polydex, Toronto, Canada), had 
shown good activity against HIV-1, HSV, HPV, Neisseria gonorrhoeae, 
Chlamydia trachomatis and Gardnerella vaginalis in preclinical studies, without 
having an effect against lactobacilli (835-838). Moreover, it was found to be safe 
in three different clinical safety trials and one contraceptive efficacy trial (837, 
839-841). Nevertheless, in two clinical efficacy trials carried out in a total of 
4716 women in high-risk populations, cellulose sulphate failed to protect against 
HIV-1 infection (842). In one of the trials there seemed to be a trend towards an 
enhanced risk of transmission, leading to the premature halting of both trials in 
January 2007 (797, 842). The cause of the apparent enhanced risk of infection 
remains unclear (797). 
 
The second polyanion to enter clinical trials was Carraguard (Population 
Council, New York, USA), which contains a carrageenan extracted from the red 
seaweed Gigartina skottsbergii (793, 843). Carrageenans are sulphated 
polysaccharides that have been widely used as gelling agents in food, cosmetics 
and lubricants. In addition to having in vitro anti-HIV-1 activity (831, 843, 844), 
they have also been shown to be active against a range of sexually transmitted 
pathogens (845-848). As Carraguard appeared safe in clinical safety studies (849, 
850) it was taken forward to clinical efficacy trials carried out in 6270 women in 
South Africa (Table 1.1.5.3.1). The results of the trials were announced in 
February 2008, revealing that no effect on HIV-1 incidence had been observed 
(851). Hence, Carraguard became the fourth microbicide candidate to fail clinical 
efficacy trials. 
 
According to some researchers (795), the failure of two polyanions to protect 
against HIV-1 transmission in clinical efficacy trials is not surprising, as the 
compounds show limited potency in vitro, particularly against CCR5-using 
viruses. Moreover, in addition to being able to inhibit HIV-1 infection, 
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polyanions have been shown to enhance in vitro infection of CCR5-using viruses 
in some studies (852-854). Preclinical studies carried out by Neurath et al. (813) 
have also shown that the in vitro antiviral activity of polyanions, including 
cellulose sulphate, carrageenans and PRO 2000/5 (discussed below), is reduced 
in the presence of semen. Up to 70-fold reductions in potency were observed in 
some cases. The reduced potency may be due to binding of the polyanions to the 
semen polyamines spermine, spermidine and putrescine, which are positively 
charged at neutral pH (813). 
 
A third polyanion, PRO 2000/5 (Indevus Pharmaceuticals, Lexington, USA), a 
synthetic naphthalene sulphonate polymer, is still in clinical efficacy trials (Table 
1.1.5.3.1). PRO 2000/5 is active against HIV-1 in vitro (533, 541, 832, 834, 855-
857) and against SHIV in the macaque model (812). Two large-scale efficacy 
trials of PRO 2000/5 were started. The first trial, funded by the USA National 
Institute of Health, is carried out in 3220 women using PRO 2000/5, Buffergel, a 
placebo or condom. The second trial, sponsored by the UK Medical Research 
Council, aimed to compare two different concentrations of PRO 2000/5. In 
February 2008, it was announced that one arm of the second trial was going to be 
discontinued due to lack of evidence of a protective effect in women (858). This 
arm of the clinical trial tested the efficacy of a 2% formulation of the PRO 
2000/5 gel compared to a placebo gel. The remaining arm of the trial, testing the 
efficacy of a 0.5% formulation of PRO 2000/5 in a total of 9395 women, will, 
however, be continued (859). 
 
HIV-1 entry inhibitors that specifically bind to gp120 or gp41 are also being 
developed and evaluated as candidate microbicides (787, 788). These compounds 
include lectins, which recognise glycans on the viral envelope glycoproteins. 
Several plant lectins have been reported to have HIV-1 inhibitory activity (860-
863). One of the most extensively studied lectin candidates is cyanovirin-N, 
which is originally isolated from the cyanobacterium Nostoc ellipsosporum. It 
recognises α1,2-mannose glycans on gp120 (864) and inhibits HIV-1 infection in 
vitro (865). Topical application of cyanovirin-N has been shown to prevent 
infection of macaques after vaginal SHIV challenge (808, 809). 
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In addition to lectins, mAbs to gp120 and gp41 are also being considered for 
microbicides use (787, 788). These mAbs include anti-gp120 mAbs b12 and 
2G12 and anti-gp41 mAb 2F5, which will be discussed in further detail in section 
1.1.6. Vaginal application of the anti-gp120 mAb b12 has been shown to protect 
macaques against vaginal SHIV challenge (668). PRO 542, which is a tetravalent 
construct consisting of CD4 fused to an IgG2 immunoglobulin has been shown to 
inhibit HIV-1 infection in cervical explant models (538, 866) and could be a 
potential microbicide candidate. 
 
Small molecules may offer advantages in terms of cost and large-scale 
production over large proteins such as full immunoglobulins (794). The small 
molecule BMS-378806 binds to gp120 and inhibits HIV-1 entry in vitro (867-
870) and in the macaque model (871) and may be useful in microbicide 
development. Peptides based on the second heptad repeat in gp41 (section 1.1.6), 
which can inhibit fusion of viral end cellular membranes, are other small 
molecules being considered as candidate microbicides (787). The gp41 peptide 
and fusion inhibitor Enfuvirtide (T-20) is already approved as a therapeutic for 
HIV-1 infection (703, 872) and could be a potential microbicide candidate (787). 
The gp41 peptides T-1249 and C52L can inhibit SHIV infection of macaques 
after vaginal challenge (787, 871). Small molecules such as CD4 mimics (873) 
and RNA aptamers binding to gp120 and able to inhibit HIV-1 infection (874, 
875) might also be potential microbicide candidates. 
 
Other entry inhibitors considered as microbicide candidates target the HIV-1 
cellular receptors, CD4, CXCR4 or CCR5. Vaginal application of PSC- 
RANTES, a modified form of the CCR5 ligand RANTES, has been shown to 
protect macaques against vaginal SHIV challenge (804). PSC-RANTES causes 
internalisation and down-regulation of CCR5, which is thought to contribute to 
its anti-HIV-1 activity (804, 876-878). The small CCR5-binding molecule 
CMPD167 can also inhibit vaginal transmission of CCR5-using SHIVs to 
macaques (871). PSC-RANTES and CMPD167 may hence be potential 
microbicide candidates, as may the CCR5 antagonist Maraviroc (704), which has 
been licensed for treatment of HIV-1 infection, and the anti-CCR5 mAb PRO 
140, which has been tested in clinical trials as an injectable therapeutic (879). In 
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addition, a range of other CCR5-binding compounds have been tested for 
antiviral and microbicide activity in in vitro studies and animal models (787, 
788). Compounds targeting CXCR4 are also being developed. The CXCR4-
binding small-molecule AMD3465 (880) is, for example, currently being 
evaluated in the macaque transmission model (787). Small molecules (881) and 
mAbs (882) that inhibit HIV-1 infection by binding to CD4 on target cells are 
also of potential interest, as are certain cyclotriazadisulfonamide (CADA) 
molecules, which have been shown to downregulate CD4 in a reversible fashion 
(883). 
 
In summary, a large number of HIV-1 entry inhibitors have been assessed for 
microbicide activity in preclinical studies. However, apart from the polyanions, 
no entry inhibitors have so far been evaluated as microbicides in clinical trials in 
humans. 
 
With disappointing results in all clinical efficacy trials completed to date (Table 
1.1.3.5.1), increasing efforts are being made to develop microbicides containing 
existing antiretroviral drugs such as the NRTIs and NNRTIs (787, 795). One 
candidate, a gel containing the NRTI Tenofovir, has so far advanced to large-
scale clinical efficacy trials (Table 1.1.5.3.1). In preclinical studies, rectal 
application of Tenofovir has been shown to protect macaques from SIV infection 
following rectal challenge (884). Microbicides containing the NNRTIs 
Dapivirine (TMC120) and UC-781 are currently being evaluated in safety trials 
(787). Combination microbicides, such as microbicides containing a mix of 
carrageenan and NNRTIs, are also being explored (885). Whether the use of 
NRTIs and NNRTIs for HIV-1 prevention will contribute to the spread of HIV-1 
resistance to the same drugs remains unclear (886, 887). 
 
Since the mucosal layer contains dendritic cells that can bind HIV-1 and possibly 
mediate transport of HIV-1 to lymph nodes, agents that are able to block binding 
of DC-SIGN to HIV-1 have also been under evaluation as microbicides (788). 
These agents include mannan, an oligosaccharide rich in mannose, which has 
been shown to bind to DC-SIGN and to block DC binding to HIV-1 gp120 (474). 
However, when tested in the macaque model, topical application of mannan 
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failed to protect against vaginal SHIV challenge (871), highlighting the notion 
that the role of DC-SIGN in HIV-1 transmission remains unclear and that a better 
understanding of the exact mechanism of HIV-1 transmission is important for 
microbicide design. 
 
Table 1.1.5.3.1. Microbicide candidates that have entered efficacy trialsa. 
Candidate Typeb Status/outcome 
Nonyxol-9 film S Completed, no effect on incidence 
Nonyxol-9 gel S Completed, increased incidence 
Savvy™ (C31G) S Halted due to too low incidence 
Ushercell™ (cellulose sulphate) PA Halted due to increased incidence 
Carraguard™ PA Completed, no effect on incidence 
2% PRO 2000/5 PA Halted due to lack of effect 
0.5% PRO 2000/5 PA Ongoing 
Buffergel and 0.5% PRO2000/5 BA, PA Ongoing 
Tenofovir NRTI Ongoing 
aMicrobicide candidates that have entered large-scale clinical efficacy trials, as of September 
2008, based on information compiled and presented by the Alliance for microbicide development 
(888) and van de Wijgert et al. (797). 
bS, Surfactant; PA, polyanion; BA, buffering agent; NRTI, nucleotide analogue reverse 
transcriptase inhibitor. 
 
In addition to developing compounds with anti-HIV-1 activity, emphasis has also 
been put on the development of microbicide formulations and delivery systems 
(788). Most of the microbicides evaluated in clinical trials to date have been 
formulated as gels to be applied intravaginally or intrarectally. However, films, 
foams and tablets are also under development, as are sustained-release devices 
like vaginal rings (889). Vaginal rings slowly releasing the NNRTI TMC-120 
have been developed and evaluated in preclinical systems (890), and clinical 
safety studies are underway. 
 
Live commensal bacteria engineered to express HIV-1 inhibitors and able to 
colonise the vagina or rectum may also offer a promising delivery system. For 
example, Chang et al. (891) engineered a human vaginal isolate of Lactobacillus 
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jensenii to secrete a two-domain version of CD4, which showed HIV-1 inhibitory 
effects in vitro. Lactobacilli expressing surface-associated two-domain CD4 have 
also been generated (892). Similarly, Rao et al. (893) engineered a probiotic 
Escherichia coli (E. coli) strain to express HIV-1 fusion inhibitors, whereas 
Pusch et al. (894, 895) developed lactobacilli strains engineered to express either 
the plant lectin cyanovirin-N or HIV-1 fusion inhibitors. The use of live 
lactobacilli as microbicides may also enhance the natural vaginal defences 
against HIV-1 and other pathogens (823). Using genetically engineered 
organisms as microbicides might, however, cause controversy, similar to the 
controversy caused by genetically modified food. 
 
1.1.6 A closer look at HIV-1 envelope, entry and neutralisation 
The HIV-1 envelope glycoproteins are the main targets for neutralising 
antibodies. The work in this thesis will focus on camelid antibodies to the CD4-
binding site (CD4bs) of the HIV-1 envelope glycoprotein gp120. The structure 
and properties of the HIV-1 envelope spike as well as the mechanism behind 
HIV-1 entry and neutralisation will therefore be further reviewed in this section. 
 
1.1.6.1 Structure and distribution of the HIV-1 envelope spike 
The HIV-1 envelope spike is made up of the surface glycoprotein gp120 and the 
transmembrane glycoprotein gp41 (128-131). The surface glycoprotein gp120 is 
weakly associated with the membrane-spanning gp41 via non-covalent 
interactions between discontinuous structures in its N- and C-terminal regions 
and the ectodomain of gp41 (896). The functional HIV-1 envelope spike exist as 
a trimer of the gp120/gp41 heterodimers (138-140, 260, 261). In addition to 
functional trimeric spikes, there is evidence for non-functional spikes on the 
virus surface, such as gp120/gp41 monomers and gp41 stumps formed after 
shedding of gp120 (141, 142, 897). Non-functional spikes could also include 
different isoforms of gp120/gp41 trimers as well as trimers or other oligomeric 
forms of uncleaved gp160 precursor (142). 
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The transmembrane protein gp41 contains a cytoplasmic tail, a membrane-
spanning domain and an ectodomain (139). The ectodomain consists of a fusion 
peptide, an N-terminal helical heptad repeat (N-HR), a loop region, a C-terminal 
heptad repeat (C-HR) and a membrane-proximal external region (MPER). The 
ectodomain is thought to be responsible for oligomerisation (898, 899). High-
resolution structural data is available for the gp41 ectodomain in its fusogenic 
state, revealing a six-helix bundle consisting of a central parallel trimeric coiled-
coil of the three N-HR helices, surrounded by the three C-HR helices in an anti-
parallel hairpin fashion (261, 900). Formation of the six-helix bundle is essential 
for fusion of the cellular and viral membranes. Little is known, however, about 
the pre-fusion structure of gp41 in the native spike, prior to interaction of the 
spike with cellular receptors. Antibody binding studies have indicated that in the 
context of the functional spike, gp41 is relatively occluded from recognition by 
antibodies (901-904). Immunising rabbits with an engineered recombinant 
trimeric molecule containing the ectodomain of gp41 and the C1 and C5 regions 
of gp120, and reported to keep gp41 in a pre-fusion configuration, has supported 
these observations, as it failed to elicit neutralising antibodies (905). The MPER 
is, however, accessible to antibodies, at least on a fusion intermediate form of 
gp41, as demonstrated by the isolation of neutralising antibodies directed against 
it (906-908). There are two atomic structures available of fragments of the 
MPER in complex with two neutralising antibodies, 2F5 and 4E10 (909, 910). 
The fusion inhibitor Enfuvirtide (T-20) is based on the C-HR and binds to the N-
HR (703, 872). 
 
The surface glycoprotein gp120 consists of five conserved (C1-C5) and five 
variable (V1-V5) regions (911-913). Prior to any high-resolution structural 
knowledge, antibody competition and mutational studies provided insight into 
the function and spatial location of the various gp120 regions (896, 914-919). 
Data from antibody competition studies predicted the variable regions to be 
located on the outside of gp120, as they were well-exposed to antibodies, 
whereas the constant regions were less exposed (917, 919). The C1 and C5 
regions were concluded to be the regions interacting with gp41, as they were 
found to be accessible to antibodies on recombinant monomeric gp120 but not in 
the context of gp120/gp41 constructs (917, 918) and since mutations in these 
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regions could abolish gp120/gp41 interactions (896). Similarly, observations 
made in mutational studies also indicated that the variable regions mask more 
conserved sites of gp120, such as the CD4bs (914, 915). For example, antibodies 
to the receptor-binding sites have been observed to bind with higher affinity to 
gp120 with deleted V1, V2 and V3 regions (914, 917, 920-922). Deletions in the 
V4 region has been observed to result in impaired folding and processing of 
gp160 into gp120 and gp41 subunits (914). In early studies, CD4 binding was 
observed to be dependent of sequences within the C3 and C4 regions (414, 923, 
924). 
 
The first high-resolution structural data came in 1998, when Kwong et al. (348) 
used X-ray crystallography to solve the atomic structure of a deglycosylated 
gp120 core (lacking the more flexible V1, V2 and V3 regions as well as the N- 
and C-termini) from the TCLA isolate HXB2 and liganded to soluble CD4 
(sCD4) and an antibody to a CD4-induced epitope, 17b. The crystal structure of a 
primary isolate gp120 core liganded to sCD4 has since been solved and found to 
be more or less superimposable with the HXB2 structure (925). In 2005, the 
atomic structure of a fully glycosylated and unliganded SIV gp120 core was 
solved by Chen et al. (926), providing further valuable insight into the 
conformational features of gp120. Structural data on the V3 region in the context 
of gp120 was also obtained in 2005, when Huang et al. (927) reported the 
structure of a V3-containing gp120 core liganded to sCD4 and X5, an antibody to 
a CD4-indiced epitope, revealing that the V3 forms a 50 Å long and 15 Å wide 
structure that protrudes from the core, confirming observations made in 
mutagenesis and antibody binding studies and further explaining its 
immunodominant properties. The tip of the V3 region, consisting of a β-hairpin 
structure, was found to be structurally conserved, as it displayed similar 
conformations in the settings of the gp120 core and as a free peptide or in the 
context of V3 peptide-antibody complexes (927). 
 
The first structure reported by Kwong et al. (348) revealed that the core of 
monomeric, CD4-liganded gp120 has the approximate dimension of 50 × 50 × 25 
Å and is made up of five α-helices, twenty-five β-strands and ten loop segments, 
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all arranged into an outer and an inner domain linked by a bridging sheet (Fig. 
1.1.6.1.1). The inner domain is made up predominantly by the C1 and C5 regions 
and is suggested to be the gp41 interaction site, based on its lack of glycosylation 
and its sequence conservation (348, 928), as well as the above mentioned 
antibody binding and mutagenesis studies (917, 919). The bridging sheet consists 
of four anti-parallel β-strands organised into the β2-β3 and β20-β21 ribbons 
(348). The V1 and V2 regions stem from the β2-β3 ribbon. The outer domain is 
thought to be located on the outside of the envelope spike and contains the V3, 
V4 and V5 variable regions (348, 927). It is heavily glycosylated, making it less 
visible to the host immune system (348, 928). 
 
The CD4bs lies at the interface of the outer domain, the bridging sheet and the 
inner domain (Fig. 1.1.6.1.1), and covers more than 800 Å2 of the gp120 surface 
(348). Twenty-six amino acid residues in gp120 make contact with twenty-two 
residues in the D1 domain of CD4 (348). In gp120, these residues are located in 
the stem of the V1/V2 region (one residue), the β20-β21 ribbon of the bridging 
sheet (six residues), the connection between an α-helix in the inner domain and a 
β-strand in the outer domain (four residues), and a loop (four residues), a 
β−strand (five residues) and an excursion made up by an α-helix and a β-strand, 
referred to as the CD4-binding loop (six residues), in the outer domain (Fig. 
1.1.6.1.1.). The CD4-gp120 interaction is mainly electrostatic but also results 
from 219 van der Waals contacts and twelve hydrogen bonds (348). Around 60% 
of the contacts are made by main-chain atoms in gp120, allowing for gp120 
sequence variability. 
 
The interface of gp120 and CD4 contains two large cavities (348). The larger 
cavity is 279 Å3 in size, lined primarily by hydrophilic residues and water-filled. 
The gp120 residues lining this cavity are highly variable, probably aiding the 
ability of HIV-1 to escape recognition by antibodies to CD4bs-related epitopes. 
The smaller cavity is 152 Å3, extends approximately 10 Å into the centre of 
gp120 and is lined mainly by highly conserved, hydrophobic residues. The 
phenylalanine-43 (Phe43) residue of CD4, responsible for 23% of the interatomic 
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contacts CD4 makes with gp120, reaches in to and interacts with this cavity, 
forming a lid at one end. 
 
Comparison of the CD4-liganded HIV-1 gp120 and the unliganded SIV gp120 
structures (Fig. 1.1.6.1.1) has demonstrated that binding of CD4 to gp120 results 
in substantial conformational changes in gp120 (926). This observation is in 
agreement with antibody binding experiments using gp120 complexed to sCD4 
(901), and the unusually large reduction in entropy that have been observed for 
gp120 upon binding to CD4 in thermodynamic studies carried out by Myszka et 
al. (929). The high entropy of the unliganded gp120 indicates conformational 
flexibility in the absence of CD4 (929), in keeping with observations made in 
mathematical modelling experiments, which have indicated that free gp120 may 
oscillate to assume a conformation resembling the CD4-bound state (930). In 
further support of these notions, Ashish et al. (931) have reported a set of 
solution small-angle X-ray scattering experiments of a fully glycosylated, full-
length gp120 in its unliganded state and bound to sCD4, demonstrating a gp120 
structure with several protrusions, some of which undergo substantial 
conformational rearrangements upon CD4 binding. 
 
According to the atomic structural data reported by Kwong et al. (348) and Chen 
et al. (926), it is predominantly the inner domain of gp120 that has undergone 
extensive rearrangements, whereas the outer domains of both the unliganded and 
the CD4-liganded gp120 structure have essentially the same conformation. 
Moreover, in the unliganded structure, the bridging sheet does not exist; even 
though its two β-ribbons are present, they are separated by up to 25 Å (926). The 
CD4bs, as seen in the CD4-liganded state, is not present in the unliganded gp120 
(Fig. 1.1.6.1.1). Instead, in the unliganded gp120, many of the residues involved 
in CD4 binding are located in a long, narrow and hydrophobic cavity made up by 
the α-helices of the inner domain, part of the outer domain and the β20-β21 
ribbon, explaining the relative inaccessibility of the CD4bs to many antibodies. 
The position of the V1 and V2 stem indicates that the V1 and V2 regions may 
cover part of the inner domain, including this cavity, whereas the V3 region may 
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cover the β20-β21 ribbon (926). The V1 and V2 regions have been suggested to 
make contact the V3 region of another gp120 subunit in the spike (926, 932). 
 
The co-receptor binding site is less well-defined than the CD4bs, as there is no 
available crystal structure of gp120 bound to any of the co-receptors. Instead, 
insight into the gp120-co-receptor interaction has come from mutagenesis studies 
and from studies of the interaction of gp120 with antibodies to CD4-induced 
epitopes, as well as from recent NMR data. The V3 region of gp120 has been 
shown to be critical for co-receptor binding (933-937) and is thought to interact 
with the second extracellular loop of the co-receptor (376-378). In addition to the 
V3 region, several highly conserved amino acid residues in the gp120 core have 
been shown to have a role in co-receptor binding (938, 939) and to interact with 
the N-terminus of the co-receptor (376-378). A recent NMR structure of the N-
terminus of CCR5 bound to CD4-liganded gp120, reported by Huang et al. 
(379), have supported these data, demonstrating that the CCR5 N-terminus binds 
to a site at the interface of the bridging sheet and the stem of the V3 region in 
gp120. 
 
In the CD4-liganded gp120 core structure, the residues implied to be involved in 
co-receptor binding are located close to each other (Fig. 1.1.6.1.1), in the region 
connecting the gp120 bridging sheet and the outer domain and close to the V3 
region (938, 939). In the unliganded structure, however, they are separated, in 
keeping with the notion that the co-receptor binding site is only assembled and 
presented after CD4 binding (139, 259, 926, 934-936). The structures of the 
liganded and unliganded gp120 core constructs, solved by Kwong et al. (348) 
and Chen et al. (926), are shown in Fig. 1.1.6.1.1. 
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Figure 1.1.6.1.1. Ribbon diagrams of HIV-1 and SIV gp120 cores. The left panel shows the 
structure of a deglycosylated HIV-1 HXB2 gp120 core (lacking the V1/V2 and V3 variable 
regions and with truncated N- and C-termini), liganded to sCD4 and an antibody to the CD4-
induced site, solved by Kwong et al. (348) The structure is shown from the perspective of CD4. 
The right panel shows the structure of a fully glycosylated, unliganded SIV gp120 core solved by 
Chen et al. (926). In the top panel, the bridging sheet is shown in orange, and the outer and inner 
domains are shown in yellow and blue, respectively. The positions of the variable regions and the 
N- and C-termini are also indicated. The location of the cavity into which the CD4 Phe43 residue 
binds is indicated by an asterisk. In the lower panel, the amino acid residues in contact with CD4 
in the liganded state are shown in orange and residues that have been shown to influence co-
receptor binding are shown in green. The figure is obtained from Pantophlet, R., and D. R. 
Burton, 2006, ‘GP120: target for neutralizing HIV-1 antibodies’, Annual Review of Immunology, 
24:739-69. 
 
All high-resolution structures of HIV-1 envelope glycoproteins solved so far are 
of recombinant monomeric gp120, gp41 peptides or gp41 in its fusogenic state. 
While these structures give invaluable insight into the mechanisms behind HIV-1 
entry into host cells and interaction with and evasion of neutralising antibodies, 
they might not be good representatives of the envelope glycoproteins as they 
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appear in the functional envelope spike, as the conformation and accessibility to 
antibodies of gp120 and gp41 in the context of the spike are likely to be affected 
by intra-spike interactions between gp120 and gp41 subunits, and by the 
proximity to the viral membrane. This notion is illustrated by the observation that 
antibody ability to bind to recombinant proteins does not necessarily correlate 
with ability to neutralise the corresponding virus (141, 142, 623-626, 897, 940). 
Instead, neutralisation has been shown to depend on the ability to recognise 
functional envelope spike (141, 142, 624-626, 897). Obtaining a high-resolution 
structure of the functional envelope spike would have obvious implications for 
understanding HIV-1 entry into cells, recognition by antibodies, and vaccine 
design. However, due to the labile and flexible nature of the spike and the high 
carbohydrate content, obtaining X-ray crystallographic data has been shown to 
be difficult. 
 
In the absence of high-resolution structures, electron microscopy and electron 
microscopy tomography experiments have provided some insight into the three-
dimensional nature of native HIV-1 spikes. Initial data came from Center et al. 
(941, 942), who used scanning electron microscopy to show that the majority of 
detergent-solubilised SIV and HIV-1 spikes are trimeric. Subsequently, in 2003, 
Zhu et al. (943) reported data from electron microscopy tomography studies, 
demonstrating trimeric spikes on the surface of chemically fixed HIV-1 and SIV 
virions, providing the first conclusive evidence for the presence of trimers on 
actual virions. Both HIV-1 and SIV had an average of 8-10 trimers per virion on 
their surface, correlating with the envelope glycoprotein content as analysed by 
biochemical assays (943). Heterogeneity was observed among different spikes, 
possible reflecting the heterogeneity and the existence of non-functional spikes 
predicted by observations made using biochemical assays (142). 
 
However, due to artefacts associated with the chemical fixing procedure, the 
envelope spikes could not be viewed in much detail. Zhu and colleagues 
therefore went on to using cryo-electron microscopy tomography to study the 
three-dimensional structure of envelope spikes on frozen, unfixed, unstained and 
hydrated HIV-1 and SIV particles. Their results were published in 2006 (140), 
showing that wild-type HIV-1 virions are around 110 nm in diameter and have 
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an estimated 14 ± 7 spikes per virion (ranging from 4 to 35, n = 40). 
Interestingly, the spikes were observed to cluster together rather than being 
uniformly dispersed on the virion surface. To facilitate the analysis of individual 
spikes, they used a mutant form of SIV, containing gp41 with a truncated 
cytoplasmic tail lacking endocytosis signals, resulting in higher levels of spikes 
on the virus surface. Cryo-electron tomography data for a total of 6175 spikes 
were used to generate an average three-dimensional density map. The results 
show a multi-lobed structure with a height of 13.7 nm, a diameter of 10.5 nm, 
and a tripod-like foot consisting of three well-separated legs (Fig. 1.1.6.1.2 A). 
The tripod-like feature has also been observed in cryo-electron tomography 
studies of the MMLV envelope spike (944). 
 
Three months after the report by Zhu et al. (140), Zanetti et al. (138) reported a 
second three-dimensional, low-resolution structure of a virion-associated SIV 
envelope spike based on cryo-electron tomography data (Fig. 1.1.6.1.2 B). Data 
from a total of 2986 spikes from 77 virions were used to create the three-
dimensional reconstruction, revealing a structure made up of three distinct gp120 
subunits on top of a narrow gp41 stalk (138), of similar height and width but 
rather different in shape compared to the tripod-like structure predicted by Zhu 
and colleagues (Fig. 1.1.6.1.2 A and B). The structure suggested by Zanetti et al. 
(138) is 120 Å in height and 110 Å in diameter, and, interestingly, has a cavity at 
the interface of gp120 and gp41. Whether the differences between the three 
suggested structures are a result of differences in methodology or limitations of 
the electron tomography technique, or whether they represent true spike 
heterogeneity remains unclear (945, 946). 
 
In 2008, Liu et al. (947) reported a third three-dimensional spike structure based 
on a density map average of cryo-electron tomographic data for 4741 HIV-1 
envelope spikes. This structure is similar in dimension to the previous SIV 
structures, with a height of 120 Å and a maximal width of 150 Å, but is rather 
different in shape, being held together by contacts at the gp41 base and at the tip 
of the trimer (Fig. 1.1.6.1.2 C). It does, however, share the narrow gp41 stalk 
feature predicted by Zanetti et al. (138). Fitting of gp120 atomic structures into 
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the density map provides further insight into the spike structure. In the report by 
Liu et al. (947), it indicates that the variable regions and the glycosylated 
residues of gp120 are located on the outside of the spike in solvent accessible 
regions, in keeping with previous predictions (932). The CD4bs is located about 
20Å from the top of the spike in a recessed cavity, covered by the V1 and V2 
regions (947). The V3 region is also suggested to be located towards the top of 
the spike. 
 
Liu et al. (947) also carried out cryo-electron microscopy tomography analysis 
for an HIV-1 spike liganded to sCD4 and mAb 17b. The obtained average 
density map shows that the spike undergoes drastic quaternary conformational 
rearrangements upon CD4 binding (Fig. 1.1.6.1.2 D). This observation is 
consistent with previous reports of conformational changes in recombinant HIV-
1 envelope glycoproteins upon binding to CD4 (901, 902, 926, 929-931), as 
discussed above. The presence of sCD4 and mAb 17b allows for an 
unambiguous fit of the atomic structure of gp120 bound to sCD4 and 17b into the 
spike density map, providing valuable insight into the nature of the 
conformational changes (947). This fit indicates that, upon CD4 binding, each 
gp120 monomer undergoes considerable rotation by up to 45°, resulting in a 
vertical upward displacement of gp120, a more open spike structure, and 
exposure of the gp41 stalk (Fig. 1.1.6.1.2 D). Furthermore, the V1, V2 and V3 
regions are suggested to move so that the V1 and V2 regions point away from the 
centre of the spike, whereas the V3 region point towards the target cell 
membrane (947). These observations are likely to further the understanding of 
HIV-1 interaction with cellular receptors and entry into target cells, which has 
implications for vaccine design. 
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Figure 1.1.6.1.2. Three-dimensional models of the SIV and HIV-1 envelope spikes based on 
cryo-electron tomography studies. A. Density map of an unliganded SIV envelope spike 
constructed by Zhu et al. (140). Image obtained from Zhu, P., J. Liu, J. Bess, Jr., E. Chertova, J. 
D. Lifson, H. Grise, G. A. Ofek, K. A. Taylor, and K. H. Roux, 2006, ‘Distribution and three-
dimensional structure of AIDS virus envelope spikes’, Nature, 441:847-52. Reprinted by 
permission from Macmillan Publishers Ltd. B. Density map of an unliganded SIV envelope spike 
constructed by Zanetti et al. (138). Image obtained from Zanetti, G., J. A. Briggs, K. Grunewald, 
Q. J. Sattentau, and S. D. Fuller, 2006, ‘Cryo-electron tomographic structure of an 
immunodeficiency virus envelope complex in situ’, PLoS Pathogens, 2:e83. C-D. Density maps 
of an unliganded HIV-1 envelope spike (C) and an HIV-1 envelope spike complexed with sCD4 
and mAb 17b (D), constructed by Liu et al. (947), with the atomic structure of gp120 liganded to 
sCD4 and mAb 17b fitted into the model. Images obtained from Liu, J., A. Bartesaghi, M. J. 
Borgnia, G. Sapiro, and S. Subramaniam, 2008, ‘Molecular architecture of native HIV-1 gp120 
trimers’, Nature 455:109-13. Reprinted by permission from Macmillan Publishers Ltd. 
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1.1.6.2 HIV-1 entry into cells 
Most variants of HIV-1 enter cells through interaction with the main cellular 
receptor CD4, followed by interaction with a co-receptor, usually CCR5 or 
CXCR4. Binding to the cellular receptors eventually leads to gp41-mediated 
fusion of the viral and cellular membranes. A schematic representation of the 
main viral and cellular elements involved in HIV-1 entry into target cells is 
shown in Fig. 1.1.6.2.1. The exact mechanisms behind HIV-1 entry remain 
unclear. Insight into the entry process has, however, come from several studies, 
some of which are discussed below. 
 
 
 
 
 
 
 
 
 
 
Figure 1.1.6.2.1. Schematic representation of the main viral and cellular elements involved 
in HIV-1 entry into target cells. The functional HIV-1 envelope spike consists of trimers of the 
surface glycoprotein g120 non-covalently bound to the membrane-spanning gp41. HIV-1 entry 
into target cells is initiated by association of gp120 with the main cellular receptor CD4. This 
engagement triggers conformational changes in the envelope spike, exposing the co-receptor 
binding site. CD4-bound gp120 then engages with a cellular co-receptor, typically CCR5 or 
CXCR4, resulting in a series of events eventually leading to the fusion of viral and cellular 
membranes. Details are given in the text. 
 
The HIV-1 entry process is initiated by attachment of the gp120 subunit of the 
viral envelope spike to the primary cellular receptor CD4 (52, 53). This 
interaction is thought to be one of the main rate-limiting events in the HIV-1 
entry process (948-951). The initial HIV-1 attachment step can be influenced by 
interactions between host-derived molecules incorporated into the viral 
membrane and their natural ligands on target cells (952). These interactions, 
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although not necessary for virus entry, can enhance the rate of adhesion and the 
efficiency of gp120 binding to CD4. For example, it has been suggested that 
interaction of host-derived intracellular adhesion molecule 1 (ICAM-1), present 
on HIV-1 particles, with its ligand lymphocyte function-associated molecule 1 
(LFA-1) can enhance infectivity (953-955). 
 
Binding of gp120 to CD4 triggers a series of conformational rearrangements in 
gp120 and in the envelope spike as a whole (348, 901, 902, 926, 929, 947), as 
discussed in section 1.1.6.1, allowing for exposure of the co-receptor binding site 
and interaction with either of the main cellular co-receptors CCR5 or CXCR4 
(933-937). The V3 loop determines co-receptor usage and thereby cell tropism, 
as initially demonstrated by Hwang et al. (417) in 1991. More specifically, co-
receptor use seems to be associated with the net charge of the V3 region, as the 
V3 regions of CXCR4-using viruses seem to have a higher net positive charge 
than those of CCR5-using viruses (421). However, even though the V3 region is 
the major determinant, sequence changes in the V1, V2, C3 and C4 regions of 
gp120 and in gp41 have also been shown to have a role (418, 420-422). 
 
Binding of gp120 to CD4 and subsequently to a co-receptor results in 
conformational changes in gp41, leading to the formation of a pre-hairpin 
intermediate, insertion of the gp41 fusion peptide into the host cell membrane, 
and finally fusion of viral and cellular membranes (951, 956). The details of this 
fusion reaction remain unclear. However, the pre-hairpin intermediate 
conformation is believed to be in the form of an energetically unstable three-
helix rod (945, 956). The formation of this pre-hairpin intermediate and the 
insertion of the fusion peptide is thought to be followed by the energetically 
favoured formation of a six-helix bundle (957). This six-helical bundle is made 
up of the N-HR and C-HR of gp41, is energetically stable, and forms when the 
three C-HR domains fall back in a hairpin configuration into the hydrophobic 
grooves formed by the three N-HR domains (261, 900). 
 
Melikyan et al. (958) have shown, using suboptimal and optimal temperatures to 
modulate fusion rate, in combination with fusion inhibitory peptides such as the 
T-20 (872) and membrane-damaging agents such as lysophosphatidylcholine, 
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that the formation of the six-helix bundle coincides with fusion of the viral and 
cellular membranes. Based on these observations, it has been suggested that it is 
the actual formation of the six-helix bundle, and not the configuration of the 
bundle itself, that induces fusion by bringing the viral and cellular membranes in 
close proximity to each other, aided by the energy release associated with bundle 
formation (956, 958). 
 
The number of spikes needed for HIV-1 entry into target cells is unknown. Yang 
et al. (959, 960), using the methodology described by Schønning et al. (961), 
produced viruses bearing mixed heterotrimers containing different ratios of wild-
type and dominant-negative envelope glycoproteins to estimate the minimal 
number of envelope spikes required for infection, and found that one functional 
spike per virion was sufficient. In contrast, influenza virus infection required 
eight to nine spikes per virion. In a subsequent study, Yang et al. (962) observed 
that only two out of the three gp120/gp41 subunits needed to be functional in 
order for infection to take place. In a set of similar experiments, using virus 
bearing mixed heterotrimers of cleavage-incompetent gp160 and wild-type 
gp160, Herrera et al. (963) estimated that at least four to five functional spikes 
are needed to support infection. More work is needed to elucidate the number of 
spikes required and the precise stochiometry of HIV-1 entry into target cells. 
 
Further insight into the HIV-1 entry process is given by a recent report by 
Sougrat et al. (964), who used electron tomography to determine the three-
dimensional architectures of SIV and HIV-1 particles in contact with T cells. 
Their results show that the contact region between virus and target cell is around 
400 Å and contains five to seven rod-like structures, assumed to be the viral 
spikes (Fig. 1.1.6.2.2). This observation is in keeping with previous observations 
indicating that multiple envelope spikes and receptors are present at the HIV-1 
fusion pore (965, 966). Sougrat and colleagues term this contact region the ‘entry 
claw’. Interestingly, the viral surface not in contact with the target cell seems to 
be devoid of viral spikes, even for SIV particles observed to have up to a hundred 
viral spikes pre-contact with target cells. Further work is needed to elucidate the 
in vivo relevance and mechanisms of the formation of the ‘entry claw’, as well as 
the stage of viral entry that it represents. 
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Figure 1.1.6.2.2. Electron tomography of an HIV-1 particle in contact with a CD4+ T cell. 
A-D. Single slices of an electron tomogram of the contact between a virus particle and a CD4+ T 
cell. E. Three-dimensional model of an HIV-1 particle in contact with a T cells, showing the viral 
core in yellow, the viral membrane in magenta, the T cell membrane in blue and the contact rods 
in red. Image obtained from Sougrat, R., A. Bartesaghi, J. D. Lifson, A. E. Bennett, J. W. Bess, 
D. J. Zabransky, and S. Subramaniam, 2007, ‘Electron tomography of the contact between T cells 
and SIV/HIV-1: implications for viral entry’, PLoS Pathogens, 3:e63. 
 
In addition to the cell-free virus dissemination and entry into target cells, 
intercellular spread of HIV-1 is also thought to take place. This means of 
transmission has been suggested to be predominant mode of HIV-1 spread, and 
moreover to be up to a thousand times more efficient than cell-free transfer (967, 
968). For example, HIV-1 has been observed to transfer from infected to 
uninfected cells via a so-called virological synapse (470, 969, 970). This transfer 
has been shown to be dependent on HIV-1 envelope glycoprotein and CD4. Cell-
cell transfer has also been suggested to occur across filopodial bridges formed 
between a viral envelope spike on the infected cell and a cellular receptor on the 
target cell (971). Furthermore, data reported by Sowinski et al. (972) have 
indicated that HIV-1 can transfer from infected to uninfected CD4+ T cells 
across so-called nanotubes in a CD4-dependent manner. While it has been 
suggested that cell-cell spread allows for more rapid replication kinetics and 
helps the virus to evade host antibody responses, more work is needed to 
elucidate the relevance of these mechanisms and the relative contributions of 
cell-cell and cell-free spread in vivo (972, 973). 
 
 117
1.1.6.3 Antigenic properties of the HIV-1 envelope glycoproteins 
In the mid-1990s, antibody competition analysis revealed that, antigenically, 
gp120 possesses a non-neutralising and a neutralising face (919), a notion which 
was later supported by high-resolution structural data (348, 928). The non-
neutralising face, which is located on the inner domain of gp120, contains a 
number of epitopes for non-neutralising antibodies (919) and consists of regions 
that are buried within the trimer and that interact with gp41 or other gp120 
protomers. These regions, which are accessible on non-functional spikes on the 
virus surface (141, 142) and on shed gp120, are highly immunogenic (974-976) 
but do not elicit neutralising antibodies (919, 928). The neutralising face of 
gp120 includes parts of the bridging sheet and the inner and outer domains, 
including the V2 and V3 regions (928). It contains the receptor-binding sites and 
epitopes for a number of neutralising antibodies (259, 919). However, conserved 
and functionally important regions of gp120, such as the CD4bs, are often 
occluded from antibody recognition (259). Moreover, as a result of the 
extraordinary genetic diversity and the immune evasive properties of gp120, 
neutralising antibodies to gp120 are typically strain-specific (259). The V3 
region is particularly immunogenic but typically elicits isolate-specific antibodies 
(259, 421). In addition to the non-neutralising and neutralising faces of gp120 
initially identified through antibody competition analyses, high-resolution 
structural data revealed an immunologically silent face of gp120, consisting of 
the highly glycosylated outer surface of the outer domain (348, 928).  
 
As discussed in section 1.1.6.1, antibody binding studies have indicated that 
gp41 is almost completely occluded from antibody recognition in the context of 
the HIV-1 envelope spike, as it is masked by glycans, gp120, and interactions 
with other gp41 molecules within the trimer (901-905). Several regions of gp41 
have, however, been found to be highly immunogenic (977-980), and a large 
number of anti-gp41 antibodies have been isolated from infected individuals 
(977, 980-982). Competition analysis has revealed that the epitopes recognised 
by these anti-gp41 antibodies can be grouped into three clusters, termed cluster I, 
II and III (977, 980). As these immunodominant regions are thought to be 
exposed only on non-functional or disassembled spikes, or on gp41 in the post-
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fusion state, the majority of anti-gp41 antibodies are non-neutralising. A few 
broadly neutralising antibodies to gp41 have, however, been isolated (section 
1.1.6.6). These antibodies are directed at the MPER, located between the viral 
membrane and the gp120-gp41 interface, which although not well-exposed on 
virus or virus-infected cells is accessible to antibodies on a fusion intermediate 
form of gp41 (906-908). Analyses of the specificity of sera from individuals with 
a broadly neutralising antibody response do, however, indicate that the 
contribution of anti-MPER antibodies is relatively small (654, 983-986). 
 
1.1.6.4 Antibody evasive properties of the HIV-1 envelope spike 
HIV-1 has evolved a number of ways to evade the humoral immune response. 
For example, as discussed in section 1.1.4.4, the high mutation rate of HIV-1 
allows for rapid escape from neutralising antibodies, and contributes to the 
extreme sequence diversity that is observed among HIV-1 isolates, particularly in 
the env gene. In addition to the high mutation rate, several other features of HIV-
1 confer protection against recognition by antibodies, the majority of which can 
be attributed to the HIV-1 envelope glycoproteins. These features, which are 
summarised in Table 1.1.6.4.1, include conformational and entropic masking, 
glycan shields, and variable regions that occlude conserved and functionally 
important receptor-binding sites. 
 
The variable regions are thought to mask receptor-binding sites (914, 915), as 
antibodies to the receptor-binding sites have been observed to bind with higher 
affinity to gp120 with deleted V1, V2 and V3 regions (914, 917, 920-922). The 
co-receptor binding site has been suggested to be masked by the V1 and V2 
variable regions (921, 922), perhaps from a neighbouring gp120 protomer (932).  
 
The glycan shield renders the outside of the envelope spike less visible to the 
immune system. It has been suggested that the glycan shield is evolving, and 
HIV-1 has been shown to reposition its glycans in order to escape neutralising 
antibodies (644, 987, 988). 
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Table 1.1.6.4.1. Antibody evasive properties of the HIV-1 envelope spike. 
Feature Comment 
Sequence 
heterogeneity 
The RT polymerase is error prone (167), giving rise to a 
high mutation rate and rapid antibody escape (622, 632, 
643, 644). 
Variable regions Conserved and functionally important receptor-binding 
sites are masked by variable regions on the surface of 
gp120 (911-913). High sequence variability in the 
variable regions allows for rapid antibody escape. 
Glycan shield Around half of gp120 is covered by complex and high-
mannose carbohydrates, which are added by the host 
cell machinery and render the underlying surface less 
immunogenic (139, 267, 270). 
Entropic and 
conformational 
masking 
The HIV-1 envelope spike is thought to exhibit a high 
degree of entropy and conformational flexibility, 
creating entropic barriers to antibody binding and giving 
the appearance of heterogeneity (929, 989, 990). The 
entry process and the conformational changes associated 
with receptor binding limit the exposure of functionally 
important and conserved regions to antibodies (901, 
922, 928). 
Non-functional 
spikes 
The presence of non-functional spikes on the virus 
surface (gp41 stumps, gp120/gp41 monomers and 
uncleaved gp160) and shed g120 may divert the 
antibody response (141, 142, 754). 
 
Thermodynamic studies carried out by Myszka et al. (929) and Kwong et al. 
(989) have shown that unliganded gp120 exhibits a high degree of entropy, 
indicating that it is conformationally flexible. Kwong et al. (989) also showed 
that binding of many non-neutralising or weakly neutralising antibodies to 
receptor-binding sites on the unliganded gp120 is accompanied by a large 
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decrease in entropy, whereas potently neutralising antibodies can bind with small 
changes in entropy. The high degree of conformational flexibility in the 
unliganded gp120 has been suggested to contribute to masking the envelope 
spike from antibodies that recognise the receptor-binding regions. A high degree 
of conformational flexibility of gp120 was also demonstrated by Yuan et al. 
(990), who fixed monomeric and trimeric gp120 constructs and probed them with 
neutralising and non-neutralising antibodies, showing that unliganded gp120 can 
adopt multiple conformations, and that potent neutralising antibodies were able 
to recognise the greatest proportion of fixed gp120 conformations. 
 
Based on these and similar observations, it has been suggested that HIV-1 uses 
entropic and conformational masking of functional sites, such as the receptor-
binding sites, to minimise recognition by antibodies (259, 754, 989, 990). 
Targeting the least conformationally variable parts of the functional envelope 
spike may be the valuable in vaccine design. Such parts could be identified by 
studying broadly and potently neutralising antibodies to the HIV-1 envelope 
glycoproteins. 
 
1.1.6.5 Specificities of anti-envelope antibodies in HIV-1 infection 
As discussed in section 1.1.6.3, a large proportion of the antibody response to 
HIV-1 in natural infection is non-neutralising and directed towards highly 
immunogenic regions accessible on non-functional or disassembled envelope 
spikes or viral debris (139, 141, 142, 623-627). The regions of gp120 and gp41 
that take part in the gp120-gp41 interaction have been found to be especially 
immunodominant (974-979). 
 
Neutralising antibodies are thought to make up only a fraction of the total 
antibody response and are often strain-specific (619, 631, 636, 638, 643-645, 
647). Many of the strain-restricted neutralising antibodies that have been isolated 
are directed at the V3 region of gp120 (991). Anti-V3 antibodies are abundantly 
elicited after immunisation as well as during natural HIV-1 infection but do 
rarely exhibit broad cross-subtype neutralisation activity (421, 992-996). 
Antibodies with relatively potent and broad neutralising activity across HIV-1 
 121
subtypes can, however, be detected in a subset of HIV-1-infected individuals, 
although little is known about the specificities that mediate this broad 
neutralisation activity (621, 641, 653, 654, 984, 985, 997-1000). In addition, it is 
not known whether broadly neutralising sera contain antibodies that target 
conserved regions on the envelope glycoproteins, or whether they contain 
polyclonal antibodies to a variety of neutralising epitopes. Further knowledge 
about the epitope specificities present in broadly neutralising sera is of obvious 
value for HIV-1 vaccine design. 
 
A recent study carried out by Li et al. (985), using adsorption and elution on a set 
of wild-type gp120 and gp120 constructs carrying mutations in the CD4bs 
followed by neutralisation experiments, has indicated that the neutralisation 
activity in broadly neutralising sera is mediated by antibodies to the CD4bs. No 
neutralising anti-MPER antibodies could be detected (985). In another study, 
Dhillon et al. (984) dissected the neutralising specificities in broadly neutralising 
sera from three HIV-1-infected but asymptomatic individuals and found that the 
neutralising activity was mediated by the IgG fraction of the sera. By using 
chimeric SIV and HIV-2 viruses grafted with HIV-1 MPER neutralising 
epitopes, they found that the specificities did not map to the MPER of gp41. 
Moreover, by evaluating the neutralisation activity of the sera in the presence and 
absence of competing V3 region peptides, they concluded that the neutralisation 
activity was not due to anti-V3 region antibodies. The same conclusion was 
made for the V1 and V2 regions. Instead, by evaluating the neutralisation activity 
after depletion on monomeric gp120, they suggest that the neutralising activities 
are due to multiple specificities and may be mediated by antibodies to the CD4bs 
of gp120, to gp120 epitopes not present on monomeric gp120, or to carbohydrate 
epitopes on gp120 (984). 
 
Similarly, Yuste et al. (986) failed to detect neutralising antibodies to the MPER 
of gp41 in serum samples from 92 HIV-1-infected individuals, by testing the 
neutralisation activity against SIV carrying HIV-1 MPER neutralising epitopes. 
Moreover, Crooks et al. (983) analysed plasma from HIV-1-infected individuals 
of varying neutralisation potencies and found that the neutralisation activity was 
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not mediated by antibodies to the MPER, as the sera were not able to inhibit 
infection of target cells post-binding of viral gp120 to CD4 and CCR5. 
 
In another study, Braibant et al. (654) used competition ELISAs to analyse the 
specificities of the antibodies in sera from LTNP, and found that all LTNP had 
antibodies that competed with the anti-CD4bs mAb b12 (section 1.1.6.6). 
Moreover, they detected higher levels of antibodies that compete with mAbs 2F5 
(anti-MPER mAb; section 1.1.6.6) and 2G12 (mAb recognising a carbohydrate 
motif on gp120; section 1.1.6.6) in LTNP sera with broad neutralising activity 
than in other LTNP sera. Some studies have also indicated that neutralising 
antibodies to CD4-induced epitopes are frequent in HIV-1-infected individuals. 
For example, Decker et al. (1001) detected antibodies that cold neutralise virus 
that had been pre-incubated with sCD4 in sera from individuals infected with 
clade A, B, C, D, F, G, and H as well as CRF01, CRF02, and CRF11. Sera from 
178 out of 189 HIV-1-infected individuals contained antibodies that could even 
neutralise HIV-2 (pre-incubated with sCD4). 
 
1.1.6.6 Neutralising antibodies to HIV-1 
Antibody-mediated virus neutralisation can be defined as a quantifiable reduction 
in virus infectivity in vitro due to the dose-dependent activity of antibodies (754, 
1002, 1003). Neutralising antibodies are thought to recognise functional spikes 
on the virus surface, whereas non-neutralising antibodies are believed to 
recognise epitopes that are exposed only on non-functional or disassembled 
envelope species, including shed gp120, gp41 stumps, gp120/gp41 monomers, 
and unprocessed trimers (141, 142, 623-626, 897, 940). 
 
The main mechanism behind antibody-mediated neutralisation of HIV-1 is 
considered to be antibody occupancy of functional viral envelope spikes (139, 
624-626, 754, 1002), with epitope specificity being less important. This notion is 
supported by the observation that the incorporation of an unrelated epitope into 
gp120 rendered a number of HIV-1 variants sensitive to neutralisation by an 
antibody to the unrelated epitope (1004). Although little is known about the 
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stochiometry behind neutralisation, it has been suggested that one antibody per 
functional envelope spike is sufficient for neutralisation (960). 
 
Some studies, however, indicate that the mechanism behind neutralisation may 
be more complex. For example, incorporation of an MPER-neutralising epitope 
into the MLV envelope spike rendered the virus sensitive to neutralisation 
(1005). Incorporation of an influenza virus neutralising epitope into the same 
region of the MLV envelope spike did, however, not render the virus sensitive to 
neutralisation. It is also possible that antibody binding may induce shedding of 
gp120, thus inactivating the viral spike (1006). A recent study has also indicated 
that binding of gp120-specific molecules to viral spikes can result in virus 
rupture. Using cryo-electron tomography techniques, Bennett et al. (1007) have 
visualised binding of D1D2-IgP, a multimeric construct consisting of CD4 fused 
to an immunoglobulin, to virus particles, showing that binding of D1D2-IgP 
correlated with virus rupture. 
 
Antibodies to HIV-1 gp120 and gp41 have provided valuable insight into the 
antigenic structure of the HIV-1 envelope spike. Studies using broadly 
neutralising mAbs have helped identifying vulnerable and conserved regions on 
the HIV-1 envelope glycoproteins. However, although many mAbs to HIV-1 
envelope have been isolated from animals post-immunisation and from humans 
following HIV-1 infection, only a handful has been found to be broadly 
neutralising across HIV-1 subtypes (754). Two of these broadly neutralising 
mAbs are directed against gp120: mAb b12, which binds to an epitope that in 
part overlaps a subset the CD4bs (1008-1012), and 2G12, which recognises a 
carbohydrate motif (981, 1013-1015). Two broadly neutralising mAbs, mAbs 
4E10 and 2F5, recognise the MPER of gp41 (906-908, 981). The Fab fragment 
X5 (1016), which recognises an epitope on gp120 that is better exposed after 
CD4 binding also display some neutralising activity across HIV-1 subtypes. All 
of the broadly neutralising mAbs reported in the literature to date are from 
individuals infected with HIV-1 of subtype B (754), although broadly 
neutralising mAbs from individuals infected with subtype C are currently being 
characterised (Davide Corti, Institute for Research in Biomedicine, Bellinzona, 
Switzerland, personal communication). 
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The anti-CD4bs mAb b12, also referred to as IgG1b12, is one of the most 
extensively studied mAbs to HIV-1 envelope. It was initially isolated in 1991 as 
a Fab fragment, through panning of a combinatorial phage library displaying 
monoclonal Fab fragments from an asymptomatic HIV-1-infected individual on 
recombinant monomeric gp120 (1011), and has since been expressed as a full 
immunoglobulin and shown to neutralise a large proportion of HIV-1 isolates 
from a wide range of subtypes (259, 1009, 1010, 1012, 1017) and to protect 
macaques against SHIV challenge (662, 668). For example, in a study carried out 
by Binley et al. (1017), mAb b12 has been shown to neutralise (to at least 50%) 
45 out of 90 viruses of various subtypes. Competition studies with sCD4 along 
with mutational studies initially indicated that b12 targets a region that is over-
lapping or near to the CD4bs (1009-1011, 1018). These observations were 
confirmed in 2007, when Zhou et al. (1008) reported high-resolution structural 
data on mAb b12 in complex with a gp120 construct that had been engineered to 
remain in an CD4-liganded conformation, revealing that mAb b12 binds to an 
epitope that overlaps part of the CD4bs (Fig 1.1.6.6.1). 
 
The structural data reported by to Zhou et al. (1008) revealed that mAb b12 
binds gp120 only with its heavy-chain. This unusual feature may be due to the 
combinatorial library approach by which mAb b12 was isolated, where the 
cloned heavy- and light-chain repertoires were randomly recombined in the 
selection process. Three b12 residues, an asparagine in the first complementarity 
determining region (CDR1), a tyrosine in CDR2, and a tryptophan in CDR3, 
were found to interact with the CD4-binding loop of gp120, and to make up 
around 40% of the total b12 contact surface (1008). The gp120 contact surface 
was found to be confined largely to the outer domain on gp120, with the CD4-
binding loop making up more than 50% of the total interface. Most of the overlap 
between the b12 epitope and the CD4bs was found to be located on the outer 
domain of gp120, in particular around the CD4-binding loop. However, the b12 
epitope overlaps only part of the CD4bs (Fig. 1.1.6.6.1). For example, the 
unusually long and protruding heavy-chain CDR3 of mAb b12 does not reach 
into the Phe43-binding cavity of the CD4bs, as had been predicted by molecular 
modelling experiments using the unbound mAb b12 structure (1019). Instead, it 
interacts with residues that are peripheral to this site. According to the data 
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presented by Zhou et al. (1008), mAb b12 is able to neutralise a wide range of 
HIV-1 isolates by interacting with the functionally conserved and vulnerable 
initial contact surface of CD4 without introducing conformational changes. This 
notion is consistent with the observation made by Kwong et al. (989), showing 
that mAb b12 is able to bind gp120 without a large change in entropy. 
 
Figure 1.1.6.6.1. The mAb b12 epitope and the CD4bs of gp120. Superposition of gp120 
bound to mAb b12 and gp120 bound to CD4. The outer domain of gp120 is shown in red, the 
inner domain in gray, and the bridging sheet in blue. Amino acid residues in contact with mAb 
b12 are shown in green and the CD4bs in depicted in yellow. The figure is obtained from Zhou, 
T., L. Xu, B. Dey, A. J. Hessell, D. Van Ryk, S. H. Xiang, X. Yang, M. Y. Zhang, M. B. Zwick, 
J. Arthos, D. R. Burton, D. S. Dimitrov, J. Sodroski, R. Wyatt, G. J. Nabel, and P. D. Kwong, 
‘Structural definition of a conserved neutralization epitope on HIV-1 gp120’, 2007, Nature 
445:732-7 (1008). Reprinted by permission from Macmillan Publishers Ltd. 
 
In addition to mAb b12, there is a number of other mAbs to the CD4bs that 
exhibit some neutralisation activity across subtypes. None, however, exhibits the 
cross-reactive neutralisation breadth exhibited by mAb b12. These antibodies 
include mAb m14 (1020) and mAb F105 (1021), which have both been shown to 
compete with CD4 for binding to gp120. A large number of non-neutralising 
anti-CD4bs mAbs and anti-CD4bs mAbs able to neutralise only neutralisation-
sensitive TCLA isolates have also been isolated. These are thought to recognise 
epitopes that are not accessible on functional spikes. For example, the non-
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neutralising human mAb b6, which was derived from the same phage library as 
mAb b12, compete with sCD4 and with mAb b12 for binding to recombinant 
gp120. Furthermore, it can capture virus particles and inhibit capture by mAb 
b12, but has no effect on the neutralisation activity of b12, suggesting it fails to 
recognise functional spike, but can bind to non-functional envelope spikes 
present on the virus surface (142, 897, 1018). 
 
The second broadly neutralising mAb that targets gp120 is 2G12 (981, 1015). 
This antibody has been shown to neutralise (to 50%) 37 out of 90 viruses of 
different subtypes in the study carried out by Binley et al. (1017). Notably, it 
failed to neutralise HIV-1 of subtype C. It recognises a cluster of oligomannose 
residues on gp120 and has an unusual structure in that it has undergone a 
domain-swap, where the heavy-chain variable regions of each Fab have swapped 
positions so that they interact with the light-chain variable region of the 
neighbouring arm (981, 1013-1015). This antibody has shown efficacy in vivo, in 
monkey models in combination with other mAbs (657-659), but also in humans, 
as intravenous administration delayed the viral rebound in individuals 
undergoing interrupted antiviral therapy (672). 
 
The remaining broadly neutralising antibodies, 4E10 (906, 908) and 2F5 (907, 
981), target neighbouring continuous epitopes within the conserved MPER of 
gp41. Antibody 4E10 is the broadest neutralising mAb to HIV-1 described to 
date. In many studies, it has shown a neutralisation activity of extraordinary 
breadth (1017, 1022, 1023). In the study carried out by Binley et al. (1017), mAb 
4E10 was able to neutralise all of the 90 viruses, when assayed in engineered cell 
lines. It has, however, been observed to be less broadly reactive in PBMC-based 
neutralisation assays (906, 908, 1017). It recognises an epitope that is located C-
terminal to the 2F5 epitope, overlapping the highly conserved sequence 
NWF(D/N)IT (906, 910). Crystal structures of mAb 4E10 with this peptide 
sequence has shown that the peptide adopts a helical conformation (910). 
Antibody 2F5 binds to an epitope overlapping the conserved sequence 
ELDKWA (907, 909). In the study carried out by Binley et al. (1017), this mAb 
was able to neutralise 60 out of 90 viruses (to more than 50%). Notably, it did 
not neutralise any of the subtype C viruses, explained by the observation that 
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most subtype C viruses lack the DKW motif present in the 2F5 recognition 
sequence (1017). Instead, many of them display a DSW motif. The epitopes for 
mAbs 4E10 and 2F5 have been shown be slightly hydrophobic and possibly 
membrane-bound (1024-1026). In addition to 4E10 and 2F5, anti-MPER mAb 
Z13 also displays some neutralisation activity, although less broad and potent 
compared to that of 4E10 and 2F5 (906). A human mAb recognising the N-HR 
of gp41 and selected from a naïve library, mAb D5, has also been shown to 
display some neutralisation activity (1027). 
 
Antibodies to the CD4-induced sites (including the co-receptor binding site) are 
generally unable to neutralise virus in vitro, or able to neutralise only weakly, 
unless the virus is pre-incubated with sCD4 (1001, 1028, 1029). The mechanism 
of neutralisation has been suggested to be interference with co-receptor binding 
(139, 934). This inability to neutralise in the absence of sCD4 is thought to be 
due to kinetic and steric constraints, as these epitopes are typically not exposed 
until after interaction with CD4 (921, 1030). In contrast, several Fab fragments to 
CD4-induced epitopes have been shown to be able to neutralise primary isolates 
(1016, 1030). Based on these notions, it has been suggested that full 
immunoglobulins are too bulky to be able to bind to CD4-induced epitopes in the 
context of the virus-associated functional spike, as there may be limited and 
short-lived access to these epitopes in the presence of viral and cellular 
membranes (997). Viruses with deleted V1 and V2 variable regions have been 
shown to be more susceptible to neutralisation by mAbs to CD4-induced 
epitopes, supporting the notion that the co-receptor binding site is masked by V1 
and V2 (920). An interesting feature of some of the isolated antibodies to the co-
receptor site is that they have sulphated tyrosines in their heavy-chain CDR3s, 
possibly mimicking the sulphated tyrosines present on CCR5 and CXCR4 and 
critical for CCR5 or CXCR4 interaction with gp120 (1031). One of the most 
broadly reactive Fab fragments to CD4-induced epitopes is Fab X5 (1016), 
which have been shown to neutralise viruses of subtype A, B, C, D, F and G. 
However, when used as a full immunoglobulin in the study carried out by Binley 
et al. (1017), mAb X5 was only able to neutralise 3 out of 90 viruses. 
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Several mAbs to the V3 region have also been described. Although most 
neutralising antibodies to the V3 region appear to be isolate-specific, a minority 
of the anti-V3 antibodies have been shown to neutralise a relatively large 
proportion of mainly subtype B isolates (991, 1032). These anti-V3 mAbs have 
been reported to recognise conformation-sensitive rather than linear V3 epitopes 
(1032). The broadest of the anti-V3 mAbs isolated to date is mAb 447-52D, 
which recognises an epitope that includes the GPXR (where X is any amino acid 
residue but often a G) motif on the tip of the V3 that is conserved among subtype 
B isolates (991, 1032). In the study carried out by Binley et al. (1017), mentioned 
above, 447-52D was able to neutralise (to at least 50%) 17 out of 90 viruses, 13 
of which were of subtype B. A small number of isolate-specific anti-V2 mAbs 
have been also isolated (1033, 1034). 
 
All of the neutralising anti-HIV-1 mAbs described to date, with one exception, 
are able to bind recombinant monomeric gp120 or gp41 constructs in addition to 
recognising functional spikes. The only reported trimer-specific mAb is mAb 
2909 (1035), which recognises an epitope involving the V2 and V3 variable 
regions and the CD4bs that is not present on monomeric gp120. Even though it 
can only neutralise neutralisation-sensitive HIV-1 isolates that have been 
cultured in vivo, it is able to do so at very low (pM) concentrations. 
 
1.1.6.7 HIV-1 envelope glycoproteins as immunogens 
Immunisation with recombinant HIV-1 envelope glycoprotein constructs 
typically elicits antibodies with weak neutralisation activity against heterologous 
isolates (1036-1043). In addition to antibodies to non-neutralising epitopes, anti-
V3 region antibodies are frequently elicited after immunisation (421, 992-996). 
In some studies, it has also been shown that vaccine-elicited autologous virus 
neutralisation can be mediated by antibodies against the V1 region of gp120, in 
particular a hypervariable region at the tip of the V1 (1042, 1044, 1045). 
Antibodies with cross-subtype reactive neutralising activity of moderate potency 
have recently been detected in rabbits immunised with a recombinant gp140 
capable of mediating CD4-independent infection and derived from an HIV-1-
infected individual whose serum was found to be broadly neutralising (1046). 
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Further knowledge about the antibody specificities present in these sera would be 
useful in vaccine design.  
 
In order to develop an immunogen able to elicit broadly neutralising antibodies, 
efforts are being made to design envelope constructs that mimic the functional 
envelope spike (259, 1047). As discussed in section 1.1.5.2, recombinant gp120 
was initially considered as an immunogen and vaccine candidate, but failed to 
protect against infection in clinical trials. To better mimic the functional spike, 
recombinant oligomeric gp140 molecules, which are gp160 molecules that have 
been truncated just before the transmembrane region of gp41, have been 
developed (1038, 1048-1053). To stabilise the typically labile gp120-gp41 
interaction, cysteine residues have been introduced in gp120 and gp41, resulting 
in the formation of disulphide bridges that prevent gp120-gp41 disassociation 
(1054-1056). Other attempts to prevent gp120-gp41 disassociation involve 
mutation of the protease cleavage site that is located between gp120 and gp41, 
resulting in the generation of unprocessed gp160 molecules (1049-1053, 1057). 
Uncleaved gp160 has, however, been shown to be antigenically different from 
fully cleaved envelope glycoproteins constructs (1056, 1058-1060). To increase 
the efficiency of cleavage in disulphide bridge-stabilised gp140 constructs, the 
cleavage site has been modified (1061). Attempts have also been made to 
improve trimerisation levels and the stability of trimers by introducing 
heterologous trimerisation domains at the C-terminus of envelope glycoproteins 
(1041, 1049, 1057). While trimeric envelope constructs have been shown to be 
somewhat better at eliciting cross-reactive neutralising antibodies compared to 
monomeric envelope glycoproteins (1036-1041), the majority of these 
oligomeric gp140 constructs have been shown to be recognised by non-
neutralising antibodies, indicating that they do not fully mimic the functional 
viral spike (259, 1056, 1060). 
 
Envelope glycoprotein constructs engineered to better present known 
functionally conserved regions and neutralising epitopes, such as the receptor-
binding sites and the epitope to which mAb b12 binds, are also being generated 
(1062). These constructs include deglycosylated gp120 molecules, gp120 with 
deletions in the immunodominant variable regions (1063, 1064), and gp120 
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locked in a CD4-bound conformation (1065, 1066). Other strategies involve 
masking of immunodominant regions, like the V3 and non-neutralising regions, 
with glycans or through mutation (1062, 1067). Masking immunodominant 
regions with glycans has, however, been shown not to improve the neutralisation 
breadth in immunisation studies in rabbits (1043). 
 
Attempts to design an immunogen that elicits 2G12-like antibodies have also 
been made based on the crystal structure of the Fab fragment of 2G12 with high-
mannose glycans (1068). No 2G12-like antibodies have, however, been reported. 
Various scaffolds that hold the MPER neutralising epitopes are also under 
evaluation (1069, 1070), as is presenting envelope glycoproteins in the context of 
viral like particles, VLPs (1071). Polyvalent vaccine approaches, which may be a 
way of dealing with HIV-1 sequence and conformational heterogeneity, are also 
being considered (754, 1072-1074). 
 
In summary, all attempts to design an immunogen able to elicit broadly 
neutralising and potent antibodies have so far been unsuccessful (754). This task 
represents one of the major challenges in HIV-1 vaccine design. To solve this 
problem, increased knowledge about the structure of the functional envelope 
spike and the way it interacts with broadly neutralising antibodies is likely to be 
needed. 
 
1.2 Camelid antibodies 
In this thesis, the use of a camelid immune system to generate antibodies to HIV-
1 envelope will be described. In this section, the unique features of the camelid 
immune system will be reviewed and an introduction to the research field of 
camelid antibodies will be given. 
 
1.2.1 The antibody repertoire in camelids 
The antibodies of all jawed vertebrates studied so far are composed of paired 
heavy and light chains (1075, 1076). In 1993, Hamers-Casterman et al. (1077) 
reported that members of the Camelidae family, in addition to these conventional 
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antibodies, produce functional antibodies devoid of light chains, so-called heavy-
chain antibodies. The Camelidae family includes the camel (Camelus 
bactrianus), dromedary (Camelus dromedarius), llama (Lama glama), alpaca 
(Lama pacos), guanaco (Lama guanicoe) and vicuna (Lama vicugna), and is the 
only remaining family within the Tylopoda suborder of the Artiodactyla order, 
and the only mammalian family in which heavy-chain antibodies have been 
detected.  
 
Analyses of the molecular mass and the protein A and G binding properties of 
camelid antibodies have revealed that camelids possess one fraction of 
conventional IgG antibodies and two fractions of heavy-chain IgG antibodies. 
The conventional IgG1 fraction binds to protein A and G, whereas the heavy-
chain IgG2 and IgG3 fractions bind to protein A, and protein A and G, 
respectively (1077). The heavy-chain antibody fraction has been estimated to 
constitute up to 50% of the total serum IgG content in camelids (1078, 1079), 
although a lack of reliable reagents makes exact quantification of the different 
immunoglobulin isotypes and subclasses difficult. Immunisation experiments 
have indicated that the kind of antibody response, consisting of heavy-chain or 
conventional antibodies, depend on the immunogen (1080). 
 
Based on germline and cDNA analysis, more than one isotype has been 
suggested to exist within the IgG1 and IgG2 fractions. The camelid genomes 
contain separate germline genes for the constant regions of the conventional and 
heavy-chain antibodies (1081). The dromedary genome has been reported to 
contain five functional γ genes, encoding for different hinge regions, therefore 
suggested to encode for different IgG subclasses (1082). Two of these genes are 
reported to encode for the constant region of the conventional IgG1 antibody 
fraction, whereas two genes encode for the constant region of the heavy-chain 
IgG2 antibodies and one gene for the constant region of the heavy-chain IgG3 
antibodies (1082). In llama, six γ genes have been reported, five of which 
correspond to the IgG1, IgG2 and IgG3 subclasses reported in dromedary, and 
the sixth giving rise to a third subclass of the heavy-chain IgG2 antibodies (1083, 
1084). 
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In addition to IgG, camelids have also been reported to produce IgA, IgD and 
IgM immunoglobulins (1085). However, so far there is no evidence for the 
presence of IgA, IgD or IgM molecules lacking light chains. In contrast, studies 
of the dromedary IgM fraction have revealed conventional antibody structures 
composed of heavy and light chains (1086). 
 
Antibodies lacking light chains have also been observed in some species of 
cartilaginous fish (1087, 1088), such as nurse shark Ginglymostoma cirratum and 
wobbegong shark (Orectobulus maculates). These antibodies are referred to as 
IgNAR (where NAR stands for novel antigen receptor) and differ in structure 
from the camelid heavy-chain antibodies (1089). For example, the constant 
region of the IgNAR contains five domains, whereas the constant region of 
camelid heavy-chain antibodies contains two domains only. Furthermore, the 
variable regions of the IgNAR show only 25% sequence identity with 
mammalian heavy-chain variable regions. In addition, they are not closely related 
to the variable regions of the heavy chain of other immunoglobulin isotypes in 
cartilaginous fish (1088, 1090, 1091). Instead, they have been reported to cluster 
with the variable regions of T cell receptors and immunoglobulin light chains 
(1088, 1090). Since cartilaginous fish were the first jawed vertebrate group to 
emerge, it has been suggested that the IgNAR may represent an evolutionary 
intermediate between a putative primordial antigen receptor and the conventional 
antibodies (1087, 1092).  
 
The ratfish (Hydrolagus colliei), another species of cartilaginous fish, have also 
been shown to produce antibodies devoid of light chains (1093). These 
antibodies are believed to be derived from IgM and, unlike shark IgNAR, their 
variable regions cluster with the variable regions of the heavy chains of other 
vertebrates (1091, 1093). 
 
Thus, heavy-chain antibodies have been detected in species from three unrelated 
taxa, in camelids and in two species of cartilaginous fish. Phylogenetic studies 
have, however, indicated that these heavy-chain antibodies have evolved 
independently from each other, reflecting an evolutionary convergence (1081, 
1089, 1091). In other words, camelid antibodies are not thought to have 
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originated in an ancestral dormant gene. Instead, phylogenetic studies have 
indicated that they evolved from conventional antibodies within the Camelidae, 
appearing after the divergence of the Tylopoda suborder from the other 
Artiodactyla suborders, but prior to the Camelus and Lama split, meaning that 
they may have emerged in the Tylopoda between 11 and 83 million years ago 
(1082, 1084, 1091, 1094). 
 
Antibodies devoid of light chains also appear in the so-called heavy-chain 
disease in humans (1095). These antibodies are somatically generated and are 
unlikely to interact with antigen. 
 
1.2.2 Basic features of camelid heavy-chain antibodies 
Conventional IgG consist of two heavy chains and two light chains (Fig. 1.2.2.1). 
The heavy chains consist of a constant region (CH), organised into three constant 
domains (CH1-CH3) and one variable domain (VH). The CH1 and CH2 domains 
are linked by a hinge region. The light chains are composed of one constant (CL) 
and one variable domain (VL). The paired VH and VL domains are responsible 
for antigen binding. 
 
The overall structure of the camelid heavy-chain antibodies resembles that of the 
typical mammalian immunoglobulins, with a number of important deviations. 
First, they lack the light chains (Fig. 1.2.2.1). As a result, and in contrast to 
conventional antibodies, the antigen-binding properties of the heavy-chain 
antibodies are provided by one single fragment, the variable region of the heavy-
chain (1077), which has been termed the VHH or Nanobody. In addition to 
lacking light chains, the heavy-chain antibodies differ from conventional 
antibodies in that they lack the first constant domain (CH1) of the constant 
region of the heavy chain (1077), meaning that the VHH is joined directly to the 
CH2 domain via the hinge region of the antibody (Fig. 1.2.2.1). However, despite 
the absence of the CH1 domain in the actual protein, all genes encoding the 
heavy-chain antibody constant regions contain sequences encoding the CH1 
domain, further indicating that camelid heavy-chain antibodies are derived from 
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conventional antibodies (1082, 1084, 1091). The absence of the CH1 domain is 
instead due to a point mutation in the 5´-end of the CH1-hinge region intron, 
resulting in the removal of the CH1 sequence in an unconventional splicing event 
during mRNA maturation, confirmed by the absence of the CH1 region in all 
analysed cDNAs (1082, 1084). 
 
 
  
 
 
 
 
 
 
Figure 1.2.2.1. Schematic representation of conventional antibodies and camelid heavy-
chain antibodies. Conventional mammalian IgG consist of two heavy chains, made up of three 
constant domains (CH1-CH3) and one variable domain (VH), and two light chains, made up of a 
constant (CL) and a variable (VL) domain. Camelid heavy-chains lack the light chains and the 
first constant domain of the heavy chains. Their variable domain has been termed the VHH. The 
hinge regions, connecting the Fc and the Fab portions of conventional antibodies, and the VHH 
and the Fc portion of heavy-chain antibodies, are indicated by arrows. 
 
The acquisition of a mechanism to remove the CH1 domain from the H-chain is 
likely to have played a key role in the evolution and emergence of heavy-chain 
antibodies, as the CH1 domain is the binding site for the chaperone protein BiP. 
Binding of BiP to the CH1 leads to retention of the heavy-chain in the ER. 
Association of the light chain with the heavy chain releases it from BiP, allowing 
for completion of the folding process and continued processing along the 
secretory pathway. Indeed, the absence or modification of the CH1 domain is a 
feature camelid heavy-chain antibodies share with both the IgNAR of sharks and 
the heavy-chain antibodies of ratfish, highlighting its importance in the 
emergence of antibodies devoid of light chains (1077, 1088, 1093). 
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The residues involved in antibody effector functions, mediated by binding of the 
Fc to complement and Fcγ receptors are conserved in the heavy-chain antibodies, 
indicating that they retain their ability to mediate effector functions (1082-1084). 
 
1.2.3 Properties of VHH 
The antigen-recognition properties of the heavy-chain antibodies are confined to 
the VHH. Sequence and structural analysis of the VHH reveal that they share 
many features with conventional VH domains (1077, 1083, 1096-1098). Like the 
VH, the VHH are organised into four relatively conserved framework regions, 
FR1-FR4, and three hypervariable complementarity-determining regions, CDR1-
CDR3 (Fig. 1.2.3.1). 
 
 
 
Figure 1.2.3.1. Schematic representation of a VHH domain. Like conventional VH domains, 
the VHH domain of heavy-chain antibodies contains four framework regions (FR1-FR4) and 
three complementarity-determining regions (CDR1-CDR3). The position of the two cysteine 
residues forming an intradomain disulphide bond in conventional VH as well as in heavy-chain 
antibody VHH are indicated by a C. The positions of the four amino acid residues conserved in 
VH but constitutively substituted in VHH are indicated by an asterisk. 
 
The amino acid residues that determine the typical immunoglobulin variable 
domain fold are conserved in the VHH, including the two cysteine residues in 
FR1 and FR3 that form an intradomain disulphide bond, and the three-
dimensional structures of VHH can be superimposed onto those of conventional 
VH (1096, 1099-1102). Furthermore, the VHH show high sequence similarity, 
around 80%, to the human VH of family III (1083), the human VH family most 
commonly incorporated into antibodies (1103). 
 
Some notable differences between VHH and VH domains have, however, been 
observed (1077, 1083, 1098, 1104). For example, four amino acid residues in the 
FR2 region are constitutively substituted in the VHH (Table 1.2.3.1). These 
amino acid residues are highly conserved in the VH and form a hydrophobic 
C                                                                 C 
          FR1                CDR1       FR2      CDR2          FR3                 CDR3            FR4 
*    * **
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patch that participates in the interaction with the VL (1076). The VHH hallmark 
substitutions, on the other hand, render the region more hydrophilic. Even the 
hydrophobic phenylalanine residue at position 37 (Table 1.2.3.1) has been 
suggested to increase VHH hydrophilicity, as structural studies have shown that 
it fills a hydrophobic pocket created by hydrophobic residues in positions 47, 91 
and 103 (1096). In keeping with the above notions, grafting of the VHH hallmark 
residues onto a human VH domain rendered it more soluble when expressed in 
the absence of a VL (1105). 
 
Table 1.2.3.1. VHH hallmark amino acid residue substitutions. 
Positiona Amino acid residue in VH Amino acid residue in VHH 
37 Valine Phenylalanine, tyrosine 
44 Glycine Glutamic acid, glutamine 
45 Leucine Arginine, cysteine 
47 Tryptophan Glycine 
aKabat numbering. 
 
In addition to the VHH hallmark substitutions, the tryptophan residue in position 
103 is sometimes also substituted for a hydrophilic residue. The CDR3 of VHH 
is also thought to fold over part of the region involved in interaction with the VL 
in conventional VH, covering hydrophobic patches (1096). Overall, the above-
mentioned features of the VHH lead to increased hydrophilicity of the VHH 
compared to the VH, which tend to aggregate when expressed on their own in the 
absence of a VL (1106), and explain how VHH base-pairing with VL domains is 
avoided. Some residues in contact with the CH1 in VH are also exchanged for 
hydrophilic residues in VHH (1097, 1098). 
 
There are also differences in the CDRs of VHH and VH. On average, camelid 
VHH display longer CDRs compared to the VH counterparts (1083, 1097, 1098). 
This notion is especially true for dromedaries, where the average length of the 
CDR3 of VHH and VH is 17 and 11 amino acids, respectively (1094). The 
CDR3 loops of llama VHH are on average slightly shorter (15 amino acids) than 
those of dromedaries but slightly longer than the average human (12 amino 
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acids) and mouse (9 amino acids) CDR3 (1083). In addition, the VHH of camels 
and dromedaries, and sometimes llamas, often include non-canonical cysteine 
residues, leading to the formation of extra disulphide bonds, typically between 
the CDR1 and FR2, resulting in a stabilised CDR3 and possibly to alternative 
loop structures (1094, 1098). Moreover, the extent of somatic hypermutation is 
much higher in VHH compared to in VH. As a result, VHH show an overall 
increased sequence diversity compared to VH, including in the otherwise 
relatively conserved FRs (1104). The N-terminal part of the CDR1, in particular, 
is more variable than its VH counterpart (1083, 1097, 1104). In addition, the 
CDR1 and CDR2 are thought to be able to adopt alternative canonical structures 
not observed in VH (1104, 1107). 
 
The VHH and VH are encoded for by separate germline genes (1108). Like the 
VH domain, the VHH domain is obtained during B cell differentiation after DNA 
recombination between a dedicated VHH germline gene with one diversity gene 
(D) and one heavy joining (JH) minigene in an event referred to as V-D-J 
rearrangement. In dromedary, 42 different germline VHH genes and 50 different 
germline VH genes have been reported (1104). In llama, five VHH genes and 
one VH gene have been reported so far (1081). The VHH and VH genes show 
high sequence homology, but are distinguished by the four hallmark VHH 
substitutions. In addition, the VHH seem to have more hotspots for mutation in 
the region upstream of the CDR1 (1091), in keeping with the increased sequence 
diversity observed in the CDR1 (1083, 1097, 1104). At the 3’-end, the VHH 
genes are flanked by conserved recombination signal sequences (RSS), essential 
for the somatic V-D-J rearrangement, supporting the notion that the VHH genes 
take part in V-D-J rearrangement. It is thought that the VHH and VH genes 
recombine with the same D and JH genes (1091). 
 
Despite their single-domain nature and small size of approximately 14 kDa, 
VHH have characteristics in terms of affinity and specificity that are similar to 
those of conventional antibodies (1109). Moreover, they exhibit diverse antigen-
binding properties (1094, 1099, 1100). The increased level of sequence diversity 
and somatic hypermutation, and the longer CDRs able to adopt alternative 
canonical structures, are likely to contribute to these features and to compensate 
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for the lack of interaction surface and combinatorial diversity provided by the 
VH-VL base-pairing (1094). 
 
VHH-antigen interface areas of up to 1700 Å2 have been reported (1110), which 
equals the size of the interaction surface typically observed between a VH-VL 
pair and its antigen (1111). Similar interface sizes have been observed for the 
interaction of VHH and conventional antibodies with the same antigen (1112). 
The lack of interaction surface provided by the VL domain of the light chains 
could also be compensated for by the involvement of framework residues in the 
interaction with antigen, as interactions of VHH framework residues with both a 
hapten (1101) and a proteinaceous antigen have been observed (1113). 
 
Conventional antibodies typically interact with protein antigens via planar 
paratopes and with haptens or peptides via concave paratopes (1114, 1115). 
Unlike conventional antibodies, the VHH of heavy-chain antibodies have been 
shown to have a preference for binding into active sites (1116) and to be able to 
recognise cryptic epitopes typically occluded to conventional antibodies (1117). 
To further investigate this feature of VHH, de Genst et al. (1112) generated high-
resolution structural data for eight VHH in complex with hen egg white lysosyme 
(HEWL), isolated from dromedaries immunised with HEWL, showing that six 
out of eight VHH bound into the HEWL active site cleft. In contrast, previous 
observations have shown that conventional antibodies typically bind to planar 
epitopes of HEWL. Unlike conventional antibodies, which often used all their six 
CDRs to interact with HEWL, the paratopes of the anti-HEWL VHH were made 
up predominantly by the CDR3. The majority (85%) of heavy-chain antibodies 
present in polyclonal sera from the immunised dromedaries were also found to 
target the active site. These observations confirm the notion that VHH have a 
preference for recognising clefts and binding into active sites of proteins, and 
that this feature tends to be conferred by a protruding CDR3 loop. 
 
1.2.4 Use of VHH in biotechnological and therapeutical applications 
VHH have several features that make them potentially suitable for use in 
biotechnological and therapeutical applications (1100). For example, the VHH 
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domain can be easily cloned from immunised camelids and expressed to high 
levels in bacteria or yeast (1118, 1119). Individual VHH can be isolated using 
well-established selection technologies such as phage display. When constructing 
libraries for phage display, the single-domain nature of VHH offers an advantage 
over conventional antibody Fab (fragment antigen-binding) or scFv (single-chain 
Fv) fragments, since there is no need for random recombination of the VH and 
VL domains. Initially, VHH domains were isolated from camels and dromedaries 
but has since been successfully generated from llamas (1100), which may be 
more readily available and easier to keep. Recently, alpacas have also been used 
(1079, 1120). 
 
Furthermore, VHH have been shown to be thermally and conformationally 
stable, exhibiting thermodynamic stabilities that have not been observed for 
functional conventional antibody fragments (1109, 1121, 1122). For example, 
unlike conventional antibodies, some VHH have been shown to retain their 
binding properties at temperatures up to 90°C (1109, 1121). In addition, 
chemically induced unfolding has been shown to be fully reversible (1122). 
 
The stability and solubility of VHH also allows for engineering of multivalent 
and bispecific molecules (1123). Engineered multivalent VHH to the epidermal 
growth factor receptor (EGFR) and tumour necrosis factor α (TNFα) have been 
shown to exhibit better binding and neutralising properties than their monovalent 
counterparts (1124, 1125). 
 
The unique properties of camelid VHH have proven them potential in a number 
of applications against a wide range of biological targets. For example, VHH 
targeting the Malf1 surface protein of the fungus Malassezia furfur, implicated in 
the formation of dandruff, has been isolated from llamas immunised with extracts 
of the fungus (1126). Remarkably, the stability of the VHH allowed for phage 
display-based selections carried out in the presence of shampoo. Furthermore, 
VHH targeting human lysosyme has been reported to inhibit in vitro aggregation 
of an amyloidogenic lysosyme variant, with implications of amyloid disease 
(1127). In addition, intracellularly expressed VHH binding to nuclear poly(A)-
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binding protein 1 (implicated in the protein aggregation disorder 
Oculopharyngeal muscular dystrophy), isolated from a VHH library derived from 
a naïve llama, has been shown to reduce protein aggregation in an in vitro model 
(1128). 
 
Moreover, VHH against EGFR have been isolated from llamas immunised with 
EGFR-containing cell preparations (1125). These VHH were able to inhibit 
EGF-induced signalling and EGF-induced cell proliferation, as well as being able 
to delay tumour outgrowth in an in vivo model for solid tumours (1125). In 
addition, VHH targeting TNFα, isolated from llamas immunised with 
recombinant TNFα, have been shown to block interaction of TNFα with its 
receptor, and to show therapeutic effects against collagen-induced arthritis in a 
mice model (1124). VHH against the human tumour-associated 
carcinoembryonic antigen, conjugated to an anti-cancer prodrug (Enterobacter 
cloacae beta-lactamase) have shown to be effective in vitro as well as in in vivo 
models (1129). 
 
VHH raised against a range of pathogens have also been isolated. These 
pathogens include Streptococcus mutans causing dental caries (1130), 
Trypanosoma brucei rhodesiense causing sleeping sickness (1131),  and foot and 
mouth virus (1132). In addition, VHH targeting rotavirus have been shown to 
reduce the severity of rotavirus-induced diarrhoea in an in vivo mice model, 
when administered orally as recombinant proteins (1133) as well as when 
expressed by orally administered lactobacilli (1134). In 2007, these VHH were 
the first to enter a phase I clinical trial. VHH to the rotavirus VP6 protein has 
also been shown to confer protection in a mice model (1135). 
 
Because of their properties in terms of stability, VHH are suitable for 
intracellular expression (1120, 1128). They can also be used in biotechnical 
applications, such as immunoaffinity chromatography (1136). In addition, 
intracellular expression of VHH against a desired antigen, fused with fluorescent 
proteins, can enable targeting and tracing of antigenic structures within living 
cells (1120). 
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In summary, the unique properties of camelid VHH in terms of size, non-
conventional binding characteristics, protruding and non-canonical CDRs, 
stability, solubility, ease of cloning and production yield, make them potentially 
valuable reagents in many therapeutical and biotechnical applications. 
 
1.3 Scope of this thesis 
Monoclonal antibodies to the HIV-1 envelope glycoproteins may be useful in the 
design of an HIV-1 vaccine as they can help define neutralising and non-
neutralising epitopes. Monoclonal antibodies able to neutralise a wide range of 
HIV-1 isolates can provide information about vulnerable, conserved and 
functionally important sites on the HIV-1 functional envelope spike, such as the 
receptor-binding sites. Broadly neutralising mAbs may also have potential use as 
HIV-1 microbicides. Only a handful of broadly neutralising mAbs have, 
however, been described, all a result of infection. To gain further insight into the 
antigenic structure of the HIV-1 envelope spike and to further define conserved 
neutralising epitopes, there is a need for additional broadly neutralising 
antibodies. The aim of the work presented in this thesis was to use the non-
conventional immune system of llamas to generate novel, neutralising antibody 
fragments, VHH, to the HIV-1 envelope surface glycoprotein gp120, and to 
characterise these antibody fragments in biological and biochemical assays. The 
methodology behind this work will be described in chapter 2, and the results will 
be presented and discussed in chapters 3-5, followed by a final discussion in 
chapter 6. 
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Chapter 2 
Materials and methods 
 
In this thesis, the isolation and characterisation of neutralising llama VHH will 
be described. This chapter provides details of the materials and methodology 
used to generate the data presented in chapter 3-5. 
 
2.1 Materials 
This section provides details of the buffers, solutions, human antibodies, and 
recombinant proteins used in this study. Cell lines and viruses will be described 
in section 2.3 and 2.4. 
 
2.1.1 Buffers and solutions 
The buffers and solutions used in this study are listed in Table 2.1.1.1. 
 
2.1.2 Recombinant HIV-1 envelope glycoproteins 
Recombinant gp120 derived from the HIV-1 subtype B’/C (CRF07_BC) primary 
isolate CN54 (1137, 1138), produced in a baculovirus expression system, was 
kindly provided by I. Jones, Reading University, UK, through the European 
Microbicide Project (EMPRO). Additional batches of recombinant gp120 from 
HIV-1 CN54 were expressed as described in section 2.7. Recombinant CN54 
gp140 and gp140 derived from the HIV-1 subtype A primary isolate 92UG037 
(1048, 1139), produced in a Chinese hamster ovary (CHO) cell system, were 
kindly provided by S. Jeffs, Imperial College London, UK. Recombinant gp120 
derived from the HIV-1 subtype B TCLA isolate IIIB (32, 1140), produced in a 
baculovirus expression system, was obtained from the Centralised Facility for 
AIDS Reagents (catalogue number EVA607) at the National Institute for 
Biological Standards and Control (NIBSC), Herts, UK. Recombinant gp120 
derived from the HIV-1 subtype A primary isolate 92UG037 (1139), the subtype 
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C primary isolate 92BR025 (1139), and the molecular clones CB7, which 
expresses gp120 cloned from plasma of an individual infected with HIV-1 of 
subtype C, were cloned, expressed and purified as detailed in section 2.5 and 2.7. 
 
2.1.3 Monoclonal antibodies to HIV-1 gp120 and gp41 
Monoclonal antibodies b12 (1011) and b6 (1011) were kindly provided by D. 
Burton, Scripps Institute, La Jolla, USA. Monoclonal antibody GP68 (1141) was 
obtained through the Centralised Facility for AIDS Reagents, NIBSC (original 
source A. Osterhaus and M. Schutten). Monoclonal antibodies 654-D (975, 1034, 
1142) and 447-52D (991, 1032) were obtained through the Centralised Facility 
for AIDS Reagents, NIBSC (original source S. Zolla-Pazner). Monoclonal 
antibody 17b (1143) was obtained from the NIH AIDS Research and Reference 
Reagent Programme, Division of AIDS, National Institute of Allergies and 
Infectious Diseases (NIAID), National Institutes of Health (NIH), USA (original 
source James E. Robinson). Monoclonal antibodies 2G12 (981) and 4E10 (908) 
were obtained from Polymun Scientific GmbH, Vienna, Austria, as part of the 
Collaboration for AIDS Vaccine Discovery (CAVD). 
 
2.1.4 Sera and plasma from HIV-1-seropositive individuals 
Quality control (QC) sera 2, 5 and 6 from HIV-1-seropositive individuals have 
been described previously (1144). Plasma from individuals infected with HIV-1 
subtype C was kindly provided by D. Yirrel, Glasgow, UK. 
 
2.1.5 Recombinant sCD4 
Recombinant sCD4 consisting of the extracellular domains D1-D4 was available 
and has been previously described (1145). In addition, recombinant sCD4 (D1-
D4) was obtained from R&D Systems (Minneapolis, USA, catalogue number 
514-CD-050/CF). 
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Table 2.1.1.1. Buffers and solutionsa. 
Buffer/solution Composition 
2 × tryptone/yeast (TY) 
medium 
1.6% (w/v) tryptone, 1% (w/v) yeast extract, 
0.5% (w/v) NaCl 
Lysogeny broth or Luria-
Bertani (LB) medium 
1% (w/v) tryptone, 0.5% (w/v) yeast extract, 
0.5% (w/v) NaCl 
LB agar LB medium plus 1.5% (w/v) agar 
Phosphate buffered saline 
(PBS) 
137 mM NaCl, 3 mM KCl, 10 mM Na2HPO4, 2 
mM K2HPO4, pH 7.4 
PBS-T 0.05% (v/v) Tween 20 in PBS 
Super optimal broth with 
catabolite repression 
(SOC) 
2% (w/v) tryptone, 0.5% (w/v) yeast extract, 10 
mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM 
MgSO4, 20 mM glucose 
Tris acetate EDTA (TAE) 40 mM Tris-HCl, 20 mM sodium acetate, 1 mM 
EDTA, pH 7.8 
Tris buffered saline (TBS) 20 mM Tris-HCl, 120 mM NaCl, pH 7.6 
TBS-T 0.05% (v/v) Tween 20 in TBS 
TMT/BS 4% (w/v) milk powder and 10% (v/v) bovine 
serum (BS) in TBS-T 
TMT/GS 4% (w/v) milk powder and 10% (v/v) goat serum 
(GS) in TBS-T 
VHH elution buffer 50 mM Na2HPO4, 300 mM NaCl, 150 mM 
imidazole, pH 7.0 
VHH equilibrium buffer 50 mM Na2HPO4, 300 mM NaCl, pH 8.0 
VHH pre-elution buffer 50 mM Na2HPO4, 300 mM NaCl, 10 mM 
imidazole, pH 7.0 
aw/v, weight/volume; v/v, volume/volume; Tris, tris-(hydroxymethyl)aminomethane; EDTA, 
ethylenediaminetetraacetic acid; Imidazole, 1,3-diazole; Tween 20, polyoxyehtylene sorbitan 
monolaurate. 
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2.2 Molecular biological techniques 
This section provides details on the general molecular biological techniques used 
in this study. 
 
2.2.1 Isolation of genomic DNA 
Total DNA was isolated from HIV-1-infected PBMC using the QIAamp DNA 
Blood Mini Kit (QIAGEN, Crawley, UK), according to the manufacturer’s 
instructions. Briefly, 5 × 106 pelleted cells were resuspended in PBS to a final 
volume of 200 µl. Cells were lysed by the addition of QIAGEN protease and AL 
lysis buffer and incubated at 56°C for 10 minutes. To ensure complete lysis and 
inactivation of virus, samples were subjected to an additional incubation step of 
30 minutes at 56°C. Total DNA was then purified using QIAamp Mini Spin 
columns and eluted in 200 µl of QIAGEN AE elution buffer. 
 
2.2.2 Isolation of RNA 
RNA was isolated from plasma of individuals infected with HIV-1 of subtype C, 
or from cell-free viral stocks of HIV-1 CN54 using the QIAamp Viral RNA Mini 
Kit (QIAGEN) according to the manufacturer’s instructions. Briefly, virus was 
lysed by the addition of QIAGEN AVL lysis buffer and incubation at room 
temperature for 10 minutes, in the presence of polyA carrier RNA. RNA was 
then purified on QIAamp Mini Spin columns and eluted in QIAGEN AVE 
elution buffer. 
 
2.2.3 Isolation of plasmid DNA 
LB medium (5 ml) containing the appropriate antibiotic for selection (typically 
100 µg/ml of ampicillin or carbenicillin) was inoculated with a single bacterial 
colony from an agar plate. Cultures were grown overnight at 37°C (or 30°C for 
bacteria containing vectors with full-length HIV-1 molecular clones or gp160 
clones) with orbital shaking at 250 revolutions per minute (rpm) and bacteria 
were pelleted by centrifugation at 3000 × g for 10 minutes at 4°C. Plasmid DNA 
was isolated from pelleted bacteria using the QIAprep Spin Miniprep Kit 
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(QIAGEN) according to the manufacturer’s instructions. Briefly, the pelleted 
bacteria were resuspended in resuspension buffer P1, which contains RNase A, 
and subsequently lysed under alkaline conditions using buffer P2, which contains 
NaOH/sodium dodecyl sulphate (SDS), and gentle inversion to avoid shearing of 
bacterial chromosomal DNA. The lysate was then neutralised and adjusted to 
high-salt binding conditions by the addition of the neutralising buffer N3. The 
samples were mixed by gentle inversion and precipitated SDS, chromosomal 
DNA, cellular debris, and denatured proteins were pelleted by centrifugation at 
17900 × g. The supernatant was added to QIAprep Spin columns containing a 
silica membrane, and adsorbed plasmid DNA was purified in a series of washing 
steps and eluted in 50 µl of QIAGEN EB elution buffer (10 mM Tris-HCl, pH 
8.5). 
 
2.2.4 Restriction enzyme digestion of plasmid DNA 
Plasmid DNA was digested using restriction enzymes obtained from Promega 
(Southampton, UK) for 1 hour under conditions specified by the manufacturer. 
Partial digests were carried out by shortening the incubation time and/or diluting 
the enzyme. Digested DNA was separated using agarose gel electrophoresis 
(section 2.2.5). 
 
2.2.5 Agarose gel electrophoresis of DNA 
DNA fragments were separated according to size by agarose gel electrophoresis. 
Gels contained 0.5 µg/ml of ethidium bromide (Sigma-Aldrich, Poole, UK) and 
were made with 1% (DNA fragments >500 bp) or 1.5-2% (DNA fragments <500 
bp) agarose (w/v; Roche Diagnostics, Lewes, UK) in 1 × TAE buffer. A 
molecular weight marker of appropriate size (GeneRuler 1 kb DNA ladder or 
GeneRuler 100 bp DNA ladder; Fermentas Life Sciences, York, UK) was run in 
parallel. Electrophoresis was carried out in 1 × TAE buffer at 80-100 V for an 
appropriate amount of time. DNA was visualised by illumination with ultraviolet 
light. 
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2.2.6 Extraction of DNA fragments from agarose gels 
DNA bands of the expected size were excised from the agarose gel, and DNA 
was extracted using the QIAquick Gel Extraction kit (QIAGEN) according to the 
manufacturer’s instructions. 
 
2.2.7 Transformation of competent bacteria 
Ligation reactions were transformed into chemically competent E. coli TOP10 
cells (Invitrogen, Paisley, UK) by adding 1 µl of ligation reaction to 25-50 µl of 
competent bacteria, followed by incubation on ice for 30 minutes. The bacteria 
were subsequently subjected to heat-shock at 42°C for 30 seconds, followed by 
incubation on ice for 1 minute and addition of 250 µl of SOC medium 
(Invitrogen). The bacteria were then incubated for 1 hour at 37°C (or 30°C for 
bacteria transformed with vectors containing full-length HIV-1 molecular clones 
or gp160 clones) and 250 rpm, and subsequently plated onto LB agar plates 
containing 100 µg/ml ampicillin or carbenicillin. Plates were then incubated 
overnight at 37°C (or 30°C for bacteria transformed with vectors containing full-
length HIV-1 molecular clones or gp160 clones). 
 
Electrocompetent E. coli TG1 cells (Stratagene, La Jolla, USA) were 
transformed by adding 1 µl of ligation reaction or plasmid DNA to 40 µl of 
bacteria. Samples were then transferred to 0.1 cm electroporation cuvettes (Bio-
Rad Laboratories, Hemel Hempstead, UK), which had been pre-chilled on ice, 
and electroporated using a MicroPulser electroporator (Bio-Rad Laboratories) 
according to the manufacturer’s instructions (1.7 kV, 200 Ω, 25 µF). After 
addition of 1 ml of SOC medium, the bacteria were incubated for 1 hour at 37°C 
and 250 rpm and subsequently plated onto LB agar plates containing 100 µg/ml 
of ampicillin (or carbenicillin) and 2% (w/v) glucose. Plates were then incubated 
overnight at 37°C. 
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2.2.8 DNA sequencing 
Plasmid DNA was sequenced using the CEQ DTCS Quick Start Kit (Beckman 
Coulter, High Wycombe, UK) according to the manufacturer’s instructions. 
Briefly, sequencing reactions were carried out in a total volume of 10 µl 
containing 100 ng of DNA, 1.6 pmol of sequencing primer and 1 × CEQ DTCS 
Quick Start master mix. Thermal cycling conditions consisted of 30 cycles of 
96°C for 20 seconds, followed by 50°C for 20 seconds and 60°C for 4 minutes. 
For each sample, the sequencing reaction was stopped by the addition of 1 µl of 
3 M NaOAc (pH 5.2), 1 µl of 100 mM Na2-EDTA (pH 8.0), and 0.5 µl of 20 
mg/ml of glycogen. The reactions were then cleaned through ethanol 
precipitation and re-suspended in 20 µl of sample loading solution (provided 
with the CEQ DTCS Quick Start Kit; contains deionised formamide). 
Resuspended sequencing reactions were covered by one drop of mineral oil and 
plates were loaded onto a CEQ 2000 DNA Analysis System sequencer (Beckman 
Coulter). 
 
Some DNA sequencing was also carried by the DNA Sequencing Service at the 
Wolfson Institute, University College London, UK, using the BigDye Terminator 
Cycle Sequencing Kit (Applied Biosystems, Foster City, USA). DNA sequencing 
of VHH clones was carried out by Ablynx NV, Porto, Portugal. 
 
2.2.9 Determination of nucleic acid concentration 
Nucleic acid concentration and purity was determined spectrophotometrically 
using the NanoDrop 1000 Spectrophotometer (NanoDrop products, Thermo 
Fisher Scientific, Wilmington, USA). 
 
2.2.10 Determination of protein concentration 
Protein concentration was determined using the Bio-Rad Protein Assay (Bio-Rad 
Laboratories), which is based on the method developed by Bradford (1146), 
according to the manufacturer’s instructions. Three dilutions of each sample 
were assayed in triplicate or quadruplicate on two separate occasions. 
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2.2.11 SDS-PAGE and Coomassie blue staining 
Proteins were resolved using SDS-polyacrylamide gel electrophoresis (PAGE). 
Separating polyacrylamide gels were made with 15% (w/v) AA-Bis 
polyacrylamide (Bio-Rad Laboratories) and 0.1% (w/v) SDS in 375 mM Tris-
HCl (pH 8.8), with 100 µl of 10% (w/v) ammonium persulphate (APS) and 10 µl 
of N, N, N', N'-tetramethylethylenediamine (TEMED) per 10 ml of gel, to 
polymerise. Stacking gels were made with 4% (w/v) AA-Bis polyacrylamide and 
0.1% (w/v) SDS in 125 mM Tris-HCl (pH 6.8), and APS and TEMED as above. 
Samples were mixed with sample buffer to a final concentration of 2% (w/v) 
SDS, 2 mM dithiothreitol (DTT), 4% (v/v) glycerol, 40 mM Tris-HCl (pH 6.8) 
and approximately 0.01% (w/v) bromophenol blue, boiled for 5 minutes, loaded 
onto gels and run at 200 V in running buffer containing 25 mM Tris-HCl, 200 
mM glycine and 0.1% (w/v) SDS. 
 
Alternatively, proteins were separated on pre-cast NuPAGE Novex 10% Bis-Tris 
gels (Invitrogen) in 3-(N-morpholino) propane sulphonic acid (MOPS) SDS 
running buffer. Samples were mixed with 1 × NuPAGE LDS Sample Buffer and 
1 × NuPAGE Reducing Agent and heated to 70°C for 10 minutes prior to being 
loaded onto gels and electrophoresed at 200 V. The PageRuler (Fermentas Life 
Sciences) or BenchMark (Invitrogen) pre-stained protein ladders were run in 
parallel, as molecular weight markers. 
 
Gels were stained using 0.1% (w/v) Coomassie Brilliant Blue R-250 (Bio-Rad 
Laboratories) in 10% (v/v) acetic acid and 40% (v/v) methanol and subsequently 
destained in 10% (v/v) acetic acid and 40% (v/v) ethanol. 
 
2.3 Cell culture 
This section describes the cell lines and the general cell culture techniques used 
in this study. 
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2.3.1 Cell lines and culture media 
The TZM-bl cell line (1147-1149), previously designated JC53-bl (clone 13), is a 
HeLa cell line, hence derived from a human cervical carcinoma (1150), which 
stably expresses human CD4 and CCR5 and contains firefly luciferase and β-
galactosidase genes under control of the HIV-1 promoter. TZM-bl cells were 
obtained through the NIH AIDS Research and Reference Reagent Programme 
(catalogue number 8129) from J. C. Kappes, X. Wu and Tranzyme Inc, and 
cultured in Dulbecco’s Modified Eagle Medium (DMEM; Invitrogen) containing 
10% (v/v) foetal calf serum (FCS). The NP2 cell lines (1151) are human glioma 
cell lines expressing human CD4 and either of the HIV-1 main co-receptors, 
CXCR4 (NP2/CD4/CXCR4) or CCR5 (NP2/CD4/CCR5). The CCC/CCR5 and 
CCC/CD4/CCR5 cell lines (349, 382, 1152, 1153) are feline kidney cells 
expressing human CCR5, and human CD4 and CCR5, respectively. NP2 and 
CCC cells were cultured in DMEM (Invitrogen) containing 5% (v/v) FCS. The 
293T cell line, of human embryonic kidney origin (1154), was cultured in 
DMEM GlutaMAX (Invitrogen), which is DMEM containing L-analyl-L-
glutamine instead of L-glutamine, supplemented with 10% (v/v) FCS. The use of 
DMEM GlutaMAX minimises ammonia build-up in cell cultures, as L-analyl-L-
glutamine does not degrade into ammonia like L-glutamine. The H9 (HUT78) 
cell line, which is of human cutaneous T cell lymphoma origin (1155), was 
cultured in Roswell Park Memorial Institute (RPMI) 1640 medium (Invitrogen) 
supplemented with 10% (v/v) FCS. Baby hamster kidney (BHK) cells (1156) 
were cultured in DMEM supplemented with 10% (v/v) FCS. 
 
2.3.2 Maintenance of cell lines 
All cells were grown in cell culture flasks at 37°C in a humidified atmosphere 
containing 5% CO2, except for 293T cells, which were kept in a humidified 
atmosphere containing 10% CO2. Cell lines were passaged every 2-5 days and 
split at a ratio of 1:3-1:20 depending of the cell line. For adherent cell lines, cell 
monolayers were disrupted and removed by treatment with trypsin-versene (0.5% 
(w/v) trypsin and 0.02% (w/v) versene in PBS) or trypsin-EDTA (0.25% (w/v) 
trypsin, 1 mM EDTA; Invitrogen) at confluency, prior to passaging. 
Trypsinisation was performed by washing cells once in trypsin-versene, trypsin-
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EDTA, or sterile PBS, followed by incubation with approximately 2 ml trypsin-
versene or trypsin-EDTA at 37°C. Once cells had detached from the flask, fresh 
culture medium was added and cells were diluted in the appropriate growth 
medium to the desired density and split into an appropriate number of flasks. 
Cells engineered to express CD4 were occasionally passaged in selective 
medium containing 1 mg/ml Geneticin G418 sulphate (Invitrogen), in order to 
maintain stable CD4 expression, whereas cells engineered to express CXCR4 or 
CCR5 were occasionally passaged in the presence of 1 µg/ml puromycin for 
selection. 
 
2.3.3 Freezing and thawing of cells 
Cells were pelleted by centrifugation at 325 × g for 10 minutes and resuspended 
at approximately 107 cells/ml in the appropriate cell culture medium (section 
2.3.1) containing 20% (v/v) FCS and 10% (v/v) dimethyl sulphoxide (DMSO). 
Adherent cells were trypsinised as described in section 2.3.2 prior to being 
pelleted. Resuspended cells were aliquoted into cryovials and subsequently 
transferred to -80°C. To allow for slow freezing, vials were wrapped in tissue 
and put into a polystyrene box. The next day, the vials were transferred to the 
vapour phase of liquid nitrogen, for long-term storage. When needed, cryovials 
containing frozen cells were transferred from the vapour phase of liquid nitrogen 
to a 37°C water bath. Once thawed, cells were added to 10 ml of growth medium 
and pelleted at 325 × g for 10 minutes. Pelleted cells were resuspended in growth 
medium, transferred to cell culture flasks and kept at 37°C. 
 
2.3.4 Preparation of peripheral blood mononuclear cells 
PBMC were prepared from fresh blood. Blood was drawn from healthy 
volunteers by me, S. Willey, or K. Aubin, under ethical approval obtained from 
the UCL Committee for the Ethics of non-NHS Human Research (Ethical 
Approval Number 0335/001), using S-Monovette collection tubes containing 
EDTA (Sarstedt, Nümbrecht, Germany). Fresh blood was diluted 1:1 in PBS, and 
a total of 35 ml was layered onto 15 ml of Lymphoprep (Axis-Shield, Oslo, 
Norway) in a 50 ml Falcon tube (BD Biosciences, Oxford, UK) and subsequently 
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centrifuged at 700 × g for 30 minutes. After centrifugation with Lymphoprep, the 
PBMC form a layer at the Lymphoprep-plasma interface. The PBMC layer was 
carefully collected and diluted in PBS to a total volume of 50 ml, followed by 
centrifugation at 325 × g for 10 minutes. Cells were washed twice more in PBS 
and finally resuspended at a density of approximately 5 × 106 cells/ml in RPMI 
1640 supplemented with 10% (v/v) FCS and 2.5 µg/ml of phytohaemagglutinin 
(PHA). The cells were ready to be infected after 3-4 days of culture. After 3 
days, the growth medium was changed to RPMI 1640 supplemented with 10% 
(v/v) FCS and 20 U/ml of interleukin-2 (Roche Diagnostics) and cultured for up 
to another 4 days. 
 
2.3.5 Transfection of 293T cells 
Exponentially dividing 293T cells were transfected with plasmid DNA using 
FuGENE 6 (Roche Diagnostics), according to the manufacturer’s instructions. 
Briefly, the 293T cells were seeded in 10 cm cell culture dishes at a density of 
2.4 × 106 cells per dish and incubated overnight at 37°C. The next day, the 
growth medium was replaced with 12 ml fresh growth medium per dish. For 
transfection, 1.2 ml of Opti-MEM (Invitrogen) was mixed with 36 µl of 
FuGENE 6 and a total of 12 µg of plasmid DNA, incubated for 15 minutes at 
room temperature, and subsequently added dropwise to cells. After 24 hours, the 
transfection medium was aspirated and replaced with fresh growth medium. For 
smaller-scale transfections, 293T cells were seeded in a 6-well cell culture plate 
at a density of approximately 4 × 105 cells per well and transfection volumes 
adjusted accordingly. 
 
2.4 HIV-1 strains and preparation of virus stocks 
In this section, details of the HIV-1 strains used in this study will be given, along 
with information on preparation of virus stocks. 
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2.4.1 HIV-1 strains 
HIV-1 TCLA isolates, primary PBMC-propagated isolates, and infectious 
molecular clones used in this study are detailed in Table 2.4.1.1. TCLA, CXCR4-
using isolates HIV-1 IIIB (32, 1140) and HIV-1 MN (33), which are subtype B 
isolates originally isolated from PBMC of HIV-1 seropositive individuals in the 
1980s, were obtained from the Centralised Facility for AIDS Reagents (NIBSC) 
as cell-free cell-culture supernatant from infected H9 cells. 
 
Cell-free stocks of PBMC-propagated primary isolates HIV-1 BaL (CCR5-
using), which was originally isolated from human infant lung tissue in 1986 
(180), and HIV-1 SF162 (CCR5-using), which was originally isolated from brain 
tissue in 1988 (1157) were also obtained from the Centralised Facility for AIDS 
Reagents (NIBSC). PBMC-propagated HIV-1 CRF07_BC primary isolate CN54 
(1137, 1138) was obtained from the European Microbicides Project (EMPRO). 
PBMC-propagated HIV-1 primary isolates 92UG037, 92UG001, 92BR025, 
97IN003 and ZA97001 were obtained from the WHO-UNAIDS collection of 
primary isolates (1139). Obtained HIV-1 TCLA and primary isolates were 
propagated as described in section 2.4.2. 
 
The replication-competent, full-length HIV-1 molecular clone YU2 (CCR5-
using), cloned directly from brain tissue from an individual with AIDS dementia 
by Li et al. (1158, 1159), was obtained from the NIH AIDS Research and 
Reference Reagent Programme, as was the replication-competent, full-length 
HIV-1 molecular clone JRFL (CCR5-using), which is derived from frontal lobe 
brain tissue of a patient with AIDS dementia (416, 1160, 1161). 
 
Replication-competent chimeric molecular clones 4.10.3 (GenBank accession 
number DQ425070), 8.8.8 (GenBank accession number DQ425074), 23.8.12 
(GenBank accession number DQ425081) and 23.2.E (GenBank accession 
number DQ425078) were recently reported by Aasa-Chapman et al. (1162), and 
contain subtype B gp120 cloned from plasma of HIV-1-infected individuals held 
in the pHXB2∆env vector (1163). Replication-competent chimeric molecular 
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clones CA6 and CB7, which contain subtype C gp120 held in the pHXB2∆env 
vector (1163), were kindly provided by M. Aasa-Chapman (UCL, London, UK). 
 
Chimeric molecular clones C222, C261, 27b and 27d were cloned by Willie Koh 
as described in section 2.6. Chimeric molecular clones 92UG037.A9, 
92BR025.C1, ZA97001.1, 97IN003.4.2, 92UG001.D8, 37.4.2 and 38.2.2 were 
cloned by me as described in section 2.6. Stocks of HIV-1 molecular clones were 
prepared as described in section 2.4.3. 
 
HIV-1 envelope pseudotyped viruses were generated using the gp160 clones 
listed in Table 2.4.1.2. The HIV-1 subtype B and subtype C reference panels of 
envelope clones, generated by Li et al. (1022, 1023), consists of clones from 
acute and early HIV-1 infections and were obtained through the NIH AIDS 
Research and Reference Reagent Programme. The subtype B panel consists of 
gp160 clones 6535.3, QH0692.42, SC422661.8, PVO.4, TRO.11, AC10.0.29, 
RHPA4259.7, THRO4156.18, REJO4541.67, TRJO4551.58, WITO4160.33 and 
CAAN5342.A2, whereas the subtype C panels consists of clones Du156.12, 
Du172.17, Du422.1, ZM197M.PB7, ZM214M.PL15, ZM233M.PB6, 
ZM249M.PL1, ZM53M.PB12, ZM109F.PB4, ZM135M.PL10a, CAP45.2.00.G3 
and CAP210.2.00.E8. 
 
HIV-1 subtype CRF07_BC gp160 clones CH181.12, CH064.20, CH091.9, 
CH117.4, CH119.10, CH110.2, CH114.8, CH120.6, CH115.12, CH070.1, 
CH111.8 and CH038.12 are derived from chronic HIV-1 infections and were 
kindly provided by D. Montefiori (Duke University Medical Centre, Durham, 
USA) through the Comprehensive Antibody Vaccine Immune Monitoring 
Consortium (CA-VIMC) as part of the CAVD, as were subtype CRF02_AG 
gp160 clones T257-31 (derived from acute/early infection) and T33-7 (derived 
from chronic infection), and the subtype C gp160 clones 93MW965.26 and 
96ZM651.02. HIV-1 envelope pseudotyped viruses were produced in 293T cells 
by co-transfection with the pSG3∆env plasmid as described in section 2.4.3. 
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Table 2.4.1.1. HIV-1 isolates and molecular clones included in this study. 
Virus Subtype Typea Sourceb Geographical originc 
92UG037.A9 A MC (gp120/HXB2) ccPBMC Uganda 
IIIB B TCLA PBMC USA 
MN B TCLA PBMC USA 
BaL B PBMC Lung USA 
SF162 B PBMC Brain USA 
JRFL B MC (full-length) Brain USA 
YU2 B MC (full-length) Brain USA 
4.10.3 B MC (gp120/HXB2) Plasma UK 
8.8.8 B MC (gp120/HXB2) Plasma UK 
23.2.E B MC (gp120/HXB2) Plasma UK 
23.8.12 B MC (gp120/HXB2) Plasma UK 
CN54 B´/C PBMC PBMC China 
97IN003 C PBMC PBMC India 
ZA97001 C PBMC PBMC South Africa 
92BR025.C1 C MC (gp120/HXB2) ccPBMC Brazil 
CA6 C MC (gp120/HXB2) Plasma No info. 
CB7 C MC (gp120/HXB2) Plasma No info. 
C222 C MC (gp120/HXB2) Plasma No info. 
C261 C MC (gp120/HXB2) Plasma No info. 
97IN003.4.2 C MC (gp160/NL43) ccPBMC India 
ZA97001.1 C MC (gp160/NL43) ccPBMC South Africa 
37.4.2 C MC (gp160/NL43) Plasma No info. 
38.2.2 C MC (gp160/NL43) Plasma No info. 
27b C MC (gp160/NL43) Plasma No info. 
27d C MC (gp160/NL43) Plasma No info. 
92UG001.D8 D MC (gp160/NL43) ccPBMC Uganda 
aTCLA, T cell line-adapted isolate; PBMC, Primary PBMC-propagated isolate; MC, molecular 
clone. Molecular clones were either full-length infectious HIV-1 clones, chimeric clones 
consisting of heterologous gp120 slotted into the HIV-1 HXB2-based pHXB2∆env backbone 
(1163), or heterologous gp160 slotted into the HIV-1 NL43-based C2 cassette (1164). 
bSource of original isolate. For molecular clones, this indicates the source of the env (gp120 or 
gp160) gene; ccPBMC, co-cultured PBMC. 
cNo info., information not available. 
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Table 2.4.1.2. HIV-1 envelope pseudotyped viruses included in this study. 
Virus Subtype Sourcea  Geographical origin Accession no.b 
T257-31 A/G No info. West Africa n/a 
T33-7 A/G No info. West Africa n/a 
6535.3 B ccPBMC USA AY835438 
QH0692.42 B ccPBMC Trinidad AY835439 
SC422661.8 B Plasma Trinidad AY835441 
PVO.4 B ccPBMC Italy AY835444 
TRO.11 B ccPBMC Italy AY835445 
AC10.0.29 B ccPBMC USA AY835446 
RHPA4259.7 B Plasma USA AY835447 
THRO4156.18 B Plasma USA AY835448 
REJO4541.67 B Plasma USA AY835449 
TRJO4551.58 B Plasma USA AY835450 
WITO4160.33 B Plasma USA AY835451 
CAAN5342.A2 B Plasma USA AY835452 
CH181.12 B´/C ccPBMC China EF117259 
CH064.20 B´/C ccPBMC China EF117254 
CH091.9 B´/C ccPBMC China EF117256 
CH117.4 B´/C ccPBMC China EF117262 
CH119.10 B´/C ccPBMC China EF117261 
CH110.2 B´/C ccPBMC China EF117257 
CH114.8 B´/C ccPBMC China EF117264 
CH120.6 B´/C ccPBMC China EF117260 
CH115.12 B´/C ccPBMC China EF117263 
CH070.1 B´/C ccPBMC China EF117255 
CH038.12 B´/C ccPBMC China EF042692 
93MW965.26 C No info. Malawi n/a 
96ZM651.02 C No info. Zambia n/a 
Du156.12 C ccPBMC South Africa DQ411852 
Du172.17 C ccPBMC South Africa DQ411853 
Du422.1 C ccPBMC South Africa DQ411854 
ZM197M.PB7 C ucPBMC Zambia DQ388515 
ZM214M.PL15 C Plasma Zambia DQ388516 
ZM233M.PB6 C ucPBMC Zambia DQ388517 
ZM249M.PL1 C Plasma Zambia DQ388514 
ZM53M.PB12 C ucPBMC Zambia AY423984 
ZM109F.PB4 C ucPBMC Zambia AY424138 
ZM135M.PL10a C Plasma Zambia AY424079 
CAP45.2.00.G3 C Plasma South Africa DQ435682 
CAP210.2.00.E8 C Plasma South Africa DQ435683 
aSource of env gene; no info., information not available; ccPBMC, co-cultured PBMC; ucPBMC, 
uncultured PBMC. 
bGenBank accession number; n/a, not applicable. 
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2.4.2 Propagation of viruses in T cell lines or PBMC 
HIV-1 primary isolates were propagated in PHA-stimulated PBMC. 
Approximately 1-2 × 107 PBMC (pooled from two donors) were incubated with 
virus at 37°C in a total volume of 1-2 ml. After 2 hours of incubation, growth 
medium (RPMI 1640 supplemented with 10% (v/v) FCS and 20 U/ml of 
interleukin-2) was added to the cells to a total volume of 10 ml. Virus production 
was monitored by evaluating the p24 content in the cell culture supernatant using 
the Vironostika HIV Uni-Form II Ag/Ab p24 assay (bioMérieux, Marcy l'Etoile, 
France). After 6-7 days, the cells were pelleted by centrifugation at 325 × g for 
10 minutes and co-cultured (in fresh growth medium) with fresh, uninfected 
PHA-stimulated PBMC from two donors at a 1:1 ratio. Cell density was adjusted 
to approximately 1-2 × 106 cell/ml. This procedure was repeated every 6-7 days 
for 4 weeks or until a sufficient volume and titre of virus had been obtained. The 
p24 content of the cell culture supernatant was monitored throughout. At the 
peak of p24 production, the cell culture supernatant was harvested by 
centrifugation of the cultures at 325 × g for 10 minutes. The supernatant was 
subsequently filtered (0.45 µm) and transferred to the vapour phase of liquid 
nitrogen in 0.5 ml aliquots. HIV-1 TCLA isolates were propagated in H9 cells in 
a similar manner, but harvested on day 5 after infection. 
 
2.4.3 Production of HIV-1 envelope pseudotyped viruses and virus from 
replication-competent molecular clones in 293T cells 
HIV-1 envelope pseudotyped viruses were produced in 293T cells by co-
transfection with the pSG3∆env plasmid, which contains the entire HIV-1 
genome except for env, as described by Li et al. (1022). The pSG3∆env plasmid 
is based on the full-length replication-competent HIV-1 pSG3.1 clone (GenBank 
accession number L02317), but with deleted env. For each 10 cm cell culture 
dish of 293T cells, 4 µg of envelope clone and 8 µg of pSG3∆env was used. 
Virus stocks from replication-competent HIV-1 molecular clones were also 
prepared by transfection of 293T cells. Transfection of 293T cells was carried 
out as described in section 2.3.5. The virus-containing cell culture supernatant 
was harvested at 48 and/or 72 hours after transfection, filtered through a 0.45 µm 
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filter, transferred to cryovials in 0.5 ml aliquots, and stored in the vapour phase 
of liquid nitrogen. 
 
2.5 Amplification and cloning of env genes 
In this section, the PCR amplification of gp120 and gp160 gene segments and the 
subsequent cloning of these fragments into expression and cloning vectors will 
be detailed. 
 
2.5.1 Sources of DNA and RNA 
HIV-1 gp120 and gp160 were amplified from viral RNA and from proviral DNA 
isolated from infected PBMC. PBMC were prepared from blood of healthy 
volunteers, as described in section 2.3.4, and were subsequently infected with 
HIV-1 primary isolates CN54, 92UG037, 92BR025, 97IN003, ZA97001 and 
92UG001, as described in section 2.4.2. After 5 days of culture, genomic DNA 
was isolated from infected cells as described in section 2.2.1. RNA was isolated 
from plasma of infected individuals or from cell-free virus stocks as described in 
section 2.2.2. HIV-1 CN54 gp120 was also amplified from plasmids holding a 
full-length proviral CN54 molecular clone or from plasmids containing a 
synthetic CN54 gp160 gene (obtained from EMPRO). HIV-1 CB7 gp120 was 
amplified from the chimeric CB7 molecular clone (section 2.4.1). 
 
2.5.2 Primers and primer design 
The primers used to amplify HIV-1 gp120 and gp160 are listed in Table 2.5.2.1. 
Primers o_envf and o_envr were designed using the Primer3 software (1165) and 
analysed for secondary structures using the IDT Oligo Analyzer software 
(available at http://www.idtdna.com). Furthermore, primers o_envf and o_envr 
were designed to target nucleotide stretches conserved among most HIV-1 
isolates, and generated an amplicon of expected size from HIV-1 group M 
subtype A, B, C, and D as well as from HIV-1 of group O. Primers fenv3 and 
renv3, which amplify gp160 and contain restriction sites XhoI and EcoRI to 
facilitate subsequent sub-cloning, were modified from primers described by 
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Zheng and Daniels (1164). Primers 988L, 943S, 609RE, 628L, 125Y and 626L, 
which amplify gp120, have been described by Aasa-Chapman et al. (1162), as 
has primer 944S, which contains a natural Kozak sequence and a start codon, to 
facilitate subsequent protein expression. Antisense primer E400010_His was 
based on primer E400010, which has been described previously (1162), but 
encoded a 6-histidine-tag in addition to the stop codon present in E400010. 
Primer E400010_His (and E400010) also encodes part of the recognition motif 
(VVQREKR) for sheep polyclonal antibody D7324 (Aalto Bio Reagents, Dublin, 
Ireland), which recognises a conserved motif at the very C-terminus of gp120 
(APTKAKRRVVQREKR).  
 
Table 2.5.2.1. Primers used for amplification of HIV-1 gp160 and gp120a. 
Primer Sequence (5´to 3´)b Positionc 
o_envf TYTCCTATGGCAGGAAGAAGC 5964 
o_envr TAACCCWTCCAGTCCCCCCTTTT 9096 
988L GTAGCATTAGCGGCCGCAATAATAATAGCAATAG 6089 
943S CAATAGYAGCATTAGTAGTAG 6084 
609RE CCCATAGTGCTTCCGGCCGCTCCCAAG 7816 
628L TCATCTAGAGATTTATTACTCC 8086 
fenv3 AGCTCGAGCAGAAGACAGTGGCAATGA 6202 
renv3 CTATGGAATTCTTCGACCACTTGCCCCCCATTT 8827 
944S AGAAAGAGCGGCCGCCAGTGGCAATG 6202 
E400010_His TTAATGATGATGATGATGATGTCTTTTTTCTCTCTGCACCACT 7778 
626L GTGGGTCACCGTCTATTATGGG 6326 
125Y CACCACGCGTCTCTTTGCCTTGGTGGG 7742 
aPrimers 944S, 626Y and 125Y have been described previously (1162). Primer E400010_His was 
based on primer E400010 described previously (1162). Primers fenv3 and renv3 were modified 
from primers described previously (1164). 
bRestriction sites (XhoI in fenv3, EcoRI in renv3, BstEII in 626L, and MluI in 125Y) are 
underlined. Y equals C or T and W equals A or T according to standard International Union of 
Pure and Applied Chemistry (IUPAC) nomenclature. 
cNucleotide position of primer 5´-end in the HIV-1 HXB2 genome (GenBank accession number 
K03455). 
 
Additional primers used for DNA sequencing of gp120 and gp160 clones are 
shown in Table 2.5.2.2. Primers A589-, E80+, 621L-, 617L-, and 015S+ were 
provided by M. Aasa-Chapman. Primers gp160 +1, gp160 +298, gp160 -317, 
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gp160 +580, gp160 -600, gp160 +901, gp160 +1198, gp160 +1581, gp160 
+1881, gp160 +2191, and gp160 +2431 had been designed by K. Aubin. 
 
Table 2.5.2.2. Primers used for sequencing of HIV-1 gp160 and gp120. 
Primer Sequence (5´to 3´) Positiona 
A589- CAGAGTGGGGTTAATTTTACAC 6600 
E80+ CCAATTCCCATACATTATTGTG 6858 
621L- GTACATTGTACTGTGCTGACATT 6967 
617L- CTGGGTCCCCTCCTGAGG 7332 
015S+ ACATTGTAACATTAGTAGAG 7211 
gp160 +1 ATGGGGACACAGAGGAATTATC 6234 
gp160 +298 GAGGATGTAATCAGCTTATG 6540 
gp160 -317 CATAAGCTGATTACATCCTC 6559 
gp160 +580 CAAGCCTGTCCAAAGATCTC 6831 
gp160 -600 GAGATCTTTGGACAGGCTTG 6850 
gp160 +901 ATAGGACCAGGACAAACATTC 7155 
gp160 +1198 TGCAGATCAAATATCACAGG 7557 
gp160 +1581 GTCTGGTATAGTGCAACAGC 7859 
gp160 +1881 GCTTGAAGAATCACAAAGCCAG 8159 
gp160 +2191 GTGAGCGGATTCTTAGCACT 8469 
gp160 +2431 GTAGCTGAGGGAACAGATAG 8688 
cNucleotide position in the HIV-1 HXB2 genome (GenBank accession number K03455). 
 
2.5.3 RT-PCR 
Specific first-strand cDNA was synthesised from RNA (section 2.5.1) and 
subsequently amplified in a one-step RT-PCR using the Titan One Tube RT-PCR 
Kit (Roche Diagnostics) and primers o_envf and o_envr (Table 2.5.2.1) 
according to the manufacturer’s instructions. The Titan One Tube RT-PCR Kit 
uses avian myeloblastosis virus (AMV) reverse transcriptase and the DNA 
polymerase mix from the Expand Long Template PCR System (Roche 
Diagnostics). Reverse transcription is initiated at the reverse primer. The reaction 
was carried out in a total of 50 µl containing 1 × Titan RT-PCR reaction buffer, 1 
µl of Titan enzyme mix, 500 µM of each of the four dNTPs, 300 nM each of 
forward (o_envf) and reverse (o_envr) primers, 5 mM of DTT, 5 U of RNase 
inhibitor, and up to 1 µg of RNA. For the reverse transcription step, the reaction 
mix was incubated at 48°C for 30 minutes. The reverse transcription step was 
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immediately followed by the PCR step, which consisted of initial denaturation at 
96°C for 5 minutes, followed by 35 cycles of denaturation at 96°C for 1.5 
minutes, annealing at 60°C for 1 minute and elongation at 68°C for 10 minutes, 
followed by a final elongation step of 20 minutes at 68°C. Negative control 
reactions containing no template RNA were included in each RT-PCR run to 
monitor possible contamination. Control reactions where reverse transcription 
was not carried out, containing the enzyme mix from the Expand Long Template 
PCR System instead of the Titan enzyme mix were also included to exclude 
amplification from genomic DNA. A 1-5 µl aliquot from the RT-PCR was taken 
forward to a second round of PCR using nested primers, to amplify gp120 or 
gp160, as described in section 2.5.4. 
 
2.5.4 PCR amplification of gp120 and gp160 
Full-length HIV-1 gp120 and gp160 was amplified from proviral DNA isolated 
from infected PBMC (section 2.5.1) in two rounds of PCR using the Expand 
Long Template PCR System (Roche Diagnostics). In addition to Taq DNA 
polymerase, the Expand Long Template PCR System enzyme mix contains the 
Tgo DNA polymerase, which has proofreading activity. 
 
The first round of PCR was carried out in a total of 50 µl containing 1× Expand 
Long Template Buffer 3, 500 µM of each of the four dNTPs, 300 nM each of the 
forward (o_envf) and reverse primer (o_envr), 3.75 U of the Expand Long 
Template enzyme mix and 300-500 ng of template genomic DNA. It consisted of 
an initial denaturation step of 5 minutes at 96°C, followed by 35 cycles of 
denaturation at 96°C for 1.5 minutes, annealing at 60°C for 1 minute and 
elongation at 68°C for 10 minutes, followed by a final elongation step of 20 
minutes at 68°C. Alternatively, for amplification of gp120 from some of the 
viruses, the first round of PCR was performed as described by Aasa-Chapman et 
al. (1162), using a mix of forward primers 988L and 943S and either of reverse 
primers 609RE and 628L and an annealing temperature of 44°C. 
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A 1-5 µl aliquot from the first round of PCR amplification (or RT-PCR 
amplification; section 2.5.3) was taken forward to a second round of PCR using 
nested primers that amplified gp120 or gp160. If the gp120 was going to be 
cloned into the pcDNA3.1-TOPO expression vector (section 2.5.5) for 
expression in a T7 RNA polymerase-recombinant vaccinia virus system, gp120 
was amplified as described by Aasa-Chapman et al. (1162) using primers 944S 
and E400010_His. For HIV-1 CN54 and CB7, gp120 was amplified from 
molecular clones using primers 944S and E400010_His. If the gp120 was going 
to be slotted into cloning vectors (section 2.5.6), gp120 was amplified from the 
outer PCR product, or re-amplified from selected gp120 clones held in the 
pcDNA3.1-TOPO expression vector, using primers 125Y and 626L. Full-length 
gp160 was amplified using primers fenv3 and renv3. The nested PCRs consisted 
of an initial denaturation step of 5 minutes at 96°C, followed by 35 cycles of 
denaturation at 96°C for 1.5 minutes, annealing at 50°C (primers fenv3/env3), 
55°C (primers 944S/E400010_His), or 57°C (primers 125Y/626L) for 1 minute, 
and elongation at 68°C for 5 minutes (gp120 amplification) or 10 minutes (gp160 
amplification), followed by a final elongation step of 20 minutes at 68°C. For 
primers that had not been previously described, the PCR conditions were 
optimised by varying annealing temperatures and elongation times. Negative 
control reactions containing no template DNA were included in each PCR to 
monitor possible contamination. PCR products were separated using agarose gel 
electrophoresis, as described in section 2.2.5, and DNA fragments of the 
expected size were purified from the gel as described in section 2.2.6. 
 
2.5.5 Cloning of amplified gp120 into expression vectors 
Gel-purified gp120 amplified using primers 944S/E400010_His was ligated into 
the expression vector pcDNA3.1-TOPO (Invitrogen) according to the 
manufacturer’s instructions. The ligation reactions were subsequently 
transformed into competent TOP10 bacteria (section 2.2.7). Screening of 
pcDNA3.1-TOPO plasmids carrying an insert of the expected size was carried 
out by restriction enzyme digestion (section 2.2.4) followed by agarose gel 
electrophoresis (section 2.2.5). Clones producing functional gp120 when 
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transfected into T7 RNA polymerase-recombinant vaccinia virus-infected 293T 
cells (section 2.7) were sequenced (section 2.2.8). 
 
2.5.6 Cloning of amplified gp120 and gp160 into cloning vectors 
Gel-purified gp120 and gp160 clones were ligated into the pGEM-T Easy 
(Promega) or the pCR2.1-TOPO (Invitrogen) cloning vectors according to the 
manufacturers’ instructions. Competent bacteria were transformed with the 
ligation reactions (section 2.2.7) and plated onto LB/ampicillin plates onto which 
40 µl of 40 mg/ml of 5-bromo-4-chloro-3-indolyl-β-galactopyranoside (X-gal) in 
N,N´-dimethylformamide (Promega) had been spread. As successful cloning of 
an insert into the pGEM-T Easy and pCR2.1-TOPO vectors interrupts the coding 
sequence of β-galactosidase, recombinant clones were identified by blue/white 
colour screening. Clones containing an insert of the correct size were 
subsequently identified using restriction enzyme digestion (section 2.2.4) and 
agarose gel electrophoresis (section 2.2.5). 
 
2.6 Generation of HIV-1 infectious recombinant molecular clones 
Chimeric, infectious HIV-1 molecular clones containing heterologous env genes 
in subtype B-based backbones were generated as described below. 
 
2.6.1 Sub-cloning of gp120 into the pHXB2∆env backbone 
Full-length gp120 was sub-cloned from the pGEM-T Easy and pCR2.1-TOPO 
vectors into the pHXB2∆env vector constructed by McKeating et al. (1163), by 
means of the BstEII recognition site present in primer 626L and the MluI 
recognition site present in primer 125Y. The pHXB2∆env backbone is based on 
HIV-1 HXB2 (subtype B) and allows incorporation of heterologous gp120 
sequences from amino acid residue 38 to six amino acids before the gp120/gp41 
junction. The gp120 DNA fragment was extracted from the pGEM-T Easy or 
pCR2.1-TOPO cloning vectors by double digestion with BstEII and MluI 
(section 2.2.4). Digested plasmid DNA was separated using agarose gel 
electrophoresis (section 2.2.5) and the gel-purified DNA fragment of the 
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expected size was then ligated (overnight at 4°C) into the pHXB2∆env backbone 
(which had also been digested with the BstEII and MluI enzymes and gel-
purified) using T4 DNA ligase (Promega) and the Rapid Ligation Buffer 
(Promega), according to the manufacturer’s instructions. For some virus isolates, 
the gp120 contained an internal BstEII recognition site. Partial restriction digests 
were then carried out (section 2.2.4) and bands of the expected size were purified 
from the gel and ligated into pHXB2∆env. 
 
2.6.2 Sub-cloning of gp160 into the pNL43-based C2 cassette 
The C2 cassette, which is constructed by Zheng and Daniels (1164), is based on 
the infectious HIV-1 NL43 (subtype B) molecular clone and allows incorporation 
of heterologous full-length env genes. Full-length gp160 was extracted from the 
pGEM-T Easy and pCR2.1-TOPO vectors by double digestion with enzymes 
XhoI and EcoRI, whose recognition sites were present in primers fenv3 and 
renv3. Digested gp160 fragments were then gel-purified and transferred into the 
similarly digested and gel-purified C2 cassette using the T4 DNA ligase 
(Promega) and the Rapid Ligation Buffer (Promega), according to the 
manufacturer’s instructions. 
 
2.6.3 Identification of infectious gp120/HXB2 and gp160/NL43 chimeras 
The gp120-pHXB2∆env and gp160-C2 ligation reactions were transformed into 
competent bacteria (section 2.2.7). Clones containing inserts of the correct sizes 
were identified and used for virus production in 293T cells as described in 
section 2.4.3. Clones producing infectious virus were identified by titration of the 
cell culture supernatant from transfected 293T cells onto NP2/CD4/CCR5 or 
NP2/CD4/CXCR4 target cells, as described in section 2.9.1. Clones producing 
infectious virus were sequenced (section 2.2.8). 
 
2.7 Expression of recombinant gp120 
Recombinant gp120 derived from HIV-1 CN54, 92UG037, 92BR025 and CB7 
was expressed as described by Aasa-Chapman et al. (631) using a bacteriophage 
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T7 RNA polymerase-recombinant vaccinia virus system developed by Fuerst et 
al. (1166) in 1986. Exponentially dividing 293T cells, seeded the day before at a 
density of 4 × 105 cells per well of a 6-well plate, were washed once in serum-
free DMEM and subsequently overlaid with 2 ml per well of serum-free DMEM. 
Cells were then incubated with approximately 4 × 104 50% tissue culture 
infectious doses (TCID50) per well of T7 RNA polymerase recombinant vaccinia 
virus (vTF7-3, American Tissue Culture Collection number VR-2153) at 37°C. 
After 2 hours of incubation, cells were washed once in DMEM, overlaid with 2 
ml per well of DMEM GlutaMAX supplemented with 10% (v/v) of FCS, and 
subsequently transfected with the gp120-pcDNA3.1-TOPO plasmids generated 
as described in section 2.5.5. Transfections were carried out as described in 
section 2.3.5 using 4 µg of plasmid DNA and 12 µl of FuGENE 6 (Roche 
Diagnostics). Cell culture media was not changed at 24 hours after transfection, 
as the monolayers of vaccinia virus-infected cells were easily disrupted. Cell 
culture supernatants were harvested 72 hours after transfection, treated with 1% 
(v/v) Igepal CA-630 (octylphenyl-polyethylene glycol; Sigma-Aldrich) to 
inactivate vaccinia virus, filtered and stored at -20°C. To monitor residual 
infectious vaccinia virus, cell culture supernatants were titrated onto Vero cells 
(1167) and cytopathic effects were observed microscopically. The gp120-
containing cell culture supernatants were then used directly in an enzyme-linked 
immunosorbent assays (ELISA) as described in section 2.16. Alternatively, 
gp120 was purified using Ni Sepharose 6 Fast Flow (GE Healthcare, Little 
Chalfont, UK) by means of the 6-histidine-tag encoded by primer E400010_His, 
according to the manufacturer’s instructions. 
 
2.8 Virus detection assays 
This section details the virus detection assays used in this study. 
 
2.8.1 Intracellular p24 immunostaining 
HIV-1 infection of NP2 cells (and CCC cells) were detected using in situ 
intracellular p24 immunostaining as previously described (1168). The cell culture 
medium was removed and the cells were fixed for 10 minutes at room 
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temperature using 200 µl per well of a mixture of methanol and acetone (at a 1:1 
ratio) that had been pre-cooled at -40°C, and subsequently washed twice in PBS 
containing 1% (v/v) FCS (Invitrogen). Fixed cells were then incubated with 200 
µl per well of an equal mixture of mouse anti-p24 mAbs ADP365 and ADP366 
(Centralised Facility for AIDS Reagents, NIBSC) at 1:40 dilution in PBS 
containing 1% (v/v) FCS, for 1 hour at room temperature. After another two 
washes in PBS containing 1% (v/v) FCS, the cells were incubated with 200 µl 
per well of a goat anti-mouse immunoglobulin antibody conjugated to β-
galactosidase (Southern Biotechnology Associates, Birmingham, USA; catalogue 
number 1010-06) at 2.5 µg/ml in PBS containing 1% (v/v) FCS, for 1 hour at 
room temperature. The stained cells were then washed twice in PBS containing 
1% (v/v) FCS and once in PBS, and subsequently incubated with 200 µl per well 
of β-galactosidase substrate solution (0.5 mg/ml 5-bromo-4-chloro-3-indolyl-β-
galactopyranoside in PBS containing 3 mM potassium ferricyanide, 3 mM 
potassium ferrocyanide and 1 mM MgCl2) at 37°C overnight. Infected cells 
turned blue, and focus-forming units (FFU) were counted under visible light 
microscopy. 
 
2.8.2 Detection of infection of TZM-bl cells 
TZM-bl cells contain a Tat-inducible, LTR-driven luciferase gene. Luminescence 
production was detected using the Bright-Glo Luciferase Assay System 
(Promega) according to the manufacturer’s instructions. Briefly, 100 µl of cell 
culture medium was removed from each well, and 100 µl per well of Bright-Glo 
reagent was subsequently added. Lysis was allowed to occur for 2 minutes and 
luminescence (in relative light units; RLU) was then detected using a GloMax 96 
Luminometer (Promega). 
 
2.8.3 HIV-1 p24 ELISA 
Cell-free virus in cell culture supernatants were detected using the HIV-1 p24 
antigen capture assay kit developed by the NCI-Frederick Cancer Research and 
Development Centre AIDS Vaccine Programme (SAIC-Frederick, Frederick, 
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USA) according to the manufacturer’s instructions. Briefly, samples were lysed 
by incubation with 1% (v/v) Triton X-100 (Sigma-Aldrich) at 37°C for 1 hour, 
and subsequently diluted in sample diluent buffer consisting of 1% (w/v) bovine 
serum albumin (BSA; Kirkegaard & Perry Laboratories, Gaithersburg, USA) and 
0.2% (v/v) Tween 20 (Sigma-Aldrich) in RPMI 1640 (Invitrogen). Two-fold 
serial dilutions of a HIV-1 p24 standard (provided with the kit) ranging from 
40000 pg/ml to 100 pg/ml was prepared using the same sample diluent. HIV-1 
p24 antigen capture assay plates (96-well microtitre plates pre-coated with an 
anti-p24 mAb and blocked with a casein solution; SAIC-Frederick) were washed 
ten times with 1 × wash buffer (0.002 M imidazole, 0.02% (v/v) Tween 20, 0.5 
mM EDTA, 160 mM NaCl; Kirkegaard & Perry Laboratories) using a 
MultiWash III automatic plate washer (TriContinent, Grass Valley, USA), 
turning the plates 180° after five washes.  
 
Samples (100 µl per well) and p24 standard (100 µl per well of each dilution, in 
duplicate) were then added to the plates. Two wells per plate were left empty 
(blank wells) and two wells per plate were left with only sample diluent, for 
measurement of background absorbance levels. After incubation at 37°C for 2 
hours, the plates were washed as described above, and 100 µl per well of a rabbit 
anti-p24 antibody (provided with the kit; SAIC-Frederick) diluted 1:200 in 10% 
(v/v) FCS and 2% (v/v) normal mouse serum (Sigma-Aldrich) in RPMI 1640 
(Invitrogen) were subsequently added. After incubation at 37°C for 1 hour, the 
plates were washed as before, and 100 µl per well of a horse radish peroxidase 
(HRP)-conjugated goat anti-rabbit IgG antibody (provided with the kit; SAIC-
Frederick) diluted 1:50 in 2% (v/v) normal mouse serum (Sigma-Aldrich), 5% 
(v/v) GS (Invitrogen) and 0.01% (v/v) Tween 20 (Sigma-Aldrich) in RPMI 1640 
were added to the plates. The plates were then incubated for 1 hour at 37°C. 
After another washing step as before, 100 µl per well of TMB MicroWell 
Peroxidase Substrate solution (Kirkegaard & Perry Laboratories) was added and 
the plates were incubated for 30 minutes at room temperature. The reaction was 
stopped by the addition of 100 µl per well of 1 M HCl. The absorbance at 450 
nm (with the absorbance at 650 nm subtracted) was then measured. Absorbance 
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readings for the standard were plotted against concentration and fitted to a 
sigmoidal equation using the XLFit 4 software (IDBS, Guildford, UK). 
 
2.9 Titration of virus stocks 
Virus stocks were titrated onto the different cell types as detailed below. 
 
2.9.1 Titration on NP2 (and CCC) cells 
NP2/CD4/CXCR4 and NP2/CD4/CCR5 (or CCC cells) were seeded in 48-well 
cell culture plates at a density of 2 × 104 cells per well and incubated at 37°C. 
The day after, ten-fold serial dilutions of viral stocks were prepared using fresh 
cell culture medium, and the cells were incubated with 100 µl per well of the 
serially diluted virus for 2 hours at 37°C. Each dilution of virus was assayed in 
duplicate or triplicate wells. The cells were then washed once in cell culture 
medium, and subsequently overlaid with 0.5 ml of fresh medium. After 72 hours 
at 37°C, the cells were fixed and infection was detected by intracellular HIV-1 
p24 immunostaining as described in section 2.8.1. FFU were counted 
microscopically and the virus titre determined as FFU/ml. 
 
2.9.2 Titration on TZM-bl cells 
Viral stocks were five-fold serially diluted in cell culture medium in 
quadruplicate wells of opaque 96-well cell culture plates, starting at a 1:5 
dilution, in a total of 100 µl per well. Eight wells were left with 100 µl of cell 
culture medium only. Approximately 1 × 104 newly trypsinised TZM-bl cells in 
100 µl of DMEM supplemented with 10% (v/v) FCS and 30 µg/ml 
diethylaminoethyl (DEAE)-dextran (Sigma-Aldrich) were then added to each 
well, giving a final concentration of 15 µg/ml of DEAE-dextran. DEAE-dextran 
and other polycations have been frequently used to enhance retroviral, including 
HIV-1, infection in vitro (1169). The optimal concentration range of DEAE-
dextran was determined by titrating DEAE-dextran into the assay (Fig. 2.9.2.1). 
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The plates, containing serially diluted virus and TZM-bl cells, were subsequently 
incubated at 37°C. After 48 hours of incubation, luminescence was detected as 
described in section 2.8.2, and background luminescence (i.e. luminescence in 
wells containing cells but no virus) was subtracted. The dilution where 50% of 
wells were positive, i.e. the TCID50, was calculated according to the method 
developed by Reed and Muench (1170) using an Excel macro set up by D. 
Montefiori at the Duke University Medical Centre, Durham, USA. 
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Figure 2.9.2.1. Determination of optimal concentration of DEAE-dextran. TZM-bl cells were 
infected with HIV-1 SF162 in the presence of two-fold serial dilutions of DEAE-dextran. After 
48 hours of incubation, luminescence was detected as described in the text. Background-
subtracted RLU were plotted against DEAE-dextran concentration. Data points represent the 
mean and bars the standard deviation of three replicates. 
 
2.9.3 Titration on PBMC 
Viral stocks were five-fold serially diluted in RPMI 1640 supplemented with 
10% (v/v) FCS and 20 U/ml of interleukin-2 (Roche Diagnostics) in 
quadruplicate wells of a V-bottomed 96-well plate in a total of 100 µl per well. 
PHA-stimulated PBMC were counted and 1 × 105 cells in 100 µl of fresh growth 
medium (containing interleukin-2) were added to each well. After 24 hours at 
37°C the cells were washed twice in growth medium by centrifugation at 210 × g 
for 5 minutes, followed by the removal of 190 µl of cell culture supernatant and 
the addition of 190 µl of fresh growth medium. Cells were then incubated at 
37°C and productive infection was monitored by removing 25 µl of cell culture 
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supernatant and replacing with fresh growth medium on day 1, 3, 5 and 8 after 
infection. Virus production was measured by p24 ELISA (section 2.8.3). 
 
2.10 Neutralisation assays 
This section details the neutralisation assays used in this study. 
 
2.10.1 HIV-1 neutralisation in NP2 cells 
VHH, mAb b12 or sCD4 neutralisation activities were assessed in 
NP2/CD4/CXCR4 or NP2/CD4/CCR5 cells as described previously (631). NP2 
cells were seeded in 48-well cell culture plates at a density of 2 × 104 cells per 
well. The day after, 100 FFU of virus were pre-incubated with two-fold serial 
dilutions of VHH (or mAb b12 or sCD4) in growth medium for 1 hour at 37°C, 
in a total of 100 µl per well, and subsequently added to the NP2 cells seeded the 
day before. The cells were incubated with the virus-antibody mixture for 2 hours 
and thereafter washed gently in growth medium. After 72 hours at 37°C, the cells 
were fixed and infection was detected by intracellular p24 immunostaining 
(section 2.8.1). FFU were counted microscopically and neutralisation titres were 
determined as the VHH (or mAb b12 or sCD4) concentration required to give 
90% reduction of infection (IC90) compared to a concentration-matched 
irrelevant (negative control) VHH/mAb. The neutralisation activity of each VHH 
(or mAb b12 or sCD4) was assayed in triplicate and on a minimum of two 
separate occasions. Control wells containing virus and cells but no VHH or mAb 
were included on each plate. 
 
2.10.2 HIV-1 neutralisation in TZM-bl cells 
HIV-1 neutralisation in TZM-bl cells was evaluated using an assay developed by 
Derdeyn et al. (1148), Wei et al. (1149) and Li et al. (1022). Serial three-fold 
dilutions of VHH and mAb b12 (starting at 50 µg/ml) were prepared in growth 
medium in duplicate wells of opaque 96-well cell culture plates, in a total volume 
of 50 µl per well. Approximately 200 TCID50 of virus, in 50 µl of growth 
medium, was then added to each well, and the plates were subsequently 
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incubated at 37°C. After 1 hour of incubation, 1 × 104 newly trypsinised TZM-bl 
cells in 100 µl of growth medium containing 30 µg/ml of DEAE-dextran (Sigma-
Aldrich) were added to each well. The plates were then incubated at 37°C for 48 
hours, after which the cells were lysed and luminescence was detected (section 
2.8.2). For each plate, eight wells containing cells and growth medium only, and 
eight wells containing virus and cells only, were included. Neutralisation was 
measured as the reduction in RLU in test wells compared to in virus control wells 
after subtraction of background luminescence. The lowest VHH or antibody 
concentration required to give 50% and 90% reduction in RLU (IC50 and IC90) 
were determined by fitting the data to a sigmoidal equation using the XLFit 4 
software (IDBS). The neutralisation activity of each VHH and mAb b12 was 
assayed in duplicate and on a minimum of two separate occasions, apart from the 
CRF07_BC pseudovirus panel, against which the VHH and mAb b12 were 
assayed once. A concentration-matched negative control VHH (VHH #3; kindly 
provided by A. Gorlani, Utrecht University, the Netherlands) was tested in 
parallel. The HIV-1 neutralisation potencies of llama sera and plasma were also 
evaluated in TZM-bl cells. Serum and plasma samples were heat-inactivated in 
order to destroy complement by incubation at 56°C for 1 hour prior to use in 
neutralisation assays. Three-fold serial dilutions of llama sera were then tested, 
starting at a 1:5 dilution. 
 
2.10.3 HIV-1 neutralisation in PBMC  
Serial three-fold dilutions of VHH (and mAb b12) were prepared in RPMI 1640 
supplemented with 10% (v/v) FCS and 20 U/ml of interleukin-2 (Roche 
Diagnostics) and subsequently incubated with the appropriate dilution of virus at 
37°C in a total volume of 100 µl per well. After 1 hour of incubation, 1 × 105 
PHA-stimulated PBMC in 100 µl of fresh growth medium (containing 
interleukin-2) were added to each well and the plates were incubated at 37°C. 
After 24 hours of incubation, the cells were washed twice in growth medium as 
described in section 2.9.3. Cells were then incubated at 37°C and productive 
infection was monitored by removing 25 µl of cell culture supernatant and 
replacing with fresh growth medium on day 1, 3, 5 and 8 after infection. For each 
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plate, eight wells containing only virus and cells were included (virus only 
controls). Virus production was measured by p24 ELISA (section 2.8.3). 
Initially, the p24 content of virus only controls from day 1, 3, 5 and 8 post 
infection were determined. The p24 content of remaining assay wells were 
determined only for the assay day for which a sufficient amount of p24 could be 
detected in the virus only controls. Neutralisation was measured as reduction in 
p24 content in test wells compared to in virus only controls. VHH and mAb b12 
IC50, IC75 and IC90 values were calculated using curve-fitting software XLfit4 
(IDBS). All VHH, including a negative control VHH (and mAb b12), were 
assayed in triplicate and in PBMC from two separate donors. 
 
2.10.4 Neutralisation of an irrelevant virus in BHK cells 
The VHH were tested against a pseudovirus bearing the rabies virus G protein, 
CVS-11 (1171). This virus was kindly provided by E. Wright, UCL, London, 
UK. Neutralisation of virus CVS-11, which contains a luciferase reporter gene, 
was evaluated in BHK target cells, as described previously (1171). Briefly, 200 
TCID50 of virus were pre-incubated with VHH and a neutralising human anti-
rabies serum (as a positive control; kindly provided by E. Wright, UCL, London, 
UK), and subsequently added to 2 × 104 BHK cells. Luminescence was detected 
after 48 hours. No specific reduction of CVS-11 infection was observed. 
 
2.11 Immunisation of Llama glama and construction of phage library 
Immunisation of llamas and construction of phage libraries expressing the VHH 
repertoires of the immunised llamas were carried out by staff at Ablynx, NV, 
Ghent, Belgium. Two llamas (numbered L40 and L44) were immunised with 
recombinant CN54 gp120. One llama (L48) was immunised with recombinant 
CN54 gp140. Immunisations and VHH library construction were carried out as 
described previously (1172). In brief, the llamas received six intramuscular 
injections at weekly intervals. Each injection consisted of a freshly prepared 4.5 
ml water-in-oil emulsion, prepared by vigorous mixing of 2 volume units of 
antigen (50 or 100 µg) with 2.5 volume units of the adjuvant Stimune (CEDI 
Diagnostics, Lelystad, the Netherlands), and was administered intramuscularly in 
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the neck divided over two spots. On days 0 and 7, the llamas received 100 µg of 
antigen, and on days 14, 21, 28 and 35, they received 50 µg of antigen. Four days 
after the last antigen injection (on day 39 post-immunisation), a 150 ml blood 
sample and a lymph node biopsy were collected as the source of B cell 
containing tissues. After another four days (on day 43 post-immunisation) a 
second 150 ml blood sample was collected. 
 
For each llama, total RNA was isolated from peripheral blood lymphocytes and 
lymph node biopsies collected post-immunisation by acid guanidinium 
thiocyanate-phenol-chloroform extraction, and RNA isolated from the two 
different tissues were subsequently pooled. Oligo-dT primed cDNA was 
prepared from total RNA using the SuperScript III First-Strand Synthesis System 
for RT-PCR (Invitrogen). The VHH repertoires were amplified in two rounds of 
PCR. In the first PCR, the repertoire of both conventional (1.6 kb) and heavy-
chain (1.3 kb) antibody gene segments were amplified using a forward primer 
specific for the leader sequence and a reverse oligo-dT primer. To allow for 
efficient separation of cDNA fragments encoding conventional and heavy-chain 
antibodies, the resulting PCR product was then treated with the BglI restriction 
enzyme, since the gene segment coding for the CH1 domain, present only in 
conventional antibodies (chapter 1.2), contains a unique BglI recognition site. 
Following restriction enzyme digestion and agarose gel electrophoresis and 
purification, the resulting 1.3 kb fragment was used as a template in a nested 
PCR using a mixture of forward primers specific for the FR1 region of VHH, 
which introduce a SfiI recognition site, and a reverse oligo-dT primer. The 
resulting PCR products were subsequently treated with SfiI and BstEII (naturally 
occurring in FR4) restriction enzymes and separated using agarose gel 
electrophoresis. The VHH-encoding DNA fragment (400 bp) was extracted from 
the gel and 330 ng was ligated into 1 µg of the pUC-derived phagemid vector 
pAX050 (Ablynx NV), followed by transformation into electrocompetent E. coli 
TG1 cells. To obtain recombinant bacteriophages expressing the VHH as fusion 
proteins with the bacteriophage geneIII product, the transformed TG1 cells were 
grown to logarithmic phase and then infected with helper phage M13KO7. The 
phage particles were precipitated with polyethylene glycol (PEG; Sigma-Aldrich) 
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to remove free VHH as described in section 2.12.3. From each library, a colony 
PCR using an M13 reverse primer and a geneIII primer was carried out on 24 
randomly picked colonies, and the proportion of clones containing an insert of 
the correct size was estimated. 
 
2.12 Selection of anti-CD4bs VHH through panning on gp120 
followed by competitive elution with sCD4 
VHH targeting the CD4bs of gp120 were selected through panning of the phage 
libraries described in section 2.11 on recombinant gp120, using the functional 
selection approach described below. The first set of selections and isolation of 
148 VHH clones were carried out by Els Beirnaert at the Ablynx NV selection 
laboratory in Porto, Portugal, although I took part in the planning of the 
experiments. The second round of selections and isolation of 672 VHH clones 
were carried out by me at the Ablynx NV selection laboratory in Porto, Portugal. 
 
2.12.1 Panning on recombinant gp120 
Recombinant IIIB or CN54 gp120 (section 2.1.2), or recombinant 92BR025 
gp120 (expressed and purified as described in section 2.7), was coated onto 96-
well MaxiSorp plates (Nalgene, NUNC International, Hereford, UK) at 2.5 and 
0.5 µg/ml in PBS in a total volume of 100 µl per well. Negative control wells 
containing only PBS were included. After an overnight incubation at 4°C, the 
plates were washed four times with PBS-T, and non-specific protein binding was 
subsequently blocked by filling the wells with 1% (w/v) casein in PBS and 
incubating for 1 hour at room temperature and orbital shaking at 200 rpm. After 
the blocking step, the plates were washed four times with PBS-T. Alternatively, 
plates were coated with 10 µg/ml of sheep antibody D7324 (Aalto Bio Reagents), 
a sheep polyclonal antibody raised against a conserved motif at the C-terminus of 
gp120. After an overnight incubation at 4°C, D7324-coated plates were washed 
and blocked as described above, and subsequently incubated with 92UG037 
gp120 in cell culture supernatant (section 2.7) at saturating and non-saturating 
dilutions in 0.2% (w/v) casein in PBS. Negative control wells containing PBS 
only, D7324 only, or D7324 plus cell culture supernatant from a negative control 
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transfection experiment (i.e. transfections carried out as described in section 2.7, 
but without addition of gp120 plasmids) were included. After 1 hour at room 
temperature, the plates were washed four times with PBS-T. 
 
Phages, expressing the cloned VHH repertoires, prepared as described in section 
2.11, were then diluted 1:10 in 0.2% (w/v) casein in PBS and subsequently pre-
incubated at room temperature for 10 minutes to allow for unspecific binding. 
Wells containing immobilised gp120 (and negative control wells) were then 
incubated with 100 µl per well of diluted phage, at room temperature and orbital 
shaking at 200 rpm. After 1 hour of incubation, wells were washed 20 times in 
PBS-T to remove unbound or unspecifically bound phage. To increase the 
stringency of the washing step, every five washes the plates were incubated with 
PBS-T for 15 minutes at room temperature and orbital shaking at 200 rpm. Plates 
were then washed twice in PBS. In order to elute phage targeting the CD4bs, the 
wells were then incubated with 100 µl per well of 30 and 200 µg/ml of sCD4 in 
0.2% (w/v) casein in PBS. Control wells were incubated with 100 µl per well of 
30 or 200 µg/ml of BSA in 0.2% (w/v) casein in PBS. Elutions were carried out 
at room temperature for 0.5-3 hours and orbital shaking at 200 rpm. Additional 
control wells were incubated with 100 µl per well of 0.1 M glycine, for elution of 
all phages through low pH shock. After for 20 minutes at room temperature and 
orbital shaking at 200 rpm, the glycine-eluted phage (100 µl), were transferred to 
50 µl of 1 M Tris-HCl, pH 7.5, for neutralisation. Each concentration of 
immobilised gp120, and negative controls, were incubated with both 
concentrations of sCD4 and BSA, and with glycine. 
 
2.12.2 Titration of eluted phage onto E. coli TG1 cells 
To determine the success of the competitive sCD4 elution and the level of 
unspecific background binding in the panning step, eluted phages were titrated 
onto E. coli TG1 cells. After the first round of panning, the eluted phages were 
diluted 1:5, 1:25 and 1:125 in PBS, whereas after the second round of panning, 
the eluted phages were diluted 1:10 and 1:100 in PBS. A 5 µl aliquot of each 
dilution (including the undiluted eluted phage) was subsequently used to infect 
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100 µl of E. coli TG1 cells at an optical density at 600 nm (OD600) of 
approximately 0.5, hence exponentially growing, in V-bottomed 96-well 
microtitre plates. After incubation at 37°C for 30 minutes, without shaking, 5 µl 
of bacteria were spotted onto LB agar plates containing 100 µg/ml of ampicillin 
and 2% (w/v) glucose. Each dilution of eluted phage was tested in duplicate. The 
LB agar plates were then incubated overnight at 37°C. 
 
2.12.3 Amplification and rescue of eluted phage 
Phages eluted by sCD4 were multiplied in TG1 cells and rescued by 
superinfection with helper phage. 40 µl of eluted phage were used to infect 0.5 
ml of exponentially growing E. coli TG1 cells (OD600 of around 0.5). After 
incubation for 30 minutes at 37°C without shaking, the cells were pelleted, 
resuspended in 5 ml of 2 × TY medium containing 100 µg/ml of ampicillin and 
2% (w/v) glucose, and subsequently incubated overnight at 37°C and 250 rpm. 
The overnight culture was used to prepare glycerol stocks. A 0.5 ml aliquot of 
the overnight culture was then used to inoculate another 50 ml of 2 × TY 
medium containing 100 µg/ml of ampicillin and 2% (w/v) glucose. At an OD600 
of around 0.5, 2.5 ml of this culture was infected with 2.5 µl of helper phage 
M13KO7 (corresponding to approximately 1011 plaque-forming units; PFU) at 
37°C for 30 minutes without shaking. Cells were then pelleted by centrifugation 
at 3200 × g for 10 minutes, resuspended in 50 ml of 2 × TY medium containing 
100 µg/ml of ampicillin and 25 µg/ml kanamycin and incubated at 37°C with 
250 rpm. After an overnight incubation, cells were pelleted by centrifugation at 
3200 × g for 10 minutes. 40 ml of the culture supernatant was then transferred to 
10 ml of 20% (w/v) PEG (Sigma-Aldrich) and 2.5 M NaCl, incubated on ice for 
30 minutes, and subsequently centrifuged for 20 minutes at 3200 × g at 4°C. The 
supernatant was then discarded and the pellet allowed to dry. Phages were then 
resuspended in 1 ml PBS, which was subsequently centrifuged at 17900 × g for 3 
minutes in a tabletop centrifuge to remove cellular debris. The supernatant was 
collected, transferred to a new 1.5 ml tube containing 250 µl of 20% (w/v) PEG 
(Sigma-Aldrich) and 2.5 M NaCl, and incubated on ice. After ten minutes of 
incubation, precipitated phage were pelleted by centrifugation at 17900 × g for 
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10 minutes and the supernatant was discarded. To remove the final traces of 
PEG, the pellet was centrifuged for another 2 minutes at 17900 × g and the 
remaining supernatant was carefully removed. Phages were then resuspended in 
1 ml of PBS and subjected to another 2 minutes of centrifugation at 17900 × g to 
remove cellular debris. The supernatant (new phage stock) was collected, titrated 
onto E. coli TG1 cells, and taken forward to a second round of panning. 
 
2.13 Isolation and small-scale expression of individual VHH 
The eluted VHH were cloned into expression vectors and individual clones were 
picked and subsequently expressed in E. coli TG1 cells as described below. 
 
2.13.1 Cloning of VHH repertoire into expression vectors 
The DNA fragments coding for VHH from selections where a larger number of 
clones had been eluted by sCD4 than by BSA were digested using restriction 
enzymes SfiI (or BglI) and BstEII, gel-purified, and ligated into the similarly 
digested expression vector pAX051 (Ablynx NV) using T4 DNA ligase 
(Promega), followed by transformation into electrocompetent E. coli TG1 cells 
(section 2.2.7). The pAX051 expression vector is a derivative of pUC19 (1173) 
and contains the LacZ promoter, which enables a controlled induction of 
expression using isopropyl-ß-D-thiogalactopyranosid (IPTG). Expression from 
the pAX051 vector incorporates a 6-histidine- and a c-myc-tag to the C-terminus 
of the VHH. Transformed bacteria were spread onto LB agar plates containing 
100 µg/ml of ampicillin and 2% (w/v) glucose and incubated at 37°C overnight. 
Individual clones were then picked and used to inoculate 1 ml of LB medium 
containing 100 µg/ml of ampicillin (or carbenicillin) and 2% (w/v) glucose in 96-
well deep-well plates. Plates were incubated overnight at 37°C with 250 rpm. 
Glycerol stocks were prepared from the overnight cultures and stored at -80°C in 
96-well plates. A subset of the isolated VHH was subjected to DNA fingerprint 
analysis using the restriction enzyme HinfI. 
 
 178
2.13.2 Small-scale expression of individual VHH in a 96-well format 
10 µl of the overnight cultures of E. coli TG1 cells prepared as described in 
section 2.13.1 were used to inoculate 1 ml of 2 × TY medium containing 100 
µg/ml carbenicillin and 0.1% (w/v) glucose in 96-well deep-well plates. Plates 
were then incubated at 37°C and 250 rpm for approximately 3 hours, after which 
VHH production was induced by the addition of 0.1 mM or 1 mM IPTG 
(Promega). Bacteria were then incubated for another 4 hours at 37°C with 250 
rpm, and subsequently pelleted by centrifugation at 3200 × g for 10 minutes. The 
supernatants were discarded and the pellets frozen at -20°C overnight. The day 
after, the pelleted bacteria were thawed and resuspended in 100 µl of PBS, and 
subsequently centrifuged at 3200 × g for 10 minutes. The resulting supernatants 
(periplasmic extracts containing the expressed VHH) were then transferred to 
new 96-well plates and stored at -80°C. 
 
2.14 Screening of individual VHH 
Individual VHH in E. coli periplasmic extracts (prepared as described in section 
2.13.2) or purified VHH (prepared as described in section 2.15.2) were screened 
for binding to recombinant gp120 in ELISA and/or for neutralisation of HIV-1. 
 
2.14.1 Screening of individual VHH for binding to gp120 
Individual VHH in E. coli periplasmic extracts (or purified VHH) were screened 
for ability to bind to recombinant CN54, IIIB, 92BR025, or 92UG037 gp120 
using the ELISA described in section 2.16.5, using 5 µl of VHH-containing E. 
coli periplasmic extract per well. Irrelevant (negative control) E. coli periplasmic 
extracts were included in each ELISA. 
 
2.14.2 Screening of individual VHH for neutralisation of HIV-1 
Individual VHH in E. coli periplasmic extracts (or purified VHH) were screened 
for ability to neutralise HIV-1 CN54, IIIB, 92BR025, or 92UG037 in NP2 cells 
or TZM-bl cells, as described in section 2.10. In the NP2 cell-based 
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neutralisation assay, 40 µl of VHH-containing E. coli periplasmic extract was 
pre-incubated with 100 FFU of virus, per well. In the TZM-bl cell-based 
neutralisation assay, 50 µl of VHH-containing E. coli periplasmic extract was 
pre-incubated 200 TCID50 of virus, per well. Irrelevant (negative control) E. coli 
periplasmic extracts, and E. coli periplasmic extract containing neutralising VHH 
(if available), were included on each plate. When E. coli periplasmic extracts 
were used in neutralisation assays, the cell culture media were supplemented 
with 50 U/ml of penicillin and 50 µg/ml of streptomycin (penicillin-
streptomycin, Invitrogen). Clones found to bind to gp120 in ELISA or to 
neutralise HIV-1 were sequenced. DNA sequencing of individual VHH clones 
was carried out at Ablynx NV, Porto, Portugal). Predicted amino acid sequences 
were aligned using the Clustal W multiple sequence alignment software (1174). 
 
2.15 Large-scale expression and purification of selected VHH 
VHH found to be neutralising or binding were expressed and purified as 
described in this section. Some of the E. coli TG1 cell-produced stocks of VHH 
were also obtained from Ablynx NV (Ghent, Belgium). 
 
2.15.1 Expression of selected VHH 
Glycerol stocks of E. coli TG1 cells containing selected VHH clones (held in the 
pAX051 vector) were used to inoculate 50 ml of LB medium containing 100 
µg/ml of ampicillin (or carbenicillin) and 2% (w/v) glucose. The cultures were 
incubated overnight at 37°C and 250 rpm, and a 5 ml aliquot was subsequently 
used to inoculate 1 l of 2 × TY medium containing 100 µg/ml of ampicillin (or 
carbenicillin) and 0.1% (w/v) glucose. This culture was incubated at 37°C and 
250 rpm until an OD600 of 0.6-0.8 was reached. VHH expression was then 
induced with 0.1 or 1 mM of IPTG and the cultures incubated overnight at 30°C 
with 250 rpm. Aliquots of pre-induced and induced samples were kept and 
analysed by SDS-PAGE (section 2.2.11). After the overnight incubations, 
bacteria were harvested by centrifugation of 4 × 250 ml aliquots at 4000 × g for 
30 minutes at 4°C. The pelleted bacteria were then frozen at -80°C overnight. 
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The day after, the bacteria were thawed, resuspended in 4 × 25 ml of PBS, 
incubated at 8°C for 1 hour at 250 rpm, and subsequently subjected to 
centrifugation at 4000 × g for 30 minutes at 4°C. The resulting supernatants, 
corresponding to the VHH-containing E. coli periplasmic extracts, were 
collected. 
 
2.15.2 Purification of selected VHH 
Expressed VHH were purified from E. coli periplasmic extracts by means of the 
attached 6-histidine-tag using TALON Metal Affinity Resin (Clontech, Mountain 
View, USA), according to the manufacturer’s instructions. Briefly, the TALON 
Metal Affinity Resin suspension was washed twice in 50 ml of VHH equilibrium 
buffer (Table 2.1.1.1). Approximately 1 ml of TALON Metal Affinity Resin was 
subsequently resuspended in 50 ml of VHH-containing E. coli periplasmic 
extract in 50 ml Falcon tubes (BD Biosciences, Oxford, UK) and incubated at 
room temperature for 1 hour with head-over-head rotation. The resin was then 
pelleted by centrifugation at 700 × g for 2 minutes at 4°C. The supernatant was 
discarded and an aliquot of was saved for analysis by SDS-PAGE (unbound 
sample). The resin was then washed twice in 50 ml of VHH equilibrium buffer 
(Table 2.1.1.1), by incubating the resin with buffer at room temperature for 10 
minutes with head-over-head rotation followed by centrifugation at 700 × g for 2 
minutes at 4°C. The resin (approximately 1.5-2 ml per VHH) was then 
resuspended in a total of 10 ml of VHH equilibrium buffer and packed into Poly-
Prep gravity/flow columns (Bio-Rad Laboratories). Packed columns were then 
washed twice with one bed volume of VHH equilibrium buffer. One bed volume 
of VHH pre-elution buffer (Table 2.1.1.1) was then added and the eluate 
collected. Bound protein was then eluted with approximately 4 × 0.5 bed 
volumes of VHH elution buffer (Table 2.1.1.1) and the eluate collected in 4 
fractions.  
 
The eluted fractions were analysed by SDS-PAGE and Coomassie blue staining 
(section 2.2.11) and fractions containing the bulk of the eluted VHH were pooled 
and dialysed for 6-8 hours at 4°C against 0.5-1 l of PBS using Slide-A-Lyzer 
 181
Dialysis Cassettes (Pierce Protein Research Products, Thermo Fisher Scientific, 
Rockford, USA) with a molecular cut-off of 3.5 kDa. The PBS was then changed 
and the samples dialysed for another 6-8 hours at 4°C. This procedure was 
repeated once more. After dialysis, the purified VHH were analysed by SDS-
PAGE and Coomassie blue staining (section 2.2.11) and the protein 
concentration was determined (section 2.2.10). 
 
2.16 Enzyme-linked immunosorbent assays 
Enzyme-linked immunosorbent assays (ELISAs) were carried out as described 
below. 
 
2.16.1 Detection of gp120 and gp140 in ELISA using anti-HIV-1 sera 
Opaque 96-well Maxisorp plates (Nalgene) were coated overnight with 10 µg/ml 
of sheep antibody D7324 (Aalto Bio Reagents) in 0.1 M NaHCO3, pH 8.5. After 
washing four times with TBS-T, non-specific protein binding was blocked by 
incubating wells with 200 µl per well of 4% (w/v) milk powder in TBS for 1 
hour at room temperature. Wells were then washed four times with TBS-T and 
subsequently incubated with 50 µl per well of serial dilutions of recombinant 
gp120 (purified or in cell culture supernatant) or gp140 in 1% (w/v) milk powder 
in TBS, for 1 hour at room temperature. Each dilution of gp120 was assayed in 
duplicate. Blank wells were included, as were wells lacking gp120, as negative 
controls, and wells containing serial dilutions of recombinant IIIB gp120, as 
positive controls. If gp120 in cell culture supernatant was used, serial dilutions of 
cell culture supernatant from a negative control transfection experiment (i.e. 
transfections carried out as described in section 2.7, but without addition of 
gp120 plasmids) were also included. After another washing step, gp120 (or 
gp140) was detected using 50 µl per well of an equal mixture of QC sera 2, 5 and 
6 (section 2.1.4) at a 1:100 dilution in TMT/GS and incubation for 1 hour at 
room temperature. After another four washes in TBS-T, wells were incubated 
with 100 µl per well of 0.5 µg/ml of an alkaline phosphatase (AP)-conjugated 
goat anti-human immunoglobulin antibody (Harlan SeraLab, Crawley Down, 
UK) in TMT/GS, for 1 hour at room temperature. After six washes with TBS-T, 
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100 µl per well of Lumi-Phos Plus substrate (Aureon Biosystems) was added and 
chemiluminescence was detected after 0.5 hours of incubation at 37°C. Blank-
corrected RLU were plotted against gp120 (or gp140) dilution. 
 
2.16.2 Binding of sCD4 to envelope proteins in ELISA 
Opaque 96-well Maxisorp plates (Nalgene) were coated with antibody D7324 
(Aalto Bio Reagents), blocked with 4% (w/v) milk powder in TBS, and washed, 
as described in section 2.16.1. Wells were then incubated with 50 µl per well of 
saturating concentrations of recombinant gp120 (or gp140) diluted in 1% (w/v) 
milk powder in TBS, for 1 hour at room temperature. After four washes in TBS-
T, the wells were incubated with 50 µl per well of serial dilutions of sCD4 
(section 2.1.5) in TMT/GS for 1 hour at room temperature. Each dilution of 
sCD4 was assayed in duplicate. Blank wells and the appropriate negative 
controls were included. After another washing step, wells were incubated with 50 
µl per well of the mouse anti-CD4 mAb L120.3 (ARP359; Centralised Facility 
for AIDS Reagents, NIBSC) at 2.5 µg/ml in TMT/GS, for 1 hour at room 
temperature. Well were then washed as before and incubated with 100 µl per 
well of 0.5 µg/ml of an AP-conjugated goat anti-mouse IgG antibody (catalogue 
number 1030004, Oxford Biotechnology, Kidlington, UK) in TMT/GS, for 1 
hour at room temperature. Luminescence was then detected as described in 
section 2.16.1, and blank-corrected RLU were plotted against sCD4 
concentration. 
 
Alternatively, opaque 96-well Maxisorp plates (Nalgene) were coated overnight 
with 10 µg/ml of sCD4 (section 2.1.5) in 0.1 M NaHCO3, pH 8.5. Some wells 
were left with 0.1 M NaHCO3, pH 8.5 only. Wells were then blocked and washed 
as above, and subsequently incubated with 50 µl per well of serial dilutions of 
purified gp120 (or gp140) in 1% (w/v) milk powder in TBS, for 1 hour at room 
temperature. After another washing step, gp120 (or gp140) binding to 
immobilised sCD4 was detected by incubation with 50 µl per well of 10 µg/ml of 
antibody D7324 (Aalto Bio Reagents) in TMT/BS for 1 hour at room 
temperature. Wells were then washed and subsequently incubated with 100 µl 
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per well 0.5 µg/ml of AP-conjugated rabbit anti-sheep IgG antibody (catalogue 
number. ab6748-1, Abcam, Cambridge, UK) in TMT/BS, for 1 hour at room 
temperature. After another six washes in TBS-T, luminescence was detected as 
above. Blank-corrected RLU were plotted against gp120 (or gp140) 
concentration. 
 
2.16.3 Binding of human mAbs to envelope proteins in ELISA 
Opaque 96-well Maxisorp plates (Nalgene) were coated with antibody D7324 
(Aalto Bio Reagents), blocked with 4% (w/v) milk powder in TBS, incubated 
with gp120 (or gp140), and washed, as described in section 2.16.2. Wells were 
then incubated with 50 µl per well of serial dilutions of mAb in TMT/GS, for 1 
hour at room temperature. Each mAb dilution was tested in duplicate. Blank 
wells and the appropriate negative controls were included. Binding of mAb to 
gp120 (or gp140) was then detected using 0.5 µg/ml of an AP-conjugated goat 
anti-human immunoglobulin antibody (Harlan SeraLab), as described in section 
2.16.1. Luminescence was detected as above and blank-corrected RLU were 
plotted against mAb concentration. 
 
2.16.4 Detection of anti-envelope antibodies in sera from immunised llamas 
Recombinant HIV-1 CN54 gp120 and gp140 at 1 µg/ml in PBS and 50 µl per 
well was coated onto 96-well Maxisorp plates (Nalgene) and left overnight at 
4°C. Wells were then washed three times with PBS-T and non-specific protein 
binding was blocked by incubation with 200 µl per well of 1% (w/v) casein in 
PBS for 1 hour at room temperature. After another washing step, wells were 
incubated at room temperature for 1 hour with 100 µl per well of three-fold serial 
dilutions of serum from immunised llamas collected on day 0 (pre-immunisation) 
and day 43 (post-immunisation). Bound immunoglobulins were detected using 
100 µl per well of a rabbit anti-llama antiserum followed by 0.5 µg/ml of an AP-
conjugated goat anti-rabbit immunoglobulin antibody (Sigma-Aldrich). Substrate 
(2 mg/ml p-nitrophenyl phosphate; 100 µl per well) was added to the wells and 
absorbance at 405 nm was measured. Absorbance readings were plotted against 
serum dilution. 
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2.16.5 VHH binding to envelope proteins in ELISA 
Opaque 96-well Maxisorp plates (Nalgene) were coated with antibody D7324 
(Aalto Bio Reagents), blocked with 4% (w/v) milk powder in TBS, incubated 
with saturating concentrations of recombinant gp120 (or gp140), and washed, as 
described in section 2.16.2. Wells were then incubated with 50 µl per well of 
serial dilutions of VHH (including an irrelevant, negative control VHH) in 
TMT/GS. Each dilution of VHH was added to duplicate wells. Blank wells were 
included. After 1 hour of incubation at room temperature, the plates were washed 
four times with TBS-T. The wells were then incubated, in two subsequent steps, 
with 0.5 µg/ml of a mouse anti-c-myc mAb (catalogue number 11667149001, 
Roche Diagnostics) in TMT/GS for 1 hour at room temperature, followed by four 
washes in TBS-T and then incubation with 100 µl per well of 0.5 µg/ml of an 
AP-conjugated goat anti-mouse IgG antibody (catalogue number 1030004, 
Oxford Biotechnology). After six washes with TBS-T, luminescence was 
detected as described in section 2.16.1, and blank-corrected RLU were plotted 
against VHH concentration. Alternatively, AP substrate p-nitrophenyl phosphate 
(2 mg/ml; 100 µl per well) was added to the wells. Absorbance at 405 nm was 
measured and absorbance readings were plotted against VHH concentration. 
 
2.16.6 VHH competition with sCD4 for binding to envelope proteins in 
ELISA 
The ability of the VHH to inhibit sCD4 binding to gp120 was evaluated in 
ELISA. Opaque 96-well Maxisorp plates (Nalgene) were coated with sCD4, 
blocked and washed, as described in section 2.16.2. Serial dilutions of VHH in 
1% (w/v) milk powder in TBS were pre-incubated with purified gp120 (or 
gp140) at 0.5 µg/ml in 1% (w/v) milk powder in TBS, for 1 hour at room 
temperature. The pre-incubated VHH-gp120 (or VHH-gp140) mixtures were 
then added to duplicate wells of the sCD4-coated plates (50 µl per well). Wells 
lacking sCD4 were included, as was an irrelevant VHH, as negative controls. 
After 1 hour at room temperature, the plates were washed four times with TBS-T 
and bound gp120 (or gp140) was then detected using antibody D7324 (Aalto Bio 
Reagents) and an AP-conjugated rabbit anti-sheep IgG antibody (Abcam), as 
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described in section 2.16.2. Alternatively, bound gp120 (or gp140) was detected 
using QC sera 2, 5 and 6 an AP-conjugated goat anti-human immunoglobulin 
antibody as described in section 2.16.1. Luminescence was detected as before 
and blank-corrected RLU were plotted against VHH concentration. 
 
2.16.7 VHH competition with anti-CD4bs mAbs for binding to envelope 
proteins in ELISA 
Opaque 96-well Maxisorp plates (Nalgene) were coated overnight with 50 µl per 
well of 10 µg/ml of mAb b12 and subsequently blocked and washed, as 
described above. VHH ability to inhibit gp120 binding to mAb b12 was assayed 
by pre-incubating serial dilutions of VHH with 0.5 µg/ml of gp120 for 1 hour at 
room temperature, followed by incubation with the immobilised mAb b12 in a 
total of 50 µl per well. Each dilution of VHH was tested in duplicate. Wells 
lacking mAb b12 were included as controls. Bound gp120 was then detected, 
using antibody D7324 (Aalto Bio Reagents) and an AP-conjugated rabbit anti-
sheep IgG antibody (Abcam), as described in section 2.16.6. Blank-corrected 
RLU were plotted against VHH concentration. 
 
VHH inhibition of human anti-gp120 mAbs b12, 2G12, 447-52D, 17b as well as 
an irrelevant mAb (4E10) was assayed by pre-incubating serial dilutions of the 
mAbs with 0.5 µg/ml of gp120 in 1% (w/v) milk powder in TBS for 1 hour at 
room temperature. The pre-incubated mAb-gp120 mixtures were then added to 
duplicate wells containing immobilised VHH, which had been pre-coated onto 
opaque 96-well Maxisorp plates as described in section 2.16.8. The mAb-gp120 
mixtures (50 µl per well) were incubated with the immobilised VHH for 1 hour 
at room temperature. Bound gp120 was then detected, using antibody D7324 
(Aalto Bio Reagents) and an AP-conjugated rabbit anti-sheep IgG antibody 
(Abcam), as described in section 2.16.2. Blank-corrected RLU were plotted 
against mAb concentration. 
 
VHH inhibition of mAb b6, 654-D and GP68 binding to gp120 was assayed by 
incubating serial dilutions of VHH in TMT/GS (50 µl per well), with wells 
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containing gp120 that had been captured at saturating concentrations onto opaque 
96-well Maxisorp plates (Nalgene) by the immobilised antibody D7324 (Aalto 
Bio Reagents), as described in section 2.16.2. After 1 hour at room temperature, 
the wells were then washed as above and subsequently incubated with 50 µl per 
well of mAbs b6, 654-D or GP68 in TMT/GS (at a concentration giving a signal 
in the linear range of a dose-response curve). Binding of the mAbs to gp120 was 
detected, using an AP-conjugated goat anti-human immunoglobulin antibody 
(Harlan SeraLab), as described in section 2.16.3. Blank-corrected RLU were 
plotted against VHH concentration. 
 
2.16.8 VHH competition with each other for binding to envelope proteins in 
ELISA 
VHH competition with each other and with fluid-phase sCD4 was also assayed 
by ELISA. Opaque 96-well Maxisorp plates (Nalgene) were coated overnight 
with 5 µg/ml of VHH in 0.1 M NaHCO3, pH 8.5. After washing four times with 
TBS-T, non-specific protein binding was blocked by incubating wells with 200 
µl per well of 4% (w/v) milk powder in TBS for 1 hour at room temperature. 
Wells were then washed four times with TBS-T. Serial dilutions of VHH (or 
sCD4) in 1% (w/v) milk powder in TBS were then pre-incubated with 0.5 µg/ml 
of gp120 in 1% (w/v) milk powder in TBS for 1 hour at room temperature. The 
pre-incubated VHH-gp120 (or sCD4-gp120) mixtures were then added to 
duplicate wells of the VHH-coated plates (50 µl per well). Wells lacking 
immobilised VHH were included, as was an irrelevant VHH. After 1 hour at 
room temperature, the plates were washed four times with TBS-T and bound 
gp120 was then detected using antibody D7324 (Aalto Bio Reagents) and an AP-
conjugated rabbit anti-sheep IgG antibody (Abcam), as described in section 
2.16.2. Luminescence was detected as above and blank-corrected RLU were 
plotted against VHH concentration. 
 
2.17 Surface plasmon resonance  
VHH affinity for recombinant IIIB gp120 was determined by Bart Hoorelbeke at 
Ablynx NV (Ghent, Belgium), using surface plasmon resonance techniques. All 
 187
experiments were carried out using a BIAcore 3000 (BIAcore, GE Healthcare, 
Uppsala, Sweden). Briefly, approximately 2700 response units (RU) of 
recombinant IIIB gp120 were immobilised onto a CM5 chip (BIAcore) using 
standard amine-coupling techniques, as described by the manufacturer. VHH D7, 
serially diluted to 75, 50, 40, 30, and 20 nM in 0.01 M 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) pH 7.4, 0.15 M NaCl, 3 mM EDTA and 
0.005% (w/v) surfactant P20 (HBS-EP buffer; BIAcore), was then injected at a 
flow rate of 45 µl/minute. The samples were allowed to dissociate for 1800 
seconds. To measure the affinity of VHH A12 and C8, 2100 RU of biotinylated 
IIIB gp120 was non-covalently captured by streptavidin pre-immobilised onto a 
SA sensor chip (BIAcore). VHH A12 and C8, serially diluted to 80, 60, 40, 20 
and 10 nM in HBS-EP buffer, were injected onto the chip at a flow rate of 45 
µl/minute for 3 minutes and were allowed to dissociate for 1200 seconds. The 
association rate constants (ka) and dissociation rate constants (kd) were computed 
from the binding curves using the BIAevaluation software (1:1 interaction). The 
equilibrium dissociation constants (KD) were calculated as KD = kd/ka. 
 
The ability of the sCD4 to bind to gp120, and the ability of VHH to inhibit 
binding of sCD4 to gp120, was assayed using a BIAcore X (BIAcore). This work 
was carried out by me together with Karolin Hijazi in the laboratory of Charles 
Kelly, King's College London, UK. Mouse anti-CD4 mAb L120.3 (ARP359; 
Centralised Facility for AIDS Reagents, NIBSC) in 10 mM sodium acetate, pH 
4, was coupled to both flow cells of a CM5 chip (BIAcore), using standard 
amine-coupling chemistry as described by the manufacturer. Briefly, the 
carboxymethylated dextran-coated surface of the CM5 chip was activated for 7 
minutes at a flow rate of 5 µl/minute, using a 1:1 ratio of 0.4 M N-ethyl-N-(3-
dimethylaminopropyl) carbodiimide (EDC) and 0.1 M N-hydroxysuccinimide 
(NHS), to give reactive succinimide esters, which can react with amino groups 
on the protein to be coupled. Approximately 3100 RU of mAb L120.3 was 
coupled to each flow cell. Remaining activated groups were blocked by injecting 
1 M ethanolamine, pH 8.5, for 7 minutes at a flow rate of 5 µl/minute. 
Approximately 1000 RU of sCD4 was then injected and subsequently cross-
linked (to allow for several injections of gp120 without having to re-inject sCD4) 
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to the anti-CD4 mAb in flow cell 2 by the addition of EDC/NHS, while flow cell 
1 was kept as a negative control reference cell. The ability of recombinant IIIB 
and CN54 gp120 to bind to this captured and cross-linked sCD4 was then 
evaluated. Three different concentrations of gp120 (100, 200 and 300 nM) in 
HBS-EP buffer were injected onto the chip over 4 minutes at a flow rate of 5 
µl/minute, and the peak background-subtracted RU reading was recorded. 
 
The same chip was used to evaluate the ability of the VHH to inhibit binding of 
CN54 gp120 to sCD4. Serial dilutions of VHH in HBS-EP buffer were pre-
incubated for 10 minutes at room temperature with 300 nM of HIV-1 CN54 
gp120 in HBS-EP buffer, and subsequently injected onto the chip at a flow rate 
of 5 µl/minute for 4 minutes. Data was analysed using the BIAevaluation 
software. Binding of HIV-1 CN54 gp120 to sCD4 was represented as the 
normalised difference in RU observed between flow cell 2 (with sCD4) and flow 
cell 1 (reference cell), plotted against time. Regeneration of the chip surfaces was 
achieved by injecting 2 M KSCN, 10 mM glycine-HCl, pH 1.5, or the Pierce 
Gentle Ag/Ab Elution Buffer (Pierce Protein Research Products, Thermo Fisher 
Scientific). 
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Chapter 3 
Generation of VHH that can inhibit HIV-1 infection 
 
In this chapter, the generation of llama VHH that can inhibit HIV-1 infection will 
be described. 
 
3.1 Introduction 
Monoclonal antibodies to HIV-1 envelope, whether obtained from natural HIV-1 
infection of from immunisation, can help defining neutralising and non-
neutralising epitopes on HIV-1 envelope proteins, and may be useful as tools in 
HIV-1 vaccine design and in the development of candidate HIV-1 microbicides. 
Many anti-envelope mAbs have been isolated from animals such as mice post-
immunisation and from humans as a result of HIV-1 infection. Out of these, only 
a handful has been found to be broadly neutralising across HIV-1 subtypes and 
all are a result of HIV-1 infection rather than immunisation (259). Two of these 
are directed against gp120, b12 which binds to an epitope that overlaps a subset 
of the CD4bs of gp120 (1008-1012), and 2G12 which recognises a carbohydrate 
motif (981, 1013-1015). Two broadly neutralising mAbs, 4E10 and 2F5, 
recognise gp41 (906-908, 981). 
 
All of the broadly neutralising mAbs reported to date are from individuals 
infected with HIV-1 of subtype B. While subtype B infections are predominant 
in Northern America and Western Europe, they account for only about a tenth of 
infections worldwide (124). HIV-1 of subtype C, on the other hand, accounts for 
about half of the infections in the world and is currently infecting more people 
than any other subtype (124). Therefore, there is an urgent need for greater focus 
on generating and characterising neutralising mAbs to non-subtype B viruses, 
and to subtype C viruses in particular. In this study, we have attempted to use the 
non-conventional immune system of camelids to generate novel antibodies 
against a subtype C envelope. We hypothesised that the small size of camelid 
VHH in combination with their protruding CDR3 loops and their preference for 
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cleft-recognition (1083, 1112) may render them able to recognise conserved 
motifs on gp120 that are occluded from conventional antibodies. 
 
Traditionally, mAbs have been generated by immortalisation of lymphocytes 
through Epstein-Barr virus (EBV)-transformation or hybridoma technologies, 
followed by selection and cloning to obtain monoclonal cell lines secreting 
antibodies with desired specificities. Köhler and Milstein (1175) were first to 
describe a mAb-secreting cell line, the result of a fusion of mouse spleen and 
myeloma cells, in 1975. A few years later, a human EBV-transformed antibody-
secreting cell line was reported, as well as a human hybridoma mAb-secreting 
cell line (1176, 1177). Since then, a vast number of mAbs have been generated 
using these techniques, from a variety of species and against a wide range of 
targets, and mAbs have become essential tools in scientific research, diagnostics 
as well as for medical and therapeutic use. The conventional hybridoma and 
EBV transformation technologies are, however, laborious and time-consuming 
and do not readily allow for rapid screening of larger numbers of mAbs. Instead, 
this challenge can be met by recombinant approaches such as the display of 
antibody libraries on filamentous bacteriophages, followed by the selection of 
individual antibodies with desired properties on immobilised target molecules, a 
technology known as phage display. Phage display was originally developed in 
1985 by Smith (1178), and used to display recombinant antibody libraries for the 
first time a few years later (1179-1182). It has since then become a well-
established and widely used technique. In 1991, the technique was used to isolate 
the broadly neutralising mAb b12 from an asymptotic, HIV-1 seropositive 
individual (1011). 
 
In phage display, the antibody repertoire in the form of recombinant scFv or Fab 
fragments, derived from the lymphocytes of immune or non-immune animals or 
humans, is expressed on the surface of filamentous phages such as the M13 
phage, typically fused to the phage pIII coat protein. Phage libraries are produced 
in E. coli and then panned on immobilised antigen in two or three sequential 
rounds of selection, to enrich for antibody fragments with wanted specificities. 
Individual antibody fragments are then isolated from enriched libraries, and 
screened for desired properties. All in all, phage display offers a versatile and 
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high-throughput tool for selection and screening of antibodies, where the 
selection methods can be adapted in a number of creative ways, to enrich for 
antibodies with very specific abilities (1183, 1184). For example, phage libraries 
have been panned on immobilised antigens in surface plasmon resonance settings 
(1185), on fixed or live cells (1186, 1187), and on tissue sections (1188). In an 
additional example, mutated variants of the CCR5 ligand RANTES, with 
improved anti-HIV-1 activities, were isolated using an extraordinarily elegant 
phage display strategy, involving panning on live CCR5 expressing cells and 
selection for internalisation (1189). 
 
The phage display technology is ideal for the isolation of camelid VHH for a 
number of reasons (1100). The single-domain nature of VHH, for example, 
offers an advantage over conventional antibody Fab or scFv fragments in library 
construction, in that there is no need for randomly recombining the VH and VL 
domains, giving rise to a larger functional size of the library. Ever since the first 
description of camelid heavy-chain antibodies in 1993 (1077), the phage display 
technique has been widely used to select for VHH against a range of biological 
targets (1099, 1124-1129, 1131, 1134, 1136, 1190).  
 
In this chapter, the use of phage display to isolate llama anti-HIV-1 envelope 
VHH will be described. First, llamas were immunised with recombinant 
envelope proteins, followed by the collection of peripheral blood and lymph node 
lymphocytes. The VHH repertoires were then cloned into a phagemid vector and 
the resulting phage libraries were panned on immobilised gp120. To increase the 
chances of isolating neutralising VHH, a functional selection approach was 
employed. This approach involved a competitive elution using sCD4, enabling 
the identification of VHH that compete with CD4 for binding to HIV-1 envelope. 
After two rounds of panning followed by competitive sCD4 elution, individual 
VHH were isolated and screened for binding to gp120 and/or neutralisation of 
HIV-1. A schematic overview of the experimental procedure is outlined in Fig. 
3.1.1. 
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Figure 3.1.1. Schematic overview of the strategy for isolation of llama VHH targeting the 
CD4bs of gp120. Llamas were immunised with recombinant envelope proteins derived from an 
HIV-1 primary isolate of subtype B′/C (CN54 gp120 and gp140) over six weeks, and blood and 
lymph node lymphocytes were subsequently collected. Total RNA was isolated and the VHH 
repertoires were amplified and cloned into a phagemid vector. Phages expressing the VHH fused 
to their pIII coat protein were produced in E. coli (upon infection with a helper phage) and 
subjected to two rounds of selection. In the selection step, the phage libraries were first allowed 
to bind to immobilised gp120. Unbound phages were then washed away and phages expressing 
VHH targeting the CD4bs were eluted by an excess of sCD4. Elution by BSA was carried out in 
parallel. Eluted phages were titrated onto E. coli, to determine whether more phages had been 
eluted by sCD4 compared to by BSA, amplified and taken through a second round of panning. 
Individual VHH were isolated from the enriched phage pools and screened for ability to bind to 
gp120 and/or to neutralise HIV-1. Fingerprint and sequence analysis of isolated clones were 
carried out. 
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There were several reasons for focusing on VHH directed to the CD4bs. First, 
the CD4bs could be readily targeted using a competitive elution with sCD4. 
Meulemans et al. (1191) were first to describe a competitive elution approach in 
the panning step of phage display, in order to select for antibodies with desired 
specificities. This approach has since then been used extensively, also for the 
successful selection of camelid VHH able to inhibit receptor-ligand interactions 
(1125), making it an attractive option when trying to select for VHH targeting the 
CD4bs of gp120. An additional reason for focusing on VHH targeting the CD4bs 
is the existence of the extensively studied broadly neutralising mAb b12 and the 
recent definition of its CD4bs-related epitope (1008). Moreover, it has recently 
been shown that the neutralising ability of a number of broadly cross-subtype 
neutralising human anti-HIV-1 sera is largely mediated by antibodies to the 
CD4bs of gp120 (985). 
 
3.2 Results 
This section describes the results of this chapter. 
 
3.2.1 Induction of a humoral anti-HIV-1 envelope response in llama, 
cloning of the VHH repertoires and construction of phage libraries 
The work described in this section was carried out by staff at Ablynx NV, Ghent, 
Belgium. At the outset of this project, two llamas (L40 and L44) were 
immunised with recombinant gp120 derived from HIV-1 CN54, as part of the 
European Microbicide Project (EMPRO). One llama (L48) was later on in the 
project immunised with recombinant CN54 gp140. HIV-1 CN54 is a subtype 
B′/C recombinant (CRF07_BC) originally isolated in China, which is entirely 
subtype C in envelope apart from the very N-terminus (1137, 1138). The 
rationale behind choosing a CN54-derived immunogen was based on CN54 
being a non-subtype B virus and the fact that recombinant baculovirus-expressed 
CN54 gp120 was already available in large amounts within the EMPRO 
consortium. This CN54 gp120 had been shown to bind to CD4 on cells in flow 
cytometry experiments (1192). In brief, each llama received six intramuscular 
injections at weekly intervals. The humoral immune response was evaluated in 
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ELISA on solid-phase gp120 or gp140, using serum samples from day 0 and 43 
post immunisation. Anti-HIV-1 envelope antibodies appeared in all three llamas 
(Fig. 3.2.1.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.1.1. Anti-envelope antibody response in Llama glama. Two llamas (llama L40 and 
L44) were immunised with recombinant HIV-1 CN54 gp120. One llama (L48) was immunised 
with recombinant HIV-1 CN54 gp140. Each llama received six intramuscular doses at weekly 
intervals. Blood samples were taken at day 0 and 43 post immunisation and the serum anti-
envelope response was evaluated in ELISA. A. Serum anti-gp120 response in llamas L40 and 
L44 evaluated on solid-phase CN54 gp120. B. Serum anti-gp140 and anti-gp120 response in 
llama L48 evaluated on solid-phase CN54 gp140 and gp120. 
 
To enable the recovery of VHH repertoires of extensive diversity, both blood and 
lymph nodes from the immunised llamas were used as B cell sources. Blood 
samples were collected at day 39 and 43 post immunisation. In addition, a lymph 
node biopsy was taken at day 39. For each llama, total RNA was isolated from 
peripheral blood lymphocytes as well as lymph node lymphocytes, and 
subsequently pooled. Oligo dT-primed cDNA was synthesised and the VHH 
repertoire was amplified and cloned into the pUC-derived pAX050 phagemid 
vector, followed by transformation into E. coli TG1 cells. The libraries derived 
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from llama L40, L44 and L48 were found to contain 3, 1 and 1.4 × 107 clones, 
respectively, out of which 58, 67 and 62% were found to contain an insert of the 
correct size. To obtain recombinant bacteriophages expressing the VHH as 
fusion proteins with the phage geneIII product, the transformed TG1 cells were 
grown to logarithmic phase and then infected with helper phage M13KO7. The 
phage particles were precipitated with polyethylene glycol to remove free VHH. 
 
3.2.2 The antigenic profile of CN54 gp120 
The ability of recombinant HIV-1 envelope proteins to bind to CD4 is an 
indicator of proper folding and biological function. To enable the selection of 
neutralising VHH able to block the gp120-CD4 interaction, it is especially 
important that the immunogen expresses an appropriately folded and structurally 
intact CD4bs. To characterise the antigenic profile and to confirm the structural 
integrity of the CN54-derived immunogen, its ability to bind to CD4 and to anti-
CD4bs mAbs was therefore evaluated in biochemical assays. 
 
First, the ability of sCD4 to bind to CN54 gp120 was evaluated in ELISA. 
Recombinant CN54 gp120, from the same batch as the immunogen for llama 
L40 and L44, was captured by sheep antibody D7324 coated onto plates. 
Antibody D7324 recognises a conserved motif in the C5 region of gp120. 
Captured gp120 was incubated with serial dilutions of sCD4 and binding was 
subsequently detected as described in section 2.16.2. Recombinant IIIB gp120 
was included as a positive control. Recombinant sCD4 was shown to bind 
poorly, barely above background levels, to CN54 gp120 from the immunogen 
batch, whereas good binding was observed to IIIB gp120 (see below). 
 
To investigate whether this observation was batch-dependent and perhaps due to 
partial denaturation of the gp120 in the immunogen batch, additional 
preparations of CN54 gp120 were produced. This was done ‘in-house’ by 
expressing CN54 gp120 in a T7 RNA polymerase-recombinant vaccinia virus 
system (1166), using the same molecular clone of CN54 that the immunogen had 
been derived from. Protein expression was confirmed in ELISA by capturing 
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gp120 in cell culture supernatant with immobilised antibody D7324 and 
detecting it with human anti-HIV-1 sera (Fig. 3.2.2.1). 
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Figure 3.2.2.1. Detection of CN54 gp120 expressed in 293T cells infected with a T7 RNA 
polymerase-recombinant vaccinia virus. Serial dilutions of cell culture supernatant from the 
expression system were incubated with sheep antibody D7324 pre-coated onto plates. Captured 
gp120 was detected in ELISA using a mix of three human anti-HIV-1 sera followed by an AP-
conjugated goat anti-human IgG antibody. A serial dilution of IIIB gp120, starting at 200 ng/ml, 
was included as a positive control. Cell culture supernatant from a mock expression was included 
as a negative control. Chemiluminescence was detected and RLU were plotted against gp120 
dilution factor. Data points represent background-subtracted readings. Several CN54 gp120 
preparations were produced; one representative experiment is shown. 
 
CN54 gp120 produced in the vaccinia virus system was then tested for ability to 
bind to sCD4 in ELISA, alongside CN54 gp120 from the immunogen batch as 
well as IIIB gp120. Poor binding of sCD4 to all preparations of CN54 gp120 was 
observed (Fig. 3.2.2.2), indicating that the CD4bs of this recombinant CN54 
gp120 is either not structurally intact, not accessible, or just not well exposed in 
this experimental setting. It should be noted that recombinant gp120 capable of 
binding to sCD4 in ELISA can be expressed in the T7 RNA polymerase-
recombinant vaccinia virus system, as will be discussed in section 3.2.4. 
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Figure 3.2.2.2. Binding of sCD4 to IIIB and CN54 gp120 in ELISA. Saturating levels of 
recombinant gp120 was captured by solid-phase sheep antibody D7324 followed by incubation 
with serial dilutions of sCD4 and subsequent detection of sCD4 using the mouse anti-CD4 mAb 
L120.3 and an AP-conjugated goat anti-mouse IgG antibody. Chemiluminescence was detected. 
Luminescence readings (in RLU) were normalised to readings obtained for 10 µg/ml of sCD4 
binding to IIIB gp120 and plotted against sCD4 concentration. CN54 gp120 were either produced 
‘in-house’ in a T7 RNA polymerase-recombinant vaccinia virus expression system, or from the 
same batch as the immunogen. Data points represent the mean and error bars the standard error of 
four independent experiments performed in duplicate. 
 
To further confirm the poor binding of sCD4 to CN54 gp120 compared to IIIB 
gp120, an additional ELISA set up was tested. Instead of capturing the gp120 by 
immobilised C5-directed antibody D7324 followed by incubation with sCD4, 
sCD4 was coated onto wells of a microtitre plate and subsequently incubated 
with gp120 in fluid phase. Binding of gp120 to immobilised sCD4 was then 
detected using antibody D7324. Again, poor binding of sCD4 to CN54 gp120 
was observed (Fig. 3.2.2.3). 
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Figure 3.2.2.3. Binding of sCD4 to IIIB and CN54 gp120 in ELISA. Recombinant sCD4 (50 
µg/ml) was coated onto wells of a microtitre plate. Wells were then incubated with IIIB gp120 
(200 ng/ml), CN54 gp120 from the immunogen batch (200 ng/ml), and CN54 gp120 produced 
‘in-house’ in the T7 RNA polymerase-recombinant vaccinia virus system (cell culture 
supernatant from the expression system, diluted 1:2). Binding of gp120 to sCD4 was detected 
using antibody D7324 followed by an AP-conjugated rabbit anti-sheep IgG antibody. 
Chemiluminescence was detected. Bars represent the mean and error bars the standard error of 
three independent experiments carried out in duplicate. 
 
Sheep antibody D7324 is raised against a peptide (APTKAKRRVVQREKR) 
derived from the very C-terminus of IIIB gp120. This motif is highly conserved 
within HIV-1 of subtype B but a slight variation has been described among other 
HIV-1 subtypes (1193). D7324 has, however, been found to bind to gp120 
derived from HIV-1 of subtype A, B, C, D and F (1048, 1193). The motif that 
D7324 recognises is present in CN54 gp120 (APTTAKRRMVEREKR), but with 
three amino acid residue differences compared to the IIIB sequence (underlined). 
In light of this notion, the ability of D7324 to bind to CN54 gp120 was tested in 
ELISA, to exclude the possibility that the poor reactivity of sCD4 with CN54 
gp120 was not in fact due to poor capture or detection of CN54 gp120 by D7324. 
Despite the three amino acid-difference, D7324 was shown to bind almost 
equally well to both IIIB and CN54 gp120 in ELISA (Fig. 3.2.2.4 A). In addition, 
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the ability of sCD4 to bind to gp120 directly coated onto ELISA wells, thus not 
captured by D7324, was tested. Again, poor binding of sCD4 to CN54 gp120 
was observed (Fig. 3.2.2.4 B). This observation suggested that the poor binding 
of sCD4 to CN54 gp120 observed in ELISA was not due to reduced ability of 
antibody D7324 to recognise CN54 gp120. This notion was further confirmed by 
the fact that part of the IIIB-derived D7324 target sequence (VVQREKR) had 
been introduced into the vaccinia virus-produced CN54 gp120 in the cloning 
step, by means of the antisense primer, as described in section 2.5, to ensure 
capture by D7324. 
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Figure 3.2.2.4. The poor binding of sCD4 to CN54 gp120 observed in ELISA is not due to 
reduced ability of sheep antibody D7324 to recognise CN54 gp120. Antibody D7324 
recognises a motif in the C5 region of gp120. A. Binding of D7324 to immobilised gp120. 
Recombinant IIIB gp120 and CN54 gp120 (immunogen batch) was coated overnight onto 
microtitre plates at 10 µg/ml and subsequently incubated with 10 µg/ml of D7324 followed by 
detection using an AP-conjugated rabbit anti-sheep antibody. Chemiluminescence was detected. 
Bars represent the mean and error bars the standard deviation of duplicate reactions. B. Binding 
of sCD4 to gp120 coated straight onto microtitre plates. Recombinant IIIB gp120 and CN54 
gp120 (immunogen batch) was coated overnight onto microtitre plates at 10 µg/ml and 
subsequently incubated with serial dilutions of sCD4 followed by detection of sCD4 using the 
mouse anti-CD4 mAb L120.3 and an AP-conjugated goat anti-mouse IgG antibody. 
Chemiluminescence was detected. Data points represent the mean and bars the standard deviation 
of duplicate reactions from one experiment. 
A  B 
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In order to elicit a neutralising humoral response, an immunogen should 
favourably present epitopes that are recognised by neutralising antibodies, rather 
than exposing epitopes recognised by non-neutralising antibodies. To further 
assess the accessibility and structural integrity of the CD4bs of CN54 gp120, its 
reactivity with human anti-CD4bs mAbs b6 and b12 was evaluated. Anti-CD4bs 
mAb b12 showed poor binding to CN54 gp120 in ELISA, compared to IIIB 
gp120, whereas mAb b6 was observed to bind well (Fig. 3.2.2.5 A and B). 
 
 
L
um
in
es
ce
nc
e 
(R
L
U
)
0
500
1000
1500
2000
2500
0.01 1 100
b12 concentration (µg/ml)
            
0
5000
10000
15000
20000
0.01 1 100
b6 concentration (µg/ml)
 
 
IIIB gp120
CN54 gp120, produced 'in-house'
CN54 gp120, immunogen batch
 
Figure 3.2.2.5. Binding of human anti-CD4bs mAbs to recombinant IIIB and CN54 gp120 
in ELISA. Saturating levels of recombinant IIIB gp120 and CN54 gp120 was captured by solid-
phase sheep antibody D7324 followed by incubation with serial dilutions of each mAb and 
subsequent detection of mAb binding to gp120 using an AP-conjugated goat anti-human 
immunoglobulin antibody. Chemiluminescence was detected and RLU were plotted against mAb 
concentration. Data points represent the mean and bars represent the standard deviation of 
duplicate reactions. A. Binding of broadly neutralising anti-CD4bs mAb b12 to IIIB and CN54 
gp120. B. Binding of non-neutralising anti-CD4bs mAb b6 to IIIB and CN54 gp120. 
 
While mAbs b12 and b6 both compete with sCD4 for binding to envelope 
glycoproteins, only b12 is able to neutralise virus (1009). The non-neutralising 
mAb b6 is thought to recognise a CD4bs-related epitope that is exposed on 
monomeric gp120, but not on gp120 in the context of the functional envelope 
  A                                  B                   
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spike (142, 624, 897, 1018, 1194). The observation that mAb b12 binds poorly to 
CN54 gp120 compared to IIIB gp120 in ELISA suggests that the b12 epitope is 
either not present, not exposed or just not accessible in this experimental setup. 
The non-neutralising epitope recognised by b6 does, however, seem to be 
exposed. 
 
Surface plasmon resonance techniques allow for real-time analysis of 
intermolecular interactions. This enables the detection of weak interactions that 
could remain undetected in ELISA. The ability of sCD4 to bind to CN54 gp120 
(produced in a baculovirus system, like the immunogen) was therefore tested by 
surface plasmon resonance technology in the BIAcore system. Recombinant 
sCD4 was captured by, and cross-linked to, the anti-CD4 (recognising domain 4) 
mAb L120.3, which was coupled to the chip using standard amine-coupling 
techniques, as described in section 2.17, followed by subsequent injection of 
gp120 at three different concentrations. Good binding of fluid-phase IIIB gp120 
to the immobilised sCD4 was observed (Fig. 3.2.2.6). Some binding of fluid-
phase CN54 gp120 to the immobilised sCD4 was also observed, although less 
than for IIIB gp120 (Fig. 3.2.2.6), in concordance with ELISA results. 
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Figure. 3.2.2.6. Binding of IIIB and CN54 gp120 to immobilised sCD4 as detected by 
surface plasmon resonance techniques. The anti-CD4 mAb L120.3 (3100 RU) was coupled to a 
BIAcore CM5 ship using standard amine-coupling techniques, as described in chapter 2.17. 
Around 1000 RU of sCD4 was then bound and cross-linked to L120.3. Recombinant gp120 (100, 
200 and 300 nM) was then injected over the chip over 4 minutes and the peak background-
subtracted RU reading was recorded. Bars represent the mean of two separate injections. 
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The lack of sCD4 and b12 binding led to doubts regarding the structural integrity 
and functionality of CN54 gp120, at least the CN54 gp120 preparations included 
in this study, that is, the baculovirus-produced preparation used to immunise 
llamas, and the preparation produced ‘in-house’ in a vaccinia virus system but 
from the same CN54 clone as the immunogen. Results obtained in previous 
studies have indicated that sCD4 dissociates fast from CN54 gp140 in surface 
plasmon experiments (1195), giving a possible explanation for the poor binding 
observed for CN54 gp120 to sCD4 in ELISA, and the weak binding observed 
using surface plasmon resonance methods in this study. However, other previous 
studies have shown that CN54 gp120 binds to CD4 on cells in flow cytometry 
and to mAb b12 in ELISA (1192, 1196). It is unclear why a different result was 
obtained in this study. 
 
To further evaluate whether CN54 gp120 derived from this clone was able to 
bind to its receptor, its ability to mediate infection when expressed on the virus 
surface in the context of an HIV-1 HXB2 backbone was tested. Chimeric 
molecular clones were generated by cloning of the CN54 gp120 sequence into an 
HIV-1 HXB2-based backbone and the resulting constructs were used to transfect 
293T cells. Three days post-transfection, cell culture supernatant was titrated 
onto NP2/CD4/CCR5 and NP2/CD4/CXCR4 cells. After another 48 or 72 hours, 
cells were fixed and infection detected by immunostaining of HIV-1 p24. Ten 
different plasmid preparations were tested. The CN54 gp120/HXB2 chimeric 
constructs did not produce any infectious virus. Infectious chimeric virus using 
gp120 derived from other virus isolates have previously been produced in this 
system (422, 631, 1162, 1163). Generation of infectious chimeric viruses 
expressing envelopes derived from subtype A and C in the HXB2-derived 
backbone is described in section 3.2.5 of this chapter. 
 
To exclude the possibility that CN54 gp120 together with an HXB2 gp41 did not 
result in a functional envelope clone, the CN54 gp160 sequence was cloned into 
an HIV-1 NL43-based backbone and the resulting chimeric construct was used to 
transfect 293T cells as described above. Ten plasmid preparations were tested 
and, again, no infectious virus was obtained. Generation of replication-competent 
chimeric viruses expressing envelopes from various subtypes has been described 
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for this system previously (1164). Production of infectious viruses expressing 
envelopes from subtype C and D in the NL43-derived backbone is described in 
section 4.2.1 of this thesis. 
 
In conclusion, the CN54-derived immunogen displayed poor binding to sCD4 
and to mAb b12 in biochemical assays and did not produce infectious virus when 
expressed on the virus surface in the context of an HIV-1 HXB2 or an HIV-1 
NL43 backbone. Taken together, these data suggest that CN54 gp120 may not be 
an optimal immunogen, if the goal is to generate neutralising llama VHH that 
recognise the CD4bs. The notion that some binding of fluid-phase CN54 gp120 
to immobilised sCD4 was observed in BIAcore studies could, however, be seen 
as encouraging. Based on the above data, it was decided to include IIIB gp120 as 
a control in the phage display panning step, alongside CN54 gp120. 
 
3.2.3 First set of selections and screening - panning of phage libraries on 
gp120 from HIV-1 CN54 and IIIB  
In this section, the first set of VHH selections and screening will be described, 
involving panning of the phage libraries on immobilised recombinant CN54 and 
IIIB gp120, followed by screening of individual VHH for ability to bind to gp120 
and ability to neutralise HIV-1. 
 
3.2.3.1 Panning of phage libraries on CN54 and IIIB gp120 
The first set of selections, described in this section (3.2.3.1), was carried out by 
Els Beirnaert at the Ablynx NV selection laboratory in Porto, Portugal. However, 
I took part in the planning of the experiments. VHH targeting the CD4bs were 
selected for by panning of the phage libraries derived from llamas L40 and L44 
on immobilised CN54 and IIIB gp120, directly coated onto microtitre plates. The 
CN54-derived immunogen displayed poor binding to sCD4 in ELISA and did not 
produce infectious virus when expressed on the virus surface in the context of an 
HIV-1 HXB2 or an HIV-1 NL43 backbone (described in section 3.2.2 of this 
thesis). Due to doubts regarding the functionality of the immunogen in terms of 
CD4 binding and ability to mediate infection, HIV-1 IIIB gp120 was included in 
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the selection protocol as a control, to enable selection of VHH targeting the 
CD4bs, while simultaneously allowing selection for VHH with cross-subtype 
recognition properties. Eluted phages were titrated onto E. coli TG1 cells. 
Selections where a larger number of clones were eluted by sCD4 compared to 
elution with BSA, possibly indicating enrichment of phage expressing VHH 
targeting the CD4bs, were taken forward to a second round of CD4bs-targeted 
selection. After two rounds of panning, the eluted phage output was again titrated 
onto E. coli TG1 cells, to determine whether more clones were eluted by sCD4 
than by BSA. Selection outputs where a larger number of clones were eluted by 
sCD4 than by BSA, possibly indicating enrichment of phage expressing VHH 
targeting the CD4bs, were chosen and individual VHH were expressed. 
 
A representative titration of eluted phage onto E. coli TG1 cells is shown in Fig. 
3.2.3.1.1, resulting from two rounds of panning on IIIB gp120 followed by 
competitive sCD4 elution. 
 
       
Figure 3.2.3.1.1. Titration of eluted phage onto E. coli TG1 cells. Phage libraries expressing 
the cloned VHH repertoires of llamas immunised with recombinant CN54 gp120 were panned on 
immobilised recombinant CN54 or IIIB gp120. To isolate phage expressing VHH targeting the 
CD4bs of gp120, a competitive elution with sCD4 was performed. Elution with BSA was 
performed in parallel, as was a general elution by low pH shock using glycine. The phage 
titration shown is from the second round of panning of the phage library expressing VHH derived 
from llama L44 on IIIB gp120, where more clones were eluted by sCD4 than by BSA, and from 
which individual clones were isolated and expressed. 
 
The phage library derived from llama L40 was panned against CN54 gp120 only, 
whereas the phage library derived from llama L44 was panned against CN54 as 
well as IIIB gp120. From each selection route, 48 individual clones were 
isolated, as outlined in Fig. 3.2.3.1.2. 
sCD4 
BSA 
pH 
1:100     1:10      neat 
 205
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.3.1.2. Overview of the first set of selections. Selections were carried out using phage 
libraries expressing VHH derived from llamas L40 and L44 on immobilised CN54 and IIIB 
gp120 as indicated. From each selection, 48 individual VHH were isolated and screened for 
binding and/or neutralisation of HIV-1, as described in sections 3.2.3.2 and 3.2.3.3. 
 
3.2.3.2 Screening of selected VHH from llama L40 
The phage libraries from llama L40 were panned on CN54 gp120. Forty-eight 
individual colonies were picked, grown in a 96-well plate and induced with 
IPTG. Culture supernatant was used in ELISA to identify clones reactive with 
solid-phase CN54 gp120. Weak binding to CN54 gp120 was observed for some 
of the 48 clones. However, as culture supernatant was used in the ELISA, the 
level of background binding was high and the results difficult to interpret. Even 
so, based on these binding data, as well as sequence and fingerprint analysis, four 
clones were selected. These four clones, designated C1, F2, F3 and F4 were re-
cloned into an expression vector, expressed in E. coli and purified by means of 
the 6-histidine-tag. The VHH also carried a C-terminal c-myc-tag. This work was 
carried out by Els Beirnaert at Ablynx. The four purified VHH, and an irrelevant, 
negative control VHH, were then sent to UCL for further characterisation. At 
UCL, they were tested for binding to CN54 and IIIB gp120 in ELISA as well as 
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for neutralisation of IIIB and CN54 virus. This work was carried out by me. An 
infectious PBMC isolate of HIV-1 CN54 was obtained through EMPRO and 
propagated in PBMC, as described in section 2.4.1. Purified VHH F2, but not 
VHH C1, F3 and F4, was found to bind to CN54 gp120 in ELISA, whereas none 
of the selected VHH bound to IIIB gp120 (Fig. 3.2.3.2.1). 
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Figure 3.2.3.2.1. Reactivity of VHH C1, F2, F3 and F4, derived from llama L40, with CN54 
and IIIB gp120 in ELISA. Recombinant envelope proteins were captured onto microtitre plates 
by the sheep polyclonal antibody D7324. Threefold serial dilutions of VHH were then added to 
the plate followed by detection using a mouse anti-c-myc antibody followed by an AP-conjugated 
goat anti-mouse IgG polyclonal antibody. Chemiluminescence was detected and background-
subtracted luminescence readings (in RLU) were normalised to readings obtained for 200 ng/ml 
of VHH C8 binding to IIIB gp120 and plotted against VHH concentration. Data points represent 
the mean and bars the standard deviation of duplicate reactions. 
 
Neutralisation was evaluated in a cell-based assay using a glioma cell line (NP2) 
expressing the HIV-1 receptor CD4 and either of the co-receptors CXCR4 or 
CCR5 (1151), followed by immunostaining of infected cells and manual 
counting of FFU. VHH F2 (at 100 µg/ml) was found to be weakly neutralising 
and reduced infection of the CN54 PBMC isolate with 47% compared to a 
negative control VHH, whereas VHH C1, F3 and F4 (at 100 µg/ml) had no 
apparent effect on CN54 infectivity (Fig. 3.2.3.2.2). None of the four VHH was 
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able to reduce IIIB infection by more than 20%, compared to a negative control 
VHH (Fig. 3.2.3.2.2). 
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Figure 3.2.3.2.2. Neutralisation of HIV-1 CN54 and IIIB in NP2 cells by VHH C1, F2, F3 
and F4, derived from llama L40. Neutralisation was assayed in NP2/CD4/CCR5 cells (CN54) 
or NP2/CD4/CXCR4 cells (IIIB) as described in section 2.10.1 of this thesis. Each VHH was 
tested at 100 µg/ml. At 72 hours post-infection, the cells were fixed and stained for p24. The 
number of FFU was counted microscopically and the percentage of FFU compared to the result 
obtained for the negative control VHH was determined. Bars represent the mean and error bars 
the standard error of two independent experiments carried out in duplicate. 
 
VHH F2 was chosen for further characterisation; a more comprehensive analysis 
of its neutralisation properties will described in chapter 4 of this thesis. VHH C1, 
F3 and F4 were also tested against two additional subtype B viruses and one 
additional subtype C virus, but were not able to reduce infection by more than 
20% (data not shown). The sequence of VHH F2 is shown in Fig. 3.2.3.2.3. 
 
AVQLVESGGGLVQAGGSLRLSCAASGFTLDDYAICWFRQAPGKEREGVSCISSSDGSRYYADSVK
GRFTISSDNAKNTVYLQMISLKPEDTAVYYCAAXSKVMFYSDYMRYGMDYWGKGTLVTVSS 
 
Figure 3.2.3.2.3. The amino acid sequence of VHH F2. VHH F2 was isolated through CD4bs-
trageted panning on immobilised CN54 gp120 of the phage library expressing the VHH 
repertoire derived from llama L40. VHH CDR1, 2 and 3 are highlighted in grey. X, undetermined 
amino acid. 
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3.2.3.3 Screening of selected VHH from llama L44 
The phage libraries from llama L44 were panned on CN54 and IIIB gp120, as 
outlined in Fig. 3.2.3.1.2. For each gp120, 48 individual colonies were picked, 
grown in a 96-well plate and induced with IPTG. Culture supernatant, or E. coli 
periplasmic extract, was used in ELISA to identify clones reactive with solid-
phase CN54 or IIIB gp120. This work was carried out by staff at Ablynx NV, 
Porto, Portugal. The 48 VHH selected on CN54 gp120 were tested (in bacterial 
culture supernatant) for reactivity with CN54 gp120 in ELISA. However, as 
culture supernatants were used in the ELISA, there were high levels of 
background binding and the ELISA results were difficult to interpret, as 
discussed in section 3.2.3.2. Even so, it could be deduced that none of these 48 
VHH reacted strongly with CN54 gp120. As a result, none of them was sent to 
UCL for test in neutralisation assays. Panning on IIIB gp120 was more 
successful. Out of the 48 VHH selected using IIIB gp120, 31 were found to bind 
to IIIB gp120 in ELISA, using VHH in E. coli periplasmic extracts. All the 48 
VHH, in E. coli periplasmic extracts, were sent to UCL and tested for ability to 
neutralise HIV-1 IIIB in a TZM-bl cell-based neutralisation assay (1147-1149). 
TZM-bl cells express endogenous CXCR4 and transgenic CD4 and CCR5, and 
contain an LTR-driven, Tat-inducible firefly luciferase reporter gene (1147-
1149). 
 
First, it had to be established whether E. coli periplasmic extracts on its own 
would non-specifically decrease the level of infection. Ten different negative 
control periplasmic extracts were pre-incubated with HIV-1 IIIB and 
subsequently added to cells. After 48 hours, luciferase substrate and cell lysis 
reagent was added to the cells and luminescence detected. Reduction in RLU in 
test wells compared to in virus control wells after subtraction of background 
luminescence was determined. The mean reduction in RLU for the ten different 
negative control periplasmic extracts was 61%. The neutralisation cut off was set 
to 90% reduction in RLU, which corresponds to the mean reduction in RLU plus 
2.1 standard deviations (Fig. 3.2.3.3.1). 
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Figure 3.2.3.3.1. Determination of the 
neutralisation cut off when using VHH in 
E. coli periplasmic extracts in TZM-bl 
cells. Ten negative control periplasmic 
extracts were tested for neutralisation of HIV-
1 IIIB in TZM-bl cells, as described in chapter 
2.14.2. The % RLU compared to virus only 
control was determined and the mean ± the 
standard deviation for the ten extracts was 
plotted. The neutralisation cut off was set to 
90% reduction of infection, which 
corresponds to the mean reduction in RLU 
plus 2.1 standard deviations. 
 
The 48 periplasmic extracts containing the VHH selected using IIIB gp120 were 
then tested for neutralisation of HIV-1 IIIB in the TZM-bl assay. Out of the 48 
clones, 24 were observed to neutralise HIV-1 IIIB in TZM-bl cells to more than 
90%. Fingerprint analysis as well as sequencing of the 31 binding clones 
(including the 24 neutralising clones) revealed some identical sequences leaving 
16 different clones that could be grouped into three families based on sequence 
similarity (Fig 3.2.3.3.2). 
 
The first group, the B7-like VHH, consisted of seven different clones with 3-16 
amino acid differences in framework 1 and 3 and in CDR1, 2 and 3 (Fig. 
3.2.3.3.2). These clones, in E. coli periplasmic extracts, did not neutralise HIV-1 
IIIB to more than 90% in TZM-bl cells, instead, 31-74% reduction of infection 
was observed. The second group, the D7-like VHH, consisted of three clones 
with 8-14 amino acid differences in the framework 1, 2 and 3 regions as well as 
in the CDR1, CDR2 and CDR3 (Fig. 3.2.3.3.2). They displayed a long CDR3 of 
18 amino acids. These VHH clones, in E. coli periplasmic extracts, were found to 
neutralise HIV-1 IIIB to 99% in TZM-bl cells. The third group of identified 
VHH, the C8-like VHH, consisted of six clones with 1-3 amino acid differences 
only, in framework regions 1 and 3 (Fig. 3.2.3.3.2). They had identical CDRs and 
displayed a considerably shorter CDR3 of 10 amino acids. These VHH clones, in 
E. coli periplasmic extracts, were found to neutralise HIV-1 IIIB to 93-99% in 
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TZM-bl cells. A summary of the selected clones derived from llama L44 is 
shown in Table 3.2.3.3.1. 
 
C10   AVQLVESGGGLVQAGGSLRLSCAASGFTFDDYAIGWFRQAPGKEREGVSCISSSDGSTYY 60 
F12   AVQLVESGGGLVQAGGSLRLSCAASGFTFDDYAIGWFRQAPGKEREGVSCISSSDGSTYY 60 
A9    EVQLVESGGGLVQAGGSLRLSCAASGFTFDDYAIGWFRQAPGKEREGVSCISSSDGSTYY 60 
B7    AVQLVESGGGLVQPGGSLRLSCAASGFTLDNYAIGWFRQAPGKEREGVSCISSSDGSTYY 60 
F11   AVQLVESGGGLVQPGGSLRLSCAASGFTLDYYAIGWFRQAPGKEREGVSCISSSDGSTYY 60 
F9    AVQLVESGGGLVQPGGSLRLSCAASGFTLGDYAIGWFRQAPGKEREGVSCISSSDGSTYY 60 
D10   QVQLVESGGGLVQPGGSLRLSCAASGFSLANYAIGWFRQAPGKEREGVSCISSSDSSTYY 60 
C8    AVQLVDSGGGLVQAGGSLRLSCVVSGSIFSINAMGWYRQAPGKQRDLVARISG-DSSTYY 59 
H9    AVQLVDSGGGLVQAGGSLRLSCVVSGSIFSINAMGWYRQAPGKQRDLVARISG-DSSTYY 59 
H8    AVQLVDSGGGLVQAGGSLRLSCVVSGSIFSINAMGWYRQAPGKQRDLVARISG-DSSTYY 59 
H10   AVQLVESGGGLVQAGGSLRLSCVVSGSIFSINAMGWYRQAPGKQRDLVARISG-DSSTYY 59 
A11   AVQLVESGGGLVQAGGSLRLSCVVSGSIFSINAMGWYRQAPGKQRDLVARISG-DSSTYY 59 
B8    QVQLVESGGGLVQAGGSLRLSCVVSGSIFSINAMGWYRQAPGKQRDLVARISG-DSSTYY 59 
D7    AVQLVESGGGLAQAGGSLRLSCTVSGRTSSSHDMGWFRQAPGKEREFVAAISWSGGTTNY 60 
D12   EVQLVESGGGLVQAGGSLRLSCTASGRISSMYDMGWFRQAPRAEREFVASISWSGGTTAY 60 
A12   AVQLVESGGGLVQAGGSLRLSCTASGRISSSYDMGWFRQAPGKEREFVAAISWSGGTTDY 60 
       ****:*****.*.********..**       :**:****  :*: *: **  ..:* * 
 
C10   ADSVKGRFTISSDNAKNTVYLQMNSLKPEDTAVYYCAVERT-------CDGSNWLGPGQG 113 
F12   ADSVKGRFTISSDNAKTTVYLQMNSLKPEDTAVYYCAVEET-------CDGSRWLGPGQG 113 
A9    ADSVKGRFTISSDNAKNTVYLQMNSLKPEDTAVYYCAVESS-------CDGSNWRGPGQG 113 
B7    ADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAIESA-------CNGSRWLGRGQG 113 
F11   ADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAKEQK-------CEGSRWLGGGQG 113 
F9    ADSVNGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCATEKR-------CDGSRWLGQGQG 113 
D10   ADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAREHK-------CFGSVWTGGGQG 113 
C8    IDSVKGRFTISRDNAANTVYLQMNSLKPEDTAVYYCAARRL-------PIG-DYTDWGQG 111 
H9    IDSVKGRFTISRDDAANTVYLQMNSLKPEDTAVYYCAARRL-------PIG-DYTDWGQG 111 
H8    IDSVKGRFTISRDNAANTVYLQMNSLKPEDAAVYYCAARRL-------PIG-DYTDWGQG 111 
H10   IDSVKGRFTISRDNAANTVYLQMNSLKPEDTAVYYCAARRL-------PIG-DYTDWGQG 111 
A11   IDSVKGRFTISRDNAASTVYLQMNSLKPEDTAVYYCAARRL-------PIG-DYTDWGQG 111 
B8    IDSVKGRFTISRDNAANTVYLQMNSLKPEDTAVYYCAARRL-------PIG-DYTDWGQG 111 
D7    ADSVKGRFAISKDNAKNAVSLQMNSLKPEDTAVYYCAAKWRPLRYSDNPSNSDYNYWGQG 120 
D12   ADSVKGRFAISKDNAKNAVSLQMNSLKPEDTAIYYCAAKWRPLRYSDDPSNSNYNVWGQG 120 
A12   ADSVKGRFAISKDNAKNAVSLQMNSLKPEDTAVYYCAAKWRPLRYSDYPSNSDYYDWGQG 120 
       ***:***:** *:* .:* **********:*:**** .           .  :   *** 
 
C10   TQVTVSS 120 
F12   TQVTVSS 120 
A9    TQVTVSS 120 
B7    TQVTVSS 120 
F11   TQVTVSS 120 
F9    TQVTVSS 120 
D10   TQVTVSS 120 
C8    TQVTVSS 118 
H9    TQVTVSS 118 
H8    TQVTVSS 118 
H10   TQVTVSS 118 
A11   TQVTVSS 118 
B8    TQVTVSS 118 
D7    TQVTVSS 127 
D12   TQVTVSS 127 
A12   TQVTVSS 127 
      *******  
 
Figure 3.2.3.3.2. Amino acid sequence alignment of three groups of VHH derived from 
llama L44. VHH were selected by panning of phage libraries derived from llama L44 on 
immobilised HIV-1 IIIB gp120 followed by a competitive elution with sCD4. The three groups, 
the B7-, C8- and D7-like were identified by testing E. coli periplasmic extracts containing the 
VHH for reactivity with IIIB gp120 in ELISA and for neutralisation of HIV-1 IIIB in TZM-bl 
cells. All three groups bound to IIIB gp120 in ELISA, whereas only the C8- and D7-like VHH 
were able to neutralise HIV-1 IIIB. The VHH CDR1, 2 and 3 are shaded in grey. Alignment 
generated using the Clustal W multiple sequence alignment software (1174). Asterisks (*) 
indicate amino acid residues that are conserved among all the aligned sequences. 
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Table 3.2.3.3.1. Selected VHH derived from llama L44. 
No. of amino 
acid 
differencesc 
C
lo
ne
 
G
ro
up
a  Total no. 
of clones 
isolatedb FRs CDRs 
Binding 
at 
Ablynxd 
Neutralisation 
at UCLe 
B7 B7 7/48 0-4 2-12 ++ - 
A9 B7    ++ - 
F9 B7    ++ - 
C10 B7    + - 
D10 B7    ++ - 
F11 B7    ++ - 
F12 B7    ++ - 
B8 C8 19/48 1-3 0 + + 
C8 C8    + + 
H8 C8    + + 
H9 C8    + + 
H10 C8    + + 
A11 C8    + + 
D7 D7 5/48 3-7 5-7 + + 
A12 D7    + + 
D12 D7    + + 
aBased on amino acid sequence analysis. 
bProportion of individual VHH clones isolated from llama L44 belonging to each of the identified 
VHH groups (including duplicates). 
cNumber of amino acid differences within each of the identified VHH groups; FR, framework 
regions; CDR, complementarity determining region. 
dBinding of unpurified VHH in E. coli periplasmic extracts to HIV-1 IIIB gp120 in ELISA 
carried out at Ablynx, NV, Porto, Portugal; - indicates less than 5-fold; + indicates 5 to 10-fold; 
++ indicates more than 10-fold increase in absorbance signal compared to a negative control. 
eNeutralisation of HIV-1 IIIB in TZM-bl cells using unpurified VHH in E. coli  periplasmic 
extracts. Neutralisation cut off set to 90% reduction in RLU; - indicates 31-74% reduction in 
RLU; + indicates >90% reduction in RLU compared to virus only control. 
 
Purified preparations of the VHH, as opposed to periplasmic extracts, were sent 
to UCL for characterisation. The VHH were re-cloned into the expression vector 
pAX051, which incorporates a 6-histidine- and a c-myc-tag to the C-terminus of 
the VHH, expressed in E. coli and purified by means of the 6-histidine-tag. This 
work was carried out by Els Beirnaert at Ablynx. Initially, only three clones were 
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sent. These were VHH B7, C8 and D7, representing the three identified VHH 
groups. The purified VHH were tested for reactivity with CN54 and IIIB gp120 
in ELISA. VHH C8 and D7 were observed to bind to IIIB gp120, but not to 
CN54 gp120 (Fig. 3.2.3.3.3). Purified VHH B7, on the other hand, did not bind 
to either IIIB or CN54 gp120, in contrast to the result obtained using VHH B7 in 
periplasmic extracts (Fig. 3.2.3.3.3 and Table 3.2.3.3.1). The reason for this 
observed discrepancy is unclear. 
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Figure 3.2.3.3.3. Reactivity of purified VHH B7, C8 and D7, derived from llama L44, with 
CN54 and IIIB gp120 in ELISA. Recombinant gp120 was captured onto microtitre plates by the 
sheep antibody D7324. Threefold serial dilutions of VHH were then added to the plate followed 
by detection using a mouse anti-c-myc mAb followed by an AP-conjugated goat anti-mouse IgG 
antibody. Chemiluminescence was detected and background-subtracted luminescence readings 
(in RLU) were normalised to readings obtained for 200 ng/ml of VHH C8 binding to IIIB gp120 
and plotted against VHH concentration. Data points represent the mean and bars the standard 
deviation of duplicate reactions.  
 
The purified VHH B7, C8 and D7 were then tested in the NP2 cell-based 
neutralisation assay. VHH C8 and D7 (at 100 µg/ml) reduced infection of CN54 
virus with 52 and 36%, respectively, compared to a negative control VHH, 
whereas VHH B7 had no apparent effect on CN54 infectivity at 100 µg/ml (Fig. 
3.2.3.3.4). VHH C8 and D7 potently neutralised IIIB infection at 100 µg/ml, 
reducing the number of FFUs by 99 and 100%, respectively, compared to a 
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negative control VHH.  Again, VHH B7 had no apparent effect on infectivity 
(Fig. 3.2.3.3.4). 
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Figure 3.2.3.3.4. Neutralisation of HIV-1 CN54 and IIIB in NP2 cells by VHH B7, C8 and 
D7, derived from llama L44. Neutralisation was assayed in NP2/CD4/CCR5 cells (CN54) or 
NP2/CD4/CXCR4 cells (IIIB) as described in section 2.10.1 of this thesis. Each VHH was tested 
at a concentration of 100 µg/ml. The number of FFU was counted microscopically 72 hours post-
infection and the percentage of FFU compared to the result obtained for the negative control 
VHH was determined. Bars represent the mean and error bars the standard error of two 
independent experiments carried out in duplicate. 
 
The above observations made using purified VHH B7, C8 and D7 confirmed the 
results obtained with the periplasmic extracts, namely that the C8- and D7-like 
VHH were able to neutralise HIV-1 IIIB, whereas the B7-like VHH were not. 
Some weak neutralisation of HIV-1 CN54 was also observed for VHH C8 and 
D7. Based on this knowledge, purified preparations of additional members of the 
identified VHH groups were tested in neutralisation assays. In total, five clones 
from the B7, C8 and D7 groups were re-cloned, expressed and purified at Ablynx 
NV, Porto, and subsequently sent to UCL for characterisation. These clones were 
the B7-like VHH F12, the C8-like VHH H9 and A11, and the D7-like VHH A12 
and D12 (Table 3.2.3.3.1). 
 
The B7-like VHH F12 did not have any apparent effect on HIV-1 IIIB or CN54 
infection, in concordance with the results observed using periplasmic extracts. 
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VHH F12 was also tested against two additional subtype B and one additional 
subtype C viruses, but was not able to reduce infection by more than 20%. No 
further neutralisation tests were done on the B7-like group of VHH. The two C8-
like VHH H9 and A11 differed from VHH C8 in one or two amino acid positions 
in the framework 1 and 3 regions, respectively. As expected, they were found to 
behave like VHH C8 in neutralisation assays. Therefore, VHH C8 was chosen 
for further characterisation, as a representative for the C8-like group of VHH. As 
for the D7-like VHH, both remaining members (VHH A12 and D12) were 
chosen for further characterisation, as in addition to differences in the framework 
regions, these VHH also contained differences in the CDRs, which is more likely 
to affect antigen recognition. 
 
3.2.3.4 Summary of the first set of selections and screening of VHH  
 In summary, 148 individual VHH clones were selected from llama L40 and L44 
through panning of phage libraries on CN54 and IIIB gp120 (Fig. 3.2.3.1.2). 
These 148 clones were screened for binding to gp120 and/or neutralisation of 
HIV-1 CN54 and IIIB. Based on this screening as well as sequence analysis of 
the identified clones, five VHH were chosen for further characterisation (Table 
3.2.3.4.1). A comprehensive analysis of the neutralisation properties of these will 
described in chapter 4 of this thesis. 
 
Table 3.2.3.4.1. Chosen VHH from the first set of selections and screeninga. 
VHH Groupb Llama Immunogen Selection 
D7 D7-like L44 CN54 gp120 IIIB gp120 
A12 D7-like L44 CN54 gp120 IIIB gp120 
D12 D7-like L44 CN54 gp120 IIIB gp120 
C8 C8-like L44 CN54 gp120 IIIB gp120 
F2 N/A L40 CN54 gp120 CN54 gp120 
aVHH libraries derived from llamas immunised with recombinant CN54 gp120 were panned on 
immobilised CN54 or IIIB gp120 followed by a competitive elution with sCD4. Individual VHH 
clones were isolated and screened for binding to recombinant gp120 and HIV-1 neutralisation 
activity. A number of similar VHH sequences were identified and representative clones were 
chosen for further characterisation. 
bBased on amino acid sequence analysis; N/A, not applicable. 
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3.2.4 Production of recombinant gp120 from HIV-1 subtype of A and C to 
enable selection of VHH with cross-subtype reactivity 
The two llamas immunised at the outset of this project (llama L40 and L44) had 
been immunised with CN54 gp120. It was therefore logical to carry out the first 
set of phage display selections using CN54 gp120. The immunogen did, 
however, show poor binding to sCD4 in biochemical assays and did not mediate 
infection when expressed on the surface of virus particles (as discussed in section 
3.2.2). Hence, recombinant gp120 derived from HIV-1 IIIB was included in the 
selection protocol, due to its availability and good binding to sCD4 in ELISA.  
 
HIV-1 IIIB is, however, a CXCR4-using TCLA isolate and does not represent 
the majority of the transmitted HIV-1 isolates. Instead, HIV-1 TCLA isolates are 
widely known to be more sensitive to neutralisation by antibodies as well as by 
sCD4, compared to primary HIV-1 isolates. Using IIIB gp120 in the phage 
display panning step may therefore enrich for VHH that are able to bind to the 
more accessible CD4bs of a TCLA virus but less so to the CD4bs of primary 
HIV-1 isolates. In addition, IIIB is a subtype B virus; a subtype which accounts 
for only about 10% of infections worldwide. IIIB gp120 had been chosen mainly 
because of its availability. To enable selection of VHH with cross-subtype 
reactivity against primary HIV-1 isolates, it would be desirable to include 
recombinant envelope glycoproteins derived from non-subtype B in the panning 
protocol. 
 
Recombinant envelope proteins from non-subtype B isolates were not readily 
available at the time of the first set of selections. Recombinant gp120 derived 
from primary isolates of non-subtype B viruses was therefore generated. To 
increase the chances of selecting for VHH able to recognise different HIV-1 
subtypes, it was decided to include gp120 from both subtype A and subtype C 
isolates. The 92UG037 (subtype A) and 92BR025 (subtype C) isolates were 
obtained from the WHO-UNAIDS collection of primary isolates; they represent 
strains that were circulating in areas chosen for vaccine trials (1197). 
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Full-length gp120 was amplified from genomic DNA isolated from PBMC 
infected with HIV-1 92UG037 and 92BR025 in a nested PCR. The reverse 
nested primer incorporated part of the motif recognised by sheep antibody D7324 
as well as a 6-histidine-tag. The amplified gp120 fragments were cloned into a 
mammalian expression vector. To ensure that only functional envelope clones 
were chosen, ten gp120 clones from each HIV-1 isolate were sub-cloned into an 
HIV-1 HXB2 backbone and screened for ability to mediate infection when 
expressed on the surface of virus particles, as will be described in section 3.2.5 of 
this thesis. Envelope clones giving rise to infectious virus were chosen (clones 
92UG037.A9 and 92BR025.C1) and recombinant gp120 was expressed in 293T 
cells infected with a T7 RNA polymerase recombinant vaccinia virus, as 
described previously (631). Envelope protein was harvested 48 hours post-
transfection and purified by means of the 6-histidine-tag (92BR025.C1 gp120) or 
kept in cell culture supernatant (92UG037.A9 gp120). 
 
Expressed gp120 was captured onto ELISA plates by the sheep antibody D7324. 
Since the D7324 antibody recognises the C-terminus of gp120, this method 
captures antigens that are fully translated and secreted. Captured gp120 was 
detected using human anti-HIV-1 sera with broad neutralising activity, to ensure 
that a saturating level of each gp120 was applied for subsequent experiments 
(Fig. 3.2.4.1). 
 
To examine the structural integrity and functionality of the expressed 
recombinant proteins, their reactivity with sCD4 was tested in ELISA. 
Recombinant sCD4 was observed to bind well to recombinant gp120 derived 
from the subtype A isolate 92UG037, giving a signal in the same range as for 
IIIB gp120 (Fig. 3.2.4.2 A). This observation is in concordance with a result 
obtained by Jeffs et al. where a recombinant gp140 derived from 92UG037 
showed relatively strong binding to sCD4 in ELISA (1048). 
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 IIIB gp120
92UG037.A9 gp120
92BR025.C1 gp120
Negative expression control
 
Figure 3.2.4.1. Detection of 92UG037.A9 and 92BR025.C1 gp120 expressed in 293T cells 
infected with a T7 RNA polymerase-recombinant vaccinia virus. Serial dilutions of gp120 
were captured with antibody D7324 and detected in ELISA using a mix of three human anti-HIV-
1 sera followed by an AP-conjugated goat anti-human IgG antibody. A serial dilution of IIIB 
gp120, starting at 0.2 or 1 µg/ml, was included as a positive control. A mock expression was 
included as a negative control. Chemiluminescence was detected and RLU were plotted against 
gp120 dilution factor. Data points represent the mean background-subtracted reading of duplicate 
reactions. A. Capture of 92UG037.A9 gp120 in cell culture supernatant. B. Capture of purified 
92BR025.C1 gp120. 
 
It is possible that the good binding to sCD4 makes the 92UG037.A9 gp120 
suitable for selecting VHH that target the CD4bs using the selection methods 
described in section 3.2.3 of this thesis. Less good binding of sCD4 was observed 
to gp120 derived from the subtype C isolate 92BR025 (Fig. 3.2.4.2 B). This may 
be because of misfolding, a less accessible CD4bs or a lower affinity for CD4. 
Due to the observation that this gp120 produces infectious virus in the context of 
an HXB2 backbone (section 3.2.5) and the notion that a weakly neutralising 
VHH could be isolated using the poor sCD4-binder CN54 gp120 (Fig. 3.4.2), this 
gp120 was still included in the subsequent panning protocols, despite its 
relatively weak binding to sCD4. Recombinant gp120 from one additional 
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subtype C virus was also produced, but could not be used in selections due to the 
limited number of time slots available in the Ablynx selection laboratory. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.4.2. Binding of sCD4 to recombinant gp120 derived from HIV-1 92UG037 and 
92BR025 in ELISA. Saturating levels of recombinant gp120 were captured by immobilised 
sheep antibody D7324 followed by incubation with serial dilutions of sCD4 and subsequent 
detection of sCD4 using the mouse anti-CD4 mAb L120.3 and an AP-conjugated goat anti-mouse 
IgG antibody. Chemiluminescence was detected and luminescence readings (in RLU) were 
normalised to readings obtained for 10 or 20 µg/ml of sCD4 binding to IIIB gp120 and plotted 
against sCD4 concentration. Data points represent the mean and error bars the standard error of 
two independent experiments performed in duplicate. A. Binding of sCD4 to 92UG037.A9 
gp120. B. Binding of sCD4 to 92BR025.C1 gp120. 
 
3.2.5 Production of chimeric viruses expressing gp120 from HIV-1 of 
subtype A and C for neutralisation screening of VHH selected using the 
corresponding envelopes 
It would be desirable to screen individual selected VHH not only for binding to 
gp120 but also for in vitro neutralisation of HIV-1, as binding to monomeric 
gp120 does not necessarily correlate with neutralisation of the corresponding 
virus. The structure of soluble, recombinant envelope glycoproteins is likely to 
be different from the structure of the envelope glycoproteins in the context of the 
functional spike (138, 140, 259). 
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To enable screening of VHH selected through panning on recombinant 92UG037 
and 92BR025 gp120 for neutralisation of the corresponding virus, the 92UG037 
and 92BR025 envelopes were sub-cloned into an HXB2-based backbone and the 
resulting chimeric molecular clones were used to transfect 293T cells. Virus was 
harvested after 48 hours and titrated onto NP2/CD4/CCR5 and 
NP2/CD4/CXCR4 target cells. Ten different gp120/HXB2 chimeric constructs 
were screened for ability to produce infectious virus. One envelope clone giving 
rise to infectious virus was chosen for each of the two virus isolates. Both the 
molecular clones were predominantly R5-tropic as determined by titration on 
NP2 target cells (Table 3.2.5.1). The same gp120 clones (92UG037.A9 and 
92BR025.C1) were used to produce recombinant gp120, for use in the panning of 
phage libraries, as well as for production of chimeric replication-competent virus, 
for use in the neutralisation screening of selected VHH. 
 
Table 3.2.5.1. HIV-1 92UG037.A9 and 92BR025.C1 titres on NP2 cellsa. 
 Titre on NP2 target cells (FFU/ml) 
 R5 X4 
92UG037.A9 5 × 106 100 
92BR025.C1 105 <10 
aThe envelope genes of HIV-1 92UG037 and 92BR025 were amplified and cloned into an HIV-1 
pHXB2∆env backbone to produce replication-competent chimeric molecular clones. Virus stocks 
were produced in 293T cells and titrated onto NP2/CD4/CCR5 and NP2/CD4/CXCR4 target 
cells. 72 hours post-infection cells were fixed and stained for HIV-1 p24 protein. FFU were 
counted microscopically and the virus titre on each cell line was determined. 
 
Since the aim of the phage display selection strategy was to select for VHH 
targeting the CD4bs of HIV-1 envelope, the sensitivity of the chimeric viruses to 
neutralisation by sCD4 was tested. This was done in NP2/CD4/CCR5 cells. None 
of the viruses were neutralised by sCD4. Instead, a slight enhancement (2-2.5 
times) of the number of FFUs was observed at high concentrations of sCD4 (Fig. 
3.2.5.1). Enhancement of HIV-1 infection has been observed previously (1198). 
Resistance to neutralisation by sCD4 has been widely observed among primary 
isolates and has been shown not to correlate with sCD4 affinity for the 
corresponding monomeric gp120 (1199-1203). 
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Figure 3.2.5.1. Effect of sCD4 on HIV-1 92UG037.A9 and 92BR025.C1 infection of NP2 
cells. Virus was pre-incubated with serial dilutions of sCD4 and subsequently incubated with 
NP2/CD4/CCR5 cells. At 72 hours post-infection, the cells were fixed and stained for p24. The 
number of FFU was counted microscopically and the percentage of FFU compared to the result 
obtained for the virus only control was determined and plotted against sCD4 concentration. Data 
points represent the mean and error bars the standard error of three independent experiments 
carried out in triplicate. 
 
There are several possible reasons for the resistance of primary isolates, 
including the 92UG037.A9 virus, to neutralisation by sCD4, despite a high 
affinity of sCD4 to monomeric gp120. It may be that the CD4bs in the context of 
the functional spike differs from the presentation of the CD4bs on monomeric 
gp120 (138, 140, 259). Recombinant sCD4 might hence be able to bind 
monomeric gp120 but not gp120 in the context of the trimeric spike. If this is the 
case, it may indicate that the 92UG037.A9 recombinant gp120 does not very well 
present the CD4bs as it is in the context of the functional spike and hence that 
this gp120 may be a bad choice for use in our selection strategies. Using similar 
reasoning, the 92BR025.C1 recombinant gp120 might better present the CD4bs, 
as the sCD4 binding and neutralisation results correlate. This notion is, however, 
speculative, and the weak binding of sCD4 to the soluble, recombinant protein 
may just as likely be due to a poor presentation of the CD4bs. An alternative 
explanation for the lack of correlation between the observed sCD4 neutralisation 
and binding data would be that sCD4 indeed binds to functional spikes on the 
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HIV-1 surface and that this triggers the same conformational changes that CD4 
on cells do, leading to increased exposure of the co-receptor binding site on HIV-
1 envelope and perhaps to increased level of infection. This mechanism is 
thought to be responsible for sCD4-mediated enhancement of SIV infection 
(1204). Such an event could possibly explain the slight enhancement of 
92UG037.A9 and 92BR025.C1 infectivity observed at high concentrations of 
sCD4. This assumption is, however, speculative and further studies are needed to 
establish the mechanisms behind the resistance of the 92UG037.A9 and 
92BR025.C1 virus to neutralisation by sCD4. Regardless of the mechanism, the 
observed results confirm that in order to increase the chances of identifying VHH 
able to inhibit cellular CD4 interaction with the functional envelope spike, it is 
important to screen selected VHH for neutralisation rather than for binding to 
recombinant envelope proteins. The generated 92UG037.A9 and 92BR025.C1 
chimeric molecular viruses may therefore be of use. 
 
The sensitivity of the 92UG037.A9 and 92BR025.C1 chimeric viruses to anti-
CD4bs antibodies was evaluated using mAb b12 (Fig. 3.2.5.2). 
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Figure 3.2.5.2. Effect of mAb b12 on HIV-1 92UG037.A9 and 92BR025.C1 infection of NP2 
cells. Virus was pre-incubated with b12 (at 25 and 100 µg/ml) and subsequently incubated with 
NP2/CD4/CCR5 cells. At 72 hours post-infection, the cells were fixed and stained for HIV-1 p24 
protein. The number FFU was counted and the percentage of FFU compared to the result 
obtained for the virus only control was determined and plotted. Bars represent the mean and error 
bars the standard error of three independent experiments carried out in duplicate. 
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Anti-CD4bs mAb b12 (at 25 and 100 µg/ml) did not reduce infection of the 
92UG037.A9 virus and reduced infection of the 92BR025.C1 virus by only 22% 
(Fig. 3.2.5.2). This finding suggests that the b12 epitope is not present, or not 
accessible, on the functional spikes of 92UG037.A9 and 92BR025.C1 virus. 
 
3.2.6 Second set of selections and screening - panning of phage libraries on 
gp120 from HIV-1 92UG037, 92BR025 and IIIB 
In this section, the second set of selections and screening will be described. 
 
3.2.6.1 Panning of phage libraries on 92UG037, 92BR025 and IIIB gp120 
The first set of selections had been carried out using IIIB gp120 in addition to 
CN54 gp120. To facilitate selection of VHH that could recognise HIV-1 primary 
isolates, as opposed to the TCLA virus HIV-1 IIIB, the phage libraries 
expressing VHH derived from the immunised llamas were panned on 
recombinant gp120 derived from primary isolates of subtype A (92UG037) and 
C (92BR025). This work was carried out by me in the Ablynx NV selection 
laboratory in Porto, Portugal. In order to allow for selection of VHH recognising 
motifs conserved among HIV-1 subtypes, the 92UG037.A9, 92BR025.C1 and 
IIIB gp120 was alternated in different combinations in two subsequent rounds of 
panning. Selections were carried out as outlined in Fig. 3.1.1. 
 
In a first round of panning, the phage libraries from llamas L40, L44 and L48 
were panned on immobilised 92UG037.A9, 92BR025.C1 and IIIB gp120. The 
92BR025.C1 and IIIB gp120 were purified and coated directly on microtitre 
plates, whereas the 92UG037.A9 gp120, which was in cell culture supernatant, 
was captured by antibody D7324 which had been pre-coated onto plates. Two 
different concentrations of each gp120 were used in parallel. The phages were 
allowed to bind to gp120 for 1 hour at room temperature, and unbound phages 
were then washed off in 20 cycles of washing. Again, an excess of sCD4 was 
used to competitively elute phage expressing VHH targeting the CD4bs, as 
described in section 3.2.3.1. This time, however, for each gp120 concentration, 
two different sCD4 concentrations were used in parallel (30 and 200 µg/ml). In 
 223
addition, for each combination, the elution was carried out for two different 
lengths of time (0.5 and 3 hours). Elution with BSA and low pH was carried out 
in parallel. Eluted phages were titrated onto E. coli. In general, no correlation 
was observed between the number of clones eluted by sCD4 and the 
concentration of sCD4 or length of incubation with sCD4 (Fig. 3.2.6.1.1). 
Selections where a larger number of clones were eluted by sCD4, compared to 
elution with BSA, were taken forward to a second round of CD4bs-targeted 
panning. The titrations from these chosen selections can be seen in Fig. 3.2.6.1.1. 
 
 
Titrations Elution Concentration Library and gp120 Output 
    1:125    1:25     1:5    neat  sCD4  gp120   
BSA 
sCD4 
Low Low Llama L40 92UG037.A9 gp120 1 
BSA  
sCD4 
Low High 
 
2 
BSA 
sCD4 
High Low Llama L44 92UG037.A9 gp120 3 
BSA  
 
sCD4 
Low Low 
 
4 
BSA 
sCD4 
 
Low Low Llama L44 92BR025.C1 gp120 5 
BSA 
 
 
sCD4 
High Low Llama L48 IIIB gp120 6 
 
Figure 3.2.6.1.1. Titrations of eluted phage from the first round of panning. Phage libraries 
from llamas L40, L44 and L48 were panned on 92UG037.A9, 92BR025.C1 and IIIB gp120. 
Phages were eluted with sCD4 and BSA. Only titrations from successful selections, where more 
clones were eluted by sCD4 than by BSA, are shown. Phages from these selections were taken 
forward to a second round of panning. No correlation was observed between gp120 or sCD4 
concentration and number of eluted phage. 
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The second round of panning was carried out in the same way as the first round. 
Eluted phages were titrated onto E. coli and selections where a larger number of 
clones were eluted by sCD4 than by BSA were chosen (Fig. 3.2.6.1.2). 
 
Titrations Elution Concentration Phage output and gp120 Output 
 1:100    1:10      neat  sCD4  gp120   
BSA 
sCD4 
Low High Output 2 92UG037.A9 gp120 A 
BSA 
sCD4 
Low High Output 4 92UG037.A9 gp120 B 
BSA 
sCD4 
High Low Output 4 92BR025.C1 gp120 C 
BSA 
 
 
 
 
 
 
 sCD4 
Low High Output 5 IIIB gp120 D 
BSA 
 
 sCD4 
High High Output 5 92BR025.C1 gp120 E 
BSA 
 
 
sCD4 
High High Output 6 IIIB gp120 F 
BSA 
 
 
sCD4 
Low Low Output 6 92BR025.C1 gp120 G 
 
Figure 3.2.6.1.2. Titrations of eluted phage from the second round of panning. Phage 
libraries from selections outputs 2, 4, 5 and 6 were panned on 92UG037.A9, 92BR025.C1 and 
IIIB gp120. Phages were eluted with sCD4 and BSA. Only titrations from successful selections, 
where more clones were eluted by sCD4 than by BSA, are shown. No correlation was observed 
between gp120 or sCD4 concentration and number of eluted phage. Individual clones were 
isolated from these selections outputs. 
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Larger numbers of sCD4-eluted clones, compared to the number of BSA-eluted 
clones, possibly indicating enrichment of phage expressing VHH targeting the 
CD4bs, could only be seen in phage outputs originating from llama L44 and L48, 
not from llama L40. Eluted phages from the chosen selection outputs were used 
to infect E. coli TG1 cells. The cells were grown overnight, after which DNA 
was isolated and the VHH fragments were cut and sub-cloned into an expression 
vector and the resulting plasmids were used to transfect electrocompetent E. coli. 
 
Negative control wells without immobilised gp120 were also included in the 
panning steps. For the purified 92BR025.C1 and IIIB gp120, the negative control 
wells were empty, whereas for the 92UG037.A9 gp120, which was in cell culture 
supernatant, the negative control wells contained the capture antibody D7324 
alone or D7324 plus cell culture supernatant from a mock expression. The empty 
negative control wells had a low background level of phage binding. In the 
D7324-coated wells, on the other hand, the level of phage eluted by low pH 
shock was just as high as the level eluted from wells containing gp120 (Fig. 
3.2.6.1.3). This result suggested that some phage bound to the antibody D7324. 
 
  
Figure 3.2.6.1.3. Titration of phage from low pH elutions in wells coated with D7324 with 
and without gp120. Phage libraries from llama L40, L44 and L48 were panned on 92UG037.A9 
gp120 (in cell culture supernatant) captured by D7324 and eluted by glycine (low pH) as a 
control. Negative control wells containing only D7324, or D7324 plus cell culture supernatant 
from a mock expression, were included in the panning protocols. Phages were found to bind to 
negative control wells as well as to gp120 wells. 
 
Attempts were made to reduce the level of phage binding sheep antibody D7324 
by including goat serum in the panning steps. This strategy did, however, not 
reduce the level of background binding. 
 
1:100  1:10     neat 
pH elution, D7324 plus 92UG037.A9 gp120 
 
pH elution, D7324 plus mock expression 
 
pH elution, D7324 only 
 226
To investigate whether the high background binding of phage to D7324 had 
influenced the CD4bs-targeted selections carried out using D7324-captured 
gp120 (selection outputs 1-4 in Fig. 3.2.6.1.1 and A-B in Fig. 3.2.6.1.2), 
polyclonal VHH was tested for reactivity with gp120 and D7324 in ELISA. The 
polyclonal VHH were expressed from the sub-cloned VHH repertoire of 
selection output B (Fig. 3.2.6.1.2). As a positive control, polyclonal VHH were 
produced from the selection output giving rise to the C8- and D7-like VHH in the 
first set of selections, described in section 3.2.3. As a negative control, 
polyclonal VHH were produced from a phage output derived from llama L48 but 
selected using recombinant gp41. The gp41 selections were carried out by Willie 
Koh in a parallel project. 
 
The three polyclonal VHH outputs were tested in ELISA. D7324 was coated 
onto the wells of a microtitre plate. Wells were blocked and then incubated with 
serial dilutions of 92UG037.A9 gp120 in cell culture supernatant or with cell 
culture supernatant from a mock expression (to exclude that the VHH reacted 
with anything in the cell culture supernatant). After a washing step, the wells 
were incubated with the three polyclonal VHH preparations. Bound VHH were 
detected by means of their anti-c-myc tag (Fig. 3.2.6.1.4). 
 
The polyclonal VHH selected using D7324-captured 92UG037.A9 gp120 
(selection output B) showed dose-dependent binding to 92UG037.A9 gp120 in 
this ELISA, as did the positive control polyclonal VHH, but not the negative 
control polyclonal VHH (Fig. 3.2.6.1.4 A). Some binding of the polyclonal VHH 
from selection output B was also observed in the wells (containing D7324) that 
had been incubated with cell culture supernatant from a mock expression (Fig. 
3.2.6.1.4 B). This binding was, however, not dose-dependent, indicating that the 
polyclonal VHH from selection output B reacts with antibody D7324 rather than 
anything present in the cell culture supernatant, as was expected. 
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Polyclonal VHH (selection output B)
Positive control polyclonal VHH
Negative control polyclonal VHH  
Figure 3.2.6.1.4. Reactivity of polyclonal VHH with unpurified 92UG037.A9 gp120 
captured by antibody D7324 in ELISA. The wells of a microtitre plate were coated with a 
constant concentration of antibody D7324 and subsequently incubated with serial dilutions of A. 
92UG037.A9 gp120 in cell culture supernatant, or B. cell culture supernatant from a mock 
expression. After a washing step, the wells were incubated with polyclonal from selection output 
B (selected through panning on 92UG037.A9 gp120 from cell culture supernatant captured by 
D7324). Positive and negative control polyclonal VHH were included, and bound VHH were 
detected by a mouse anti-c-myc mAb followed by an AP-conjugated rabbit anti-mouse antibody 
as described in the text. Absorbance readings were plotted against reciprocal culture medium 
dilution. 
 
Since the 92UG037.A9 gp120 was in cell culture supernatant and could not be 
coated directly, without capture with D7324, the polyclonal VHH were tested for 
reactivity with directly coated IIIB gp120 as well as with D7324 alone. Serial 
dilutions of IIIB gp120 and D7324 in parallel were coated onto microtitre plate 
wells. Wells were blocked and then incubated with the polyclonal VHH which 
again were detected by means of their c-myc-tag. The polyclonal VHH selected 
using D7324-captured 92UG037.A9 gp120 showed dose-dependent binding to 
IIIB gp120 in ELISA (Fig. 3.2.6.1.5 A), although some binding to D7324 was 
also observed (Fig. 3.2.6.1.5 B). 
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Polyclonal VHH (selection output B)
Positive control polyclonal VHH
Negative control polyclonal VHH  
Figure 3.2.6.1.5. Reactivity of polyclonal VHH with IIIB gp120 and antibody D7324 in 
ELISA. Polyclonal VHH from selection output B (selected through panning on 92UG037.A9 
gp120 from cell culture supernatant captured by D7324) were incubated with serial dilutions of 
IIIB gp120 or antibody D7324 pre-coated onto a microtitre plate. Bound VHH were then detected 
by a mouse anti-c-myc mAb followed by an AP-conjugated rabbit anti-mouse antibody. Positive 
and negative control polyclonal VHH were included, as described in the text. A. Polyclonal VHH 
reactivity with serial dilutions of IIIB gp120. B. Polyclonal VHH reactivity with serial dilutions 
of antibody D7324. 
 
The above observations suggested that selections on D7324-captured gp120 
results in some enrichment for VHH that react with the capture antibody D7324, 
but to a greater extent in enrichment for VHH that react with gp120. Individual 
clones were therefore picked from the re-cloned VHH repertoires of all the 
chosen selection outputs (Fig. 3.2.6.1.2), including those selected through 
panning on gp120 captured by D7324. For each output, 96 clones were isolated. 
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3.2.6.2 Screening of selected VHH for HIV-1 neutralisation and binding to 
gp120 
The isolated monoclonal VHH were expressed overnight in E. coli TG1 cells in 1 
ml of medium in deep-well 96-well plates. For each clone, approximately 90 µl 
of E. coli periplasmic extract containing the expressed VHH was prepared and 
tested for ability to neutralise HIV-1. A total of 672 VHH were expressed. 
 
VHH selected through panning on 92UG037.A9 gp120 were screened for ability 
to neutralise HIV-1 92UG037.A9, whereas VHH selected using 92BR025.C1 
gp120 were screened against HIV-1 92BR025.C1. In addition, all VHH were 
screened for ability to neutralise HIV-1 IIIB, based on the rationale that IIIB is 
generally sensitive to neutralisation, and the observation that both the 
92UG037.A9 and the 92BR025.C1 viruses appeared to be resistant to CD4bs-
targeted neutralisation (at least to sCD4 and the anti-CD4bs mAb b12). Each 
VHH was tested in one well only against each virus. HIV-1 CN54 was not 
included in the neutralisation screening, due to difficulties in propagating the 
isolate in PBMC to a high enough titre. In addition, the quasispecies that a 
PBMC-propagated primary isolate represents may also be more resistant to 
neutralisation and may not pick up neutralising VHH. Instead, VHH were 
screened for neutralisation of molecularly cloned chimeric viruses expressing the 
exact same envelope against which the phage libraries had been panned. 
 
VHH neutralisation of HIV-1 was evaluated in NP2/CD4/CCR5 (HIV-1 
92UG037.A9 and HIV-1 92BR025.C1) or NP2/CD4/CXCR4 (HIV-1 IIIB) target 
cells. Since the VHH were unpurified in E. coli periplasmic extracts, it had to be 
evaluated whether periplasmic extracts on its own would have any effect on 
HIV-1 infection of NP2 cells. Seven different negative control periplasmic 
extracts were therefore pre-incubated with HIV-1 92BR025.C1 gp120/HXB2 
chimeric virus and subsequently added to cells. At 72 hours post infection, cells 
were fixed and stained for HIV-1 p24 protein in a β-galactosidase assay. FFU 
were counted microscopically and reduction in FFU in test wells compared to in 
virus control wells was determined. The mean reduction in FFU for the seven 
different negative control periplasmic extracts was 15%. The neutralisation cut 
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off was set to 70% reduction in FFU, which corresponds to the mean reduction in 
FFU plus 2.1 standard deviations (Fig. 3.2.6.2.1). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.6.2.1. Effect of E. coli periplasmic 
extracts on HIV-1 infection of NP2 cells. Seven 
negative control periplasmic extracts were tested 
for effect of HIV-1 92BR025.C1 infection of 
NP2/CD4/CCR5 cells. The % FFU compared to 
virus only control was determined and the mean ± 
the standard deviation for the seven extracts was 
plotted. 
 
 
 
The neutralisation screening revealed that out of the 192 clones isolated from 
llama L44 and selected using 92UG037.A9 gp120, none were able to neutralise 
the corresponding 92UG037.A9 virus to more than 20%. Two out of the 192 
were, however, able to neutralise IIIB and 92BR025.C1 virus to more than 90%.  
 
Out of the 96 clones derived from llama L44 and selected using 92UG037.A9 
and 92BR025.C1 gp120, one clone was able to neutralise 92BR025.C1 and IIIB 
virus to more than 90%, whereas none of the others neutralised to more than 
50%. 
 
Out of the 192 clones derived from llama L44 and selected using IIIB and 
92BR025.C1 gp120, or 92BR025.C1 gp120 alone, 16 and 24 clones, 
respectively, were able to neutralise 92BR025.C1 and IIIB virus to more than 
80%. In contrast, none of the 192 VHH isolated from llama L48 were able to 
neutralise 92BR025.C1 or IIIB virus to more than 50%. 
 
In summary, out of the 672 clones isolated in total, 43 were observed to 
neutralise HIV-1. All the 672 VHH were also screened for ability to bind to IIIB 
gp120 in ELISA. The results from the neutralisation and binding screening 
0
10
20
30
40
50
60
70
80
90
100
110
120
Negative control
periplasmic extract,
N=7
%
 F
FU
 c
om
pa
re
d 
to
 n
o 
vi
ru
s o
nl
y 
co
nt
ro
l
__
Cut off
 231
showed complete correlation in that the same 43 clones were found to bind to 
IIIB gp120. The relatively low frequency of VHH able to bind to gp120 and to 
neutralise HIV-1 (43 out of 672, roughly corresponding to 6%) probably reflects 
the nature of the competitive elution method, as a significant number of clones 
were non-specifically eluted by BSA, as can be seen in Fig. 3.2.6.2.2. The fact 
that the antigen was varied in the panning protocol and that binding VHH 
therefore need to recognise motifs that are conserved between the different 
subtypes may also contribute. 
 
Sequence analysis of the 43 neutralising clones revealed that they were all 
identical to VHH A12 (21 clones), which had already been selected from the 
same library through panning on HIV-1 IIIB gp120 as described in section 3.2.3, 
or identical to A12 with one amino acid difference in the framework 1 region (22 
clones; a leucine to arginine in position 18). Characterisation of the latter VHH 
revealed a neutralisation profile similar to that of A12 (data not shown). 
 
3.2.6.3 Summary of the second set of selections and screening of VHH  
Phage libraries expressing the VHH repertoires derived from llamas L40, L44 
and L48 were panned on gp120 from 92UG037.A9 (subtype A), 92BR025.C1 
(subtype C) and IIIB gp120 followed by a competitive elution with sCD4. The 
antigen was alternated to allow for the enrichment of VHH able to recognise 
motifs conserved among HIV-1 subtypes. Larger numbers of sCD4-eluted 
clones, compared to the number of BSA-eluted clones, possibly indicating 
enrichment of phage expressing VHH targeting the CD4bs, were only observed 
for phage libraries derived from llama L44 and L48. In summary, 672 individual 
VHH clones were selected, out of which 43 were found to neutralise HIV-1 and 
bind to gp120. All 43 VHH turned out to be identical to the already identified 
VHH A12, or identical to A12 with one amino acid difference in the framework 
1 region. A more thorough analysis of the neutralisation ability of VHH A12 will 
be described in chapter 4. The second set of selections as well as the 
neutralisation screening is summarised in Fig. 3.2.6.3.1. 
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 VHH library from 
llama L44 
 VHH library from 
llama L48 
        
1st round 92UG037 
gp120 
92BR025 
gp120 
 IIIB 
gp120 
        
2nd round 92UG037 
gp120 
92BR025 
gp120 
IIIB   
gp120 
92BR025 
gp120 
 IIIB 
gp120 
92BR025 
gp120 
 192 
VHH 
96 
VHH 
96 
VHH 
96 
VHH 
 96 
VHH 
96 
VHH 
Output  A, B C D E  F G 
Neutralising 
92UG037 0/192 0/96 NT NT  NT NT 
Neutralising 
92BR025 2/192 1/96 16/96 24/96  0/96 0/96 
Neutralising 
IIIB 2/192 1/96 16/96 24/96  0/96 0/96 
Binding to 
IIIB gp120 2/192 1/96 16/96 24/96  0/96 0/96 
 
Figure 3.2.6.3.1. Schematic overview of the second set of selections and screening of VHH. 
Phage libraries expressing VHH derived from llamas immunised with CN54 envelope proteins 
were panned on immobilised gp120 followed by a competitive elution using an excess of sCD4. 
The antigen was altered in subsequent rounds of panning to possibly allow for the selection of 
VHH with cross-subtype neutralisation ability. Eluted phages were titrated onto E. coli cells and 
individual clones were isolated from selections where more phage had been eluted by sCD4 
compared to by BSA. Only the panning routes where enrichment of clones could be observed are 
shown. A total of 672 VHH were screened for ability to neutralise HIV-1 as well as for binding to 
IIIB gp120. Out of the 672 clones, 43 were able to neutralise HIV-1; these were all identical to 
VHH A12 or identical to A12 with one amino acid difference. 
 
3.3 Discussion 
In this chapter, the generation of llama antibody fragments able to inhibit HIV-1 
infection has been described. The antibody fragments, or VHH, were isolated 
from llamas immunised with recombinant envelope proteins derived from the 
HIV-1 primary isolate CN54. Phage libraries expressing the VHH repertoires 
were panned on immobilised gp120. To increase the chances of isolating 
neutralising VHH, a functional selection approach was employed, using a 
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competitive elution with sCD4, possibly allowing for the identification of VHH 
targeting the CD4bs. It can be argued that such an approach would by default 
only elute VHH with an affinity for gp120 that is lower than that of sCD4. 
However, by using a molar excess of sCD4, this problem may have been 
circumvented. 
 
The efficiency of the competitive elution was not definitely evaluated. In order to 
assess whether the competitive elution actually lead to enrichment of phage 
expressing VHH targeting the CD4bs, the proportion of anti-CD4bs VHH eluted 
by each elution method could have been determined. Alternatively, panning on 
gp120 followed by sCD4, BSA and pH elution could have been carried out using 
a mini-library of phage expressing a set of VHH with known specificities, 
including anti-CD4bs VHH as well as VHH to other regions of gp120, followed 
by evaluation of the specificities of the VHH eluted using the different methods. 
In chapter 5 it will be evaluated whether the neutralising VHH isolated using the 
selection strategy described in this chapter actually target the CD4bs of gp120.  
 
The phage libraries were panned on HIV-1 IIIB gp120 alone, subtype A gp120 
alone, or subtype C gp120 alone, as well as on the same antigens alternated in 
various combinations in two subsequent rounds of panning, always using the 
competitive elution with sCD4. Interestingly, when selecting using HIV-1 IIIB 
gp120 alone, a range of neutralising VHH that could be grouped into two 
families (the C8-like and D7-like VHH) were isolated from one llama, whereas 
when the subtype A and C envelopes were included in the panning, only one of 
the VHH in the set were selected for (VHH A12, belonging to the D7-like group 
of VHH). This result may imply that VHH A12 is more broadly reactive across 
HIV-1 subtypes compared to the other VHH selected using IIIB gp120 only, but 
further studies are needed to determine whether this is true. Such studies will be 
described in chapter 4. 
 
Further studies are also needed to determine the optimal panning protocol for 
selecting potent VHH with good cross-reactive properties. Previous studies have 
shown that panning of phage libraries expressing antibody fragments, derived 
from individuals infected with HIV-1, on a sequentially alternated antigen results 
 234
in enhanced identification of antibodies with broader neutralising ability, 
compared to panning on one single antigen (1020, 1205, 1206). In these studies, 
the phage libraries were panned on envelope proteins from different subtype B 
isolates as well as on envelope proteins in complex with sCD4. It would be 
interesting to see whether such an approach would be successful for isolating 
llama VHH. 
 
The llamas used in this study were immunised with recombinant monomeric 
gp120 or trimeric gp140. Previous studies have shown that purified trimeric 
envelope proteins are somewhat better at eliciting cross-subtype-neutralising 
antibodies than monomeric recombinant gp120 (1036-1041). It is possible that 
immunising llamas with recombinant trimeric gp140, followed by panning of the 
resulting VHH libraries on trimeric gp140 as opposed to monomeric gp120, 
would result in VHH with more potent and cross-reactive neutralisation activity. 
However, in the study described here, immunising one llama with CN54 gp140 
followed by panning of the VHH libraries on gp120 did not result in the 
identification of neutralising VHH. Furthermore, using the selection strategy 
described in this study, we could only isolate potently neutralising VHH from 
one out of three immunised llamas, despite all animals showing a significant 
antibody response, stressing that for future studies, more than one llama should 
be used for immunisation. 
 
In conclusion, in this chapter it has been shown that the non-conventional 
immune system of llamas can be used to generate antibody fragments that are 
able to inhibit HIV-1 infection of target cells. Further studies are needed to 
evaluate the extent and breadth of this inhibitory effect. Such studies will be 
described in chapter 4. 
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Chapter 4 
VHH neutralisation of HIV-1 
 
In this chapter, the ability of the selected VHH to neutralise HIV-1 will be 
evaluated. 
 
4.1 Introduction 
Since the first reports in 1985 of in vitro neutralisation of HIV-1 by sera from 
individuals with suspected AIDS (628-630), various assays have been used to 
measure antibody neutralisation of HIV-1 in vitro. These assays differ in the 
source of virus used, the target cell and the way to measure infection. Initially, 
neutralisation was assessed in human T cell lines using virus propagated in T cell 
lines. In the mid-1990s, however, it became widely accepted that the adaptation 
of HIV-1 to replicate in T cell lines increases its sensitivity to antibody-mediated 
neutralisation and affects co-receptor usage, as most T cell lines express CXCR4 
but not CCR5 (386, 1207-1211). Since then, HIV-1 neutralisation has commonly 
been measured in human PHA-stimulated PBMC, using virus produced in 
PBMC. While PBMCs offer the advantage of being natural target cells for HIV-
1, their use carries problems of assay standardisation due to, for example, donor 
variability (1212, 1213). In addition, the PBMC assay is laborious and does not 
readily allow for high-throughput analysis of HIV-1 neutralisation. To overcome 
this problem, a number of neutralisation assays using engineered cell lines has 
been developed (1147, 1149, 1151, 1214-1217). These cell lines are typically 
engineered to express the HIV-1 receptors and sometimes contain a reporter 
gene, such as the luciferase or green fluorescent protein (GFP) genes, to allow 
for easy measurement of infection. To further increase reproducibility and allow 
for standardisation, the use of cloned viruses has been introduced. Cloned 
viruses, such as replication-competent molecular clones or envelope pseudotyped 
viruses, have been suggested to offer advantages in terms of reproducibility and 
well-defined envelope sequences, useful in for example epitope mapping studies, 
over the quasispecies-natured PBMC isolates (1022, 1023, 1215, 1218, 1219). 
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Moreover, the propagation of HIV-1 in PBMC has been shown to lead to 
increased neutralisation sensitivity, at least to anti-CD4bs-targeted neutralisation 
(1200, 1203). On the other hand, virus produced in PBMC may better represent 
the in vivo situation, and cloned viruses produced in 293T cells have in some 
studies been shown to differ in terms of neutralisation properties compared to the 
PBMC isolates they were derived from (1022, 1218). As a consequence, a range 
of neutralisation assays are currently being used, using T cell lines, engineered 
cell lines or primary cells, as well as using different sources of virus, including 
cloned virus produced in 293T cells and primary isolates propagated in PBMC. 
To be able to compare results obtained in different laboratories, there is a need 
for standardisation. However, a recent global consortium working on the 
standardisation of HIV neutralisation assays has come to the conclusion that, 
since there is little information available on which in vitro assay correlates with 
in vivo protection, it is necessary to use a range of neutralisation assays when 
assessing in vitro neutralisation of HIV-1 (1220). Assessing antibody ability to 
neutralise not only cell-free virus, but also their ability to inhibit virus spread 
through cell-cell fusion, may also be of importance (1221), as may activities such 
as complement-mediated antibody-dependent enhancement or inactivation of 
infection (682, 694). 
 
In addition to the problem with which target cell line to use, and how to 
propagate or generate viruses, assessing antibody-mediated neutralisation of 
HIV-1 in vitro also involves the problem of the extreme genetic variation 
observed among HIV-1 isolates, in particular in the envelope region (discussed in 
chapter 1 of this thesis). Cloned viruses exhibiting a wide range of sensitivities to 
broadly neutralising mAbs, have been isolated from single infected individuals, 
even at single time-points (652, 1222). To deal with the extreme genetic 
variation, Mascola et al. (1219) has suggested the use of a tier 1, 2 and 3 
approach for the assessment of neutralising antibodies to HIV-1, using standard 
panels of viruses belonging to different HIV-1 subtypes and with well-
characterised and varying neutralisation sensitivities. This approach would 
involve initial testing against a tier 1 panel of viruses of different subtypes, 
shown to be sensitive to antibody-mediated neutralisation, followed by testing 
against a tier 2 panel of viruses, of the same subtype as the immunogen or 
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vaccine strain, shown to be of intermediate sensitivity to neutralisation. Tier 3 
assessment would then be accomplished by testing against virus panels of 
additional subtypes. 
 
Numerous mAbs to HIV-1 envelope have been isolated, from infected 
individuals as well as from immunised animals, and their abilities to neutralise 
HIV-1 have been characterised in a range of neutralisation assays. Many of these 
mAbs have been found to inhibit infection of neutralisation sensitive TCLA 
isolates of HIV-1, or homologous isolates post-immunisation. Only a handful 
have, however, been found to neutralise a broad range of primary HIV-1 
subtypes.  In chapter 3, a number of VHH were isolated from llamas immunised 
with recombinant HIV-1 CN54 gp120. These VHH were selected using phage 
display methods through panning on immobilised gp120 followed by a 
competitive elution using sCD4. Large numbers of VHH were screened for 
ability to neutralise HIV-1 in vitro.  Five VHH were found to neutralise HIV-1 to 
various extents, when tested at one concentration only. These VHH were selected 
for further characterisation (Table 4.1.1). In this chapter, their neutralisation 
abilities will be further assessed, to characterise the breadth and potency by 
which they neutralise HIV-1 of different subtypes. 
 
Table 4.1.1. VHH chosen for further characterisationa. 
VHH Groupb Llama Immunogen Selection 
A12 D7-like L44 CN54 gp120 IIIB, 92UG037 & 92BR025 gp120 
D7 D7-like L44 CN54 gp120 IIIB gp120 
D12 D7-like L44 CN54 gp120 IIIB gp120 
C8 C8-like L44 CN54 gp120 IIIB gp120 
F2 N/A L40 CN54 gp120 CN54 gp120 
aVHH derived from llamas immunised with recombinant CN54 gp120 were isolated using a 
functional selection approach allowing for the enrichment of VHH that compete with sCD4 for 
binding to gp120, as described in chapter 3 of this thesis. Large numbers of individual VHH were 
screened for binding to gp120 and/or in vitro neutralisation of HIV-1. A number of similar VHH 
sequences were identified and representative clones were chosen for further characterisation. 
bBased on amino acid sequence analysis; N/A, not applicable. 
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4.2 Results 
This section describes the results of this chapter. 
 
4.2.1 Generation of chimeric viruses expressing envelopes from HIV-1 of 
subtype A, C and D 
To evaluate the neutralisation breadth of the VHH, they needed to be tested 
against HIV-1 of different subtypes. HIV-1 isolates of subtype B have been 
extensively studied, and large numbers of isolates and clones are characterised 
and available. At the outset of this project, there were, however, very few non-
subtype B viruses readily available. A small panel of non-subtype B viruses was 
therefore acquired, to be used alongside a panel of commonly used subtype B 
isolates, as well as recently described chimeric viruses expressing envelopes 
cloned from plasma of individuals infected with subtype B (1162). Two chimeric 
molecular clones (HIV-1 CA6 and CB7) containing R5-tropic gp120 cloned from 
plasma of individuals infected with HIV-1 of subtype C held in the pHXB2∆env 
vector (1163), were kindly provided by M. Aasa-Chapman (UCL, London, UK). 
 
A number of non-subtype B PBMC-propagated viruses were obtained from the 
WHO panel of primary isolates, which contains viruses representative of strains 
circulating in areas chosen for vaccine trials (1197). These included two subtype 
C isolates (IN97003 and ZA97001) as well as a subtype D isolate (92UG001). 
Some of the obtained isolates proved laborious to propagate to high titre in 
PBMCs. In addition, culturing primary isolates in PBMC has been shown to 
increase sensitivity to anti-CD4bs-targeted neutralisation (1200, 1203). For 
reasons of reproducibility, chimeric molecular clones, containing envelopes 
cloned from these primary isolates, were therefore generated. This was done by 
the isolation of genomic DNA from infected PBMC, followed by the 
amplification of the envelope gene from proviral DNA in a nested PCR. To 
ensure amplification of HIV-1 of all subtypes, the outer primers were designed to 
target conserved regions of the HIV-1 genome and were shown to amplify 
sequences from HIV-1 of subtype A, B′/C, C, D and F as well as from HIV-1 of 
group O. The nested primer pair was modified from Zheng and Daniels (1164). 
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The amplified gp160 gene was cloned into a cloning vector followed by sub-
cloning into the HIV-1 NL43-based env gene cassetting system C2 (1164) to 
produce replication-competent chimeric molecular clones. Virus was produced in 
293T cells. For each virus isolate, ten different gp160/NL43 chimeric constructs 
were screened for ability to infect NP2/CD4/CXCR4 and NP2/CD4/CCR5 target 
cells. One envelope clone giving rise to infectious virus was chosen for each of 
the virus isolates. The clones derived from the ZA97001 and 92UG001 isolates 
were found to be predominantly X4-tropic, whereas the clone derived from the 
97IN003 isolate was predominantly R5-tropic, as determined by titration on NP2 
target cells (Table 4.2.1.1). The generation and characterisation of chimeric 
viruses expressing envelopes derived from the subtype A (92UG037) and 
subtype C (92BR025) isolates has already been described in section 3.2.5 of this 
thesis. 
 
To further extend the virus panel, envelope genes were also amplified from 
plasma of individuals infected with HIV-1 of subtype C. This work was carried 
out together with Willie Koh, who is a PhD student working on a related project. 
RNA was isolated from plasma and cDNA generated. Full-length gp160 was 
amplified from the cDNA and cloned into the C2 cassette as described above. 
Alternatively, gp120 was amplified and cloned into an HXB2-based backbone 
(1163). Chimeric virus was produced in 293T cells and titrated onto NP2 
indicator cells. Chimeric viruses expressing envelopes derived from five different 
individuals were included in the study. The viruses were designated 37.4.2, 
38.2.2, 27b, 27d, C222 and C261. Viruses 27b, 27d, C222 and C261 were cloned 
by Willie Koh. All viruses were found to be predominantly R5-tropic, apart from 
27d which was predominantly X4-tropic (Table 4.2.1.1). 
 
Again, attempts were made to generate a replication-competent chimeric 
molecular clone expressing an envelope derived from HIV-1 CN54. Previously, 
the same envelope clone from which the immunogen had been expressed was 
cloned into HXB2- or NL43-based backbones. This chimeric molecular clone did 
not, however, produce infectious virus, as described in section 3.2.2 of this 
thesis. This time, the CN54 envelope gene was amplified from cDNA generated 
from PBMC-propagated HIV-1 CN54 as well as from proviral DNA isolated 
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from infected PBMCs. More than twenty different clones were screened for 
ability to infect NP2 target cells, but again, no infectious virus could be 
generated. Failure to generate infectious pseudotyped virus expressing CN54 
envelope has also been noted elsewhere (Neil Sheppard, DPhil thesis, University 
of Oxford, 2006). 
 
Table 4.2.1.1. HIV-1 chimeric virus titres in NP2 cellsa. 
    
Titre on NP2 target 
cells (FFU/ml) 
Virus Sourceb Chimera Subtype R5 X4 
ZA97001.1 ccPBMC gp160/NL43 C <10 2 × 105 
97IN003.4.2 ccPBMC gp160/NL43 C 1.8 × 105 <10 
92UG001.D8 ccPBMC gp160/NL43 D <10 1.2 × 104 
37.4.2 Plasma gp160/NL43 C 4 × 103 <10 
38.2.2 Plasma gp160/NL43 C 1.4 × 105 <10 
27b Plasma gp160/NL43 C 3 × 105 <10 
27d Plasma gp160/NL43 C <100 2.5 × 106 
C222 Plasma gp120/HXB2 C 2.5 × 105 <50 
C261 Plasma gp120/HXB2 C 2 × 105 <50 
aThe envelope genes were amplified and cloned into an HIV-1 pHXB2∆env backbone (gp120) or 
the HIV-1 NL43-based env gene cassetting system C2 (gp160) to produce replication-competent 
chimeric molecular clones. Viruses 27b, 27d, C222, C261 were generated by Willie Koh. Virus 
stocks were produced in 293T cells and titrated onto NP2/CD4/CCR5 and NP2/CD4/CXCR4 
target cells. At 48 or 72 hours post infection, the cells were fixed and stained for HIV-1 p24 
protein. FFU were counted microscopically and the virus titre in each cell line was determined. 
bEnvelope genes were amplified from i) proviral DNA isolated from PBMCs infected with virus 
stocks obtained from the WHO-UNAIDS collection of primary isolates (1197), or ii) cDNA 
generated from RNA isolated from plasma obtained from individuals infected with HIV-1 of 
subtype C, as described in chapter 2 of this thesis. ccPBMC, co-cultured PBMC. 
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4.2.2 ‘Large-scale’ expression of VHH 
To be able to test the VHH against larger numbers of viruses, the VHH 
expression needed to be scaled up. Initial batches of recombinant VHH were 
produced at Ablynx. Later on, VHH A12, C8, D7 and negative control VHH 
were produced at UCL. The VHH DNA fragments were sent to UCL and re-
cloned into an expression vector, followed by expression in E. coli TG1 cells and 
subsequent purification by means of the C-terminal 6-histidine-tag. The 
purification was monitored by SDS-PAGE (Fig. 4.2.2.1 A). The induction time 
was optimised. An overnight induction was shown to give the highest yield of 
VHH (Fig. 4.2.2.1 B). 
 
A.             B. 
 
 
 
 
                  
Figure 4.2.2.1. Expression and purification of VHH. Recombinant VHH were expressed in E. 
coli TG1 cells and purified by means of the C-terminal 6-histidine-tag, as described in chapter 2. 
A. The purification was monitored by SDS-PAGE followed by Coomassie blue staining. Shown 
is a representative analysis of the purification of VHH A12. The lanes contain E. coli periplasmic 
extract from the uninduced sample, E. coli periplasmic extract from the induced sample, the 
unbound fraction, the pre-elution fraction and elutions 1-5 (E1-E5). M, molecular weight marker. 
B. Optimisation of the induction time. The induction time was varied between 2, 4 or 6 hours or 
overnight (o/n). E. coli periplasmic extracts were prepared from the different inductions and 
analysed by SDS-PAGE and Coomassie blue staining. Shown is the expression of VHH A12. 
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4.2.3 Initial characterisation of VHH neutralisation of HIV-1 in NP2 cells 
The neutralisation activities of the selected VHH were initially evaluated in a 
cell-based assay using a glioma cell line (NP2) engineered to express the HIV-1 
main receptor CD4 and either of the co-receptors CXCR4 or CCR5. This cell line 
was established by Soda et al. (1151) and has since been used to assay antibody 
neutralisation of HIV-1 (631, 682). 
 
4.2.3.1 Effect of negative control VHH on HIV-1 infection of NP2 cells and 
assay reproducibility 
To exclude any non-specific effect of camelid VHH on the infectivity of HIV-1 
in this assay format, the effect of two irrelevant VHH on HIV-1 infection of 
NP2/CD4/CXCR4 or NP2/CD4/CCR5 target cells was evaluated using 12 
different X4- or R5-tropic HIV-1 isolates. Virus was incubated with irrelevant 
VHH (at 100 µg/ml) and subsequently incubated with target cells. At 48 or 72 
hours post infection, the cells were fixed and infection detected by 
immunostaining of HIV-1 p24 protein. FFU were counted microscopically. The 
level of infection was determined as the percentage of FFUs in test wells 
compared to virus only control wells. Wells containing the irrelevant VHH were 
found to contain 96-156% FFU compared to in virus only control wells, showing 
that in this assay system, at least two irrelevant VHH do not cause any non-
specific reduction of infection (Fig. 4.2.3.1.1). 
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Figure 4.2.3.1.1. Negative control VHH effect on HIV-1 infection of NP2 cells. The effect of 
an irrelevant VHH on infection with 12 different X4- or R5-tropic HIV-1 isolates was evaluated 
in NP2 cells. Virus was incubated with the irrelevant VHH and subsequently incubated with 
NP2/CD4/CXCR4 or NP2/CD4/CCR5 indicator cells. At 48 or 72 hours post infection, the cells 
were fixed and stained for HIV-1 p24 protein. The number FFU was counted microscopically and 
the percentage of FFU compared to the result obtained for the virus only control was determined. 
Bars represent the mean and error bars the standard error of two or three independent experiments 
carried out in triplicate. 
 
The reproducibility of the neutralisation assay was demonstrated by testing VHH 
C8 against the HIV-1 92BR025.C1 molecular clone on four separate occasions 
(Fig. 4.2.3.1.2). Serial dilutions of VHH C8 were incubated with HIV-1 
92BR025.C1, in triplicate reactions, and subsequently incubated with 
NP2/CD4/CCR5 target cells for 72 hours, after which the cells were fixed and 
immunostained for HIV-1 p24 protein. FFU were counted microscopically and 
neutralisation titres were determined as the VHH concentration required to give 
90% reduction of infection (IC90) compared to a control VHH at 100 µg/ml. The 
variation between the four observed IC90 values was found to be 1.2-2.4-fold 
(Fig. 4.2.3.1.2 B). For the remaining VHH-virus isolate combinations, each VHH 
was assayed in duplicate or triplicate and on a minimum of two separate 
occasions, to ensure reproducibility. 
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A.          B. 
 
 
 
 
 
 
 
 
 
 
Figure 4.2.3.1.2. Evaluation of NP2 cell-based neutralisation assay reproducibility. HIV-1 
92BR025.C1 was incubated with serial dilutions of VHH C8 and subsequently incubated with 
NP2/CD4/CCR5 target cells for 72 hours, after which the cells were fixed and stained for HIV-1 
p24 protein. FFU were counted microscopically and neutralisation titres were determined as the 
VHH concentration required to give 90% reduction of infection (IC90) compared to a control 
VHH at 100 µg/ml. IC90 titres were calculated using the curve-fitting software XLfit 4. A. 
Percentage FFU in wells containing VHH C8 compared to in wells containing a negative control 
VHH. Data points represent the mean and bars the standard error of four independent 
experiments carried out in triplicate. B. VHH C8 IC90 titres observed in four independent runs. 
The diamonds represent values from individual runs and the short horizontal bar represents the 
mean. 
 
4.2.3.2 VHH neutralisation of the autologous virus HIV-1 CN54 
VHH A12, D7, D12, C8 and F2 were tested for ability neutralise the autologous 
virus HIV-1 CN54. Each VHH was tested in duplicate at a final concentration of 
100 µg/ml, in two independent experiments. The VHH were observed to weakly 
neutralise HIV-1 CN54 in NP2 cells, reducing infection by 29-62%, compared to 
a negative control VHH (Fig. 4.2.3.2.1). The lack of potent neutralisation of the 
autologous isolate may be due to the quasispecies nature of the HIV-1 CN54 
PBMC isolate. The CN54 gp120 clone used as an immunogen may not be 
representative of the gp120s present on the majority of the infectious viruses 
within the swarm of the CN54 PBMC isolate. 
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Figure 4.2.3.2.1. VHH ability to neutralise the autologous virus HIV-1 CN54 in NP2 cells. 
PBMC-propagated HIV-1 CN54 was incubated with VHH A12, D7, D12, C8 and F2 or an 
irrelevant VHH and subsequently incubated with NP2/CD4/CCR5 indicator cells. Each VHH was 
tested at 100 µg/ml. At 48 or 72 hours post infection, the cells were fixed and stained for HIV-1 
p24 protein. The number FFU was counted microscopically and the percentage of FFU compared 
to the result obtained for the negative control VHH was determined. Bars represent the mean and 
error bars the standard error of two independent experiments carried out in duplicate. 
 
4.2.3.3 VHH neutralisation of HIV-1 of subtype A, B, B′/C, C and D 
As an initial assessment of neutralisation breadth and potency, the selected VHH 
(Table 4.1.1) were assayed against nine HIV-1 isolates of subtypes A, B, B′/C, C 
and D. In addition to the autologous PBMC isolate, HIV-1 CN54, this small 
panel of HIV-1 isolates included the viruses from which the envelopes used in 
the panning were derived. These were HIV-1 IIIB as well as the chimeric 
molecular clones 92UG037.A9 and 92BR025.C1, the generation of which were 
described in section 3.2.5. The TCLA isolate IIIB is known to be generally 
sensitive to antibody-mediated neutralisation. 
 
Also included in the virus panel were the chimeric molecular clones 4.10.3, 8.8.8 
and 23.2.E, expressing envelopes cloned from plasma of individuals infected 
with HIV-1 of subtype B (1162). These molecular clones have been shown to 
exhibit a varying degree of sensitivity to neutralisation by human anti-HIV-1 sera 
as well as anti-envelope mAbs. Virus 4.10.3 has been found to be sensitive, virus 
8.8.8 has been found to be intermediately sensitive and virus 23.2.E has been 
found to be resistant to neutralisation by human anti-HIV-1 sera (M. Aasa-
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Chapman, et al., in preparation). In addition, they show a varying degree of 
sensitivity to neutralisation by mAb b12 and sCD4, with 8.8.8 being sensitive 
and 23.2.E being resistant to both mAb b12 and sCD4, and 4.10.3 being sensitive 
to sCD4 but not to mAb b12 (M. Aasa-Chapman, et al., in preparation). 
 
Finally, a chimeric molecular clone of subtype C was included, as was the 
chimeric subtype D virus described in section 4.2.1. The neutralisation activity of 
each VHH was assayed in triplicate and on a minimum of two separate 
occasions. The lowest VHH concentration required to achieve 90% reduction of 
infectivity (IC90) compared to a negative control VHH was determined. Human 
anti-CD4bs mAb b12 as well as sCD4 was tested in parallel. 
 
The results of this initial characterisation are summarised in Table 4.2.3.3.1. In 
summary, VHH A12, D7 and C8 were found to be more potent than VHH D12 
and F2. VHH A12 and D7 could potently neutralise three out of the four subtype 
B viruses with IC90 values in the range of 0.01-1 µg/ml, whereas C8 potently 
neutralised two out of the four subtype B viruses with an IC90 of 0.4 and 12 
µg/ml. VHH A12 and C8 also displayed some cross-subtype neutralisation 
ability, neutralising one out of the two subtype C viruses, 92BR025.C1 with IC90 
titres of 25 µg/ml. Against this small virus panel, mAb b12 and sCD4 displayed a 
similar neutralisation breadth, neutralising two and three out of the four subtype 
B viruses, respectively, as well as one of the two subtype C viruses. None of the 
VHH, nor mAb b12 or sCD4, was able to neutralise the subtype A or D virus to 
90%. VHH D12 and F2 did not neutralise any of the viruses included in this 
panel to 90% (Table 4.2.3.3.1), although weak neutralisation by up to 50% was 
observed against some isolates (data not shown). 
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Table 4.2.3.3.1. VHH, mAb b12 and sCD4 IC90 against HIV-1 in NP2 cellsa. 
IC90 in NP2 cells (µg/ml) 
Virusb T
yp
ec
 
Su
bt
yp
e 
A
12
 
D
7 
D
12
 
C
8 
F2
 
b1
2 
sC
D
4 
92UG037.A9 MC A • • • • • • • 
IIIB TCLA B 0.8 0.8 • 12 • <5 <5 
4.10.3 MC B <1 0.01 • 0.4 • •d 0.4d 
8.8.8 MC B 1 1 • • • 1.9d 20d 
23.2.E MC B • • • • • •d •d 
CN54 PBMC B′/C • • • • • • nd 
92BR025.C1 MC C 25 • • 25 • • • 
CB7 MC C • • • • • <50 50 
92UG001.D8 MC D • • • • • • • 
aVHH neutralisation activity was assessed in a cell-based neutralisation assay using a glioma cell 
line expressing CD4 and either of CXCR4 or CCR5, and immunostaining of p24 at 48 or 72 
hours post-infection, as described in the text. • indicates >50 or >100 µg/ml; nd, not determined. 
bViruses are described in section 2.4. 
cTCLA, T cell line adapted isolate; PBMC, PBMC-propagated primary isolate; MC, molecular 
clone. 
dData from M. Aasa-Chapman, et al., in preparation. 
 
Based on the above observation, VHH A12, D7 and C8 were chosen for further 
characterisation and were tested against an extended virus panel consisting of an 
additional ten viruses, which were PBMC isolates or chimeric molecular clones 
of subtype B and C. Included were commonly used subtype B strains such as 
SF162, BaL and JRFL, PBMC-propagated primary isolates of subtype C, as well 
as chimeric molecular clones expressing envelopes of subtype B and C. VHH 
A12, D7 and C8 each neutralised three out of the four subtype B viruses included 
in this extended panel to at least 90% (Table 4.2.3.3.2). Human mAb b12 as well 
as sCD4 are known to neutralise all the four subtype B viruses (873, 1022, 1145, 
1200, 1201, 1203). VHH A12, D7 and C8 as well as mAb b12 all neutralised one 
out of the six subtype C viruses included. Recombinant sCD4, on the other hand, 
could neutralise three out of the six subtype C viruses (Table 4.2.3.3.2). 
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Table 4.2.3.3.2. VHH, mAb b12 and sCD4 IC90 against HIV-1 in NP2 cellsa. 
IC90 in NP2 cells (µg/ml) 
Virusb T
yp
ec
 
Su
bt
yp
e 
A
12
 
D
7 
C
8 
b1
2 
sC
D
4 
SF162 PBMC B 12 6 50 S S 
BaL PBMC B 25 25 6 S S 
JRFL MC B • • • S S 
23.8.12 MC B <1 <1 <1 S S 
ZA97001 PBMC C • • • • • 
97IN003 PBMC C • • • • • 
37.4.2 MC C • • • • <50 
38.2.2 MC C • • • • • 
27b MC C • • • • <50 
27d MC C 1.2 1.2 <5 <5 <5 
aVHH neutralisation activity was assessed in a cell-based neutralisation assay using a glioma cell 
line expressing CD4 and either of CXCR4 or CCR5, and immunostaining of p24 at 48 or 72 
hours post-infection, as described in the text. • indicates >50 µg/ml (for mAb b12 and sCD4) or 
>100 µg/ml (for VHH); S indicates sensitive to neutralisation according to several reports (873, 
1022, 1145, 1200, 1201, 1203) and M. Aasa-Chapman et al., in preparation. 
bViruses are described in section 2.4. 
cPBMC, PBMC-propagated primary isolate; MC, molecular clone. 
 
4.2.3.4 Summary of VHH neutralisation of HIV-1 in NP2 cells 
The initial neutralisation characterisation, carried out against a panel of nine 
viruses of subtype A, B, B′/C, C and D of varying sensitivity to neutralisation by 
sCD4 and the anti-CD4bs mAb b12, revealed VHH A12, D7 and C8 as being 
more potent than VHH F2 and D12. VHH A12 could neutralise four and VHH 
D7 and C8 three out of the nine viruses to 90% or more. VHH D12 and F2, on 
the other hand, were not able to neutralise any of the nine viruses to 90% (Table 
4.2.3.3.1). VHH A12, D7 and C8 were therefore tested against an extended panel 
of ten viruses of subtype B and C. Against this panel, the three VHH showed 
similar neutralisation profiles, neutralising four out of the ten viruses to 90% or 
more (Table 4.2.3.3.2). 
 
Overall, VHH A12, D7 and C8 were tested against 19 viruses in this assay 
format. VHH A12 was able to neutralise 8 of the 19 viruses (42%), whereas D7 
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and C8 could neutralise 7 out of the 19 (37%). Against this virus panel, the 
broadly neutralising mAb b12 was of comparable breadth, also neutralising 8 out 
of the 19 viruses (42%). 
 
In summary, the results observed in the NP2 assay suggested that three of the 
selected VHH could potently neutralise HIV-1 of subtype B and C. Moreover, 
the findings suggested that VHH A12, D7 and C8 may show a breadth of 
neutralisation that is comparable to that of the broadly neutralising anti-CD4bs 
mAb b12. Therefore, it was decided to subject VHH A12, D7 and C8 to a more 
comprehensive neutralisation characterisation, to better evaluate the extent of 
their cross-subtype reactivity. 
 
4.2.4 Comprehensive characterisation of VHH neutralisation of HIV-1 in 
TZM-bl cells 
The results observed in the NP2 cell assay indicated that three of the selected 
VHH may exhibit relatively broad cross-subtype neutralisation reactivities, 
possibly comparable to that of the broadly neutralising mAb b12. As no mAbs 
with broad neutralisation activities have previously, to our knowledge, been 
isolated from immunised animals, this encouraged us to test the VHH against a 
larger panel of viruses, preferably against viruses whose neutralisation 
susceptibilities had already been well-characterised. At this point of time in the 
study, the use of standard panels of viruses for tier 1, 2 and 3 assessment of 
neutralising antibody responses elicited by candidate HIV-1 vaccines, had been 
recommended by Moore and Burton (1215) and Mascola et al. (1219), and 
standard virus panels of envelope pseudotyped viruses for assessment of 
neutralising antibodies had been generated (1022, 1023, 1219, 1223). The tier 1, 
2 and 3 classification is based on the sensitivity of the envelope pseudotyped 
viruses to neutralisation by sCD4, the broadly neutralising mAbs b12, 2G12, 2F5 
and 4E10 as well as a set of human individual and pooled plasma samples (1022, 
1023, 1223). Some of these envelope panels had been made available through the 
NIH AIDS Research and Reference Reagent Program, as well as from the 
pseudovirus repository of the CAVD Vaccine Immune Monitoring Centre, led by 
D. Montefiori (Duke University Medical Centre, Durham, USA). To further 
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evaluate the neutralisation breadth and potencies of the VHH, we decided to 
include some of these reference virus panels in this study. 
 
The NP2 cell assay, especially the microscopical counting of FFUs, is, however, 
rather laborious and testing the VHH against large panels of viruses would 
therefore be very time-consuming. To enable a more high-throughput 
neutralisation characterisation, a neutralisation assay with a luciferase read-out 
was used. This neutralisation assay utilises TZM-bl cells, which are HeLa cells 
expressing endogenous CXCR4 and engineered to express CD4 and CCR5 and 
to contain a Tat-induced, LTR-driven firefly luciferase reporter gene. The assay 
was developed by the group of G. Shaw (1147-1149) and validated by the group 
of D. Montefiori (1022, 1214). It measures neutralisation as a reduction of Tat-
induced luciferase expression. 
 
VHH neutralisation potencies were assayed against HIV-1 of subtypes A, B, C, 
D, CRF07_BC and CRF02_AG using either PBMC-propagated primary isolates, 
TCLA isolates, or recombinant replication-competent chimeric viruses as well as 
envelope pseudotyped viruses. Included was the panel of 19 viruses against 
which the VHH had been tested in the NP2 cell assay format, as well as the 
additional chimeric molecular clones expressing envelopes cloned from plasma 
of infected individuals or PBMC isolates, which were described in section 4.2.1 
of this thesis. Included were also the subtype B, C and CRF07_BC reference 
panels of envelope pseudotyped viruses and part of the CRF02_AG panel, as 
well as one tier 1 and an additional tier 2 virus of subtype C. For references and 
accession numbers, see section 2.4. 
 
Virus was incubated with serial dilutions of VHH for 1 hour and subsequently 
incubated with TZM-bl cells. At 48 hours post infection, cells were lysed by the 
addition of a combined cell lysis and luciferase substrate reagent. Luminescence 
was measured and background luminescence subtracted. The percentage of RLU 
in test wells, compared to in virus only control wells, was then determined. The 
lowest VHH concentration required to achieve 50% and 90% reduction of 
infectivity (IC50 and IC90) compared to a virus control was calculated using the 
XLfit 4 software. To ensure reproducible results, the neutralisation activity of 
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each VHH was assayed in duplicate and on a minimum of two separate occasions 
(apart from the HIV-1 subtype CRF07_BC pseudovirus panel, which was tested 
once). Anti-CD4bs mAb b12 was tested in parallel. Against each virus included 
in the study, a negative control VHH (VHH #3; at 50 µg/ml) was included in at 
least two wells, in at least one of the experiments. 
 
The selected VHH were also tested against a pseudotyped virus expressing an 
irrelevant envelope (rabies virus G protein CVS-11; kindly provided by E. 
Wright, UCL, London, UK), to exclude non-specific virus inactivation. No dose-
dependent, non-specific virus inactivation was observed (data not shown). 
 
4.2.4.1 VHH neutralisation of the autologous virus 
The VHH were first tested for ability to neutralise the autologous virus, HIV-1 
CN54. VHH A12, D7 and C8 at 50 µg/ml were found to neutralise HIV-1 CN54 
to 97, 88 and 87%, respectively (Fig. 4.2.4.1.1). This result represents more 
potent neutralisation compared to the results obtained in the NP2 cell assay, 
where VHH A12, D7 and C8 at 200 µg/ml could only neutralise HIV-1 CN54 to 
62, 36 and 52%, respectively (Fig. 4.2.3.2.1). It is possible that the NP2 assay is 
more stringent than the TZM-bl assay. Discrepancies between results obtained in 
different neutralisation assays may be expected, taken the different target cells, 
differences in virus inputs and incubation times, as well as the use of the 
polycation DEAE-dextran to enhance the level of infection in some cell lines, 
including the TZM-bl cells. Differences between assays have been previously 
observed, for example in a global collaboration working on the standardisation of 
HIV-1 neutralisation assays (1220). 
 
VHH IC50 and IC90 titres against HIV-1 CN54 in TZM-bl cells are shown in 
Tables 4.2.4.4.1 and 4.2.4.4.2. Against CN54 virus, VHH A12 was found to be 
slightly more potent than VHH D7 and C8. Anti-CD4bs mAb b12 could not 
reduce the infection of HIV-1 CN54 (Fig. 4.2.4.1.1). 
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Figure 4.2.4.1.1. VHH and mAb b12 neutralisation of the autologous virus HIV-1 CN54 in 
TZM-bl cells. PBMC-propagated HIV-1 CN54 was pre-incubated with serial dilutions of VHH 
A12, D7, C8 and #3 (irrelevant negative control VHH) as well as mAb b12 and subsequently 
incubated with TZM-bl indicator cells. At 48 hours post infection, cell lysis and luciferase 
substrate reagent was added to the cells and luminescence detected. The percentage of RLU in 
test wells compared to in virus only control wells (after subtraction of background luminescence) 
was determined and plotted against VHH or mAb b12 concentration. Data points represent the 
mean and error bars the standard error of three independent experiments carried out in duplicate. 
 
4.2.4.2 VHH neutralisation of HIV-1 of subtype B 
The VHH and mAb b12 was assayed for ability to neutralise 22 HIV-1 viruses of 
subtype B. VHH IC50 and IC90 titres were determined. The results are shown in 
Fig. 4.2.4.2.1 and summarised in Tables 4.2.4.2.1 and 4.2.4.2.2. 
 
In summary, VHH A12 showed the most potent and broad neutralisation 
reactivity of the VHH against the subtype B viruses included in this study. It 
neutralised 13 out of the 22 HIV-1 subtype B viruses, with IC50 values in the 
range of <0.003-27 µg/ml (Table 4.2.4.2.1). It was less potent on IC90 level, 
neutralising 8 out of 22 subtype B viruses with IC90 titres in the range of 0.005-
27 µg/ml (Table 4.2.4.2.2). VHH D7 and C8 were slightly less reactive against 
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this panel, neutralising 10 and 9 out of the 22 viruses to 50%, respectively. Anti-
CD4bs mAb b12 was found to be more broadly reactive against this panel, 
neutralising 17 out of the 22 viruses with IC50 titres in the range of 0.02-32 
µg/ml. 
 
Interestingly, the VHH and mAb b12 showed a different pattern of neutralisation, 
indicating that they recognise different epitopes. For example, the R5-tropic 
chimeric molecular clone 4.10.3 was shown to be very sensitive to neutralisation 
by the VHH, above all to VHH A12, which neutralised 4.10.3 with an IC90 of 
0.005 µg/ml, whilst at the same time being completely resistant to neutralisation 
by mAb b12. This differential neutralisation pattern will be further discussed in 
section 4.3.4. A summary of the proportion of viruses neutralised by the VHH 
and mAb b12 will be given in section 4.2.4.7. 
 
All of the VHH were able to neutralise the neutralisation sensitive TCLA isolates 
IIIB and MN, although A12 and D7 was found to be more potent than C8, 
especially against HIV-1 MN, which A12 neutralised with an IC50 of 0.004 
µg/ml (Fig. 4.2.4.2.1 and Table 4.2.4.2.1). For HIV-1 IIIB, two different results 
were obtained for two different stocks of T cell line-propagated virus, with up to 
a 10-fold difference in observed IC90 titre. This difference may be due to the fact 
that these stocks may originate from stocks propagated in different T cell lines 
and for a different number of passages. 
 
Against the envelope pseudotyped subtype B reference panel of viruses, mAb 
b12 was clearly more broadly reactive than the VHH, neutralising eight and six 
out of the twelve clones at IC50 and IC90 level, respectively. VHH A12, on the 
other hand, could neutralise five out of the twelve on IC50 level and only one 
virus on IC90 level (Fig. 4.2.4.2.1 and Tables 4.2.4.2.1 and 4.2.4.2.2). 
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Figure 4.2.4.2.1 (continued on next page). VHH and mAb b12 neutralisation of HIV-1 of 
subtype B in TZM-bl cells. 
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Figure 4.2.4.2.1 (continued from previous page and on next page). VHH and mAb b12 
neutralisation of HIV-1 of subtype B in TZM-bl cells. 
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Figure 4.2.4.2.1 (continued from previous page and on next page). VHH and mAb b12 
neutralisation of HIV-1 of subtype B in TZM-bl cells. 
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Figure 4.2.4.2.1 (continued from 
previous page) VHH and mAb b12 
neutralisation of HIV-1 of subtype B in 
TZM-bl cells. The experimental 
procedure is described in the text. The 
percentage of RLU in test wells compared 
to in virus only control wells (after 
subtraction of background luminescence) 
was determined. Data points represent the 
mean and error bars the standard error of 
two or three independent experiments 
carried out in duplicate. 
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Table 4.2.4.2.1. VHH and mAb b12 IC50 titres against HIV-1 subtype Ba. 
IC50 in TZM-bl cells (µg/ml) 
Virusb T
yp
ec
 
Su
bt
yp
e 
T
ie
rd
 
A12 D7 C8 b12 
IIIB stock A TCLA B 1 0.01 0.03 0.3 0.04 
IIIB stock B TCLA B 1 0.07 0.1 0.8 0.07 
MN TCLA B 1 0.004 0.06 1 0.02 
SF162 PBMC B 1 1.3 2.3 • 0.4 
BaL PBMC B nd 3.6 8.1 3.9 0.4 
JRFL MC B nd • • • <1.9 
YU2 MC B nd 34 • • 8.6 
23.8.12 MC B nd 0.02 0.03 0.1 0.1 
4.10.3 MC B nd <0.003 <0.003 0.07 • 
8.8.8 MC B nd 0.003 0.1 • 0.03 
23.2.E MC B nd • • • 7.4 
6535.3 PV B 2 0.1 0.2 28 2.5 
QH0692.42 PV B 2 13 17 21 0.7 
SC422661.8 PV B 2 • • • <1.9 
PVO.4 PV B 2 • • • • 
TRO.11 PV B 2 • • • • 
AC10.0.29 PV B 2 • • • 2.2 
RHPA4259.7 PV B 2 • • • <1.9 
THRO4156.18 PV B 2 6.2 7.2 18 0.5 
REJO4541.67 PV B 2 27 • 32 32 
TRJO4551.58 PV B 2 16 • • • 
WITO4160.33 PV B 2 • • • 11 
CAAN5342.A2 PV B 2 • • • • 
aVHH and mAb b12 neutralisation activity was assessed in TZM-bl cells, as described in the text, 
• indicates >50 µg/ml. To aid comprehension, the titres have been colour-coded so that the darker 
the colour, the more potent the neutralisation. Where b12 has not been titrated below 1.9 µg/ml, 
the IC50 is colour-coded as being 0.1-1 rather than 1-10 µg/ml. 
bViruses are described in section 2.4. 
cTCLA, T cell line adapted isolate; PBMC, PBMC-propagated primary isolate; MC, molecular 
clone; PV, envelope pseudotyped virus. 
dClassified as suitable for tier 1, 2 or 3 assessment of neutralising antibodies (1219); nd, not 
determined. 
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Table 4.2.4.2.2. VHH and mAb b12 IC90 titres against HIV-1 subtype Ba. 
IC90 in TZM-bl cells (µg/ml) 
Virusb T
yp
ec
 
Su
bt
yp
e 
T
ie
rd
 
A12 D7 C8 b12 
IIIB stock A TCLA B 1 0.2 0.3 2.8 0.3 
IIIB stock B TCLA B 1 1.7 3.3 11 0.5 
MN TCLA B 1 0.03 0.4 11 0.1 
SF162 PBMC B 1 7.8 9.3 • 1.2 
BaL PBMC B nd 27 • 20 1.4 
JRFL MC B nd • • • 5 
YU2 MC B nd • • • 28 
23.8.12 MC B nd 0.1 0.3 0.6 1.4 
4.10.3 MC B nd 0.005 0.01 0.8 • 
8.8.8 MC B nd 0.05 0.6 • 0.2 
23.2.E MC B nd • • • • 
6535.3  PV B 2 0.7 1 • 21 
QH0692.42  PV B 2 • • • 3 
SC422661.8  PV B 2 • • • 3.5 
PVO.4  PV B 2 • • • • 
TRO.11  PV B 2 • • • • 
AC10.0.29  PV B 2 • • • 16 
RHPA4259.7  PV B 2 • • • <1.9 
THRO4156.18  PV B 2 • • • 5 
REJO4541.67  PV B 2 • • • • 
TRJO4551.58  PV B 2 • • • • 
WITO4160.33  PV B 2 • • • • 
CAAN5342.A2  PV B 2 • • • • 
aVHH and mAb b12 neutralisation activity was assessed in TZM-bl cells, as described in the text, 
• indicates >50 µg/ml. To aid comprehension, the titres have been colour-coded so that the darker 
the colour, the more potent the neutralisation. Where b12 has not been titrated below 1.9 µg/ml, 
the IC90 is colour-coded as being 0.1-1 rather than 1-10 µg/ml. 
bViruses are described in section 2.4. 
cTCLA, T cell line adapted isolate; PBMC, PBMC-propagated primary isolate; MC, molecular 
clone; PV, envelope pseudotyped virus. 
dClassified as suitable for tier 1, 2 or 3 assessment of neutralising antibodies (1219); nd, not 
determined. 
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4.2.4.3 VHH neutralisation of HIV-1 of subtype C 
The VHH and mAb b12 were then tested against 27 HIV-1 of subtype C. Again, 
IC50 and IC90 titres were determined. Results are shown in Fig. 4.2.4.3.1 and in 
Tables 4.2.4.3.1 and 4.2.4.3.2. 
 
In summary, A12 showed the most potent neutralising activity of the VHH, being 
able to neutralise 13 out of the 27 viruses with IC50 values in the range of 
<0.003-38 µg/ml, again being less potent at the IC90 level, neutralising 6 out of 
the 27 viruses with IC90 titres of 0.04-50 µg/ml (Fig. 4.2.4.3.1 and Tables 
4.2.4.3.1 and 4.2.4.3.2). VHH C8 was as broadly reactive as VHH A12 against 
these subtype C viruses, also neutralising 13 out of the 27 viruses to 50%, but 
generally with higher IC50 titres. Interestingly, VHH C8 neutralised a different 
pattern of viruses compared to VHH A12, indicating that they recognise different 
epitopes. VHH D7 was less reactive against these subtype C viruses, neutralising 
9 out of the 27 viruses with IC50 titres in the range of 0.004-34 µg/ml. 
 
Anti-CD4bs mAb b12 could neutralise 15 out of the 27 viruses, again a partially 
different set of viruses compared to the VHH. For example, VHH A12 showed 
strong neutralisation of the R5-tropic chimeric virus C261, which expresses an 
envelope cloned from plasma of an infected individual, with an IC50 of <0.003 
µg/ml. In contrast, b12 was not able to reduce infection of this virus. The 
opposite was observed for several viruses such as, for example, the tier 1-
classified pseudovirus 93MW965.26, which was neutralised by mAb b12 but not 
by VHH A12. Moreover, mAb b12 was more reactive than the VHH against the 
subtype C tier 2-classified envelope pseudotyped viruses included in the study, 
neutralising 6 out of the 13 viruses on IC90 level, compared to 0 out of 13 for 
VHH A12. Interestingly, viruses 27b and 27d, showed different sensitivities to 
neutralisation, despite their envelopes being cloned from a single plasma sample 
from the same individual, something which has been observed previously (652). 
 
The observed IC90 titres were typically around 10-fold higher than the 
corresponding IC50 titres, an observation that has been made previously (1017). 
On a few occasions, however, this was not the case. Instead, the neutralisation 
 261
curve was found to plateau on a level of >10% of residual infection. This was the 
case for, for instance, mAb b12 against 93MW965.26 and VHH A12 against 
ZM109F.PB4 and 96ZM651.02 (Fig. 4.2.4.3.1). The IC50 titre of mAb b12 
against 93MW965.26 was as low as 0.02 µg/ml. Still, 90% reduction of infection 
was not observed at the highest concentration tested (50 µg/ml). Instead, the 
residual infection (as measured by percentage RLU compared to virus only 
control) levelled out at approximately 20% (Fig. 4.2.4.3.1). This observation was 
reproducible in three independent experiments. A similar observation was made 
for VHH A12 against ZM109F.PB4 and 96ZM651.02, where 90% neutralisation 
could not be observed, despite IC50 titres at 0.8 and 0.1 µg/ml, respectively (Fig. 
4.2.4.3.1 and Table 4.2.4.3.1). The reason for this observation is not known. 
When using PBMC isolates, neutralisation that levels out at levels below 90% 
have previously been observed and is thought to be due to the quasispecies 
nature of PBMC isolates, which may contain populations of virus which are 
more resistant to neutralisation (1224, 1225). This could, however, not be the 
explanation for the plateaus observed here, as they were seen using cloned 
envelope pseudotyped viruses. 
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Figure 4.2.4.3.1 (continued on next page). VHH and mAb b12 neutralisation of HIV-1 of 
subtype C in TZM-bl cells. 
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Figure 4.2.4.3.1 (continued from previous page and on next page). VHH and mAb b12 
neutralisation of HIV-1 of subtype C in TZM-bl cells. 
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Figure 4.2.4.3.1 (continued from previous page and on next page). VHH and mAb b12 
neutralisation of HIV-1 of subtype C in TZM-bl cells. 
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Figure 4.2.4.3.1 (continued from previous page and on next page). VHH and mAb b12 
neutralisation of HIV-1 of subtype C in TZM-bl cells. 
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Figure 4.2.4.3.1 (continued from previous page). VHH and mAb b12 neutralisation of HIV-
1 of subtype C in TZM-bl cells. Virus was incubated with serial dilutions of VHH A12, D7 and 
C8 and mAb b12 and subsequently incubated with TZM-bl cells. After 48 hours, cell lysis and 
luciferase substrate reagent was added to the cells and luminescence detected. The percentage of 
RLU in test wells compared to in virus only control wells (after subtraction of background 
luminescence) was determined. Data points represent the mean and error bars the standard error 
of two or three independent experiments carried out in duplicate. For each virus, a negative 
control VHH at 50 µg/ml was included in at least one of the runs in at least two wells. 
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Table 4.2.4.3.1. VHH and mAb b12 IC50 titres against HIV-1 subtype Ca. 
IC50 in TZM-bl cells (µg/ml) 
Virusb T
yp
ec
 
Su
bt
yp
e 
T
ie
rd
 
A12 D7 C8 b12 
97IN003 PBMC C nd • • • • 
ZA97001 PBMC C nd • • • • 
92BR025.C1 MC C nd 0.2 • 2 • 
CA6 MC C nd • • • <1.9 
CB7 MC C nd 0.7 4 36 0.17 
37.4.2 MC C nd • • • 36 
38.2.2 MC C nd 5.4 22 33 • 
27b MC C nd 38 • • 13 
27d MC C nd 0.02 0.03 0.7 0.02 
C222 MC C nd 0.03 49 3 • 
C261 MC C nd <0.003 0.004 32 • 
97IN003.4.2 MC C nd • • • • 
ZA97001.1 MC C nd 0.05 0.05 1.1 0.02 
93MW965.26 PV C 1 • • 0.3 0.02 
96ZM651.02 PV C 2 0.1 • 4.3 • 
Du156.12 PV C 2 • • • <1.9 
Du172.17 PV C 2 • • • <1.9 
Du422.1 PV C 2 • • • <1.9 
ZM197M.PB7 PV C 2 6 22 24 7.4 
ZM214M.PL15 PV C 2 • • • <1.9 
ZM233M.PB6 PV C 2 7 34 38 • 
ZM249M.PL1 PV C 2 • • • 5.6 
ZM53M.PB12 PV C 2 • • • • 
ZM109F.PB4 PV C 2 0.8 6.6 38 • 
ZM135M.PL10a PV C 2 • • • • 
CAP45.2.00.G3 PV C 2 • • • <1.9 
CAP210.2.00.E8 PV C 2 1.2 • 11 6.7 
aVHH and mAb b12 neutralisation activity was assessed in TZM-bl cells, as described in the text, 
• indicates >50 µg/ml. To aid comprehension, the titres have been colour-coded so that the darker 
the colour, the more potent the neutralisation. 
bViruses are described in section 2.4. 
cTCLA, T cell line adapted virus; PBMC, PBMC-propagated primary isolate; MC, molecular 
clone; PV, envelope pseudotyped virus. 
dClassified as suitable for tier 1, 2 or 3 assessment of neutralising antibodies (1219); nd, not 
determined. 
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Table 4.2.4.3.2. VHH and mAb b12 IC90 titres against HIV-1 subtype Ca. 
IC90 in TZM-bl cells (µg/ml) 
Virusb T
yp
ec
 
Su
bt
yp
e 
T
ie
rd
 
A12 D7 C8 b12 
97IN003 PBMC C nd • • • • 
ZA97001 PBMC C nd • • • • 
92BR025.C1 MC C nd 2.3 • 13 • 
CA6 MC C nd • • • 17 
CB7 MC C nd 50 • • 3.4 
37.4.2 MC C nd • • • • 
38.2.2 MC C nd • • • • 
27b MC C nd • • • • 
27d MC C nd 0.2 0.2 3.4 0.2 
C222 MC C nd 0.2 • 13 • 
C261 MC C nd 0.04 0.1 • • 
ZA97001.1 MC C nd 0.6 1 5.5 0.2 
97IN003.4.2 MC C nd • • • • 
93MW965.26 PV C 1 • • 2.4 • 
96ZM651.02 PV C 2 • • • • 
Du156.12 PV C 2 • • • 4.5 
Du172.17 PV C 2 • • • 3.2 
Du422.1 PV C 2 • • • <1.9 
ZM197M.PB7 PV C 2 • • • • 
ZM214M.PL15 PV C 2 • • • 31 
ZM233M.PB6 PV C 2 • • • • 
ZM249M.PL1 PV C 2 • • • 35 
ZM53M.PB12 PV C 2 • • • • 
ZM109F.PB4 PV C 2 • • • • 
ZM135M.PL10a PV C 2 • • • • 
CAP45.2.00.G3 PV C 2 • • • 5.3 
CAP210.2.00.E8 PV C 2 • • • • 
aVHH and mAb b12 neutralisation activity was assessed in TZM-bl cells, as described in the text, 
• indicates >50 µg/ml. To aid comprehension, the titres have been colour-coded so that the darker 
the colour, the more potent the neutralisation. 
bViruses are described in section 2.4. 
cTCLA, T cell line adapted virus; PBMC, PBMC-propagated primary isolate; MC, molecular 
clone; PV, envelope pseudotyped virus. 
dClassified as suitable for tier 1, 2 or 3 assessment of neutralising antibodies (1219); nd, not 
determined. 
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4.2.4.4 VHH neutralisation of HIV-1 of subtype B′/C 
The selected VHH were derived from llamas immunised with gp120 from HIV-1 
CN54. Furthermore, they had been shown to neutralise the autologous CN54 
isolate (Fig. 4.2.4.1.1). HIV-1 CN54 is a CRF07_BC recombinant which is 
mainly subtype C in envelope, apart from the very N-terminus of gp120. Because 
of this notion, it would be interesting to test whether the VHH would be reactive 
against other CRF07_BC viruses. A panel of CRF07_BC tier 2-classified 
envelopes to be used for pseudovirus production was therefore obtained from the 
pseudovirus repository of the CAVD Vaccine Immune Monitoring Centre and 
pseudoviruses were produced. The VHH were tested for ability to neutralise 
these viruses in TZM-bl cells. VHH and mAb b12 IC50 and IC90 titres were 
determined. Results are shown in Fig. 4.2.4.4.1 and Tables 4.2.4.4.1 and 
4.2.4.4.2. 
 
Apart from the autologous virus, the VHH were not able to neutralise any of the 
twelve CRF07_BC viruses tested (IC50 level). In contrast, mAb b12 was able to 
neutralise three out of the twelve viruses on an IC50 level, and two viruses on 
IC90 level, but did not reduce infection of HIV-1 CN54. 
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Figure 4.2.4.4.1 (continued on next page). VHH and mAb b12 neutralisation of HIV-1 of 
HIV-1 of subtype B′/C (CRF07_BC) in TZM-bl cells. 
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Figure 4.2.4.4.1 (continued from 
previous page). VHH and mAb b12 
neutralisation of HIV-1 of subtype B′/C 
(CRF07_BC) in TZM-bl cells. The 
experimental procedure is described in the 
text. Data points represent the mean of 
one single experiment carried out in 
duplicate. 
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Table 4.2.4.4.1. VHH and mAb b12 IC50 titres against HIV-1 subtype B´/Ca. 
IC50 in TZM-bl cells (µg/ml) 
Virusb T
yp
ec
 
Su
bt
yp
e 
T
ie
rd
 
A12 D7 C8 b12 
CN54 PBMC B'/C nd 1.4 5.1 9.9 • 
CH181.12 PV B'/C 2 • • • <1.9 
CH064.20 PV B'/C 2 • • • • 
CH091.9 PV B'/C 2 • • • • 
CH117.4 PV B'/C 2 • • • • 
CH119.10 PV B'/C 2 • • • • 
CH110.2 PV B'/C 2 • • • • 
CH114.8 PV B'/C 2 • • • • 
CH120.6 PV B'/C 2 • • • • 
CH115.12 PV B'/C 2 • • • 36 
CH070.1 PV B'/C 2 • • • • 
CH038.12 PV B'/C 2 • • • <1.9 
aVHH and mAb b12 neutralisation activity was assessed in TZM-bl cells, as described in the text, 
• indicates >50 µg/ml. To aid comprehension, the titres have been colour-coded so that the darker 
the colour, the more potent the neutralisation. Where b12 has not been titrated below 1.9 µg/ml, 
the IC90 is colour-coded as being 0.1-1 rather than 1-10 µg/ml. 
bViruses are described in section 2.4. 
cTCLA, T cell line adapted isolate; PBMC, PBMC-propagated primary isolate; MC, molecular 
clone; PV, envelope pseudotyped virus. 
dClassified as suitable for tier 1, 2 or 3 assessment of neutralising antibodies (1219); nd, not 
determined. 
 
 273
Table 4.2.4.4.2. VHH and mAb b12 IC90 titres against HIV-1 subtype B´/Ca. 
IC90 in TZM-bl cells (µg/ml) 
Virusb T
yp
ec
 
Su
bt
yp
e 
T
ie
rd
 
A12 D7 C8 b12 
CN54 PBMC B'/C nd 18 • • • 
CH181.12 PV B'/C 2 • • • 13 
CH064.20 PV B'/C 2 • • • • 
CH091.9 PV B'/C 2 • • • • 
CH117.4 PV B'/C 2 • • • • 
CH119.10 PV B'/C 2 • • • • 
CH110.2 PV B'/C 2 • • • • 
CH114.8 PV B'/C 2 • • • • 
CH120.6 PV B'/C 2 • • • • 
CH115.12 PV B'/C 2 • • • • 
CH070.1 PV B'/C 2 • • • • 
CH038.12 PV B'/C 2 • • • <1.9 
aVHH and mAb b12 neutralisation activity was assessed in TZM-bl cells, as described in the text, 
• indicates >50 µg/ml. To aid comprehension, the titres have been colour-coded so that the darker 
the colour, the more potent the neutralisation. Where b12 has not been titrated below 1.9 µg/ml, 
the IC90 is colour-coded as being 0.1-1 rather than 1-10 µg/ml. 
bViruses are described in section 2.4. 
cTCLA, T cell line adapted isolate; PBMC, PBMC-propagated primary isolate; MC, molecular 
clone; PV, envelope pseudotyped virus. 
dClassified as suitable for tier 1, 2 or 3 assessment of neutralising antibodies (1219); nd, not 
determined. 
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4.2.4.5 VHH neutralisation of HIV-1 of subtype A, A/G and D 
In the above sections, the selected VHH had been shown to potently neutralise a 
number of HIV-1 isolates of subtypes B and C. To elucidate whether the VHH 
would have any effect on infection of TZM-bl cells with HIV-1 from isolates 
outside subtype B or C, they were tested against a total of four HIV-1 isolates of 
subtype A and D, as well as CRF02_AG. The results are summarised in Fig. 
4.2.4.5.1 and Table 4.2.4.5.1. 
 
In summary, none of the VHH, nor mAb b12, were able to reduce infection of 
the subtype A, D or CRF02_AG viruses. Taken the small size of this panel, it is 
still possible the VHH would exhibit some subtype A, D, or CRF02_AG 
neutralisation reactivity. At least, this is true for mAb b12. In one study, mAb 
b12 was shown to neutralise eight out of eleven subtype D viruses to IC50 level 
(1017). It does, however, seem like mAb b12 has limited reactivity against 
subtype A viruses. In the same study, mAb b12 neutralised four out of twelve 
subtype A viruses to IC50 level (1017). In another study, mAb b12 was only able 
to neutralise one out of twelve subtype A pseudoviruses to IC50 level (1223). In 
the latter report, the viruses were also relatively resistant to neutralisation by 
sCD4 and the authors speculate whether this may be related to the observed 
relatively high affinity of subtype A envelopes for CD4 (1223). 
 
Worth noting is that the subtype A virus included in this study, 92UG037.A9, is 
a chimeric virus expressing the same envelope that was used in the second set of 
phage display panning, leading to the selection of VHH A12 as described in 
section 3.2.6. It is interesting that even though VHH A12 was selected upon 
panning on recombinant 92UG037.A9 gp120, A12 was not able to neutralise the 
corresponding virus, expressing the exact same gp120. In addition, 92UG037.A9 
was slightly enhanced, not neutralised, by sCD4, despite good binding of sCD4 
to the recombinant 92UG037.A9 gp120, as shown and discussed in chapter 3. In 
chapter 5, it will be evaluated whether A12 actually binds to 92UG037.A9 
gp120. The lack of correlation between binding and neutralisation will be further 
discussed in the final discussion of this thesis. 
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Figure 4.2.4.5.1. VHH and mAb b12 neutralisation of HIV-1 of subtype A, A/G 
(CRF02_AG) and D in TZM-bl cells. The experimental procedure is described in the text. For 
viruses T257-2 and T33-7 (subtype A/G), data points represent the mean of duplicate reactions in 
one single experiment. For viruses 92UG037.A9 (subtype A) and 92UG001.D8 (subtype D) data 
points represent the mean and bars the standard error of two independent experiments carried out 
in duplicate. For each virus, a negative control VHH at 50 µg/ml was included in at least one of 
the runs in at least two wells. 
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Table 4.2.4.5.1. VHH and b12 IC50 against HIV-1 subtype A, A/G and Da. 
IC50 in TZM-bl cells (µg/ml) 
Virusb T
yp
ec
 
Su
bt
yp
e 
T
ie
rd
 
A12 D7 C8 b12 
92UG037.A9 MC A nd • • • • 
T257-31 PV A/G 2 • • • • 
T33-7 PV A/G 2 • • • • 
92UG001.D8 MC D nd • • • • 
aVHH and mAb b12 neutralisation activity was assessed in TZM-bl cells, as described in the text, 
• indicates >50 µg/ml. 
bViruses are described in section 2.4. 
cTCLA, T cell line adapted isolate; PBMC, PBMC-propagated primary isolate; MC, molecular 
clone; PV, envelope pseudotyped virus. 
dClassified as suitable for tier 1, 2 or 3 assessment of neutralising antibodies (1219); nd, not 
determined. 
 
4.2.4.6 Test of VHH neutralisation of HIV-1 in an independent lab against 
a standard panel of viruses 
As part of the Collaboration for AIDS Vaccine Discovery (CAVD), the VHH 
were sent to Michael Seaman, Harvard Medical School, Boston, USA, to be 
tested against some of the CAVD Vaccine Immune Monitoring Centre tier 1 and 
tier 2 pseudoviruses. The VHH were tested against one tier 1 subtype A envelope 
pseudotyped virus (DJ263), two tier 1 subtype B viruses (SF162.LS and BaL.26), 
one tier 1 subtype C virus (93MW965.26), as well as one tier 2 subtype B virus 
(SC422661.8). The results obtained by the CAVD Vaccine Immune Monitoring 
Centre are shown in Table 4.2.4.6.1. 
 
According to the results obtained at the CAVD Vaccine Immune Monitoring 
Centre, VHH A12 and D7 neutralised SF162.LS and BaL.26 with IC50 titres of 
<0.02-0.21 µg/ml, whereas VHH C8 could neutralise BaL.26 but not SF162.LS. 
These results are in concordance with results obtained at UCL, where VHH A12 
and D7 were able to neutralise uncloned PBMC-propagated SF162 and BaL, 
while VHH C8 was found to neutralise BaL only (Table 4.2.4.2.1). 
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Table 4.2.4.6.1. VHH IC50 titres in TZM-bl cells in an independent laba. 
 IC50 in TZM-bl cells (µg/ml) 
Virusb T
yp
ec
 
Su
bt
yp
e 
T
ie
rd
 
A12 D7 C8 #3 (-) 
SF162.LS PV B 1 <0.02 0.03 • • 
BaL.26 PV B 1 0.08 0.11 0.12 • 
DJ263 PV A 1 <0.02 0.09 0.32 • 
93MW965.26 PV C 1 • • 0.2 • 
SC422661.8 PV B 2 • • 25.1 • 
aVHH neutralisation activity was assessed in TZM-bl cells in the lab of Michael Seaman 
(Harvard Medical School, Boston, USA) at the CAVD Vaccine Immune Monitoring Centre. 
VHH were tested in duplicate in one experiment; • indicates >50 µg/ml. VHH #3 is an irrelevant 
VHH. The titres are colour-coded to aid comprehensibility: the darker the colour, the more potent 
the neutralisation. 
bViruses are part of the CAVD Vaccine Immune Monitoring Centre standard panel of 
pseudoviruses. 
cPV, envelope pseudotyped virus. 
dClassified as suitable for tier 1 or 2 assessment of neutralising antibodies (1219). 
 
VHH A12 and D7 neutralised the SF162 and BaL viruses more potently at the 
CAVD Vaccine Immune Monitoring Centre, compared to when tested against 
SF162 and BaL at UCL. The IC50 titres observed at UCL were 30 to 120-fold 
higher than the IC50 titres obtained by the CAVD Vaccine Immune Monitoring 
Centre (Tables 4.2.4.2.1 and 4.2.4.6.1). Such differences in IC50 titres may be 
due to the different sources of virus. PBMC isolates have previously been 
observed to be more neutralisation resistant compared to envelope pseudotyped 
viruses (1022). In contrast to a molecularly cloned envelope pseudotyped virus, 
an uncloned PBMC isolate represents a quasispecies which may contain viruses 
with different neutralisation properties. Several virus clones isolated from one 
patient sample have previously been shown to display a wide range of 
neutralisation sensitivities (652, 1222). In addition, the envelope content in 
viruses produced in PBMC compared to in, for example, 293T cells can differ, 
which can have an effect on neutralisation sensitivity (1226). Passage for 4-6 
days only of a molecularly cloned virus in PBMC have been shown to give 
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increased neutralisation resistance to neutralising antibodies, an effect thought to 
be due to a higher level of envelope on the virus surface (1218). 
 
Furthermore, according to the results obtained by the CAVD Vaccine Immune 
Monitoring Centre, VHH C8 was the only VHH able to neutralise the tier 1 
subtype C virus, 93MW965.26. The observed IC50 was 0.2 µg/ml. This result is, 
again, in concordance with results obtained at UCL, where C8 could neutralise 
the 93MW965.26 virus with an IC50 of 0.3 µg/ml (Table 4.2.4.3.1). VHH C8 
was, moreover, the only VHH able to neutralise the tier 2 subtype B virus 
SC422661.8, with an IC50 of 25.1 µg/ml. This result is not in concordance with 
results obtained at UCL, where VHH C8 could not neutralise SC422661.8 to 
50%; instead, infection was reduced by 20% (Fig. 4.2.4.2.1 and Table 4.2.4.2.1). 
All of the tested VHH could neutralise the tier 1 subtype A virus. 
 
4.2.4.7 Summary of VHH neutralisation of HIV-1 in TZM-bl cells 
The selected VHH were tested against a panel of 65 viruses belonging to HIV-1 
of subtypes A, A/G, B, B′/C, C and D. The broadly neutralising mAb b12 was 
tested in parallel. The percentage of viruses neutralised in each subtype by each 
of the VHH and mAb b12 are shown in Fig. 4.2.4.7.1. In brief, mAb b12 was 
more broadly reactive than any of the VHH against the subtype B viruses 
included in this study. It neutralised 77% and 64% of the subtype B viruses on an 
IC50 and IC90 level, respectively. VHH A12 was the most subtype B-reactive out 
of the three selected VHH, neutralising 59% and 36% on an IC50 and IC90 level, 
respectively.  
 
As for subtype C viruses, VHH A12 and C8 displayed equally broad reactivity, 
neutralising 48% (IC50 level) and 22% (IC90 level) of the included viruses (Fig.  
4.2.4.7.1). They did not, however, neutralise the exact same set of viruses. VHH 
D7 was less reactive against subtype C isolates; neutralising 33% and 7% on an 
IC50 and IC90 level, respectively. The broadly neutralising mAb b12 was slightly 
more reactive against subtype C viruses compared to the VHH. It could 
neutralise 55% (IC50 level) and 37% (IC90 level) of the subtype C viruses 
included in the study (Fig. 4.2.4.7.1). 
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None of the VHH, nor mAb b12, was particularly potent against the subtype B′/C 
viruses tested. The VHH neutralised one and mAb b12 three out of twelve 
viruses to 50%. Moreover, neither of the VHH or mAb b12 could neutralise the 
subtype A, A/G or D viruses that were part of this study (Fig.  4.2.4.7.1). 
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Figure 4.2.4.7.1. Percentage of HIV-1 isolates neutralised by the VHH and by mAb b12, 
according to HIV-1 subtype. Virus neutralisation was assayed in TZM-bl cells as described in 
the text. The percentage of viruses neutralised with an IC50 and IC90 of less than or equal to 50 
µg/ml of antibody is shown. 
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4.2.5 VHH neutralisation of HIV-1 in primary cells 
Despite the extensive use of engineered cell lines when assessing antibody 
neutralisation of HIV-1, they are not natural target cells for HIV-1 infection. The 
ability of the VHH to inhibit HIV-1 SF162 infection of primary cells was 
therefore tested in a PBMC-based assay. Serial dilutions of VHH A12, D7, C8, 
and a negative control VHH, as well as mAb b12, were incubated with virus for 
1 hour at 37°C and subsequently added to PHA-stimulated PBMC obtained from 
blood donors. All VHH, including a negative control VHH (and mAb b12), were 
assayed in triplicate and in PBMC from two separate donors. After 24 hours at 
37°C the cells were washed twice in growth medium. Cell culture supernatant 
was collected on day 1, 3, 5 and 8 after infection and assayed for HIV-1 p24 
content to monitor virus replication. Virus replication in virus only control wells 
is shown in Fig. 4.2.5.1. 
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Figure 4.2.5.1. Replication of HIV-1 SF162 in PBMC from two donors in virus control wells 
of a PBMC neutralisation assay. For each donor, the replication of HIV-1 SF162 in one of the 
virus control wells was monitored by assaying the p24 content in the cell culture supernatant. 
PHA-stimulated PBMC (105 cells per well) were infected with HIV-1 SF162. After 24 hours at 
37°C the cells were washed twice in growth medium. Cell culture supernatant was collected on 
day 1, 3, 5 and 8 after infection and assayed for HIV-1 p24 antigen in an antigen capture assay 
kit, as described in section 2.8.3. Data points represent the mean and bars the standard deviation 
of three replicates. 
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Neutralisation was measured on day 5 post infection as reduction in p24 content 
in test wells compared to in virus control wells (Fig. 4.2.5.2). 
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Figure 4.2.5.2. VHH and mAb b12 neutralisation of HIV-1 SF162 in PBMC. VHH A12, D7, 
C8 and #3 (negative control VHH) and mAb b12 was assayed for ability to neutralise HIV-1 
SF162 in PBMC from two different donors as described in the text. HIV-1 p24 content on day 5 
post infection in test wells compared to in virus only control wells was determined. Data points 
represent the mean and bars the standard deviation of the three replicates. 
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VHH and mAb b12 IC50, IC75 and IC90 titres against SF162 in two different 
PBMC donors, on day 5 post infection, are shown in Table 4.2.5.1. 
 
Table 4.2.5.1. VHH and mAb b12 neutralisation of HIV-1 SF162 in PBMCa. 
 IC50 (µg/ml) IC75 (µg/ml) IC90 (µg/ml) 
 
PBMC 
donor 1 
PBMC 
donor 2
PBMC 
donor 1
PBMC 
donor 2
PBMC 
donor 1
PBMC 
donor 2 
IC90 in 
TZM-bl 
cells 
(µg/ml)  
A12 24 16 35 44 50 • 7.8 
D7 • <1.9 • 46 • • 9.3 
C8 • • • • • • • 
#3 (-) • • • • • • • 
b12 <1.9 1.9 <1.9 2 <1.9 2.1 1.2 
aVHH A12, D7, C8 and #3 (negative control VHH) as well as mAb b12 was assayed in triplicate 
for ability to neutralise HIV-1 SF162 in PBMC from two different donors, as described in the 
text. HIV-1 p24 content on day 5 post infection in test wells compared to in virus only control 
wells was determined and the lowest concentration giving rise to 50%, 75% and 90% reduction in 
p24 content was calculated using XLfit 4 software, • indicates >50 µg/ml. 
 
VHH A12 showed dose-dependent inhibition of infection of SF162 in PBMC 
from both of the two donors, with and IC75 of 35 and 44 µg/ml, respectively. 
VHH C8 could not inhibit SF162 infection in primary cells, which is in 
concordance with results obtained in the TZM-bl assay (Fig. 4.2.4.2.1 and Table 
4.2.4.2.1). For VHH D7, the results were less clear, with D7 inhibiting infection 
in PBMC from just one of the two donors. Donor variability has, however, 
previously been observed to affect HIV-1 neutralisation (1212, 1213). The 
broadly neutralising mAb b12 potently inhibited SF162 infection in PBMC. It 
was more than twenty-fold more potent compared to VHH A12 against SF162 in 
PBMC, whereas in TZM-bl cells, mAb b12 was only about six-fold more potent 
(Fig. 4.2.4.2.1 and Table 4.2.4.2.1). The irrelevant VHH, which served as a 
negative control, did not reduce infection in any of the donors. Instead, there was 
up to approximately an eight-fold increase in p24 content in PBMC from one of 
the donors, in wells containing the irrelevant VHH (Fig. 4.2.5.2). The reason for 
this observed increase is unclear. 
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4.2.6  Neutralisation activity in sera and plasma from llama L44 
In light of the relatively broad and sometimes potent neutralisation activity 
observed for VHH A12, D7 and C8, the neutralisation activities in heat-
inactivated serum and plasma samples from llama L44, the llama from which the 
neutralising VHH were derived, were evaluated. Serum samples from day 0 (pre-
immunisation) and day 28 (post-immunisation) and plasma samples from day 39 
and 43 (post-immunisation) were available. The neutralisation activities in these 
samples were assayed against the autologous PBMC isolate, HIV-1 CN54, as 
well as against HIV-1 IIIB. HIV-1 IIIB was included since VHH A12, D7 and 
C8 had been selected through panning on IIIB gp120 (chapter 3) and had been 
observed to neutralise IIIB virus in with IC50 values of 0.07, 0.1, and 0.8 µg/ml 
in TZM-bl cells, respectively (Table 4.2.4.2.1). Viruses 27d and C261 were also 
included, as they had been found to be sensitive to neutralisation by the VHH 
(Tables 4.2.4.3.1 and 4.2.4.3.2). Neutralisation was assayed in the in the TZM-bl 
assay (Fig. 4.2.6.1). 
 
Some virus inactivation was observed in the serum sample from day 28 (but not 
in plasma samples from day 39 and 43) against HIV-1 CN54 at high serum 
concentrations (1:5 dilution; Fig. 4.2.6.1). At a 1:15 and 1:45 serum dilution, a 
slight enhancement of infection was observed (around 2.5 times). No 
neutralisation (to more than 50%) was observed against HIV-1 IIIB and 27d in 
any of the samples. Against HIV-1 C261, relatively weak but dose-dependent 
neutralisation was observed in all samples obtained post-immunisation (Fig. 
4.2.6.1). The serum or plasma dilutions giving 50% reduction in RLU were 1:21, 
1:22, and 1:37, for the serum sample from day 28 and the plasma samples from 
day 39 and 43, respectively. HIV-1 C261 is more sensitive to neutralisation by 
VHH A12 and D7 than HIV-1 CN54, IIIB and 27d (Tables 4.2.4.3.1 and 
4.2.4.3.2), suggesting it may be sensitive neutralisation by anti-CD4bs 
antibodies. It is, however, resistant to neutralisation by VHH C8 and mAb b12 
(Tables 4.2.4.3.1 and 4.2.4.3.2). The IC50 of VHH A12 is <0.003 µg/ml against 
HIV-1 C261, and 1.4, 0.07 and 0.02 µg/ml against  HIV-1 CN54, IIIB and 27d, 
respectively, possibly indicating that it is the presence of A12-like (or D7-like) 
antibodies in the llama sera and plasma that mediates neutralisation of HIV-1 
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C261 (but not HIV-1 CN54, IIIB and 27d). However, this notion is speculative, 
and more work would be needed to map the specificities of the weak neutralising 
activity observed in the llama serum and plasma samples. 
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Figure 4.2.6.1. Neutralisation activity in sera and plasma from llama L44, immunised with 
HIV-1 CN54 gp120. The neutralisation activity in serum samples from day 0 (pre-immunisation) 
and 28 (post-immunisation) and plasma samples from day 39 and 43 (post-immunisation) was 
evaluated against HIV-1 CN54, IIIB (stock B in Table 4.2.4.2.1), 27d and C261 in TZM-bl cells 
as described in section 2.10.2. The percentage of RLU obtained in samples wells compared to the 
RLU obtained in wells containing virus and cells only is plotted against the reciprocal serum 
dilution. Data points represent the mean of duplicate reactions. Each serum or plasma sample was 
assayed against each virus on one occasion only, due to the limited amounts available. 
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In addition to not knowing the specificities of the weak neutralisation activity 
observed in the llama L44 post-immunisation sera and plasma, it should be noted 
that it remains unknown whether the neutralisation activity was mediated by 
conventional or heavy-chain antibodies. The ability of post-immunisation sera 
from llama L40 and L48 to neutralise HIV-1 was not evaluated, even though this 
would have been of interest. 
 
4.3 Discussion 
The results described in this chapter will be further discussed in the following 
sections. 
 
4.3.1 Comparison of different neutralisation assays 
Neutralisation results obtained in the NP2 and TZM-bl cell-based assays were 
overall fairly concordant. Nineteen of the viruses were tested in both assays for 
sensitivity to VHH A12, D7 and C8, making it 57 VHH-virus combinations. 
Results were qualitatively concordant for 51 out of the 57 VHH-virus 
combinations tested in both assays, in terms of whether or not 90% neutralisation 
could be achieved (section 4.2.3 and 4.2.4). For most virus isolates, the TZM-bl 
assay seemed slightly more sensitive, giving IC90 titres that were on average 
around 4-fold lower. The slight discrepancies observed may be due to differences 
between the two target cells, such as receptor expression levels, differences in 
infection kinetics, different incubation times, the use of DEAE-dextran to 
enhance infection of TZM-bl cells, or the different assay read-outs (1017, 1213, 
1216, 1227). 
 
In addition to in NP2 and TZM-bl cells, the ability of the VHH to neutralise 
HIV-1 SF162 was assessed in PBMC from two different donors. Unlike in the 
TZM-bl cell-based neutralisation assay, only VHH A12 was able to clearly 
neutralise HIV-1 SF162 in PBMCs. Furthermore, 90% neutralisation was only 
observed in PBMC from one of the two donors, and it required a 6-fold higher 
concentration of A12 compared to in TZM-bl cells (Table 4.2.5.1). Human anti-
CD4bs mAb b12 was more than 20-fold more potent than VHH A12 at IC90 level 
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in the PBMC assay, whereas the difference between mAb IgG1 b12 and VHH 
A12 was only 6-fold in TZM-bl cells. Further studies will be needed to explain 
this observed discrepancy between the results obtained in the PBMC and the 
TZM-bl assays. Such discrepancies have, however, been reported previously. 
The broadly neutralising mAb 4E10 has, for example, been shown to be more 
broadly cross-subtype reactive and potent in engineered cell lines than in PBMCs 
(1017). It has been suggested that the choice of target cell affects HIV-1 
neutralisation, and neutralisation assays using engineered cell lines have been 
shown to be more sensitive than PBMC assays (1017, 1213, 1216, 1218, 1227). 
 
In addition, one study has shown that the presence of NK cells may contribute to 
the anti-HIV-1 activity when assaying HIV-1 neutralisation in PBMCs (1228). 
Neutralisation was shown to be more potent in non-adherent PBMCs than in 
purified CD4-positive lymphocytes and this increased neutralisation was reported 
to be due to Fc-FcR interactions. It is possible that the lack of the Fc domain on 
VHH might make them less potent in a PBMC neutralisation assay compared to 
a full immunoglobulin, although this notion is highly speculative. Further work, 
such as expressing the VHH in the context of a full immunoglobulin, is needed to 
determine whether this is a possibility. 
 
4.3.2 VHH A12 is the most potent and broadly neutralising of the selected 
VHH  
VHH A12 was shown to be the most broadly cross-subtype reactive out of the 
selected VHH. It neutralised 42% of the viruses included in this study on an IC50 
level. On an IC90 level it was less potent, neutralising 23% of the viruses. The 
corresponding numbers for VHH D7 and C8 were 31% and 35% (IC50 level) and 
14% and 17%, respectively. VHH A12 was also shown to be the most potent out 
of the VHH. It neutralised subtype B viruses with IC50 titres that were 1.2-33-
fold lower than those of VHH D7 and 1.1-280-fold lower than those of VHH C8 
(where IC50 for both VHH were ≤50 µg/ml). Against subtype C viruses, A12 
required 1-1633-fold lower concentrations than D7 and 4-100-fold lower 
concentrations than C8. VHH A12 and C8 neutralised a partially different set of 
viruses, indicating that they recognise different epitopes. VHH D7, on the other 
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hand, neutralised the same, but smaller, set of viruses compared to VHH A12. 
This observation is in concordance with the fact that VHH A12 and D7 could be 
grouped together based on sequence similarity, as shown in section 3.2.3.3. 
 
4.3.3 Comparing neutralisation data obtained for mAb b12 to data already 
published 
The human anti-CD4bs mAb b12 is one of the most extensively studied mAbs to 
HIV-1 envelope and is one of only a handful mAbs that have been shown to 
neutralise a wide range if HIV-1 isolates of different subtypes. The neutralisation 
ability of mAb b12 has been tested in a large number of studies, using various 
assays and different virus panels of viruses. It is of interest to compare the results 
obtained in this study to results obtained in previous studies. 
 
In this study, mAb b12 was tested in parallel to the VHH against a panel of 65 
viruses. It was able to neutralise 54% of the viruses on an IC50 level, and 40% on 
an IC90 level. These findings are in concordance with a previous study carried out 
by Binley, et al. (1017), where a small panel of mAbs was tested against an 
extensive panel of 90 viruses using a high-throughput pseudovirus-based 
neutralisation assay and where mAb b12 was shown to neutralise 50% and 34% 
of viruses on an IC50 and IC90 level, respectively. In another study, Quakkelaar, 
et al. (1222), tested 149 viruses from ten individuals infected with HIV-1 of 
subtype B for neutralisation susceptibility to broadly neutralising mAbs in a 
PBMC-based assay, with b12 being able to neutralise 54% of viruses. 
Furthermore, mAb b12 was used in the characterisation of the subtype B and C 
reference panels of envelope pseudotyped viruses described by Li et al. (1022, 
1023), which were included in this study. Neutralisation data obtained in this 
study are almost completely concordant with the data previously published 
(Table 4.3.3.1), demonstrating high reproducibility and low inter-laboratory 
variability of the assay.  
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Table 4.3.3.1. Comparing mAb b12 IC50 titres to those previously reporteda. 
b12 IC50 (µg/ml) b12 IC50 (µg/ml) Subtype B 
reference  
panel 
Li et al. 
2005 
This 
study 
Subtype C 
reference  
panel 
Li et al. 
2006 
This 
study 
6535.3 1.4 2.5 Du156.12 0.8 <1.9 
QH0692.42 0.3 0.7 Du172.17 1 <1.9 
SC422661.8 0.2 <1.9 Du422.1 0.2 <1.9 
PVO.4 • • ZM197M.PB7 19.9 7.4 
TRO.11 • • ZM214M.PL15 3 <1.9 
AC10.0.29 1.9 2.2 ZM233M.PB6 • • 
RHPA4259.7 0.1 <1.9 ZM249M.PL1 3.2 5.6 
THRO4156.18 0.5 0.5 ZM53M.PB12 25.9 • 
REJO4541.67 0.7 32 ZM109F.PB4 • • 
TRJO4551.58 • • ZM135M.PL10a • • 
WITO4160.33 3.1 11 CAP45.2.00.G3 0.7 <1.9 
CAAN5342.A2 • • CAP210.2.00.E8 20.4 6.7 
aIC50 titres for mAb b12 against subtype B and C reference panels (1022, 1023) of envelope 
pseudotyped viruses in TZM-bl cells. 
 
4.3.4 The VHH and mAb b12 show different patterns of neutralisation 
The VHH neutralisation profiles were compared to that of broadly neutralising 
human anti-CD4bs mAb b12 (sections 4.2.3 and 4.2.4). Overall, mAb b12 was 
more reactive against the viruses included in this study, neutralising 54% of 
viruses included in this study, compared to 42% for A12, the most potent of the 
VHH (Fig. 4.2.4.7.1). Interestingly, the VHH displayed inhibitory profiles that 
were different to that of mAb b12. For example, mAb b12 was able to neutralise 
twelve subtype B’/C or C viruses that VHH A12 was not able to neutralise (IC50 
level). At the same time, VHH A12 was able to neutralise eight subtype B’/C or 
C viruses that b12 was unable to neutralise (IC50 level). This observation may 
indicate that mAb b12 and VHH A12 recognise different epitopes. Additional 
studies are needed to determine whether the VHH and mAb b12 epitopes are 
related. 
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It should be noted that the VHH are approximately ten times smaller than mAb 
b12, and therefore less potent on a molar level, but that mAb b12, on the other 
hand, has two antigen-recognising sites per molecule, making accurate estimates 
of relative neutralisation potencies impossible. To be able to make a direct 
comparison, the VHH would need to be presented in the context of a complete 
camelid immunoglobulin. 
 
4.3.5 Lack of potent neutralisation in serum and plasma from llama L44 
As the selected VHH exhibited relatively broad neutralisation activity when 
assayed against a panel of 65 viruses in TZM-bl cells, it was of interest to see 
whether any neutralising activity could be detected in serum of the llama from 
which the VHH were derived. Three sequential serum and plasma samples from 
llama L44 were therefore assayed against the autologous HIV-1 CN54 PBMC 
isolate, as well as three viruses that had been shown to be sensitive to 
neutralisation by the VHH (HIV-1 IIIB, 27d and C261). Some weak, albeit dose-
dependent, neutralisation was observed against HIV-1 C261, a virus that had 
been shown to be particularly sensitive to neutralisation by VHH A12 and D7 
(IC50 of <0.003 and 0.004 µg/ml, respectively; Table 4.2.4.3.1). This finding may 
indicate that the neutralisation activity against C261 in the serum and plasma 
samples is due to A12- and D7-like antibodies, although this notion is 
speculative. However, overall, no potent neutralisation activity could be detected 
in the sera/plasma. As immunisation with recombinant envelope glycoproteins 
rarely results in potent and broad neutralising serum responses (754, 997, 1229), 
this finding is expected. Immunising llamas with an antigen that elicits a broad 
neutralising antibody response of high magnitude is likely to increase the 
chances of isolating more potent and broadly neutralising VHH. Identifying such 
an immunogen represents one of the major challenges in HIV-1 vaccine 
development. 
 
4.3.6 Summary and conclusions 
In this chapter, it has been shown that the non-conventional immune system of 
camelids can be used to generate antibody fragments to HIV-1 envelope with 
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relatively broad and potent cross-subtype neutralising ability. The VHH could 
potently neutralise HIV-1 in two different cell-based neutralisation assays, using 
two different target cell lines. They were, however, less potent at neutralising 
HIV-1 in primary cells. 
 
The VHH were tested against HIV-1 from subtype A, B, C, D, CRF02_AG and 
CRF07_BC. The most potent of the characterised VHH was able to neutralise 
59% of the subtype B viruses and 48% of the subtype C viruses included in the 
study on an IC50 level, a neutralisation breadth that is comparable to that of the 
broadly neutralising anti-CD4bs mAb b12. On an IC90 level, mAb b12 was, 
however, more broadly reactive. It should also be noted that mAb b12 was more 
reactive against the well-characterised subtype B and C reference panels of 
envelope pseudotyped viruses, which has been classified as suitable for tier 2 
assessment of neutralising antibodies. Nevertheless, to our knowledge, this is the 
first description of a broadly neutralising mAb to HIV-1 envelope that is derived 
from an immunised animal, as all previously reported broadly neutralising anti-
HIV-1 mAbs have been a result of natural infection rather than immunisation 
(754). 
 
Despite being derived from a llama immunised with a recombinant gp120 from 
the CRF07_BC isolate CN54, the selected VHH were not able to neutralise any 
of the eleven CRF07_BC reference panel viruses that were included in this study. 
Taking the relatively broad neutralisation properties of the VHH against viruses 
from subtype B and C, this finding is a bit surprising. Further studies are needed 
to elucidate the extent to which these VHH-resistant CRF07_BC envelope clones 
differ from the CN54 envelope. Such studies would be especially interesting 
once more is known about the VHH epitopes. An initial attempt to characterise 
the VHH epitopes will be described in chapter 5 of this thesis. 
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Chapter 5 
Characterisation of VHH epitope recognition 
 
In this chapter, the way in which the VHH react with recombinant envelope 
glycoproteins will be evaluated using biochemical assays. 
 
5.1 Introduction 
In chapter 3, the isolation of HIV-1 neutralising anti-envelope VHH derived from 
llamas immunised with recombinant gp120 was described. The VHH were 
selected through panning of phage libraries, expressing the VHH repertoires of 
the immunised llamas, on immobilised gp120. To increase the chances of 
isolating neutralising VHH, a competitive elution with an excess of sCD4 was 
employed, possibly allowing for the elution of VHH targeting the CD4bs. Five of 
the selected VHH were chosen for further characterisation. These were VHH 
A12, D7, D12, C8 and F2. The neutralising abilities of these VHH were 
characterised in chapter 4, revealing VHH A12, D7 and C8 as the most potent. In 
this chapter, biochemical assays will be used to confirm that the neutralising 
VHH actually bind to gp120. Their cross-subtype binding reactivities will also be 
evaluated. In addition, an initial attempt to characterise the VHH epitopes will be 
carried out through competition studies. 
 
5.2 Results 
This section describes the results of this chapter. 
 
5.2.1 VHH binding to recombinant envelope glycoproteins 
In this section, the ability of the VHH to bind to HIV-1 recombinant envelope 
glycoproteins will be evaluated. 
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5.2.1.1 VHH binding to the immunogen in ELISA 
All of the five VHH chosen for further characterisation were tested for their 
ability to bind to the immunogen, recombinant gp120 derived from HIV-1 CN54, 
in ELISA. VHH F2 was the only VHH found to bind well to CN54 gp120 (Fig. 
5.2.1.1.1). This observation is in keeping with the notion that VHH F2 was the 
only VHH that had been selected through panning on CN54 gp120, as described 
in chapter 3. Nevertheless, it is surprising that the remaining VHH showed such 
poor binding to CN54 gp120, despite having been raised against the same 
protein. It is possible that the failure to detect any interaction between CN54 
gp120 and the VHH is caused by the ELISA setting. The ability of the VHH to 
react with CN54 gp120 was therefore also evaluated in a surface plasmon 
resonance setting. This experiment is described in section 5.2.2.2. 
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Figure 5.2.1.1.1. VHH binding to the immunogen in ELISA. The selected VHH and a negative 
control VHH were assayed for binding to the immunogen, recombinant gp120 derived from HIV-
1 CN54, in ELISA. Recombinant CN54 gp120 was captured by antibody D7324 immobilised 
onto microtitre plates. Serial dilutions of VHH were added and binding detected using a mouse 
anti-c-myc antibody followed by an AP-conjugated goat anti-mouse IgG polyclonal antibody. 
Background-subtracted luminescence readings (in RLU) were plotted against VHH 
concentration. Data points represent the mean and bars the standard deviation of duplicate 
reactions. 
 
5.2.1.2 The VHH bind to gp120 and gp140 of subtype A, B and C in ELISA 
The neutralisation characterisation described in chapter 4 had revealed VHH 
A12, D7 and C8 as more potent and broadly cross-subtype neutralising than 
VHH D12 and F2. In the following sections, characterisation of envelope 
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reactivity will therefore only be carried out for VHH A12, D7 and C8. VHH D12 
and F2 will be further discussed in section 5.2.2.8. 
 
In spite of their ability to neutralise HIV-1 strains of subtype B and C, none of 
VHH A12, D7 and C8 was found to bind well to the protein against which they 
had been raised, CN54 gp120, in ELISA. This contradictory observation might to 
some extent be explained by doubts regarding the structural integrity of the 
immunogen, as discussed in chapter 3, and the notion that these VHH had been 
selected through panning on gp120 derived from HIV-1 IIIB, as opposed to on 
CN54 gp120. To evaluate whether that the VHH could actually bind to HIV-1 
gp120, their reactivity with recombinant IIIB gp120 was assayed in an ELISA. 
All three VHH were observed to bind well to the subtype B HIV-1 IIIB gp120 in 
a dose-dependent manner, as shown in Fig. 5.2.1.2.1. The data were fitted to a 
four parameter logistics equation and the concentrations yielding half-maximal 
binding was determined using the XLfit 4 software. The concentrations yielding 
half-maximal binding, sometimes used as an estimate of the equilibrium 
dissociation constant, were determined to be 14.7, 13.4 and 12.1 ng/µl for A12, 
D7 and C8, respectively, corresponding to 0.92, 0.84 and 0.76 nM. 
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Figure 5.2.1.2.1. VHH binding to recombinant gp120 derived from HIV-1 IIIB in ELISA. 
VHH A12, D7, C8 and a negative control VHH were assayed for binding to HIV-1 IIIB gp120. 
Recombinant IIIB gp120 was captured by immobilised antibody D7324. Serial dilutions of VHH 
were added and binding was detected as described in chapter 2. Background-subtracted 
luminescence readings (in RLU) were normalised to a positive control reaction (VHH A12 at 10 
µg/ml) and plotted against VHH concentration. Data points represent the mean and bars the 
standard error of two independent experiments carried out in duplicate. 
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The VHH had been shown to neutralise a fairly wide range of HIV-1 of subtype 
B and C. To further characterise their cross-subtype reactivity, their ability to 
bind to gp120 of subtype C was evaluated in ELISA. Dose-dependent binding of 
VHH A12, D7 and C8 to subtype C envelope proteins is shown in Fig. 5.2.1.2.2. 
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Figure 5.2.1.2.2. VHH binding to subtype C gp120 derived in ELISA. VHH A12, D7, C8 and 
a negative control VHH were assayed for binding to recombinant gp120 derived from HIV-1 
92BR025 and HIV-1 CB7. Recombinant gp120 was captured by immobilised antibody D7324. 
Serial dilutions of VHH were added and binding was detected as described in chapter 2. Data 
points represent the mean and bars the standard deviation of background-subtracted luminescence 
readings (in RLU) from duplicate reactions. 
 
As seen in Fig. 5.2.1.2.2, VHH A12 and C8 were able to bind well to the subtype 
C HIV-1 92BR025.C1 gp120 in ELISA, whereas D7 bound with a much weaker 
signal. This observation is in concordance with the finding that VHH A12 and 
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C8, but not D7, were able to neutralise the chimeric virus expressing the 
92BR025.C1 envelope (Fig. 4.2.4.3.1 and Table 4.2.4.3.1). VHH C8, however, 
bound with a slightly greater signal strength to the 92BR025.C1 gp120, 
compared to VHH A12, which is not in complete concordance with the 
neutralisation results, where VHH A12 neutralised the 92BR025.C1 virus with 
an IC50 that was ten times lower than the IC50 of VHH C8 (Table 4.2.4.3.1). Of 
note is also that when the 92BR025.C1 gp120 was included in the phage display 
panning step, only VHH A12 was selected for, as described in chapter 3. VHH 
A12 was also found to show very weak reactivity with the CB7 gp120, whereas 
VHH D7 and C8 showed even poorer reactivity, barely above background level 
(Fig. 5.2.2.2). This finding is in agreement with the neutralisation data described 
in chapter 4, where VHH A12 was the only VHH able to just about neutralise 
CB7 virus to 90% with an IC90 of 50 µg/ml (Fig. 4.2.4.3.1 and Table 4. 2.4.3.2). 
 
The VHH were also tested for reactivity with the subtype A 92UG037.A9 gp120. 
All three VHH showed dose-dependent binding with relatively high signal 
strength to this subtype A gp120 (Fig. 5.2.2.3). 
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Figure 5.2.2.3. VHH binding to gp120 of subtype A in ELISA. VHH A12, D7, C8 and a 
negative control VHH were assayed for binding to 92UG037.A9 gp120. Recombinant gp120 was 
captured by immobilised antibody D7324. Serial dilutions of VHH were added and binding was 
detected as described in chapter 2. Data points represent the mean and bars the standard deviation 
of background-subtracted luminescence readings (in RLU) from duplicate reactions. 
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This observation is not in agreement with neutralisation results, where none of 
the VHH was able to neutralise the chimeric virus expressing the exact same 
gp120 (Fig. 4.2.4.5.1). 
 
To investigate whether the VHH inability to neutralise the 92UG037.A9 virus 
was due to an ability to bind only to monomeric gp120, but not to gp120 in the 
context of the envelope trimer, the VHH were tested for reactivity with 
predominantly trimeric 92UG037 gp140. All three VHH showed dose-dependent 
reactivity with the trimeric 92UG037 gp140, indicating that the failure to 
neutralise 92UG037.A9 virus was not due to lack of reactivity with trimeric 
envelope (Fig. 5.2.2.4). It is still possible, though, that the lack of neutralisation 
is due to inability to bind to 92UG037.A9 gp120 in the context of the functional 
envelope spike, as opposed to the recombinant trimeric protein. Lack of 
correlation between antibody ability to bind recombinant envelope proteins and 
ability to neutralise the corresponding virus has been previously observed (141, 
142, 623-626, 897, 940), and will be further discussed in section 5.2.3. 
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Figure 5.2.2.4. VHH binding to 92UG037 gp140 in ELISA. VHH A12, D7, C8 and a negative 
control VHH were assayed for binding to 92UG037 gp140 in ELISA. The experimental 
procedure is described in chapter 2. Background-subtracted luminescence readings were 
normalised to a positive control reaction (VHH A12 at 10 µg/ml) and plotted against VHH 
concentration. Data points represent the mean and bars the standard error of two independent 
experiments carried out in duplicate. 
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5.2.1.3 The VHH bind to recombinant gp120 with high affinity 
To study the kinetics by which the VHH bound to gp120 and determine their 
affinities, their binding to gp120 was monitored using surface plasmon resonance 
techniques. Surface plasmon resonance techniques measure the angle by which 
polarised light is reflected from a gold-covered glass surface, to which molecules 
are immobilised through what is often a dextran layer linked to the gold. The 
technique was first used to measure real-time intermolecular interactions in 1991 
(1230), and has since then been used extensively. The angle by which the 
polarised light is reflected is used to calculate the density above the glass surface, 
enabling real-time analysis of the interactions between the immobilised molecule 
and molecules added to the fluid-phase. 
 
Initially, attempts to detect VHH binding to gp120 were made together with 
Karolin Hijazi in the laboratory of Charles Kelly at the Department of Oral 
Immunology, King's College London, UK, as part of the EMPRO collaboration. 
Recombinant CN54 and IIIB gp120 was either coupled to one of the flow cells of 
a biosensor chip using standard amine coupling, or captured by sheep antibody 
D7324 coupled to the chip. VHH was then injected and the binding monitored. 
All the VHH tested, including the negative control VHH, did, however, bind to 
the control cell of the chip, i.e. the cell lacking gp120 (data not shown). Any 
specific binding to gp120 could not be distinguished from the background 
binding, and specific binding could hence not be detected. The reasons behind 
this non-specific binding are unclear. 
 
Instead, the experiment was successfully repeated by Bart Hoorelbeke at Ablynx 
NV, Ghent, Belgium. Recombinant gp120 was coupled to a CM5 biosensor chip 
using standard amine coupling techniques, or captured by streptavidin on a SA 
biosensor chip, and VHH A12, D7 and C8 binding to the immobilised gp120 was 
subsequently monitored. The association and dissociation rate constants (ka and 
kd) were determined and used to calculate the equilibrium dissociation constants 
(KD). Kinetic data are summarised in Table 5.2.1.3.1. In summary, VHH A12 
and D7 showed affinities in the high picomolar range for recombinant IIIB 
gp120, with equilibrium dissociation constants of 100 and 97 pM, respectively. 
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VHH C8 was found to have a faster off-rate, leading to a more than eight-fold 
higher KD. 
 
Table 5.2.1.3.1. VHH kinetic constants and affinities for IIIB gp120a. 
VHH KD (nM) ka (1/(Ms)) kd (1/s) 
A12 0.1 2.73 × 105 2.98 × 10-5 
D7 0.097 4.00 × 105 3.89 × 10-5 
C8 0.85 2.05 × 105 1.74 × 10-4 
aVHH A12, D7 and C8 association rate constants (ka), dissociation rate constants (kd) and 
equilibrium dissociation constants (KD = kd/ka) for recombinant IIIB gp120 were determined by 
surface plasmon resonance studies. Data were kindly provided by Bart Hoorelbeke, Ablynx NV, 
Ghent, Belgium. 
 
Camelid VHH usually bind to their target with affinities comparable to those of 
conventional antibodies (1099, 1100). VHH with KD values as low as those 
reported in this study (100 pM) have, however, been described on a few 
occasions, according to a recent review by Harmsen and de Haard (1100). Such 
low KD values equate the affinity ceiling that has been suggested for antibodies 
generated through in vivo affinity maturation (1231-1233). 
 
As a comparison, Fab b12 has been reported to bind to IIIB gp120 with a KD of 
6.3 nM (1234). Furthermore, sCD4 has been reported to bind to envelope 
proteins, including IIIB gp120, with KD values of 22-35 nM (929, 1021, 1235). 
Another study reported KD values in the range of 2.2-16 nM for range of anti-
CD4bs Fab fragments (including Fab b12) to MN gp120 (624). Yet another 
human anti-CD4bs mAb, F105, has been shown to bind to IIIB gp120 with a KD 
of 0.62 nM (1021). 
 
5.2.1.4 Summary of VHH binding experiments 
In summary, the VHH were shown to bind to gp120 of subtype A, B and C, 
indicating that they recognise a motif that is accessible on soluble recombinant 
envelope proteins and relatively conserved among HIV-1 subtypes. Furthermore, 
they were shown to bind to IIIB gp120 with a high affinity, perhaps lending 
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some explanation to the potency with which they can neutralise some viruses. 
Antibody neutralisation of virus has, however, been reported to show no 
significant correlation with ability to bind to monomeric gp120, but instead to 
correlate with affinity for oligomeric envelope (624). 
 
5.2.2 VHH competition studies 
In this section, an initial attempt to characterise the VHH epitopes through sCD4 
and antibody competition studies will be described. 
 
5.2.2.1 The VHH compete with sCD4 for binding to gp120 and gp140 in 
ELISA 
The VHH had been specifically selected for ability to compete with sCD4, using 
the functional phage display panning method described in chapter 3. To 
investigate whether the VHH actually bound to gp120 in a way that prevented 
binding of CD4, and to possibly cast some light on the mechanism by which the 
VHH inhibit HIV-1 infection, the VHH capacity to inhibit sCD4 binding to 
recombinant envelope proteins was evaluated in ELISA. 
 
An inhibition ELISA was set up. Titrations of VHH were pre-incubated with IIIB 
gp120 followed by subsequent incubation with solid-phase coated four-domain 
sCD4 after which gp120 binding to sCD4 was detected. VHH A12, D7 and C8 
all inhibited binding of sCD4 to HIV-1 IIIB gp120 in a dose-dependent manner 
(Fig. 5.2.2.1.1, left panel). This finding indicates that the VHH bind to epitopes 
that overlap with the CD4bs, bind in a way that sterically hinders binding of 
sCD4, or that their binding locks gp120 in a conformation that prevents binding 
of sCD4. 
 
The VHH were also tested for ability to inhibit sCD4 binding to the subtype A 
92UG037 gp140. All three VHH were able to inhibit sCD4 binding to 92UG037 
gp140 in a dose-dependent way (Fig. 5.2.2.1.1, right panel). VHH A12 was, 
however, able to inhibit sCD4 binding to recombinant 92UG037 gp140 at 
slightly lower concentrations than did the remaining VHH. This observation 
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indicates that the VHH failure to neutralise the 92UG037.A9 virus is not due to 
inability to bind to 92UG037.A9 envelope in a way that prevents CD4 binding. 
The reasons behind the VHH failure to neutralise 92UG037.A9 virus, despite 
being able to compete with sCD4 for binding to recombinant 92UG037 envelope 
proteins, will be further discussed in section 5.2.3. 
 
In summary, the ability of the neutralising VHH to compete with sCD4 for 
binding to recombinant envelope proteins suggests that they inhibit HIV-1 
infection by binding to the functional envelope spike prior to interaction with 
CD4. The ability of the selected VHH to inhibit sCD4 binding to the 
immunogen, CN54 gp120, could not be evaluated in ELISA, as no binding of 
sCD4 to CN54 gp120 could be observed (section 3.2.2). 
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Figure 5.2.2.1.1. Dose-dependent competition of VHH A12, D7 and C8 with sCD4 for 
binding to recombinant envelope proteins in ELISA. Three-fold serial dilutions of VHH were 
pre-incubated with subtype B IIIB gp120 or subtype A 92UG037 gp140 and subsequently 
incubated with sCD4 pre-coated on microtitre plates. Envelope protein binding to sCD4 was 
detected as described in chapter 2. Background-subtracted luminescence readings were plotted 
against VHH concentration. Data points represent the mean and bars the standard deviation of 
duplicate reactions. 
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5.2.2.2 The VHH compete with sCD4 for binding to gp120 in a surface 
plasmon resonance assay 
To further confirm that the selected VHH recognise an epitope over-lapping the 
CD4bs, or at least bind in a way that sterically hinders binding of sCD4, the 
VHH were assessed for their ability to inhibit sCD4-gp120 binding in a BIAcore 
surface plasmon resonance assay. Surface plasmon resonance techniques enables 
real-time monitoring of protein-protein interactions, which allows for the 
detection of weak interactions that can remain undetected in ELISA (1236-1238). 
This notion was supported by the results described in chapter 3.2.2 of this thesis, 
where weak binding of immobilised sCD4 to fluid-phase CN54 gp120 could be 
detected using BIAcore surface plasmon resonance techniques, but not using 
ELISA. This advantage of the surface plasmon resonance assay enabled testing 
whether the VHH could inhibit binding of sCD4 to CN54 gp120, something 
which could not be evaluated using conventional ELISA techniques. The surface 
plasmon resonance sCD4-gp120 inhibition assay was set up and optimised 
together with Karolin Hijazi in the laboratory of Charles Kelly at the Department 
of Oral Immunology, King's College London, UK, as part of the EMPRO 
collaboration. Initially, recombinant four-domain sCD4 was coupled straight to 
the biosensor chip using standard amine coupling techniques. No binding of this 
coupled sCD4 could, however, be observed to fluid-phase IIIB or CN54 gp120, 
but to an anti-CD4 antibody recognising domain 4 of CD4 (data not shown). This 
observation indicated that the amine coupling affects the structure and/or limits 
the accessibility of the gp120-binding site of this sCD4. The anti-CD4 antibody 
mentioned above was instead coupled to the chip and used to capture sCD4. 
Binding of the captured sCD4 could now be observed, both to IIIB and CN54 
gp120, as described in section 3.2.2. To allow for several injections of gp120, 
without having to re-inject sCD4, sCD4 was cross-linked to the anti-CD4 
antibody. This cross-linking had no apparent effect on the gp120-binding ability 
(data not shown). 
 
To test VHH ability to inhibit sCD4 binding to gp120, titrations of VHH were 
pre-incubated with gp120 and then injected onto the chip. VHH C8 and D7 were 
tested. VHH A12 was not included in this experiment, as it had not yet been 
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isolated at the time of the BIAcore experiments. Both C8 and D7 showed dose-
dependent inhibition of sCD4 binding to HIV-1 CN54 gp120, as can be seen in 
the BIAcore sensogram depicted in Fig. 5.2.2.2.1. Complete inhibition was 
observed, even at equimolar concentrations of VHH and gp120. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2.2.2.1. Dose-dependent inhibition of sCD4 binding to CN54 gp120 by VHH C8 
and D7 as assayed by surface plasmon resonance. Recombinant sCD4 was cross-linked to an 
anti-CD4 mAb coupled to the chip. Serial dilutions of VHH were pre-incubated with HIV-1 
CN54 gp120 and subsequently injected onto the chip. Data were analysed using the 
BIAevaluation software. Binding of HIV-1 CN54 gp120 to sCD4 is represented as the 
normalised difference between the response units (RU) observed in the cell containing the chip 
with sCD4 and the negative control flow cell, plotted versus time. 
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This finding confirms the observation described in section 5.2.2.1, that the VHH 
compete with sCD4 for binding to gp120, either through binding to an epitope 
that partly overlaps with the CD4bs, or by binding in a way that sterically hinders 
biding of sCD4, alternatively locks the gp120 in a conformation that hampers 
interaction with sCD4. Again, this finding may suggest that the VHH inhibit 
HIV-1 infection by interacting with gp120 prior to its engagement to CD4.  
 
This observation furthermore suggests that the VHH are indeed able to interact 
with the immunogen, CN54 gp120, despite the failure to detect such an 
interaction in ELISA. This is in analogy with the observation that sCD4 binding 
to CN54 gp120 could not be detected in ELISA, whereas a weak interaction was 
observed in a surface plasmon resonance biosensor setting, as described in 
chapter 3. The ability of the surface plasmon resonance technique to detect weak 
protein-protein interactions that cannot be detected in ELISA is well-established 
(1236-1238). Therefore, it is possible that the failure to detect VHH binding to 
CN54 gp120 in ELISA is due to the weak nature of the interactions. Nonetheless, 
the interactions were potent enough to completely inhibit the (equally weak) 
binding of sCD4 to CN54 gp120 at an equimolar ratio, suggesting that this is the 
mechanism by which neutralisation occurs. 
 
5.2.2.3 The VHH compete with mAb b12 for binding to gp120 in ELISA 
In section 5.2.2.1 and 5.2.2.2, it had been shown that the VHH compete with 
sCD4 for binding to envelope proteins of subtype A, B and C, and hence are 
likely to recognise CD4bs-related epitopes. The broadly neutralising mAb b12 
has been shown to bind to a relatively conserved epitope that overlaps a subset of 
the CD4bs (1008). In chapter 4, it was shown that the VHH and mAb b12 
neutralise a different spectrum of viruses, indicating that they recognise different 
epitopes. To further map the epitopes of the selected VHH, they were tested for 
their ability to compete with mAb b12 in ELISA. VHH A12, D7 and C8 were all 
found to compete with mAb b12 for binding to recombinant IIIB gp120 (Fig. 
5.2.2.3.1). This finding may indicate that the VHH bind to epitopes that overlap 
with the epitope recognised by mAb b12, or that they bind in such a way that 
they sterically hinder binding of mAb b12 to gp120. Alternatively, their binding 
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may induce conformational changes in gp120 which inhibits subsequent mAb 
b12 binding. VHH A12 was found to inhibit mAb b12 binding to IIIB gp120 at 
slightly lower concentrations than the other VHH. This observation may suggest 
that VHH A12 recognises an epitope that overlaps with the b12 epitope to a 
greater extent, which could be in line with the neutralisation results described in 
chapter 4, where VHH A12 showed a broader neutralising ability compared to 
the other VHH, indicating that it binds to an epitope that is more conserved. It 
may also imply that VHH A12 bind to IIIB gp120 with a higher affinity. VHH 
A12 and D7 were, however, shown to bind to IIIB gp120 with similar affinities, 
as described in section 5.2.1.3. 
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Figure 5.2.2.3.1. Dose-dependent competition of VHH A12, D7 and C8 with mAb b12 for 
binding to recombinant IIIB gp120 in ELISA. Serial dilutions of VHH were pre-incubated 
with IIIB gp120 and subsequently incubated with immobilised mAb b12. Envelope protein 
binding to mAb b12 was detected using the sheep polyclonal antibody D7324 followed by an AP-
conjugated rabbit anti-sheep IgG antibody. Background-subtracted luminescence readings were 
plotted against VHH concentration. Data points represent the mean and bars the standard 
deviation of duplicate reactions. 
 
5.2.2.4 The VHH compete with non-neutralising anti-CD4bs mAbs for 
binding to gp120 in ELISA 
To further confirm that the VHH bind to CD4bs-related epitopes, they were 
tested for ability to inhibit the binding of additional anti-CD4bs mAbs to gp120. 
Human mAbs 654-D and GP68 have been shown to compete with sCD4 for 
binding to recombinant gp120 but can only neutralise some TCLA isolates and 
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not primary isolates (975, 1141, 1198, 1239). VHH A12, D7 and C8 were all 
able to completely inhibit binding of mAbs 654-D and GP68 to gp120, further 
confirming that the VHH recognise CD4bs-related epitopes (Fig. 5.2.2.4.1). 
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Figure 5.2.2.4.1. Dose-dependent inhibition of mAb 654-D and mAb GP68 binding to HIV-1 
IIIB gp120 by VHH A12, D7 and C8. Serial dilutions of VHH were incubated with gp120 
captured by antibody D7324 immobilised onto microtitre plates. Wells were washed and 
incubated with mAb 654-D or GP68. Binding of 654-D and GP68 to gp120 was detected using an 
AP-conjugated goat anti-human IgG antibody. Background-subtracted luminescence readings 
were plotted against VHH concentration. Data points represent the mean and bars the standard 
deviation of duplicate reactions. 
 
VHH D7 and C8 were also tested for ability to inhibit binding of mAb b6 to 
gp120. Anti-CD4bs mAb b6 was isolated from the same individual and at the 
same point in time as mAb b12 (624). It competes with sCD4 for binding to 
envelope proteins, but can only neutralise some TCLA viruses (142, 897, 1009, 
1018). VHH D7 inhibited binding of mAb b6 to HIV-1 IIIB gp120 (Fig. 
5.2.2.4.2), possibly indicating that the VHH D7 and mAb b6 epitopes overlap or 
that VHH D7 inhibits mAb b6 binding through steric effects. VHH C8 was less 
potent at inhibiting mAb b6 binding to gp120, suggesting that its binding 
imposes less of a steric hinder for mAb b6 binding (Fig. 5.2.2.4.2). VHH A12 
was not tested for ability to inhibit mAb b6 binding, as it had not been identified 
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at the time of the b6 experiments, and at the time of its identification, the source 
of mAb b6 was exhausted. 
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Figure 5.2.2.4.2. Dose-dependent inhibition of mAb b6 binding to HIV-1 IIIB gp120 by 
VHH D7 and C8. Serial dilutions of VHH were incubated with gp120 captured by immobilised 
antibody D7324. Wells were washed and incubated with mAb b6. Binding of mAb b6 to gp120 
was detected using an AP-conjugated goat anti-human IgG antibody. Background-subtracted 
luminescence readings were plotted against VHH concentration. Data points represent the mean 
and bars the standard deviation of duplicate reactions. 
 
5.2.2.5 The VHH compete to some extent with mAb 2G12, 447-52D and 
17b for binding to gp120 in ELISA 
In order to gain further understanding of the VHH epitopes, their ability to 
compete with mAbs to non-CD4bs epitopes of gp120 was evaluated. Included in 
the study was the broadly neutralising mAb 2G12, which recognises a 
carbohydrate motif on gp120 (981, 1013-1015), the anti-V3 mAb 447-52D, 
which neutralises primary isolates of subtype B (991, 1032), and mAb 17b, 
which recognises a CD4-induced epitope and which neutralises mainly TCLA 
isolates (1143). In addition, anti-CD4bs mAb b12 was included. The anti-gp41 
mAb 4E10 (907, 981) was included as a control. 
 
An inhibition ELISA was set up. Each of the VHH was coated onto microtitre 
plates. Titrations of the anti-gp120 mAbs were pre-incubated with IIIB gp120 
and subsequently added to the VHH-coated microtitre plates. Binding of gp120 
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to the immobilised VHH was detected using the sheep antibody D7324, which 
recognises the very C-terminus of gp120, followed by an anti-sheep IgG 
antibody. The resulting graphs are shown in Fig. 5.2.2.5.1. 
 
In summary, anti-CD4bs mAb b12 could clearly inhibit binding of VHH A12 
and C8 to IIIB gp120. Binding VHH D7 to IIIB gp120 was inhibited to a slightly 
lesser extent, possible indicating that the epitopes recognised by VHH D7 and 
mAb b12 overlap to a lesser extent (provided that they overlap at all), or that 
mAb b12 binding to gp120 imposes less of a steric hinder for VHH D7 binding. 
However, overall, the results observed in this ELISA are in keeping with the 
results reported in section 5.2.2.3, where the VHH were found to inhibit binding 
of mAb b12 to IIIB gp120. This observation, again, indicates that the VHH bind 
to CD4bs-related epitopes. Some inhibition of VHH-gp120 binding was also 
observed for the three remaining non-CD4bs anti-gp120 mAbs, 2G12 
(carbohydrate motif), 17b (CD4-induced epitope) and 447-52D (V3 epitope). It is 
possible that binding of these mAbs to gp120 imposes some steric hindrance, 
hence inhibiting VHH binding. The sheer bulk of an antibody binding to gp120 
may reduce the ability of gp120 to bind the immobilised VHH. This is, however, 
not true for the antibody D7324, binding to the very C-terminal region of gp120, 
as it has been used both to capture and detect gp120 throughput this study. 
Including an irrelevant mAb in this competition ELISA, in this case the anti-
gp41 mAb 4E10, did not lead to reduced VHH-gp120 binding, indicating that it 
is the binding, and not just the presence, of mAbs 2G12, 17b and 447-52D that 
slightly inhibits VHH-gp120 binding. 
 
It is possible that reversing the ELISA, i.e. testing whether the VHH would 
inhibit binding of the mAbs to gp120, would cast further light on the extent to 
which these mAbs and the VHH compete for binding to gp120. It is possible that 
VHH binding to gp120 induces conformational changes that result in alteration 
of the exposure of other epitopes, such as for example the CD4-induced and V3 
epitopes. Reversing the ELISA set up was, however, only carried out for mAb 
b12, as described in section 5.2.2.3. Strong reciprocal inhibition of binding to 
gp120 was observed for mAb b12 and the VHH. CD4-induced epitopes, such as 
the 17b epitope, have been found to be better exposed after sCD4 binding (1143), 
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but not after binding of anti-CD4bs mAbs (919). Whether the exposure of CD4-
induced epitopes is affected by VHH binding to gp120 remains to be determined. 
In summary, the competition profiles of the VHH were found to be similar to 
competition profiles previously reported for anti-CD4bs mAbs (919, 1020), 
suggesting that the VHH recognise CD4bs-related epitopes. 
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Figure 5.2.2.5.1. VHH competition with mAb b12 and mAbs to non-CD4bs epitopes of 
gp120 for binding to recombinant gp120 in ELISA. VHH A12, D7 and C8 were coated onto 
the wells of microtitre plates, as indicated above each graph. Serial dilutions of each mAb were 
pre-incubated with IIIB gp120 and subsequently incubated with the immobilised VHH. Envelope 
protein binding to VHH was detected as described in the text. Background-subtracted 
luminescence readings were plotted against mAb concentration. Data points represent the mean 
and bars the standard deviation of duplicate reactions. 
L
um
in
es
ce
nc
e 
(R
L
U
) 
 309
5.2.2.6 The VHH compete with each other for binding to gp120 in ELISA 
In sections 5.2.2.1-5.2.2.5, it was shown that VHH A12, D7 and C8 all compete 
with sCD4 and with anti-CD4bs mAbs for binding to gp120, indicating that they 
all bind to CD4bs-related regions. Earlier, in chapter 3, it was shown that VHH 
A12 and D7 showed high sequence similarity and could be grouped into the 
same sub-family, whereas VHH C8 could not. Hence, it is likely that A12 and 
D7, but perhaps not C8, recognise similar epitopes. In chapter 4, it was 
furthermore shown that VHH D7 neutralised a subset of the viruses neutralised 
by VHH A12, in line with the assumption that they bind to related epitopes. 
VHH C8, on the other hand, neutralised a different but overlapping spectrum of 
viruses, suggesting that it recognises a different epitope. 
 
To further investigate whether the VHH bind to epitopes that are related, VHH 
A12, D7 and C8 were tested for their ability to compete with each other for 
binding to gp120. Each of the VHH was coated onto the wells of microtitre 
plates. Titrations of VHH were then pre-incubated with IIIB gp120 and 
subsequently incubated with the solid-phase VHH followed by detection of 
gp120 binding to the solid-phase VHH. The ability of fluid-phase sCD4 to inhibit 
binding of gp120 to each of the VHH was also assayed. An irrelevant VHH was 
included as a control. Results are shown in Fig. 5.2.2.6.1. 
 
Each of the VHH was able to inhibit binding of IIIB gp120 to itself and to the 
other two VHH, indicating that the VHH either bind to epitopes that overlap, or 
that steric hindrance inhibits simultaneous binding. VHH C8 required higher 
concentrations than VHH A12 and D7 to completely inhibit gp120 binding to 
VHH A12 and D7, as well as to itself. This finding is in concordance with the 
higher affinity for IIIB gp120 observed for VHH A12 and D7 compared to for 
VHH C8 (section 5.2.1.3). VHH A12 and D7 showed similar inhibition curves, 
again in line with their similar affinities for IIIB gp120. 
 
In section 5.2.2.1, it was shown that binding of the VHH to recombinant gp120 
can completely inhibit sCD4 binding gp120. In this section the reverse was 
shown, as sCD4 was observed to completely inhibit VHH binding to gp120 
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binding in a dose-dependent manner (Fig. 5.2.2.6.1), further confirming that the 
VHH target CD4bs-related epitopes. 
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Figure 5.2.2.6.1. VHH competition with each other for binding to recombinant gp120 in 
ELISA. VHH A12, D7 and C8 were coated onto the wells of microtitre plates, as indicated above 
each graph. Serial dilutions of each VHH and sCD4 were pre-incubated with IIIB gp120 and 
subsequently incubated with the immobilised VHH. Envelope protein binding to VHH was 
detected as described in the text. Background-subtracted luminescence readings were plotted 
against mAb concentration. Data points represent the mean and bars the standard deviation of 
duplicate reactions. 
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5.2.2.7 Summary of VHH competition studies 
In summary, the VHH were found to compete with sCD4 and four different anti-
CD4bs mAbs for binding to gp120. Moreover, the VHH were found to compete 
with each other and to a lesser extent with three mAbs to non-CD4bs epitopes of 
gp120. Taken together, these observations indicate that the VHH bind to epitopes 
overlapping, or in proximity to, the CD4bs of gp120. 
 
5.2.2.8 VHH D12 and F2 also compete with sCD4 for binding to gp120 
The neutralisation characterisation described in chapter 4 had revealed VHH D12 
and F2 as less potent than VHH A12, D7 and C8. VHH D12 and F2 had also 
been selected using the competitive sCD4 elution. To evaluate whether they also 
bound to CD4bs-related epitopes, their ability to inhibit sCD4 binding to gp120 
was assayed. 
 
VHH D12 had been selected through panning on IIIB gp120. Its ability to 
compete with sCD4 for binding to IIIB gp120 was therefore tested in ELISA. It 
was found to inhibit binding of sCD4 to gp120, indicating that it binds to a 
CD4bs-related epitope or binds in a way that sterically hinders binding of sCD4 
(Fig. 5.2.2.8.1). This is not unexpected, since VHH D12 showed some sequence 
similarity to VHH A12 and D7, as discussed in chapter 3. 
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Figure 5.2.2.8.1. VHH D12 competition 
with sCD4 for binding to recombinant 
gp120 derived from HIV-1 IIIB in 
ELISA. Serial dilutions of VHH D12 were 
tested for ability to inhibit gp120 binding to 
solid-phase sCD4, using the experimental 
procedure described in section 5.2.2.1. Data 
points represent the mean and bars the 
standard deviation of duplicate reactions. 
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VHH F2 had been selected through panning on CN54 gp120 and had also been 
shown to bind to CN54 but not to IIIB gp120 in ELISA (Fig. 5.2.1.1.1 and 
chapter 3). Furthermore, as described in chapter 3, CN54 gp120 did not show 
good binding to sCD4 in ELISA, which is why the ability of VHH F2 to inhibit 
this sCD4-gp120 binding could not be evaluated in ELISA. Instead, it was tested 
in the BIAcore surface plasmon resonance assay developed in section 5.2.2.2. 
Unlike VHH D7 and C8, which could completely inhibit sCD4 binding to CN54 
gp120, VHH F2 was only found to inhibit binding by approximately 50%, at a 
10:1 VHH:gp120 molar ratio (Fig. 5.2.2.8.2). This lack of complete inhibition 
could indicate that VHH F2 binds to CN54 gp120 with a lower affinity compared 
to sCD4 and compared to VHH D7 and C8. Alternatively, VHH F2 recognises an 
epitope that overlaps with the CD4bs to a lesser extent or that its binding imposes 
less of a steric hinder for sCD4 binding. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2.2.8.2. VHH F2 inhibition of sCD4 binding to CN54 gp120 as assayed by surface 
plasmon resonance. The experimental set up is described in section 5.2.2.2. Data were analysed 
using the BIAevaluation software. Binding of HIV-1 CN54 gp120 to sCD4 is represented as the 
difference between the response units (RU) observed in the cell containing the chip with sCD4 
and the negative control flow cell, plotted versus time. 
 
More work is needed to determine why VHH D12 and F2 were not as potent at 
neutralising HIV-1 as VHH A12, D7 and C8. It is possible that the epitopes 
which they recognise are not conserved or well-presented in the context of the 
functional envelope spike. 
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5.2.3 Lack of correlation between VHH reactivity with recombinant 
envelope glycoproteins and ability to neutralise the corresponding virus 
The results described in this chapter confirm previous findings, that antibody 
binding to gp120 in biochemical assays does not necessarily correlate with 
ability to neutralise HIV-1 (141, 142, 623-626, 897, 940). This observation was 
made, for example, for HIV-1 CN54. As described in chapter 4, the VHH were 
found to neutralise HIV-1 CN54 infection of NP2/CD4/CCR5 cells to 29-62%. 
VHH F2 was, however, the only VHH found to bind well to CN54 gp120 in 
ELISA, but did not show more potent neutralisation than the other VHH, 
neutralising HIV-1 CN54 to 47% in the NP2 cell-based neutralisation assay. 
Observations made using BIAcore surface plasmon resonance studies did, 
however, reveal that the VHH were indeed able to interact with CN54 gp120 and 
inhibit its binding to sCD4. This finding is in line with the assumption that 
surface plasmon resonance techniques can detect weak interactions that may be 
undetectable by ELISA. Lack of correlation between VHH binding to CN54 
gp120 and ability to neutralise CN54 virus may also be due to the CN54 gp120 
construct not being a good representative of the gp120s expressed on the surface 
of the infectious particles present in the swarm of viruses that is the CN54 PBMC 
isolate. 
 
Lack of correlation between reactivity with recombinant envelope and ability to 
neutralise the corresponding virus was furthermore observed for the subtype A 
92UG037.A9 virus. The VHH were found to bind well to 92UG037 monomeric 
gp120 and trimeric gp140 in ELISA and to compete with sCD4 for this binding, 
but were still not able to neutralise 92UG037.A9 virus. As described in chapter 3, 
sCD4 was also found to bind to 92UG037.A9 envelope with high signal strength 
in ELISA, without being able to neutralise the 92UG037.A9 virus. There are at 
least two possible explanations for this observation. First, it is possible that the 
regions recognised by the VHH and by sCD4 are not accessible or not present on 
the 92UG037.A9 gp120 in the context of the functional envelope spike, despite 
being present on the recombinant gp120 and gp140 constructs. Second, it is 
possible, but perhaps less likely, that sCD4 and the VHH are indeed able to bind 
to the HIV-1 92UG037.A9 functional envelope spike, but that they do so in a 
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way that still allows for interaction of the functional spike with the receptor or 
the co-receptor. For instance, if HIV-1 92UG037.A9 was capable of CD4-
independent infection, sCD4 and VHH binding to the functional spike might not 
be able to reduce virus infectivity. This notion is, however, speculative. In an 
initial attempt to investigate the reasons behind the 92UG037.A9 neutralisation 
resistance, 92UG037.A9 capability of CD4-independent infection was evaluated. 
HIV-1 92UG037.A9 was titrated onto CCC/CCR5 as well as CCC/CD4/CCR5 
target cells. These cell lines are feline renal epithelial cell lines engineered to 
express human CD4 and/or human CCR5. HIV-1 SF162, known not to be 
capable of CD4-independent infection, was titrated in parallel as a control. HIV-
1 92UG037.A9 and SF162 were able to infect CCC/CD4/CCR5 cells to a similar 
level as they did NP2/CD4/CCR5 cells. HIV-1 92UG037.A9, but not HIV-1 
SF162, was also able to infect CCC/CCR5 cells, the target cell line lacking CD4, 
although very inefficiently, to a titre that was approximately 4 logs lower than 
the titre on CCC/CD4/CCR5 cells (Fig. 5.2.3.1). This observation indicates that 
the inability of sCD4 (and perhaps anti-CD4bs antibodies such as the VHH) to 
inhibit 92UG037.A9 infection is not due to ability of the 92UG037.A9 virus to 
infect target cells in a CD4-independent manner. Further studies, possibly 
involving fluorescent activated cell sorter (FACS) analysis of infected cells, are 
needed to shed light on why sCD4 and the VHH are unable to neutralise 
92UG037.A9 virus despite being able to bind to 92UG037 gp140. 
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Figure 5.2.3.1. HIV-1 92UG037.A9 titre on cells lacking CD4. HIV-1 92UG037.A9 and SF162 
were titrated onto NP2/CD4/CCR5, CCC/CD4/CCR5 and CCC/CCR5 cells. At 72 hours post-
infection, cells were fixed and stained for HIV-1 p24 protein, as described in chapter 2. Titre was 
determined as number of focus-forming units (FFU) per ml. 
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Overall, the observation that the VHH could bind to recombinant gp120 and 
gp140 derived from HIV-1 92UG037 in ELISA, despite not being able to 
neutralise 92UG037.A9 virus, may suggest that these recombinant envelope 
constructs are not good representatives of the functional spike. Such antigens 
may not be suitable as an immunogens and for panning of VHH libraries. 
 
Interestingly, VHH binding to recombinant 92BR025.C1 gp120 seemed to 
correlate with ability to neutralise 92BR025.C1 virus. A12 and C8 were able to 
bind well to recombinant 92BR025.C1 gp120 in ELISA, whereas D7 bound with 
weaker signal (Fig. 5.2.2.2). This observation correlates with the corresponding 
neutralisation data, where A12 and C8 neutralise HIV-1 92BR025.C1 with IC50 
titres of 0.2 and 2 µg/ml, respectively, whereas the IC50 for D7 were found to be 
>50 µg/ml (Table 4.2.4.3.1). This finding may indicate that recombinant 
92BR025.C1 gp120 represents a good mimic of the 92BR025.C1 gp120 structure 
in the functional spike. This notion is, however, speculative and further studies 
are needed to evaluate the antigenic properties of this gp120. 
 
5.3 Discussion 
In this chapter, it has been shown that the VHH bind to recombinant envelope 
proteins in two different biochemical assay settings, and that they do so with 
affinities that are close to the suggested affinity ceiling for in vivo maturated 
antibodies. Furthermore, it has been shown that they compete with sCD4 for this 
binding, indicating that they recognise epitopes that overlap or are in proximity 
to the CD4bs. Envelope binding competition analysis, using a set of anti-gp120 
mAbs with defined epitopes, further confirmed that the VHH somehow target the 
CD4bs. Hence, it is likely that the VHH neutralise HIV-1 by interacting with the 
envelope spike prior to its interaction with CD4. 
 
For VHH A12 and D7, the KD values obtained in surface plasmon resonance 
experiments differ from the concentrations yielding half-maximal binding to IIIB 
gp120 in the direct binding ELISA described in Fig. 5.2.1.2.1, whereas for VHH 
C8 the values are in agreement. Such discrepancies have been described 
previously (1240). 
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The results described in this chapter further highlight the cross-subtype reactivity 
of the selected VHH. VHH A12, D7 and C8 were found to bind to envelope 
proteins of subtype A, B and C, indicating that they bind to a motif that is 
relatively conserved across HIV-1 subtypes. The lack of ability of the VHH to 
neutralise some of the corresponding viruses does, however, indicate that their 
epitopes are either not accessible or not present in the context of the functional 
envelope spike, despite being present on the soluble recombinant envelopes. 
 
Thus, the observations described in this chapter confirm previous findings that 
antibody binding to recombinant envelope proteins not necessarily correlates 
with ability to neutralise virus. Such a result is expected, since the structure of 
soluble, recombinant envelope glycoproteins is likely to be different from the 
structure of the envelope glycoproteins in the context of the functional spike 
(138, 140, 259). This has been previously observed in, for example, the case of 
mAbs b12 and b6, where both b12 and b6 compete with sCD4 for binding to 
envelope proteins, whereas b12 is the only of the two that is able to neutralise the 
corresponding virus (1009). The non-neutralising human mAb b6 can capture 
virus particles and inhibit capture by mAb b12, but has no effect on the 
neutralisation activity of b12, suggesting it can bind to non-functional envelope 
spikes present on the virus surface (142, 897, 1018, 1194). Whether the VHH can 
bind to non-functional spikes present on the surfaces of viruses that they are 
unable to neutralise, as in the case of mAb b6, has yet to be determined. 
 
In conclusion, the results reported in this chapter have shown that the VHH 
behave as anti-CD4bs antibodies. More work, such as alanine scanning of gp120 
as well as structural studies, would shed further light on their epitopes. The 
crystal structure of the unliganded VHH D7 has been solved to a resolution of 
2.4 Å by Winfried Weissenhorn at the European Molecular Biology Laboratory 
(EMBL) in Grenoble, France. This structure, in combination with molecular 
modelling experiments and mutagenesis studies, may provide insight into the 
way in which VHH D7 and the D7-like VHH interact with gp120. Atomic 
structures of the VHH in complex with recombinant gp120 would define their 
precise epitopes. Once their epitopes are known, they may prove useful in 
characterising recombinant envelope proteins. 
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Chapter 6 
Final discussion 
 
Our study shows that HIV-1 neutralising VHH can be isolated from llamas 
immunised with recombinant gp120 (1241). To increase the chances of isolating 
neutralising VHH, we employed a functional selection approach which enabled 
the identification of VHH that compete with CD4. By panning of phage libraries 
displaying the VHH repertoires of the immunised animals on recombinant 
gp120, and by introducing a competitive elution step using sCD4, we could 
select for VHH targeting the CD4bs of gp120. Immunising with gp120 derived 
from an HIV-1 CRF07_BC primary isolate, followed by panning on gp120 from 
either a subtype B virus or sequentially on gp120 from subtypes A, B and C, 
allowed for selection of VHH with cross-subtype neutralising activity. Three 
VHH (A12, D7 and C8) able to neutralise HIV-1 primary isolates of subtype B 
and C were identified. These were shown to bind to recombinant envelope 
proteins with affinities that are close to the suggested affinity ceiling for in vivo 
maturated antibodies, and to compete with sCD4 and anti-CD4bs mAbs for this 
binding, indicating that they somehow target the CD4bs of gp120. In light of this 
observation, it is likely that they are able to inhibit HIV-1 entry into target cells 
by interacting with the functional envelope spike prior to its interaction with the 
main cellular CD4. 
 
Given the unique properties attributed to VHH, in terms of solubility, thermal 
and chemical stability, and high expression levels leading to a low production 
cost (1109, 1119, 1121, 1122), neutralising VHH might prove useful in a number 
of applications, for example as candidate HIV-1 microbicides as well as anti-
retroviral drugs or prophylactics. Topical application of mAb b12 has been 
shown to protect macaques from infection after vaginal challenge with SHIV, 
which supports the potential use of antibodies for topical prevention of HIV-1 
transmission (668). Further studies are needed to establish whether the identified 
VHH would have preventive effects in vivo. Anti-envelope VHH may also be of 
use in characterising epitopes on HIV-1 envelope proteins. Attempts to design an 
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HIV-1 immunogen that can elicit a broadly neutralising humoral immune 
response have so far failed (259, 754, 1229), although a recent study reports that 
extensively cross-reactive antibodies (albeit at low titre) have been induced by 
immunisation of rabbits with a recombinant gp140 (1046). It is possible that a set 
of neutralising and non-neutralising VHH may become useful in the design of 
such an immunogen. 
 
The stability and solubility of VHH allows for engineering of multivalent and 
bispecific molecules (1123). Engineered multivalent VHH to other antigens have 
previously been shown to exhibit better binding and neutralising properties than 
their monovalent counterparts (1124). It is possible that introduction of 
multivalency will increase the potency of the identified anti-gp120 VHH. 
Construction and evaluation of such multivalent VHH, using the VHH identified 
in this study, is ongoing, but has so far not led to increased neutralisation potency 
or breadth (data not shown). Selecting for VHH recognising other epitopes and 
linking them to the CD4bs-targeted VHH described in this study, thus producing 
a bispecific VHH, might also result in more potent binding and neutralisation 
properties. 
 
The neutralising activities of the VHH were evaluated in the TZM-bl 
neutralisation assay against a panel of 65 HIV-1 isolates from subtype A, B, C, 
D, CRF02_AG and CRF07_BC. The most potent and broadly reactive VHH was 
A12. VHH A12 was able to neutralise 59% of the subtype B viruses and 48% of 
the subtype C viruses included in the study on an IC50 level, compared to 77% 
and 56% for the broadly neutralising anti-CD4bs mAb b12. The difference in 
neutralisation breadth between VHH A12 and mAb b12 was even more 
pronounced at an IC90 level. While mAb b12 neutralised 64% of subtype B 
viruses and 36% of subtype C viruses on an IC90 level, VHH A12 neutralised 
only 36% of subtype B viruses and 22% of subtype C viruses, indicating that 
VHH A12 is less potent and less broad in its cross-subtype neutralisation ability 
than mAb b12. Moreover, the VHH were less potent at neutralising HIV-1 in 
primary PBMC. Furthermore, it should be noted that the VHH are approximately 
ten times smaller than mAb b12, making mAb b12 more potent on a molar level. 
On the other hand, mAb b12 has two antigen-binding sites. To be able to make a 
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direct comparison of neutralisation ability, the VHH would need to be expressed 
in the context of a full immunoglobulin. 
 
Interestingly, the VHH were found to neutralise a different spectrum of viruses 
compared to mAb b12. These differential neutralisation reactivities may indicate 
that the VHH and mAb b12 recognise different epitopes on gp120, despite 
competing with each other for binding to gp120 in ELISA. VHH A12 and C8 
were also observed to neutralise different but overlapping sets of viruses, 
indicating that they may be directed at different CD4bs-related regions of gp120. 
VHH D7, on the other hand, was observed to neutralise a subset of the viruses 
neutralised by VHH A12. This finding together with the notion that VHH A12 
and D7 showed a high degree of sequence similarity indicated that they may 
recognise similar epitopes. To further characterise the VHH epitopes and to 
determine whether they overlap with the mAb b12 epitope, additional studies are 
needed, including structural studies of VHH in complex with gp120, mutagenesis 
studies, and neutralisation escape studies. Determining the epitopes of these 
VHH may provide additional information about vulnerable sites in proximity to 
the CD4bs of gp120. 
 
The CD4bs is thought to be a good target for HIV-1 vaccine design (754), as it is 
functionally conserved, and furthermore targeted by the extensively studied, 
broadly neutralising mAb b12, which binds to an epitope overlapping the CD4bs 
(1008). In addition, Li et al. (985) have recently mapped the specificities of the 
neutralising activity in some broadly neutralising sera from HIV-1-seropositive 
individuals to the CD4bs. These anti-CD4bs antibody fractions were able to 
neutralise viruses not neutralised by b12, indicating that they contain antibodies 
directed at epitopes that may be different to the b12 epitope. Moreover, in a 
recent study, Binley et al. (1242) mapped the neutralising activities in plasma 
from 24 individuals with broad neutralising responses, and found that a large 
proportion of the neutralising activity (50-99%) was directed to CD4bs epitopes 
in 9 out of the 24 plasmas, further highlighting the notion that the CD4bs is a 
good target for vaccine design. In contrast, antibodies to the V3 region or to 
2G12-like epitopes did not seem to contribute to the neutralisation activity. 
However, the specificities of around two-thirds of the neutralising activity could 
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not be determined, indicating that the sera contained neutralising antibodies 
directed against epitopes that have not yet been characterised. The 
characterisation of such novel neutralising epitopes may aid vaccine 
development. It is possible that a panel of anti-envelope VHH, which can be 
selected from immunised llamas using the versatile phage display technology, 
may help to define such epitopes. More specifically, a panel of neutralising VHH 
recognising CD4bs-related epitopes may help to further characterise the 
functionally important CD4bs, and may possibly help to define additional 
neutralising epitopes in the vicinity of it. 
 
The immunogen, CN54 gp120, showed poor binding to sCD4 in biochemical 
assays and did not mediate infection when expressed on viruses. It was chosen as 
immunogen due to its availability before these properties were known. 
Nonetheless, despite immunising with an immunogen that appeared to be non-
functional, broadly neutralising VHH could be isolated. It is possible that 
immunising with an immunogen that better exposes the CD4bs would have 
resulted in more potent and broadly reactive VHH. For example, a gp120 
construct engineered to be locked in a CD4-bound conformation by the 
introduction of two point mutations in the Phe43 cavity has been shown, by Dey 
et al. (1066), to be better at eliciting neutralising antibodies compared to the 
corresponding native gp120. Immunising with such an antigen, alternatively 
including it in the panning step, may result in the isolation of more potent and 
broadly neutralising VHH. 
 
Overall, immunising llamas and selecting for anti-CD4bs VHH using an antigen 
that is a better representation of the functional envelope spike might result in 
VHH with broader cross-subtype neutralising activities and lower inhibitory 
doses. Again, identification of such an envelope antigen is one of the major 
challenges when screening for agents that can act as HIV-1 entry inhibitors as 
well as in HIV-1 vaccine design (259). Previous studies have shown that purified 
trimeric envelope proteins are somewhat better at eliciting cross-subtype-
neutralising antibodies than monomeric recombinant gp120 (1036, 1038-1041, 
1243). Immunising llamas with recombinant CN54 gp140 in this study did not, 
however, result in the isolation of neutralising VHH. 
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Zhang et al. (1046) immunised rabbits with a recombinant gp140 construct from 
an HIV-1-seropositive individual whose serum exhibited broad neutralising 
activity, and found that it elicited broad, although not so potent, neutralising 
serum responses. It is possible that immunising llamas with recombinant 
envelope glycoproteins from individuals with broadly neutralising antibody 
responses, or including such an antigen in the panning protocol, may result in 
increased chances of isolating broadly neutralising VHH. Additional VHH 
selection strategies may include panning on virus-like particles or infected cells 
to expose them to native spike, followed by elution with sCD4. 
 
In this study, the phage libraries were panned on gp120 derived from the TCLA 
isolate IIIB, or on gp120 derived from HIV-1 primary isolates of subtype A or C. 
Panning was carried out on each antigen alone, or on the same antigens 
alternated in various combinations in two subsequent rounds of panning, always 
using the competitive elution with sCD4. Interestingly, using this method of 
selection, we could select for VHH that could bind to envelope proteins of 
subtype A, B, and C, regardless of which of the above antigens that were used in 
the panning. However, when selecting using HIV-1 IIIB gp120 only, a range of 
VHH were isolated that could be grouped into two families, whereas when the 
subtype A and C envelopes were included in the panning, only the most potent 
and broadly reactive VHH in the set were selected. This finding suggests that 
alternating the antigen in the panning procedure enables selection of VHH with 
better cross-reactive properties. Sequential alternation of the antigen in the 
panning step has previously been shown to result in the isolation of antibody 
fragments with more broad and potent neutralising activity (1020, 1205, 1206). 
 
In conclusion, this study provides proof-of-concept that the camelid immune 
system can be used to generate anti-envelope VHH with relatively broad 
neutralising activity across HIV-1 subtypes. Three cross-reactive VHH able to 
neutralise several HIV-1 primary isolates of subtype B and C were characterised. 
These VHH competed with sCD4 and anti-CD4bs mAbs for binding to 
recombinant gp120 and gp140. To our knowledge, this is the first description of 
broadly neutralising mAbs to HIV-1 envelope, which are derived from an 
immunised animal, as all previously reported broadly neutralising anti-HIV-1 
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mAbs have been a result of natural infection rather than immunisation (259, 754, 
1229). The results indicate that heavy-chain antibody fragments have a possible 
use as potent HIV-1 entry inhibitors. Since VHH are stable and can be produced 
at a relatively low cost, they may be considered for applications such as HIV-1 
microbicide development. Combined with structural studies, such VHH could be 
used to characterise conserved neutralising epitopes on the HIV-1 envelope 
spike, which may be of value for HIV-1 immunogen design. 
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